10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2013

Commission File Number 001-34251

MEAD JOHNSON NUTRITION COMPANY

(Exact Name of Registrant as Specified in Its Charter)

Delaware	80-0318351
(State or Other Jurisdiction of Incorporation or Organization)	(IRS Employer Identification No.)

2701 Patriot Blvd.Glenview, Illinois 60026(Address of Principal Executive Offices and Zip Code)

Registrant’s Telephone Number, Including Area Code: (847) 832-2420

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of each exchange on which registered
Common Stock, $0.01 Par Value	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

______________________________________

        Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ý    No o

         Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes o    No ý

         Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ý    No o

         Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý    No o

         Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o

         Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ý Accelerated filer o Non-accelerated filer o Smaller reporting company o

         Indicate by check mark if the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o    No ý

         The aggregate market value of the shares of common stock held by non-affiliates of the registrant, computed by reference to the closing price as reported on the New York Stock Exchange, as of June 28, 2013, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $16.0 billion.

As of February 10, 2014, there were 201,660,776 shares of common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

         Part III of this Annual Report on Form 10-K incorporates by reference portions of the registrant’s Proxy Statement for its 2014 Annual Meeting of Stockholders, which Proxy Statement will be filed with the United States Securities and Exchange Commission within 120 days after the end of the registrant’s 2013 fiscal year.

MEAD JOHNSON NUTRITION COMPANY

TABLE OF CONTENTS

PART I
Item 1.	BUSINESS
Item 1A.	RISK FACTORS
Item 1B.	UNRESOLVED STAFF COMMENTS
Item 2.	PROPERTIES
Item 3.	LEGAL PROCEEDINGS
Item 4.	MINE SAFETY DISCLOSURES
PART II
Item 5.	MARKET FOR REGISTRANT’S COMMON STOCK, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES
Item 6.	SELECTED FINANCIAL DATA
Item 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Item 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Item 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Item 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
Item 9A.	CONTROLS AND PROCEDURES
Item 9B.	OTHER INFORMATION
PART III
Item 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Item 11.	EXECUTIVE COMPENSATION
Item 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Item 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
Item 14.	PRINCIPAL ACCOUNTANT FEES AND SERVICES
PART IV
Item 15.	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

PART I

Item 1.    BUSINESS.

        In this Annual Report on Form 10-K, we refer to Mead Johnson Nutrition Company and its subsidiaries as “the Company,” “MJN,” “Mead Johnson,” “we” or “us.”

Our Company

        Mead Johnson Nutrition Company is a global leader in pediatric nutrition with $4.2 billion in net sales for the year ended December 31, 2013. We are committed to being the world’s leading nutrition company for infants and children and to helping nourish the world’s children for the best start in life. Our Enfa family of brands, including Enfamil infant formula, is the world’s leading brand franchise in pediatric nutrition, based on retail sales. Our comprehensive product portfolio addresses a broad range of nutritional needs for infants, children and expectant and nursing mothers. We have over 100 years of innovation experience during which we have developed or improved many breakthrough or industry-defining products across each of our product categories. Our singular focus on pediatric nutrition and our implementation of a business model that integrates nutritional science with health care and consumer marketing expertise differentiate us from many of our competitors.

        We market our portfolio of more than 70 products to mothers, health care professionals and retailers in more than 50 countries in North America, Europe, Asia and Latin America. Our three reportable segments are Asia, Latin America and North America/Europe, which comprised 52%, 20% and 28%, respectively, of our net sales for the year ended December 31, 2013. See “Item 8. Financial Statements – Note 5. Segment Information.” For the year ended December 31, 2013, 77% of our net sales were generated in countries outside of the United States.

        We believe parents and health care professionals associate the Mead Johnson name and the Enfa family of brands with quality, science-based pediatric nutrition products. We believe the strength of our brands allows us to create and maintain consumer loyalty across our product portfolio and stages of pediatric development.

        The two principal product categories in which we operate are infant formula and children’s nutrition, which represented 59% and 39% of our net sales for the year ended December 31, 2013, respectively.

Our History

        Mead Johnson was founded in 1905 and introduced Dextri-Maltose, our first infant feeding product, in 1911. Over the next several decades, we built upon our leadership in science-based nutrition, introducing many innovative infant feeding products while expanding into vitamins, pharmaceutical products and adult and children’s nutrition. Some of our products, developed in cooperation with clinicians and leading nutrition researchers, established a partnership betweenMead Johnson and the scientific community that continues to this day.

        During the course of our history, we have expanded our operations into geographies outside of the United States, including Asia, Latin America and Europe and now focus solely on pediatric nutrition. Throughout our history, our deeply-held commitments to support good nutrition early in life and to improve the health and development of infants and children around the world have been hallmarks of our organization.

Our Brands

        The Mead Johnson name has been associated with science-based nutritional products for more than a century. In addition to the Mead Johnson name, our products are marketed around the world under brands that we have developed through our global sales and marketing efforts.

Enfa Family of Brands

The Enfa family of brands includes several of the world’s leading infant formula and children’s nutrition brands, and we have positioned them as providing unique, clinically supported health and developmental benefits. The Enfa infant formula products often include docosahexaenoic acid (“DHA”) and other key nutrients to support brain and immune system development. Our Enfa family of brands accounted for approximately 80% of our net sales for the year ended December 31, 2013 and is the world’s leading brand franchise in pediatric nutrition, based on retail sales.

1

        Building upon the strength of our brand equity, we have extended the Enfa family of brands into the growing children’s nutrition category. We believe we have enhanced consumer retention by creating links between age groups and leveraging brand loyalty.

        Additionally, the use of the Enfa prefix in our prenatal nutrition products (such as EnfaMama) links the scientific basis, quality and innovation that these products hold in common with our core pediatric nutrition line.

        We consistently promote the brand through our global sales and marketing operations. Our studies show mothers and health care professionals often associate the Enfa family of brands with science, superior nutrition, quality and good value. Mothers often describe the Enfa family of brands as science-based, sophisticated, trustworthy, reliable and comforting.

Complementary Brands

        In addition to the Enfa family of brands, we market several other powerful brands on a local, regional or global basis. These brands complement the Enfa family of brands portfolio and are designed to meet the specific nutritional needs of infants under the supervision of health care professionals (such asNutramigen), the nutritional needs of children (such as Lactum) orthe nutritional needs of broad consumer populations (such asChocoMilkandCal-C-Tose).

Stages of Development

        Generally, there are six stages of pediatric development and we produce different products for each of these stages globally. The general stages of pediatric development are illustrated below:

       Outside of the United States, we market both infant formula products (Stages 1 and 2) and an extended range of children’s nutrition products designed for the changing nutritional needs of growing toddlers and children (Stages 3, 4and 5). In the United States, our business is primarily focused on the infant formula category (including newborn and infant), but the children’s nutrition business is growing rapidly. This strategy allows us to take advantage of brand loyalty developed in the early stages to retain consumers as they grow older. 

Our Products

        Our pediatric nutrition products are grouped by category of feeding: (1) infant formula products, (2) children’s nutrition products and (3) other products. Infant formula, children’s nutrition and other product sales comprised approximately 59%, 39% and 2% of our net sales for the year ended December 31, 2013, respectively.

Infant Formula

General

        Our infant formula products include routine feeding formula, solutions formulas for mild feeding problems and specialty formula products, including formulas for severe intolerance, formulas for premature and low birth weight infants and medical nutrition products. The table below illustrates our key infant formula brands and products:

ROUTINE INFANT FORMULA		SOLUTIONS INFANT FORMULAS FOR COMMON FEEDING PROBLEMS		SPECIALTY INFANT FORMULAS AND SUPPLEMENTS
•	Enfamil Premium	•	Enfamil Gentlease: for gas/fussiness	•	Nutramigen: for mild to moderate cow’s milk or soy allergies
•	Enfamil Premium Newborn	•	Enfamil ProSobee: soy formula	•	Puramino: for severe cow’s milk protein or multiple food allergies
•	Enfamil A+	•	Enfamil LactoFree: for lactose intolerance	•	Pregestimil: for fat malabsorption
•	Enfalac A+	•	Enfamil AR: for anti-regurgitation	•	Enfamil Premature: for premature infants
•	SanCor Bebé	•	Enfamil HA: for infants at risk of cow’s milk protein allergy	•	Enfacare: for premature infants when they are able to go home
•	SanCor Bebé Premium	•	Enfamil Comfort: for gas/fussiness	•	Enfamil Human Milk Fortifier: liquid supplement added to human milk for premature and low birth weight infants
		•	Enfamil for Supplementing: for when mothers choose to introduce formula
				•	Other Medical Nutrition Products: for children with metabolic disorders

2

Routine Infant Formula

        We design routine infant formula as a breast milk substitute for healthy, full-term infants without special nutritional needs both for use as the infant’s sole source of nutrition and as a supplement to breastfeeding. We endeavor to develop routine infant formula closer to breast milk.

    Each product is referred to as a “formula,” as it is formulated for the specific nutritional needs of an infant of a given age. Generally, our routine infant formula has the following four main components: (1) protein from cow’s milk that is processed to have a profile similar to human milk, (2) a blend of vegetable fats (including DHA and arachidonic acid (“ARA “)) to replace bovine milk fat in order to better resemble the composition of human milk, (3) a carbohydrate, generally lactose from cow’s milk and (4) a vitamin and mineral “micronutrient” pre-mix that is blended into the product to meet the specific needs of the infant at a given age. Patterned after breast milk, which changes composition to meet the infant’s changing nutritional needs, we produce two stages of infant formula. Stage 1 formulas are consumed by newborn infants up to six months of age (up to three months of age in the case ofEnfamil Premium Newborn). Stage 2 formulas are generally consumed by infants from age six to twelve months. Our most prominent product form around the world is milk-based powder, but we also produce several infant formulas in ready-to-use and concentrated liquid form for sale primarily in the United States, Canada and Argentina.

        We market the same product under different names in different regions, based on regional marketing strategies and regional brand recognition. For example, our premium infant formulas containing DHA and ARA are sold under the brandsEnfamil PremiumandEnfamil Premium Newbornin the United States. Outside the United States, we use the brands Enfamil A+ and Enfalac A+ for our DHA and ARA supplemented formulas.

Routine infant formula products comprised 41% of our total net sales for each of the years ended December 31, 2013, 2012 and 2011.

Solutions Infant Formulas for Common Feeding Problems

        We design several solutions infant formulas to address common feeding tolerance problems in normal infants, including spit-up, fussiness, gas and lactose intolerance. We market our solutions infant formulas for mild intolerance such as Gentlease and Prosobee under the Enfa family of brands name.

        Solutions infant formula products comprised 10% of our total net sales for each of the years ended December 31, 2013, 2012 and 2011.

Specialty Infant Formulas and Supplements

        Our specialty infant formulas include: (1) formulas for severe intolerance, (2) formulas for premature and low birth weight infants and (3) medical nutrition products. Specialty infant formulas comprised 8% of our total net sales for each of the years ended December 31, 2013, 2012 and 2011.

Formulas for Severe Intolerance

        We design formulas for severe intolerance to be used on the specific recommendation and under the supervision of a doctor. We specially formulate these products for use by infants displaying symptoms of certain conditions or diagnosed with special medical needs.

Nutramigen infant formula was the first infant formula to include protein hydrolysate in the United States. This ingredient is easier for infants with severe intolerance to digest because its protein is extensively hydrolyzed (or broken down into peptides, a process that would otherwise be performed in the infant’s stomach). We designed Nutramigen infant formula for use by infants with cow’s milk protein allergies. Nutramigen with LGG infant formula is a variant of Nutramigen. LGG is a probiotic ingredient that has been associated with reduced incidence of infant atopic dermatitis, a non-contagious skin disease characterized by chronic inflammation of the skin, resulting from an allergy to cow’s milk. Puramino infant formula is an amino acid formula that we formulated with fully broken-down proteins, which can be consumed without the need for digestion of the protein. We designed this product for infants who experience a severe allergy to cow’s milk or multiple other food allergies. Pregestimil infant formula is a variation of the Nutramigen formulation designed mainly for fat malabsorption. It contains medium chain triglycerides oil instead of fat.

Formulas and Supplements for Premature and Low Birth Weight Infants

        We also design products for premature and low birth weight infants to meet these infants’ unique needs under the supervision of a doctor, most often in the hospital. Typically, such infants need extra assistance obtaining the requisite nutrition. They require a higher density of nutrients and calories because they cannot take in enough volume of breast milk or routine infant formula.Enfamil Prematureis an infant formula used primarily in the hospital.EnfaCareinfant formula is a hypercaloric formula available through retail channels for

3

premature babies when they are able to go home. Furthermore, we designed our Enfamil Human Milk Fortifier product as a supplement to a mother’s breast milk that improves nutritional density.

Medical Nutrition

        We also produce medical foods, or foods for special medical purposes, for nutritional management of individuals with rare, inborn errors of metabolism such as maple syrup urine disease (Mead Johnson BCAD) and phenylketonuria (Mead Johnson Phenyl-Free). Category 1 products are intended for infants and young children from zero to three years of age and Category 2 products are suitable for children and adults. We produce approximately 17 formulas targeted at specific disorders for use under the direct and continuous supervision of a physician. We market these medical nutrition products under the Mead Johnson brand name.

Children’s Nutrition Products

        Children’s nutrition products are designed to provide children with enhanced nutrition. Our children’s nutrition business is present primarily in Asia and Latin America. We separate our children’s nutrition products into two categories: (1) Enfa branded children’s nutrition products and (2) other children’s nutrition products. The table below illustrates our key children’s nutrition products:

ENFA BRANDED CHILDREN’S NUTRITION PRODUCTS		OTHER CHILDREN’S NUTRITION PRODUCTS
•	Enfagrow	•	Sustagen KID
•	Enfagrow A+	•	Lactum
•	Enfagrow Premium	•	Alacta
		•	ChocoMilk
		•	Cal-C-Tose
		•	SanCor Bebé
		•	SanCor Bebé Premium

Enfa Branded Children’s Nutrition Products

        We market children’s nutrition products under the Enfa family of brands. We design these products to meet the changing nutrition needs of children at different stages of development. We offer products at Stages 3, 4 and 5 that are designed for children’s nutritional needs at one to three years of age, three to five years of age and beyond five years of age, respectively. These products are not breast milk substitutes and are not designed for use as the sole source of nutrition but instead are designed to be a part of a child’s appropriate diet. Enfa branded children's nutrition products comprised 29%, 27% and 27% of our total net sales for the years ended December 31, 2013, 2012, 2011, respectively.

Other Children’s Nutrition Products

We also offer other children's products in select markets to meet specific nutritional needs. We offer products at Stages 3, 4 and 5 designed to complete children's dietary requirements. Sustagen Kid is a nutritionally-balanced milk supplement for children targeting unique nutritional needs during specific stages of development. Lactum and Alacta are also powered milk supplements intended to ensure that essential nutrients are incorporated into children's diets.

We make ChocoMilk and Cal-C-Tose which are “milk modifiers” in powder form that, when added to a glass of milk, maximize the milk's nutritional value. These products contain a unique blend of important vitamins and minerals, including iron and calcium, and are intended to ensure that essential nutrients are incorporated into children's diets.

Other children's products comprised 10%, 11% and 11% of our total net sales for the years ended December 31, 2013, 2012, 2011, respectively.

Other Products

        We also produce a range of other products, including pre-natal and post-natal nutritional supplements for expectant and nursing mothers, includingExpectaandEnfaMama.Our products for expectant or nursing mothers provide the developing fetus or breastfed infant with vitamin supplements and/or an increased supply of DHA for brain development. These products also supplement the mother’s diet by providing DHA with increased proteins, as well as 24 vitamins and minerals. Our pediatric vitamin products sold in some geographies, such as Enfamil Poly-Vi-Sol, provide a range of benefits for infants, including multivitamins and iron supplements. Other products comprised 2%, 3% and 3% of our total net sales for the years ended December 31, 2013, 2012, 2011, respectively.

4

The Special Supplemental Nutrition Program for Women, Infants, and Children (“WIC”)

        The WIC program is a U.S. Department of Agriculture (“USDA”) program created to provide nutritious foods, nutrition education and referrals to health care professionals and other social services to those considered to be at nutritional risk, including low-income pregnant, postpartum and breastfeeding women and infants and children up to age five. It is estimated that approximately 51% of all infants born in the United States during the 12-month period ended December 31, 2013 benefited from the WIC program. The USDA program is administered individually by each state.

        Participation in the WIC program is an important part of our U.S. business based on the volume of infant formula sold under the program. Our financial results reflect net WIC sales, after taking into account the rebates we paid to the state WIC agencies, which represented approximately 6% of our U.S. net sales and 1% of our global net sales in the year ended December 31, 2013.

        Most state WIC programs provide vouchers that participants use at authorized food stores to obtain the products covered by the program, including infant formula. State WIC agencies enter into contracts with manufacturers, pursuant to which the state agency provides mothers with vouchers for a single manufacturer’s brand of infant formula and, in return, the manufacturer gives the state agency a rebate for each can of infant formula redeemed by WIC participants. Retailers purchase infant formula directly from the manufacturer, paying the manufacturer’s published wholesale price. Mothers redeem the vouchers received fromthe WIC agency for infant formula at authorized retailers. The retailer is then reimbursed the full retail price by the WIC agency for redeemed vouchers. On a monthly basis, each state WIC agency invoices the contracted manufacturer for an amount equal to the number of cans of infant formula for which vouchers were redeemed by the agency and reimbursed to retailers during the month multiplied by the agreed rebate per can.

        The bid solicitation process is determined by each state’s procurement laws, but the process is relatively standardized across the WIC program. Some states form groups and hold their bid processes jointly while other states solicit bids individually. Some states split bids between separate contracts for milk- and soy-based formulas. During the bid process, each manufacturer submits a sealed bid. The manufacturer with the lowest net price, calculated as the manufacturer’s published wholesale price less the manufacturer’s rebate bid, is awarded the contract. No other factors are considered. WIC contracts are generally three years in duration with some contracts providing for extensions. Specific contract provisions can vary significantly from state to state.

        Manufacturers that choose to compete for WIC contracts must have a widely distributed infant formula brand in order to meet the requirements of the contract bidding process. As of December 31, 2013, we held the contracts that supplied approximately 39% of WIC births in the United States.

        As of December 31, 2013, we held the exclusive WIC contract for the following states:

State	Date of Expiration	% of Total WIC Infant Participation (1)
California (2)	July 31, 2015	14.3%
Colorado (2)	December 31, 2014	1.1%
Connecticut (2)	September 30, 2014	0.7%
Illinois (2)	January 31, 2016	3.7%
Louisiana (2)	September 30, 2015	1.9%
Maine (2)	September 30, 2014	0.3%
Massachusetts (2)	September 30, 2014	1.4%
Michigan	October 31, 2016	3.2%
Missouri (2)	September 30, 2014	1.9%
Nebraska (2)	September 30, 2014	0.5%
New Hampshire (2)	September 30, 2014	0.2%
New Jersey (2)	September 30, 2015	1.9%
New York (2)	June 30, 2014	5.9%
North Dakota (2)	June 30, 2015	0.2%
Rhode Island (2)	September 30, 2014	0.3%
South Dakota (2)	September 30, 2014	0.2%
WSCA Consortium - Soy Infant Formula Only (2) (3)	September 30, 2015	1.1%

(1) As of October 2013, as reported by the United States Department of Agriculture Food and Nutrition Service (the “USDA FNS”).

(2) Contract contains extension provisions.

(3) The WSCA (Western States Contracting Alliance) Consortium includes the states of Alaska, Arizona, Delaware, District of Columbia, Hawaii, Idaho, Kansas, Maryland, Montana, Nevada, Oregon, Utah, Washington, West Virginia and Wyoming.

5

Sales and Marketing

        We conduct regional marketing in North America, Europe, Asia and Latin America within a global strategic framework focused on both parents and health care professionals in compliance with our policy with respect to the International Code of Marketing of Breast-milk Substitutes (the “WHO Code”). See “ – Regulatory – Global Policy and Guidance – WHO.” We maintain ahealth care professional sales force and retail sales organization throughout the world. Our marketing activities vary from region to region depending on our market position, consumer trends and the regulatory environment. Our marketing teams seek to anticipate market and consumer trends, and attempt to capture consumer insights to determine strategy for brand communication, product innovation and demand-generation programs. The marketing teams work with external agencies to create strong marketing campaigns for consumers, health care professionals and retail sales organizations, as permitted under the WHO Code and individual countries’ laws and regulations.

Consumers

        Parental preference plays an important role in brand selection with influence from health care professionals. We participate in a variety of marketing activities, where permitted by regulation and policy, includingprint and television advertising, direct mail, online / internet, digital and promotional programs. Our marketing is evidence-based and emphasizes our superior nutritional science. In particular, our digital marketing program provides new or prospective parents with many resources to help them with their newborns, including free samples, nutritional and developmental information for mothers and widely accepted instantly redeemable coupons, where permitted by regulation and policy. We are increasing our investment in direct marketing with a focus on emerging channels such as social media and mobile.

Health Care Professionals

        Our sales force educates health care professionals about the benefits of our infant formula products in each of the countries where we market our infant formula products. We focus our product detailing efforts on neonatal intensive care units, physicians and other health care professionals, hospital group purchasing organizations and other integrated buying organizations.We also support health care professionals by organizing continuing medical education programs, symposia and other educational interfaces.

Retail Sales Organization

        Our sales force markets our products to each of the retail channels where our products are purchased by consumers, including mass merchandisers, club stores, grocery stores, drug stores and, to a limited extent, convenience stores. The size, role and purpose of our retail sales organization varies significantly from country to country depending on our market position, the consolidation of the retail trade, shopper trends and the regulatory environment. In North America, Eastern Europe, Latin America and Asia, we focus on all retail channels, while in Western Europe we focus primarily on specialty products sold through pharmacies. We have entered into logistics partnerships with distributors and wholesalers in most of our markets.

Global Supply Chain

        We manage sourcing, manufacturing and distribution through our fully integrated global supply chain. We currently operate in-house production facilities at eight different locations around the world and additionally use third-party manufacturers for a portion of our requirements.

Locations

        Our manufacturing and finishing facilities are located in the United States, Mexico, the Netherlands, China, the Philippines, Thailand and Brazil. Our new manufacturing and technology center in Singapore is currently under construction and is expected to be operational in the second half of 2014. See “Item 2. Properties” for a description of our global manufacturing facilities.

        As the production process advances, regional or sub-regional teams support the global team, overseeing manufacturing activities such as the finishing of our products. Our four regional quality departments perform regional and manufacturing site quality control and assurance. These departments focus on regulatory requirements, food safety, pest control, continuous quality improvement, third-party compliance and ingredient supplier manufacturing operations.

6

Suppliers

        We generally enter into long-term supply agreements. We source approximately 80% of our materials from approximately 52 suppliers. Through these suppliers, we obtain key raw materials and primary packaging materials.

        We procure key raw materials and primary packaging materials on a global basis. Certain raw materials, while managed and contracted on a global basis, are subject to regional and local variations in price under the terms of the supply agreement. These raw materials are subject to review and approval by our regional teams to ensure compliance with regulatory requirements. For example, milk prices vary at the local level around the world partly due to government pricing regulation. We saw a significant rise in dairy prices in 2013. Dairy products, consisting primarily of milk powders, non-fat dry milk, lactose and whey protein concentrates, accounted for approximately 43% of our global expenditures for raw materials in the year ended December 31, 2013.

Distribution

        We manage our distribution networks locally with regional oversight. We generally enter into distribution agreements with third-party logistics providers and distributors and maintain a small staff at the local or regional level to track performance and implement initiatives.

Customers

Our products are sold principally to wholesale and retail customers, both nationally and internationally. Sales to two of our customers, DKSH International Ltd. (primarily in Asia and including sales to its regional affiliates) and Wal-Mart Stores, Inc. (including sales to Sam’s Club), accounted for approximately 16%, 15% and 14%, and approximately 10%, 11% and 12% of our gross sales for the years ended December 31, 2013, 2012, and 2011, respectively.

Competition

        We compete in two primary categories, infant formula and children’s nutrition. The competitive landscape in each category is similar around the world, as the majority of the large global players are active in these categories. Our main global competitors for sales of infant formula and children’s nutrition products are Abbott Laboratories, Danone and Nestlé S.A.

        Other companies, including manufacturers of private label, store brand and economy products, manufacture and sell one or more products that are similar to those marketed by us. We believe sources of our competitive advantage include clinical claims for efficacy and product quality, brand image and associated value, broad distribution capabilities and consumer satisfaction. Significant expenditures for advertising, promotion and marketing, where permitted by regulation and policy, are generally required to achieve acceptance of products among consumers and health care professionals.

Research and Development

        Continuing to invest in research and development (“R&D”) capabilities is an important part of our business. Our R&D organization consists of professionals, many of who have extensive industry experience and advanced educational backgrounds. Our global R&D operations are headquartered in Evansville, Indiana, and our additional key R&D facilities are located in Mexico, Thailand, China and the Netherlands. Our Pediatric Nutrition Institutes ("PNI") are located in Evansville, Indiana; Mexico City, Mexico and Guangzhou, China. In 2014 we expect to complete our new manufacturing and technology center in Singapore which will include a fourth PNI.

        We organize our research and development on a global basis because our science-based products address nutritional needs that are broadly common around the world. We then rely on our regional R&D teams to incorporate any geographic-specific consumer behaviors and preferences. 

        We have a global formulation management system that supports our innovative portfolio management and product development process. This system provides significant benefits throughout the product development and manufacturing process.

        We also have strong external development relationships that complement our internal research and development capabilities. We manage our research and development activities in collaboration with leading scientists and institutes around the world and we have an active portfolio of projects involving commercial technology suppliers. We believe this approach allows us to be at the forefront of scientific and technological developments relevant for pediatric nutrition. Research and development expense was $102.4 million, $95.4 million, and $92.5 million in the years ended December 31, 2013, 2012, and 2011, respectively.

7

Intellectual Property

Patents

        We own or license approximately 56 active U.S. patents and 370 active non-U.S. patents and have 88 pending U.S. patent applications and 775 pending non-U.S. patent applications as of December 31, 2013.

Trademarks

        We file and maintain our trademarks in those countries in which we have, or desire to have, a business presence. We hold an extensive portfolio of trademarks across our key geographies. We maintain more than 6,100 trademark registrations and applications in more than 100 countries worldwide.

Regulatory

        We are subject to the laws and regulations in each country in which we market our products. We have proven processes, systems and resources in place to manage the current regulatory requirements and to participate proactively in the shaping of future country, regional and global policy, guidance and regulations.

United States Food and Drug Administration

        One of the main regulatory bodies in the United States is the United States Food and Drug Administration (“U.S. FDA”). The U.S. FDA’s Center for Food Safety and Applied Nutrition is responsible for the regulation of food, including infant formula. The Office of Nutrition, Labeling, and Dietary Supplements (“ONLDS”) has program responsibility for, among other matters, infant formula while the Office of Food Additive Safety (“OFAS”) has program responsibility for food ingredients and packaging. ONLDS evaluates whether the infant formula manufacturer has met the requirements under the Federal Food, Drug and Cosmetic Act (“FFDCA”) and consults with OFAS regarding the safety of ingredients in infant formula and of packaging materials for infant formula.

        All manufacturers of pediatric nutrition products must begin with safe food ingredients, which are either generally recognized as safe or approved as food additives. The specific requirements for infant formula are governed by the Infant Formula Act of 1980, as amended (“Formula Act”). The purpose of the Formula Act is to ensure the safety and nutrition of infant formulas, including minimum and, in some cases, maximum levels of specified nutrients.

        Once an infant formula product is formulated, the manufacturer must provide regulatory agencies assurance of the nutritional quality of that particular formulation before marketing the infant formula. The U.S. FDA has established requirements for certain labeling, nutrient content, manufacturer quality control procedures (to assure the nutrient content of infant formulas), as well as company records and reports. A manufacturer must notify the U.S. FDA 90 days before market introduction of any infant formula that differs fundamentally in processing or in composition from any current or previous formulation produced by the manufacturer.

        In addition, as part of its responsibility to implement the provisions of the Formula Act, the U.S. FDA continuously monitors infant formula products. The Formula Act requires infant formula manufacturers to test product composition during production and shelf-life, to keep records on production, testing and distribution of each batch of infant formula and to use good manufacturing practices and quality control procedures. In addition, the Formula Act requires infant formula manufacturers to maintain records of all complaints, some of which are reviewed to evaluate the possible existence of a hazard to health. The U.S. FDA conducts yearly inspections of all facilities that manufacture infant formula.

Outside of the United States

Country-specific regulations and laws have provisions that include requirements for compositional criteria, quality criteria and labeling, as well as other specific standards with which manufacturers must comply, including requirements for placing new formulas on the market.  Most country regulatory provisions are comparable to or will refer to the general conditions defined by Codex Alimentarius (“Codex”) standards, described below, or will refer to globally recognized regulatory authorities (e.g. the European Commission and the U.S. FDA) and the scientific opinions issued by expert authorities (e.g. the European Food Safety Authority).

8

Global Policy and Guidance

WHO

        The World Health Organization (“WHO”) is the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters, shaping the health research agenda, articulating policy recommendations, providing technical support to countries and monitoring and assessing health trends.

        In 1981, many Member States of the WHO’s World Health Assembly voted to adopt theWHO Code. The WHO Code aims to protect and promote breastfeeding and to ensure the proper use of breast-milk substitutes, when they are necessary, on the basis of adequate information and through appropriate marketing and distribution. Countries have taken variable action to enact legislation based on the recommendations of the WHO Code. In 1983, we believe we were the first U.S. infant formula manufacturer to develop internal marketing guidelines for developing countries based on the WHO Code. While the WHO Code is not international law, it is our policy to comply with all applicable laws and regulations and take guidance from the WHO Code in developing countries.

Codex

The Codex, or the food code, has become the global reference point for consumers, food producers and processors, national food control agencies and the international food trade. The Codex system, established in 1963 by the United Nations Food and Agriculture Organization and the WHO, presents a unique opportunity for all countries to join the international community in formulating and harmonizing food standards and fostering their global implementation. It also allows them a role in the development of codes governing hygienic processing practices and recommendations relating to compliance with those standards. The Codex regulatory provisions have been established for formulas and foods for infants and young children. It is usual practice for countries in Latin America, Africa and Asia to incorporate Codex standards either directly or with minor modifications into national law. It is our policy to comply with all national laws and with Codex standards where national regulatory requirements have not yet been enacted.

International Association of Infant Food Manufacturers

The International Association of Infant Food Manufacturers (“IFM”) is an international association of some of the leading global and regional infant food manufacturers. We are a member of the IFM and, in 2013, signed the IFM Rules of Responsible Conduct (the “IFM Rules”). The IFM Rules are a set of voluntary commitments detailing how IFM member companies will conduct themselves in most markets around the world with regard to topics such as safety, marketing, interactions with health care professionals and disaster aid. The IFM Rules were drafted by IFM members in order to clarify and bring specificity to the aims and principles of the WHO Code. We are committed to respecting and adhering to all local laws and regulations related to topics addressed in the IFM Rules.

Environmental, Health and Safety

        Our facilities and operations are subject to various environmental, health and safety ("EHS") laws and regulations in each of the jurisdictions in which we operate. We have programs that are designed to ensure that our operations and facilities meet or exceed standards established by applicable EHS rules and regulations globally. Each of our manufacturing facilities undergoes periodic internal audits relating to EHS requirements and we incur operating and capital costs to improve our facilities or maintain compliance with applicable requirements on an ongoing basis.

Insurance

        Our business involves an inherent risk of product liability and any claims of this type could have an adverse impact on us. We will take what we believe are appropriate precautions to provide adequate coverage for possible product liability claims. Though our insurance coverage and cash flows have been adequate to provide for liability claims in the past, product liability claims could exceed our insurance coverage limits and cash flows, and insurance may not be available on commercially reasonable terms or at all. We evaluate our insurance requirements on an ongoing basis to ensure we maintain adequate levels of coverage.

9

Employees

        As of December 31, 2013, we employed approximately 7,200 people worldwide. Our manufacturing workforces in Zeeland, Michigan; Evansville, Indiana; Guangzhou, China; and Chonburi, Thailand are not unionized. The manufacturing workforces in Delicias, Mexico, and São Paulo, Brazil, are unionized and covered by collective bargaining agreements that are negotiated annually. The manufacturing workforce and non-supervised sales force in Makati, Philippines, are unionized and covered by a three-year collective bargaining agreement, which was renewed effective January 2014. In addition, European Works Councils represent the manufacturing workforce in Nijmegen, the Netherlands, and the commercial organizations in France and Spain.

Available Information

        Our internet website address is www.meadjohnson.com. On our website, we make available, free of charge, our annual, quarterly and current reports, including amendments to such reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the United States Securities and Exchange Commission (the “SEC”). Stockholders and other interested parties may request email notification of the posting of these documents through the section of our website captioned “Investors.”

        The information on our website is not, and shall not be deemed to be, a part of this Annual Report on Form 10-K or incorporated into any other filings we make with the SEC.

Item 1A.    RISK FACTORS.

In addition to the other information in this Annual Report on Form 10-K, any of the factors described below could significantly and negatively affect our business, prospects, financial condition or operating results, which could cause the trading price of our securities to decline.

Risks Relating to Our Business

Our success depends on sustaining the strength of our brands, particularly our Enfa family of brands.

The Enfa family of brands accounts for a significant portion of our net sales. The willingness of consumers to purchase our products depends upon our ability to offer attractive brand value propositions. This in turn depends in part on consumers attributing a higher value to our products than to alternatives. If the difference in the value attributed to our products as compared to those of our competitors narrows, or if there is a perception of such a narrowing, consumers may choose not to buy our products. If we fail to promote and maintain the brand equity of our products across our markets, then consumer perception of our products’ nutritional quality may be diminished and our business could be materially adversely affected. Our ability to maintain or improve our value propositions will impact whether these circumstances will result in decreased market share and profitability.

We may experience liabilities or negative effects on our reputation as a result of real or perceived quality issues, including product recalls, injuries or other claims.

        Whether real or perceived, contamination, spoilage or other adulteration, product mislabeling or product tampering could result in our recall of products. From time to time we have experienced recalls of our products. While such recalls have not been material to our business on a global level in the past, we cannot assure you that such material product recalls will not occur in the future. We may also be subject to liability if our products or operations violate or are alleged to violate applicable laws or regulations or in the event our products cause, or are alleged to cause, injury, illness or death.

        Powder milk products are not sterile. Because the possibility of environmental contamination exists, we conduct numerous quality checks during production to confirm that our products are free of contaminants when they leave our facilities. Furthermore, a substantial portion of our products must be prepared and maintained according to label instruction to retain their flavor and nutritional value and avoid contamination or deterioration. Depending on the specific type of product, a risk of contamination or deterioration may exist at each stage of the production cycle, including the purchase and delivery of raw food materials, the processing and packaging of food products and upon use and handling by health care professionals, hospital personnel and consumers. In the event that certain of our products are found, or are alleged, to have suffered contamination or deterioration, whether or not such products were under our control, our brand reputation and business could be materially adversely affected.

        Whether real or perceived, reports or allegations of inadequate product quality control with respect to our products or those of other manufacturers of pediatric nutrition products could adversely impact our sales. Such reports or allegations could contribute to a perceived safety risk for our products or for pediatric nutrition products generally and adversely impact our sales or otherwise disrupt our business.

10

Moreover, the risk of reputational harm may be magnified and/or distorted through the rapid dissemination of information over the Internet, including through news articles, blogs, chat rooms and social media sites. For example, unfounded media reports in late 2011 alleging cronobacter contamination of one of our products in the United States resulted in several retailers temporarily removing such product from their store shelves. Such actions, whether or not justified, could have a material adverse effect on our reputation, brand image and results of operations. Moreover, federal, state and local governments and municipalities could propose or pass legislation banning the use of such products. Events such as these may create a perception of contamination risk among consumers with respect to all products in our industry.

        In addition, we advertise our products and could be the target of claims relating to false or deceptive advertising under foreign laws and U.S. federal and state laws, including the consumer protection statutes of some states. A significant product liability or other legal claim or judgment against us or a widespread product recall may negatively impact our profitability. Even if a product liability or consumer fraud claim is unsuccessful or is not merited or fully pursued, the negative publicity surrounding such assertions regarding our products or processes could materially adversely affect our reputation and brand image and therefore our business.

We are subject to numerous governmental regulations, and it can be costly to comply with these regulations. Changes in governmental regulations could harm our business.

        As a producer of pediatric nutrition products, our activities are subject to extensive regulation by governmental authorities and international organizations, including rules and regulations with respect to product manufacturing, the environment, employee health and safety, hygiene, quality control, advertising and tax laws. It can be costly to comply with these regulations and to develop compliant product processes. In particular, if government regulations (e.g. China’s new food safety law and related regulations) impact how and where we are able to manufacture or source product, we may face unfavorable cost pressure and a significant change in our geographic earnings mix. Because we operate in markets with significant variances in effective tax rates, such change in geographic earnings mix could have a material adverse effect on our global tax liability. Further, our activities may be subject to barriers or sanctions imposed by countries or international organizations limiting international trade. For example, in 2013, the Hong Kong government imposed a regulation designed to limit the flow of products out of the territory. Regulations may also dictate the specific content of our products and limit information and advertising about the benefitsof products that we market. Public policy changes or decisions that restrict the marketing, promotion and availability of our products, continued access to health care professionals, the ability to include genetically modified organisms in our products, as well as the manufacture and labeling of our products, could materially adversely affect our business. For example, regulations in the Philippines require governmental review of all advertisements for products intended for children under the age of two. In addition, certain advocates, along with governmental agencies and non-governmental organizations, have lobbied against the marketing and sale of some pediatric nutrition products. These efforts could result in increased governmental restrictions on our activities in the future. Our activities could be materially adversely affected by any significant changes in such policies or their enforcement. Our ability to anticipate and comply with changing global standards requires significant investment in monitoring the global external environment and we may be unable to comply with changes in policies restricting our ability to continue to operate our business or manufacture, market or sell our products.

Commodity price increases will increase our operating costs and may reduce our profitability.

        Our business is particularly vulnerable to commodity price increases. Commodity prices impact our business directly through the cost of raw materials used to make our products (such as skim milk powder, whole milk powder, lactose and whey protein concentrate), the cost of inputs used to manufacture and ship our products (such as crude oil and energy) and the amount we pay to produce or purchase packaging for our products (such as cans, pouches, cardboard and plastic). Commodities such as these are susceptible to price volatility caused by conditions outside of our control, including fluctuations in commodities markets, currency fluctuations, availability of supply, weather, consumer demand and changes in governmental agricultural programs. Dairy costs are the largest component of our cost of goods sold. We recently saw a significant rise in dairy prices which we expect to impact our gross margin in the short term. In general, increases in the price of dairy and other raw materials negatively impact our gross margins if we are unable to offset such increases by raising our selling price, changes in product mix or cost reduction/productivity enhancement efforts. The prices of these materials may continue to rise due to a general increase in commodities prices, especially for agricultural products. This would in turn affect the unit costs of products sold for our pediatric nutrition products. Although wemonitor our exposure to commodity prices as an integral part of our overall risk management program and, from time to time, attempt to mitigate some of this risk with commodity hedging activities, continued volatility in the prices of commodities we purchase could increase the costs of our products and we may experience lower profitability and be unable to maintain historical levels of productivity. Furthermore, increases in our selling prices imposed to offset increases in commodity prices could result in lower sales volume; as such, we may be unable to offset increased commodity costs with price increases if such price increases were to weaken demand for our product.

         We employ various purchasing and pricing contract techniques in an effort to minimize commodity price volatility. Generally, these techniques include incorporating clauses setting forth unit pricing that is based on an average commodity price over a corresponding period of time. If we fail to manage our commodity price exposure adequately, our business may be materially adversely affected.

11

Our profitability may suffer as a result of competition in our markets.

        The pediatric nutrition industry is intensely competitive. Our primary competitors, including Abbott Laboratories, Danone and Nestlé S.A., have substantial financial, marketing and other resources. We compete against large global companies, as well as regional and local companies, in each of the regions in which we operate. In most product categories, we compete not only with other widely advertised branded products, but also with private label, store brand and economy brand products that are generally sold at lower prices. Competition in our product categories is based on the following factors:

•    brand recognition and loyalty;

•    product quality;

•    effectiveness of marketing, promotional activity and the ability to identify and satisfy consumer preferences;

•    product innovation;

•    price; and

•    distribution and availability of products.

        From time to time, in order to protect our existing market share or capture increased market share, we may need to improve our brand recognition and product value proposition, and increase our spending on marketing, advertising and new product innovation. The success of marketing, advertising and new product innovation is subject to risks, including uncertainties about trade and consumer acceptance. We may also need to reduce prices for some of our products in order to respond to competitive and customer pressures and to maintain our market share. Market share losses could also lead to higher than necessary inventory levels held by our customers. Competitive and customer pressures, as well as price controls, may restrict our ability to increase prices, including in response to commodity and other cost increases. Our business will suffer if profit margins decrease, either as a result of a reduction in prices or an increase in costs with an inability to increase prices proportionally.

Economic downturns could cause consumers to shift their purchases from our higher-priced premium products to lower-priced products, which could materially adversely affect our business.

        The willingness of consumers to purchase premium brand pediatric nutrition products depends in part on local economic conditions. In periods of economic uncertainty, consumers may shift their purchases from our higher-priced premium products to lower-priced products or delay having children.

Volatility in the financial markets could adversely affect our liquidity, cash flow and financial flexibility, as well as the demand for our products.

        Volatility in the financial markets could adversely affect economic activity and credit markets in the United States and other regions of the world in which we do business. This could have an adverse impact on our customers, distributors, suppliers, counterparties to certain financial instruments, financial service providers and other service providers.

Our operations face significant foreign currency exchange exposure that could materially negatively impact our operating results.

We hold assets, incur liabilities, earn revenue and pay expenses in a variety of currencies other than the U.S. dollar, primarily the Chinese renminbi, the Hong Kong dollar,  the euro, the Philippine peso, the Malaysian ringitt and the Mexican peso.  Because our financial statements are presented in U.S. dollars, we must translate our assets, liabilities, sales and expenses into U.S. dollars at the then-applicable exchange rates.  Consequently, changes in the value of the U.S. dollar versus these non-U.S. currencies may negatively affect the value of these items in our financial statements, even if their value has not changed in their original currency.  Currency rates in smaller markets, such as Venezuela and Argentina, could also impact our results due to high volatility in exchange rates in such markets.  While we attempt to mitigate some of this risk with hedging and other activities, our business will nevertheless remain subject to substantial foreign exchange risk from foreign currency translation exposure. 

High volatility in exchange rates may also require us to apply inflationary accounting.  For example, we apply highly inflationary accounting to our business in Venezuela, the impact of which on our consolidated financial statements is dependent upon movements in the official exchange rate, including devaluations, between the Bolivares Fuertes and the U.S. dollar. The operating environment in Venezuela could include high inflation, governmental restrictions in the form of currency exchange, price and margin controls, and the possibility of further government actions such as further devaluations or other business intervention.  In addition, the foreign exchange controls in Venezuela limit our ability to repatriate earnings and our Venezuela subsidiary’s ability to remit dividends and pay intercompany balances at

12

any official exchange rate or at all.  For additional information, see “Item 7A. Quantitative and Qualitative Disclosures About Market Risk - Venezuela Risk”. 

Foreign governments may also restrict our ability to exchange local currencies for more marketable currencies and may limit our ability to pay dividends, to pay non-local currency accounts payable or to obtain currencies (other than the local currency) which may be more desirable to hold.  Foreign governments may also simultaneously restrict our ability to increase prices in inflationary environments where local currencies are under significant pressure.  Without the ability to increase prices to offset the impact of local currency devaluation, our ability to manage foreign exchange risk may be further limited.

The global nature of our business subjects us to additional business risks that could cause our sales and profitability to decline.

        We operate our business and market our products internationally in more than 50 countries. For the years ended December 31, 2013, 2012, and 2011, 77%, 75%, and 72%, respectively, of our net sales were generated in countries outside of the United States. The risks associated with our operations outside of the United States include:

• multiple regulatory requirements that are subject to change and that could restrict our ability to manufacture, market or sell our products;

• inflation, recession, fluctuations in foreign currency exchange and interest rates and discriminatory fiscal policies;

• adverse tax consequences from the repatriation of earnings;

• trade protection measures, including increased duties and taxes, and import or export licensing requirements;

• price controls;

• government health promotional programs intended to discourage the use of our products;

• differing local product preferences and product requirements;

• difficulty in establishing, staffing and managing operations;

• differing labor regulations;

• potentially negative consequences from changes in or interpretations of tax laws;

• political and economic instability;

• enforcement of remedies in various jurisdictions;

• changes in foreign medical reimbursement policies and programs; and

• diminished protection of intellectual property.

        These and other risks could have a material adverse effect on our business.

Our global operations are subject to political and economic risks of developing countries, and special risks associated with doing business in corrupt environments.

        We operate our business and market our products internationally in more than 50 countries, and we are focusing on increasing our sales and operations in regions, including Asia, Latin America, the Indian subcontinent and eastern Europe, which are less developed, have less stability in legal systems and financial markets, and are potentially more corrupt business environments than the United States, and therefore present greater political, economic and operational risks. We have in place policies, procedures and certain ongoing training of employees with regard to business ethics and many key legal requirements, such as applicable anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (“FCPA”), which make it illegal for us to give anything of value to foreign officials in order to obtain or retain any business or other advantages; however, there can be no assurance that our employees will adhere to our standards of business conduct and ethics or any other of our policies, applicable anti-corruption laws, including the FCPA, or other legal requirements. If we fail to enforce our policies and procedures properly,detect violations in a timely manneror maintain adequate record-keeping and internal accounting practices to accurately record our transactions, we may be subject to regulatory sanctions. If we believe or have reason to believe that our employees have or may have violated applicable anti-corruption laws, including the FCPA, or other laws or regulations, we investigate or have outside counsel

13

investigate the relevant facts and circumstances. If violations are found or suspected, we could face civil and criminal penalties, and significant costs for investigations, litigation, fees, settlements and judgments, which in turn could have a material adverse effect on our business.See Item 3. Legal Proceedings for further information regarding the company’s ongoing investigation. In addition, some of our competitors may not be subject to the FCPA or other anti-corruption laws.

Our China operations subject us to risks that could negatively affect our business.

        A significant portion of our revenue and profit is derived from sales in China. Consequently, our overall financial results are dependent on this market, and our business is exposed to risks there.These risks include changes in economic conditions (including wage and commodity inflation, consumer spending and unemployment levels), tax rates, laws and consumer preferences, changes in the regulatory environment and increased competition, and potential non-compliance with local laws and regulations. In 2013, China's National Development and Reform Commission ("NDRC") assessed a $33.4 million administrative penalty against us in connection with their antitrust review of the infant formula industry's resale pricing practices. In addition, the translation into U.S. dollars of our operating results and asset value in China is affected by fluctuations in currency exchange rates, which may adversely affect reported earnings. There can be no assurance as to the future effect of any such changes on our results of operations, financial condition or cash flows.

        Furthermore, any significant or prolonged deterioration in China’s relations with the U.S. and other countries could adversely affect our China business. Certain risks and uncertainties of doing business in China are solely within the control of the Chinese government, and Chinese law regulates the scope of our foreign investments and business conducted within China. There are also uncertainties regarding the interpretation and application of laws and regulations and the enforceability of intellectual property and contract rights in China. If we were unable to enforce our intellectual property or contract rights in China, our business could be materially adversely impacted.

Sales of our products are subject to changing consumer preferences, and our success depends upon our ability to predict, identify and interpret changes in consumer preferences and to develop, offer and communicate the benefits of new products rapidly enough to meet those changes.

        Our success depends on our ability to define the benefits of our products and to effectively communicate these benefits in the current regulatory environment. Our success also depends on our ability to predict, identify and interpret the tastes, dietary habits and nutritional needs of consumers and to offer products that appeal to those preferences. If we do not succeed in offering products that consumers want to buy, our sales and market share will decrease, resulting in reduced profitability. If we are unable to predict accurately which shifts in consumer preferences will be long lasting, or to introduce new and improved products to satisfy those preferences, our sales will decline. In addition, given the variety of cultures and backgrounds of consumers in our global consumer base, we must offer a sufficient array of products to satisfy the broad spectrum of consumer preferences. As such, we must be successful in developing innovative products across our product categories.

The consolidation of our retail customers and their reduction of inventory levels may put pressures on our profitability.

        Our retail customers, such as mass merchandisers, club stores, grocery stores, drug stores and convenience stores, have consolidated in recent years. This consolidation has produced large, sophisticated customers with increased buying power, which are more capable of operating with reduced inventories, resisting price increases and demanding lower pricing, increased promotional programs and specifically tailored products. In addition to reducing their inventory levels, these customers may use shelf space currently used for our products for their private label or store brand products. Meeting demands from these customers may adversely affect our margins and, if we fail to effectively respond to these demands, our sales could decline, each of which could materially adversely affect our profitability.

We rely on third parties to provide us with materials and services in connection with the manufacturing and distribution of our products.

        Unaffiliated third-party suppliers provide us with materials necessary for commercial production of our products, including certain key raw materials and primary packaging materials (such as cans). In particular, Royal DSM N.V. (“DSM”) (which acquired Martek Biosciences Corporation) provides us with most of the supply of DHA and ARA that we use in our products. We may be unable to manufacture our products in a timely manner, or at all, if any of our third-party suppliers, including DSM, should cease or interrupt production or otherwise fail to supply us or if the supply agreements are suspended, terminated or otherwise expire without renewal. If these suppliers are not able to supply us with the quantities of materials we need or if these suppliers are not able toprovide services in the required time period, this could have a material adverse effect on our business. We also utilize third parties in several countries throughout the world to distribute our products. If any of our third-party distributors fail to distribute our products in a timely manner, or at all, or if our distribution agreements are suspended, terminated or otherwise expire without renewal, our profitability could be materially adversely affected. In addition, quality concerns could result from contamination, spoilage or other adulteration of raw materials shipped to us by third-party suppliers and utilized in our products. An ensuing recall by either us or our supplier could have a material adverse effect on our business.

14

The manufacture of many of our products is a highly exacting and complex process, and if we or one of our suppliers should encounter problems manufacturing products, our business could suffer.

        The manufacture of many of our products is a highly exacting and complex process, in part due to strict regulatory requirements. Problems may arise during the manufacturing process for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials, maintenance of our manufacturing environment, natural disasters, various contagious diseases and process safety issues. If problems arise during the production of a batch of product, such batch may have to be discarded. This could, among other things, lead to increased costs, lost sales, damage to customer relations, time and expenses being spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. If problems are not discovered before the affected product is released to the market, recall and product liability costs as well as reputational damage may also be incurred. To the extent that we or one of our suppliers experience significant manufacturing problems, this could have a material adverse effect on our business.

We may experience difficulties and delays inherent in the manufacturing and selling of our products.

        We may experience difficulties and delays inherent in the manufacturing and selling of our products, such as: (1) seizure or recalls of products and raw materials or forced closings of manufacturing plants; (2) the failure to obtain, the imposition of limitations on the use of, or loss of, patent, trademark or other intellectual property rights; (3) our failure, or the failure of any of our vendors or suppliers, to comply with current good manufacturing practices and other applicable regulations and quality assurance guidelines that could lead to temporary manufacturing shutdowns, product shortages and delays in product manufacturing; (4) construction delays related to the construction of new facilities (such as our manufacturing and technology center in Singapore) or the expansion of existing facilities, including those intended to support future demand for our products; (5) other manufacturing or distribution problems, including changes in manufacturing production sites and limits to manufacturing capability due to regulatory requirements, changes in types of products produced or physical limitations that could impact continuous supply; (6) availability of raw materials; and (7) restrictions associated with the transportation of raw materials or goods in and out of foreign countries. In particular, if government regulations (e.g. China’s new food safety law and related regulations) impact how and where we are able to manufacture or source product, we may face unfavorable cost pressure and a significant change in our geographic earnings mix. Because we operate in markets with significant variances in effective tax rates, such change in geographic earnings mix could have a material adverse effect on our global tax liability.

If we fail to increase our production and manufacturing capacity, we will be unable to continue to grow and our ability to produce new products, expand within our existing markets and enter into new markets will be limited.

        Global growth and demand for our products has increased the utilization of our production and manufacturing facilities, including manufacturing capacity provided by third-party manufacturers and packaging capacity with respect to our products. If we are unable to successfully expand our production and manufacturing capacity, we will be unable to continue our growth and expand within our existing markets or enter into additional geographic markets or new product categories. In addition, failure to successfully expand our production and manufacturing capacity will limit our ability to introduce and distribute new products, including our existing pipeline of innovations and product improvements, or otherwise take advantage of opportunities in new and existing markets.

Further, increasing our production and manufacturing facilities requires significant investment and time to build. Delays in increasing capacity could also limit our ability to continue our growth and materially adversely affect our business. For example, we are currently in the process of completing the construction of our new manufacturing and technology center in Singapore; any potential delays could have an adverse impact on our business.

Disruption of our global supply chain could materially adversely affect our business.

        Our ability to manufacture, distribute and sell products is critical to our success. Damage or disruption to raw material supplies or our manufacturing or distribution capabilities due to weather, natural disaster, fire, terrorism, strikes, various contagious diseases, changes in government regulations or other reasons could impair our ability to manufacture or sell our products. Failure to take adequate steps to mitigate the likelihood or potential impact of such events, or to effectively manage such events if they occur, particularly when a product is sourced from a single location, could materially adversely affect our business.

Changes in WIC, or our participation in it, could materially adversely affect our business.

        Participation in WIC involves a competitive bidding process and is an important part of our U.S. business based on the volume of infant formula sold under the program. As of December 31, 2013, we held the contracts that supply approximately 39% of WIC births in the United States. As a result, our business strategy includes bidding for new WIC contracts and maintaining current WIC relationships. Our failure to win bids for new contracts pursuant to the WIC program or our inability to maintain current WIC relationships could have a material adverse effect on our business. In addition, any changes to how the WIC program is administered and any changes to the eligibility requirements and/or overall participation in the WIC program could also have a material adverse effect on our business.

15

Our business could be harmed by a failure of our information technology, administrative or outsourcing systems.

        We rely on our information technology, administrative and outsourcing systems to effectively manage our business data, communications, supply chain, order entry and fulfillment and other business processes. Difficulties or failure to implement our information technology initiatives by us or our service providers or the failure of our information technology, administrative or outsourcing systems to perform as we anticipate could disrupt our business and result in transaction errors, processing inefficiencies and the loss of sales and customers, causing our business to suffer. In addition, our information technology, administrative and outsourcing systems may be vulnerable to damage or interruption from circumstances beyond our control, including fire, natural disasters, systems failures, security breaches and viruses. Any such damage or interruption could have a material adverse effect on our business and prevent us from paying our suppliers or employees, invoicing and receiving payments from our customers or performing other information technology, administrative or outsourcing services on a timely basis.

Increased IT security threats and more sophisticated and targeted computer crime could pose a risk to our systems, networks, products, solutions and services.

        Increased global IT security threats and more sophisticated and targeted computer crime pose a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data. While we attempt to mitigate these risks by employing a number of measures, our systems, networks, products, solutions and services remain potentially vulnerable to advanced persistent threats. Depending on their nature and scope, such threats could potentially lead to the compromising of confidential information, improper use of our systems and networks, manipulation and destruction of data, defective products, production downtimes and operational disruptions, which in turn could materially adversely affect our reputation, competitiveness and results of operations.

We may face difficulties as we expand our operations into countries in which we have no prior operating experience or as we expand our operations into new product categories.

        We intend to continue to expand our global footprint in order to enter into new markets. This may involve expanding into countries other than those in which we currently operate. It may involve expanding into less developed countries, which may have less political, social or economic stability and less developed infrastructure and legal systems. We also intend to expand our product portfolio by adding new product categories. As we expand our business into new countries or product categories we may encounter regulatory, personnel, technological and other difficulties that increase our expenses or delay our ability to start up our operations or become profitable in such countries or product categories. This may affect our relationships with customers, suppliers and regulators and could have a material adverse effect on our business.

Resources devoted to research and development may not yield new products that achieve commercial success.

        Our ability to develop new pediatric nutrition products depends on, among other factors, our ability to understand the composition and variation of breast milk. Analyzing breast milk requires significant investment in research and development and testing of new ingredients and new production processes. We devote significant resources to investment in research and development in order to gain a deep understanding of the composite ingredients of breast milk, as well as the optimal nutritional requirements of infants and children. The research and development process is expensive, prolonged and entails considerable uncertainty. Development of a new product, from discovery through testing and registration to initial product launch, typically takes between five and seven years, but may require an even longer timeline. Each of these periods varies considerably from product to product and country to country. Because of the complexities and uncertainties associated with research and development, products that we are currently developing may not complete the development process or obtain the regulatory approvals required for us to market such products successfully. In addition, new regulations or changes to existing regulations may have a negative effect on innovations in our pipeline, especially late-stage pipeline products. The development of new products may take longer and cost more to develop and may be less successful than we currently anticipate as a result of:

• products that may appear promising in development but fail to reach market within the expected or optimal time frame, or fail to ever reach market, for any number of reasons, including efficacy and the difficulty or excessive cost to manufacture;

• failure to enter into or successfully implement optimal alliances where appropriate for the discovery and commercialization of products, or otherwise to maintain a consistent scope and variety of promising late-stage pipeline products;

• failure of one or more of our products to achieve or maintain commercial viability; or

• changing and increasing obstacles to achieving regulatory approval in key markets.

        We cannot assure you that any of our products currently in our development pipeline will be commercially successful.

16

We could incur substantial costs to comply with environmental, health and safety laws and regulations and to address violations of, or liabilities under, these requirements.

        Our facilities and operations are subject to various environmental, health and safety laws and regulations in each of the jurisdictions in which we operate. Among other things, these requirements regulate the emission or discharge of materials into the environment, the use, management, treatment, storage and disposal of solid and hazardous substances and wastes, the control of combustible dust, the reduction of noise emissions and fire and explosion risks, the cleanup of contamination and the prevention of workplace exposures and injuries. Pollution controls and various permits and programs are required for many of our operations. We could incur or be subject to, among other things, substantial costs (including civil or criminal fines or penalties or clean-up costs), third party damage claims, requirements to install additional pollution control or safety control equipment and/or permit revocations in the event of violations by us of environmental, health, and safety requirements applicable to our facilities and operations or our failure to obtain, develop or comply with required environmental permits or programs.

In addition, most of our facilities have a history of production operations in the food and drug industry, and some substances used in such production require proper controls in their storage and disposal. We were named as a “potentially responsible party,” or were involved in investigation and remediation, at three third party disposal sites (see “Item 3. Legal Proceedings”). We can be held responsible, in some cases without regard to knowledge, fault, or ownership at the time of the release, for the costs of investigating or remediating contamination of any real property we or our predecessors ever owned, operated, or used as a waste disposal site. In addition, we can be required to compensate public authorities or private owners for damages to natural resources or other real property, or to restore those properties, in the event of off-site migration of contamination. Changes in, or new interpretations of, existing laws, regulations or enforcement policies, could also cause us to incur additional or unexpected costs to achieve or maintain compliance. The assertion of claims relating to on- or off-site contamination, the discovery of previously unknown environmental liabilities or the imposition of unanticipated investigation or cleanup obligations, could result in potentially significant expenditures to address contamination or resolve claims or liabilities. Such costs and expenditures could have a material adverse effect on our business, financial condition or results of operations.

We may not be able to adequately protect our intellectual property rights.

        Given the importance of brand recognition to our business, we have invested considerable effort in seeking trademark protection for our brands, including the Enfa family of brands. However, we cannot be certain that the steps we have taken will be sufficient to protect our intellectual property rights in our brands adequately or that third parties will not infringe upon or misappropriate any such rights. We also cannot be certain that the steps we have taken to protect our brands will be sufficient to discourage or eliminate counterfeiting of our products. Our trademark registrations and applications can potentially be challenged and canceled or narrowed. Moreover, some of the countries in which we operate offer less protection for these rights, and may subject these rights to higher risks, than is the case in Europe or North America. In addition, it is costly to litigate in order to protect any of our intellectual property rights. If we are unable to prevent third parties from infringing or misappropriating these rights in our core products or brands, including our Enfa family of brands, our future financial condition and our ability to develop our business could be materially adversely affected.

        Other companies have from time to time taken, and may in the future take, actions that we believe violate our intellectual property rights and we may decide to enforce (and in some cases are currently enforcing) those rights against such actions. Uncertainties inherent in such litigation make the outcome and associated costs difficult to predict. If unsuccessful, the legal actions could result in the invalidation of some of our intellectual property rights, which could materially adversely affect our business.

        We rely on a combination of security measures, confidentiality policies, contractual arrangements and trade secret laws to protect our proprietary formulae and other valuable trade secrets. We also rely on patent, copyright and trademark laws to further protect our intellectual property rights. We cannot, however, be certain that the steps we take will prevent the development and marketing of similar, competing products and services by third parties. Our existing patents and any future patents that we obtain may not be sufficiently broad to protect us against third parties with similar products or to provide us with a competitive advantage. Moreover, our patents can potentially be challenged and narrowed or invalidated. Trade secrets are difficult to protect, and despite our efforts may become known to competitors or independently discovered. The confidentiality agreements we rely on with our employees, customers, contractors and others may be breached, and we may not have adequate remedies for such breach. Failure to adequately protect our valuable intellectual property from being infringed or misappropriated could materially adversely affect our business.

We may be required to defend ourselves against intellectual property claims from third parties, which could harm our business.

        Regardless of merit, there are third-party patents that may cover our products. Third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If a third party asserts that our products or services are infringing upon its intellectual property, these claims could cause us to incur significant expenses and, if successfully asserted against us, could require that we pay substantial damages and/or prevent us from selling our products. Even if we were to prevail against such claims, any litigation regarding intellectual property could be costly and time-consuming and could divert the attention of our management and key personnel from our

17

business operations. Furthermore, as a result of an intellectual property challenge, we may find it necessary to enter into royalty licenses or other costly agreements, and we may not be able to obtain such agreements at all or on terms acceptable to us.

Our sales and marketing practices may be challenged by consumers and competitors, which could harm our business.

        We participate in a variety of marketing activities, including print and television advertising, direct mail, online/internet and promotional programs. We work with external agencies to create strong marketing campaigns for consumers, health care professionals and retail sales organizations. Although our marketing is evidence-based and emphasizes our superior nutritional science, consumers and competitors may challenge, and have challenged, certain of our practices by claiming, among other things, false and misleading advertising with respect to advertising for certain of our products. Such challenges could result in our having to pay monetary damages or limit our ability to maintain current sales and marketing practices.

Increases in costs of current and post-retirement benefits may reduce our profitability.

        Our profitability may be affected by increases in costs of current and post-retirement medical and other employee benefits, particularly within the United States. These costs can vary substantially as a result of changes in both health care costs and health care regulation, volatility in investment returns on pension plan assets and changes in discount rates used to calculate related liabilities. These factors may put upward pressure on the cost of providing medical and other benefits. We can provide no assurance that we will succeed in limiting future cost increases, and upward pressure would reduce our profitability.

Labor disputes may cause work stoppages, strikes and disruptions.

        Our manufacturing workforces in Zeeland, Michigan; Evansville, Indiana; Guangzhou, China; and Chonburi, Thailand are not unionized. The manufacturing workforces in Delicias, Mexico, and São Paulo, Brazil, are unionized and covered by collective bargaining agreements that are negotiated annually. The manufacturing workforce and non-supervised sales force in Makati, Philippines, are unionized and covered by a three-year collective bargaining agreement, which was renewed effective January 2014. In addition, European Works Councils represent the manufacturing workforce in Nijmegen, the Netherlands, and the commercial organizations in France and Spain. Any labor disputes, including work stoppages, strikes and disruptions, could have a material adverse impact on our business.

Our success depends on attracting and retaining qualified people in a competitive environment.

        Our business strategy and future success depends, in part, on our ability to attract, hire and retain, in a competitive environment, highly-skilled and diverse leaders, managers and professionals who are critical to our business functions and growth strategy. The market for highly-skilled employees is competitive in the labor markets in which we operate. Our business could be materially adversely affected if we are unable to retain key employees or recruit qualified personnel in a timely fashion, or if we are required to incur unexpected increases in compensation costs to retain key employees or meet our hiring goals. If we are not able to attract and retain the personnel that we require, or we are not able to do so on a cost-effective basis, it could be more difficult for us to sell and develop our products and services and execute our business strategy.

We derive a significant percentage of our sales from two customers. The loss of either of these customers could materially adversely affect our financial performance.

        Our products are sold principally to the wholesale and retail trade, both nationally and internationally, and sales to two customers, DKSH International Ltd. and Wal-Mart Stores, Inc. (including sales to Sam’s Club), accounted for approximately 16% and 10%, respectively, of our gross sales for the year ended December 31, 2013. If either of these customers ceases doing business with us or if we encounter any difficulties in our relationship with either of them, our business could be materially adversely affected.

An adverse change in demographic and economic trends as well as a change in scientific opinion regarding our products in any of our largest markets could materially adversely affect our business and reduce our profitability.

        Our growth plan relies on favorable demographic and economic trends in various markets, including: (1) rising incomes in emerging markets, (2) increasing number of working mothers and (3) increasing consumer global awareness of the importance of pediatric nutrition on wellness and health outcomes. If these demographic trends change in an adverse way, our business could be materially adversely affected. In addition, an adverse change in scientific opinion regarding our products, such as the health benefits of DHA, or a continued decline in birth rates could materially adversely affect our business.

We have substantial debt, which could materially adversely affect our business and our ability to meet our obligations.

        We had total indebtedness of $1.5 billion as of December 31, 2013. See “Item 8. Financial Statements – Note 15. Debt” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources.”

18

        This amount of debt could have important consequences to us and our investors, including:

• requiring a substantial portion of our cash flow from operations to make payments on this debt;

• requiring us to repay the full amount of our debt upon a change of control triggering event;

• making it more difficult to satisfy other obligations;

• increasing the risk of future credit rating downgrades of our debt, which could increase future debt costs;

• increasing our vulnerability to general adverse economic and industry conditions;

• reducing the cash flow available to fund capital expenditures and other corporate purposes and to grow our business;

• limiting our flexibility in planning for, or reacting to, changes in our business and industry;

• placing us at a competitive disadvantage to our competitors that may not be as leveraged as we are;

• limiting our ability to borrow additional funds as needed or take advantage of business opportunities as they arise; and

• limiting our ability to pay cash dividends or repurchase common stock. 

To the extent we become more leveraged, the risks described above could increase. In addition, our actual cash requirements in the future may be greater than expected. Our cash flow from operations may not be sufficient to repay at maturity all of the outstanding debt as it becomes due and we could incur substantial cost if we need to repatriate earnings to the United States in order to repay such debt. Further, we may not be able to borrow money, sell assets or otherwise raise funds on acceptable terms, or at all, to refinance our debt. Specifically, $500M of our long term debt comes due November 2014; if we are unable to refinance this debt on favorable terms, or at all, our results of operations may be materially affected. Further, if the terms of the debt cause our existing hedge to be ineffective, all or a portion of the hedge instrument would need to be recognized immediately, which may also have a material impact.

        In order to achieve a desired proportion of variable versus fixed rate debt, we have in the past entered into and exited interest rate swap agreements. Developing an effective strategy for dealing with risks from movements in interest rates is complex, and no strategy can completely insulate us from risks associated with such fluctuations. In addition, we are exposed to counter-party credit risk for nonperformance and, in the event of nonperformance, to market risk for changes in interest rates. Finally, our interest rate risk management activities could expose us to substantial losses if interest rates move materially differently from our expectations. As a result, our economic hedging activities may not effectively manage our interest rate sensitivity or have the desired beneficial impact on our financial condition or results of operations. Further discussion of our hedging of interest rate risk is included in “Item 7A. Quantitative and Qualitative Disclosures About Market Risk.”

We could evaluate acquisitions, joint ventures and other strategic initiatives, any of which could distract our management or otherwise have a negative effect on our sales, costs and stock price.

Our future success may depend on opportunities to buy or obtain rights to other businesses or technologies that could complement, enhance or expand our current business or products or that might otherwise offer us growth opportunities. We could evaluate potential mergers, acquisitions, joint ventures, strategic initiatives, alliances, vertical integration opportunities and divestitures. If we attempt to engage in these transactions, we expose ourselves to various inherent risks, including:

• accurately assessing the value, future growth potential, strengths, weaknesses, contingent and other liabilities and potential profitability of acquisition candidates;

• the potential loss of key personnel of an acquired or combined business;

• our ability to achieve projected economic and operating synergies;

• difficulties successfully integrating, operating, maintaining and managing newly-acquired operations or employees;

• difficulties maintaining uniform standards, controls, procedures and policies;

• unanticipated changes in business and economic conditions affecting an acquired business;

19

• the potential discovery of latent unethical business practices;

• the possibility we could incur impairment charges if an acquired business performs below expectations; and

• the diversion of our management’s attention from our existing business to integrate the operations and personnel of the acquired or combined business or implement the strategic initiative.

If any of the foregoing risks materializes, our results of operations and the results of the proposed transactions would likely differ from ours, and market expectations, and our stock price could, accordingly, decline. In addition, we may not be able to complete desirable transactions for various reasons.

We depend on cash flows generated by our subsidiaries, and a failure to receive distributions from our subsidiaries may result in our inability to meet our financial obligations, or to pay dividends.

        We are a holding company with no material assets other than the equity interests of our subsidiaries and certain intellectual property. Our subsidiaries conduct substantially all of our operations and own substantially all of our assets and intellectual property. Consequently, our cash flow and our ability to meet our obligations and pay dividends to our stockholders depends upon the cash flow of our subsidiaries and the payment of funds by our subsidiaries to us in the form of dividends, tax sharing payments or otherwise. There are a number of other factors that could affect our ability to pay dividends, including the following:

• lack of availability of cash to pay dividends due to changes in our operating cash flow, capital expenditure requirements, working capital requirements and other cash needs;

• unexpected or increased operating or other expenses or changes in the timing thereof;

• restrictions under Delaware law or other applicable law on the amount of dividends that we may pay;

• a decision by our board of directors to modify or revoke its policy to pay dividends; and

• the other risks described in this “Risk Factors” section.

        Each of our subsidiaries is a distinct legal entity and its ability to make any payments will depend on its earnings, the terms of its indebtedness and legal restrictions. Under certain circumstances, legal restrictions may limit or delay our ability to obtain cash from our subsidiaries and our subsidiaries may not be able to, or be permitted to, make distributions to us in the future. In the event that we do not receive distributions from our subsidiaries, we may be unable to meet our financial obligations.

Risks Related to Our Relationship with Our Former Parent

If our split-off from Bristol-Myers Squibb Company (“BMS”) fails to qualify for non-recognition of gain and loss, we may in certain circumstances be required to indemnify BMS for any resulting taxes and related expenses, and we believe that the payment if required could have a material adverse effect on our financial condition and results of operations.

In connection with our split-off from BMS on December 23, 2009, BMS and its counsel have relied on certain assumptions and representations as to factual matters from us, as well as certain covenants by us regarding the future conduct of our business and other matters, the incorrectness or violation of which could affect the qualification for non-recognition of gain and loss of our split-off from BMS. As a result, we agreed, generally, to indemnify BMS for taxes and certain related expenses resulting from the failure of our split-off from BMS to qualify for non-recognition of gain and loss to the extent attributable to (i) the failure of any of our representations to be true or the breach by us of any of our covenants, (ii) the application of Section 355(e) or Section 355(f) of the Internal Revenue Code to any acquisition of our stock or assets or any of our affiliates or (iii) certain other acts or omissions by us or our affiliates. To the extent we become obligated to make an indemnification payment to BMS, we believe that the payment could have a material adverse effect on our financial condition and results of operations.

20

Risks Related to Our Common Stock

Our failure to successfully execute our growth strategy could adversely affect our business and results of operations and cause our stock price to decline.

        Our continued success in part depends on our ability to successfully execute our growth strategy. We intend to grow our business profitably through several strategic initiatives, including geographic and category expansion and productivity savings. There can be no assurance that we will be successful in achieving our strategic plan. If we fail to fully implement any material part of our strategic initiatives, or if we achieve these initiatives and they fail to yield the expected benefits, there could be an adverse effect on our business and results of operations. Any such adverse effect on our business and results of operations could result in a decline in the price of our common stock.

Anti-takeover provisions in our charter documents could discourage, delay or prevent a change of control of our company and may result in an entrenchment of management and diminish the value of our common stock.

        Several provisions of our certificate of incorporation and by-laws could make it difficult for our stockholders to change the composition of our board of directors, preventing them from changing the composition of management. In addition, the same provisions may discourage, delay or prevent a merger or acquisition that our stockholders may consider favorable.

        These provisions include:

• authorizing our board of directors to issue “blank check” preferred shares without stockholder approval;

• prohibiting cumulative voting in the election of directors;

• prohibiting shareholder action by written consent;

• limiting the persons who may call special meetings of stockholders; and

• establishing advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings.

        Additionally, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder.

        These anti-takeover provisions could substantially impede the ability of our common stockholders to benefit from a change of control and, as a result, could materially adversely affect the market price of our common stock and our stockholders’ ability to realize any potential change-in-control premium.

Item 1B.    UNRESOLVED STAFF COMMENTS

  None.

Item 2.    PROPERTIES.

        Our corporate headquarters are located in Glenview, Illinois, where we lease office space. We maintain our global supply chain and R&D headquarters in Evansville, Indiana, where we own office, operations and laboratory buildings comprising approximately 1,200,000square feet. We also own or lease the manufacturing facilities identified in the table below. For additional information related to our manufacturing facilities around the world,see “Item 1. Business – Global Supply Chain.” We lease the vast majority of our office facilities worldwide. 

21

        The following table illustrates our global manufacturing locations, the approximate square footage of the facilities, the reportable segment served by such locations and whether the facility is owned or leased:

Location	Square Feet	Segment(s) Served	Owned / Leased
Zeeland, Michigan, United States(1)	691,043	All segments	Owned
Evansville, Indiana, United States(1)(2)	301,389	All segments	Owned
Nijmegen, The Netherlands(1)	109,792	All segments	Owned
Delicias, Chihuahua, Mexico(1)	134,549	North America / Europe Latin America	Owned
Chonburi, Thailand(1)	158,456	Asia	Owned
Guangzhou, China(1)	149,944	Asia	Owned(4)
Makati, Philippines(1)	85,487	Asia	Owned(4)
Sao Bernardo do Campo, Brazil(1)	64,583	Latin America	Leased
Singapore (3)	466,077	Asia	Owned(4)

(1)    Powder manufacturing facility.

(2)    Liquid manufacturing facility.

(3) Our new manufacturing and technology center in Singapore is currently under construction and is expected to be operational in the second half of 2014.

(4) The land on which this facility is built is subject to a long term lease.

Item 3.    LEGAL PROCEEDINGS.

 In the ordinary course of business, we are subject to lawsuits, investigations, government inquiries and claims, including, but not limited to, product liability claims, advertising disputes and inquiries, consumer fraud suits, other commercial disputes, premises claims and employment and environmental, health and safety matters.

       From time to time, we may be responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating substances at our current or former sites, and/or at waste disposal or reprocessing facilities operated by third parties. Liability under CERCLA and analogous state or foreign laws may be imposed without regard to knowledge, fault, or ownership at the time of the disposal or release. Most of our facilities have a history of production operations in the food and drug industry, and some substances used in such production require proper controls in their storage and disposal. We were named as a “potentially responsible party”, or were involved in investigation and remediation, at three third-party disposal sites. As of December 31, 2013, two of these matters have been settled in their entirety. With regard to the third such matter, the substance of this matter has been resolved, and management believes that any actual or expected remediation cost related to such matter, individually or in the aggregate, would be immaterial.

We were served with a lawsuit filed on October 16, 2012 in St. Clair County (Illinois) Circuit Court under the caption Shelby Schrack, et al. v. Mead Johnson Nutrition Company and Mead Johnson & Company, which lawsuit alleges that certain bacteria in powdered formula were responsible for the death of one infant and serious illness in two others and seeks unspecified monetary damages. These events were widely publicized in December 2011 and January 2012. The infants allegedly consumed formula from batches that were extensively tested by the Company, the Centers for Disease Control (“CDC”) and the U.S. FDA. These tests detected no bacteria in our infant formula. The CDC further noted that while these bacteria have sometimes been found in formula, they also exist in the environment and may potentially cause illness through person to person contact or through contamination of infant feedings at the point of use. We believe that the claims in this matter are without merit. Nevertheless, in November 2013, the Company and the plaintiffs agreed to settle the disputed claims asserted in this litigation, and on December 12, 2013, we obtained court approval of the proposed settlement and release of all such claims. The settlement did not materially affect our consolidated financial position, results of operations or cash flows.

We record accruals for contingencies when it is probable that a liability will be incurred and the loss can be reasonably estimated. Although we cannot predict with certainty the final resolution of lawsuits, investigations and claims asserted against us, we do not believe any currently pending legal proceeding to which we are a party will have a material effect on our business or financial

22

condition, although an unfavorable outcome in excess of amounts recognized as of December 31, 2013, with respect to one or more of these proceedings could have a material effect on our results of operations and cash flows for the periods in which a loss is recognized.

Following an SEC request for documents relating to certain business activities of the Company’s local subsidiary in China, the Company is continuing an internal investigation of such business activities. The Company’s investigation is focused on certain expenditures that were made in connection with the promotion of the Company’s products or may have otherwise been made. Certain of such expenditures were made in violation of Company policies and may have been made in violation of applicable U.S. and/or local laws, including the U.S. Foreign Corrupt Practices Act (the “FCPA”).  The investigation is being conducted by outside legal counsel and overseen by a committee of independent members of the Company’s board of directors. The status and results of the investigation are being discussed with the SEC and other governmental authorities.  At this time, the Company is unable to predict the scope, timing or outcome of this ongoing matter or any regulatory or legal actions that may be commenced related to this matter.  If a violation of the FCPA or other laws is determined to have occurred, the Company could become subject to monetary penalties as well as civil and criminal sanctions.

Item 4.    MINE SAFETY DISCLOSURES

        Not applicable.

23

PART II

Item 5. MARKET FOR REGISTRANT’S COMMON STOCK, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES.

Market Prices and Dividend Information

        Mead Johnson Nutrition Company common stock is traded on the New York Stock Exchange (“NYSE”) under the symbol “MJN.” The following table describes the per share range of high and low sales prices, as reported by the NYSE, for shares of our common stock and dividends declared per share of our common stock for the quarterly periods indicated.

	Market Price for MJN Common Stock				Dividends Declared Per Share
	High		Low
2012
First Quarter	$	83.95	$	70.38	$	0.30
Second Quarter	$	88.72	$	77.72	$	0.30
Third Quarter	$	82.30	$	68.09	$	0.30
Fourth Quarter	$	74.25	$	61.27	$	0.30
2013
First Quarter	$	81.04	$	65.38	$	0.34
Second Quarter	$	86.87	$	74.44	$	0.34
Third Quarter	$	80.98	$	66.80	$	0.34
Fourth Quarter	$	86.63	$	73.69	$	0.34

Holders of Common Stock

        The number of record holders of our common stock at December 31, 2013 was 1,357. Thenumber of record holders is based upon the actual number of holders registered on our books at such date and does not include holders of shares held in “street name” or persons, partnerships, associations, corporations or other entities identified in security position listings maintained by depository trust companies.

Issuer Purchases of Equity Securities

The following table includes information about our stock repurchases during the three-month period ended December 31, 2013:

(Dollars in millions, except per share amounts) Period	Total Number of Shares Purchased  (1)	Average Price Paid per Share (2)		Total Number of  Shares Purchased as Part of Publicly Announced Program	Approximate Dollar  Value of Shares  that May Yet Be Purchased Under  the Program (3)
October 1, 2013 through October 31, 2013	437	$	74.14	437	$	502.1
November 1, 2013 through November 30, 2013	35,000	84.04		35,000	499.1
December 1, 2013 through December 31, 2013	105,000	83.99		105,000	490.3
	140,437	$	83.97	140,437	$	490.3

(1) The total number of shares purchased does not include shares surrendered to the Company to pay the exercise price in connection with the exercise of employee stock options or shares surrendered to the Company to satisfy tax withholding obligations in connection with the exercise of employee stock options or the vesting of restricted stock units and performance share awards.

(2)  Average Price Paid per Share includes commissions.

(3) On March 17, 2010, we announced that our board of directors authorized the repurchase of up to $300.0 million of Company common stock (the “2010 Authorization”). The 2010 Authorization ends on May 1, 2015; however, during the three-month period ended December 31, 2013, we completed all purchases remaining under the 2010 Authorization. On September 11, 2013, we announced that our board of directors approved a new, additional share repurchase authorization of up to an additional $500.0 million of Company common stock (the “2013 Authorization”). The 2013 Authorization does not have an expiration date. As of December 31, 2013, we had $490.3 million remaining available under the 2013 Authorization.

24

Performance Graph

Comparison of Cumulative Total Return

The following graph compares the cumulative total return on our common stock for the periods indicated with the performance of the Standard & Poor's 500 (S&P 500) Stock Index, the S&P 500 Packaged Foods Index and the Mead Johnson custom performance peer group index described below. Starting with the year ended December 31, 2013, for comparative purposes, Mead Johnson is converting from a custom performance peer group index to the commonly used S&P 500 Packaged Foods Index. We have reviewed our post-IPO practices with regard to this graph and have concluded that the utilization of a published index, and, in particular, the S&P 500 Packaged Foods Index, is consistent with the practice of a majority of our peers.

The Mead Johnson custom performance peer group index consisted of the following corporations considered to be comparable companies in the food and beverage and consumer products industries on the basis of industry leadership and global focus: Campbell's Soup Company, Colgate-Palmolive Company, General Mills, Inc., H.J. Heinz Company, The Hershey Company, The J.M. Smucker Company, Kellogg Company, McCormick & Company, Incorporated and Sara Lee Corp. Sara Lee Corp is included through its last day of trading prior to June 29, 2012, when Sara Lee effected a 1-for-5 reverse stock split of Sara Lee common stock and changed its name to The Hillshire Brands Company. This occurred immediately after Sara Lee's separation of certain businesses and prior to the market open on June 29, 2012. The Hillshire Brands Company is not a comparable peer to Mead Johnson for this purpose and is not included in the Peer Group Index. Additionally, on June 7, 2013, H. J. Heinz Company was acquired by H.J. Heinz Holding Corporation, a Delaware corporation controlled by Berkshire Hathaway Inc. and 3G Special Situations Fund III, L.P. As a result of the merger, H.J. Heinz Company common stock is no longer publicly traded, and is included in this graph through its last day of trading prior to June 7, 2013.

The graph assumes $100 invested on February 11, 2009, the date shares of our common stock commenced trading, in each of Mead Johnson common stock, the S&P 500 Index, the S&P 500 Packaged Foods Index as well as our custom performance peer group index, and the reinvestment of all dividends for each of the reported time periods.

Comparison of Cumulative Total Return
Among Mead Johnson NutritionCompany, the S&P 500 Index,S&P 500 Packaged Foods Indexand a Peer Group

Assumes Initial Investment of $100

	2/11/2009	12/31/2009	12/31/2010	12/31/2011	12/31/2012	12/31/2013
Mead Johnson Nutrition Company	100.00	168.49	244.03	273.70	266.55	344.86
S&P 500 Index	100.00	136.57	157.14	160.46	186.13	246.42
S&P 500 Packaged Foods Index	100.00	122.78	142.87	167.43	184.83	241.83
Peer Group	100.00	128.16	140.86	161.10	181.97	227.55

25

Item 6.    SELECTED FINANCIAL DATA.

	For the Years Ended December 31,
(In millions, except per share data)	2013		2012		2011		2010		2009
Net Sales	$	4,200.7	$	3,901.3	$	3,677.0	$	3,141.6	$	2,826.5
Earnings before Interest and Income Taxes	$	924.6	$	870.0	$	774.1	$	682.9	$	679.6
Interest Expense—net	$	50.6	$	65.0	$	52.2	$	48.6	$	92.6
Net Earnings Attributable to Shareholders	$	649.5	$	604.5	$	508.5	$	452.7	$	399.6
Basic Earnings Per Share Attributable to Shareholders*	$	3.20	$	2.96	$	2.48	$	2.20	$	1.99
Diluted Earnings Per Share Attributable to Shareholders*	$	3.19	$	2.95	$	2.47	$	2.20	$	1.99
Cash Dividends Declared Per Share*	$	1.36	$	1.20	$	1.04	$	0.90	$	0.70
Weighted-average Shares - basic*	202.4		203.6		204.3		204.7		200.6
Depreciation and Amortization	$	83.1	$	76.9	$	75.3	$	64.7	$	58.9
Cash Paid for Capital Expenditures	$	240.4	$	124.4	$	109.5	$	172.4	$	95.8

	As of December 31,
(In millions)	2013		2012		2011			2010			2009
Total Assets	$	3,474.1	$	3,258.2	$	2,766.8		$	2,293.1		$	2,070.3
Short-Term Borrowings and Current Portion of Long-Term Debt	$	507.6	$	187.0	$	—		$	1.2		$	120.0
Long-Term Debt	$	1,009.1	$	1,523.2	$	1,531.9		$	1,532.5		$	1,484.9
Total Equity (Deficit)	$	300.5	$	29.0	$	(168.0	)	$	(358.3	)	$	(664.3	)
* On February 17, 2009, we completed the offering of 34.5 million shares of common stock in an initial public offering.

Item 7.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

This management’s discussion and analysis of financial condition and results of operations contains forward-looking statements that involve risks and uncertainties. See “Item 1A. Risk Factors” for a discussion of the uncertainties, risks and assumptions associated with those statements. The following discussion should be read in conjunction with our audited financial statements and the notes to our audited financial statements. Our results may differ materially from those discussed in the forward-looking statements as a result of various factors, including but not limited to those in “Risk Factors.”

Overview of Our Business

We are a global leader in pediatric nutrition. We are committed to building trusted nutritional brands and products that help improve the health and development of infants and children around the world and provide them with the best start in life. Our comprehensive product portfolio addresses a broad range of nutritional needs for infants, children and expectant and nursing mothers. We have over 100 years of innovation experience during which we have developed or improved many breakthrough or industry-defining products across each of our product categories.

We operate in four geographic segments: Asia, Europe, Latin America and North America. Previously, we aggregated these four geographic segments into two reportable segments: Asia/Latin America and North America/Europe. In the fourth quarter of 2013, we expanded the number of reportable segments to three as we separated the Asia/Latin America segment into two reportable segments: Asia and Latin America. The North America/Europe reportable segment remains unchanged. This change in segment reporting presentation does not change any consolidated totals. We made this segment reporting change because we believe that the new presentation will provide investors with greater insight into our consolidated results and operating performance. Throughout this filing, all segment information for the years ended December 31, 2012 and 2011 has been recast to conform to the new segment reporting presentation.

26

Executive Summary

For the year ended December 31, 2013, sales grew 8% compared to 2012. Sales increased by double-digits from category growth and market share gains and higher pricing throughout each of our Asia and Latin America segments offset in part by unfavorable currency impacts. North America/Europe sales decreased slightly compared to the prior year period driven by the impact of the late 2012 exit of certain non-core businesses and the continued decline of U.S. category consumption, partially offset by U.S. price increases.

Earnings per share grew by 8% in 2013. This growth was primarily attributable to sales growth and an improved gross margin, which was driven by higher pricing as well as strong productivity. These increases were partially offset by higher demand-generation investment and costs for an administrative penalty assessed by China’s NDRC as described below.

Results of Operations

Year Ended December 31, 2013 Compared to Year Ended December 31, 2012

Below is a summary of comparative results of operations for the years ended December 31, 2013 and 2012: 

									% of Net Sales
(In millions, except per share data)	2013			2012			% Change		2013		2012
Net Sales	$	4,200.7		$	3,901.3		8	%
Earnings before Interest and Income Taxes	924.6			870.0			6	%	22	%	22	%
Interest Expense—net	50.6			65.0			(22	)%	1	%	1	%
Earnings before Income Taxes	874.0			805.0			9	%	21	%	21	%
Provision for Income Taxes	219.1			192.6			14	%	5	%	5	%
Effective Tax Rate	25.1		%	23.9		%
Net Earnings	654.9			612.4			7	%	16	%	16	%
Less: Net Earnings Attributable to Noncontrolling Interests	5.4			7.9			(32	)%	(1	)%	(1	)%
Net Earnings Attributable to Shareholders	649.5			604.5			7	%	15	%	15	%
Weighted-Average Common Shares— Diluted	203.1			204.3
Earnings per Common Share—Diluted	$	3.19		$	2.95		8	%

The results for the years endedDecember 31, 2013and2012included several items that affect the comparability of our results. These items include significant expenses/(income) not indicative of on-going results (“Specified Items”) and are listed in the table below:

	Years Ended December 31,
(In millions)	2013			2012
IT/other separation costs	$	—		$	19.9
Gain on sale of certain non-core intangible assets	—			(6.5		)
Severance and other costs	2.6			21.1
Administrative penalty (China)	33.4			—
Legal, settlements and related costs	9.2			2.8
Specified Items	$	45.2		$	37.3
Tax matters and the income tax impact on Specified Items	(3.3		)	(11.7		)
Specified Items attributable to Noncontrolling Interests	(3.8		)	—
Specified Items after taxes	$	38.1		$	25.6

        For the year ended December 31, 2013, the Specified Items after taxes increased compared to the prior year. In 2013, the Company incurred costs for an administrative penalty assessed by China’s NDRC in connection with the NDRC’s antitrust review of the infant formula industry’s resale pricing practices (the “China Antitrust Review”), and had higher legal, settlements and related costs primarily due to costs associated with our ongoing internal investigation.

        The2012 IT/other separation costs related to the completion of our stand-alone operating structure. The 2012 severance and other costs related primarily to the relocation of our regional office in Asia and the implementation of our new business model in Europe.

27

Net Sales

       Our net sales by reportable segment:

	Years Ended December 31,						% Change Due to
(Dollars in millions)	2013		2012		% Change		Volume				Price/Mix		Foreign Exchange
Asia	$	2,179.3	$	1,967.0	11	%	8	%			2	%	1	%
Latin America	861.4		752.5		14	%	11	%	(1	)	11	%	(8	)%
North America/Europe	1,160.0		1,181.8		(2	)%	(5	)%			3	%	—	%
Net Sales	$	4,200.7	$	3,901.3	8	%	5	%			4	%	(1	)%

⁽¹⁾ Our 2012 acquisition in Argentina represented 2% of Latin America net sales increase.

Asia sales increased 11% compared to the prior year and accounted for more than 50% of MJN's net sales. The growth was largely driven by volume attributable to market share gains, including the recovery of market share in China and category growth. The impact of higher prices in a majority of markets in the segment were partially offset by slightly lower prices in China.

Latin America sales increased 14% in comparison to the prior year. Sales volume grew due to continued category growth and market share gains throughout the segment. Price grew by 11% with the largest contribution from high inflation in the markets of Venezuela and Argentina, but were largely offset by weaker local currency rates in these markets. At this time, we are unable to predict with certainty how recent and future developments in Venezuela and Argentina will affect our sales growth or operations in 2014.

North America/Europe sales decreased 2% compared to the prior year. Volume was lower by 5%, with 3% of this decline due to the impact of the late 2012 exit of certain non-core businesses. The balance of the volume reduction was primarily driven by the continued decline of U.S. category consumption, partially offset by market share gains in Canada. Price increases were realized primarily in the U.S.

Our net sales by product category are shown in the table below:

	Years Ended December 31,
(Dollars in millions)	2013		2012		% Change
Infant Formula	$	2,459.7	$	2,295.5	7	%
Children’s Nutrition	1,653.3		1,487.0		11	%
Other	87.7		118.8		(26	)%
Net Sales	$	4,200.7	$	3,901.3	8	%

In 2013,Infant Formula accounted for the large majority of our sales in North America/Europe and approximately half of our sales in each of our Asia and Latin America segments. Given this product category mix, lower sales in North America/Europe reduced the year-over-year growth rate of Infant Formula products. At the same time, stronger growth in each of our Asia and Latin America segments positively impacted the year-over-year growth of Children’s Nutrition products. Other category sales declined due to the prior year exit of certain non-core products primarily in the North America/Europe segment.

        We recognize revenue net of various sales adjustments to arrive at net sales as reported on the statements of earnings. These adjustments are referred to as gross-to-net sales adjustments. The reconciliation of our gross sales to net sales is as follows:

	Years Ended December 31,				% of Gross Sales
(Dollars in millions)	2013		2012		2013		2012
Gross Sales	$	5,346.6	$	5,038.5	100	%	100	%
Gross-to-Net Sales Adjustments
WIC Rebates	702.3		730.0		13	%	14	%
Sales Discounts	215.5		191.9		4	%	4	%
Returns	81.0		82.5		1	%	2	%
Cash Discounts	44.6		45.2		1	%	1	%
Coupons and Other Adjustments	72.2		55.6		1	%	1	%
Prime Vendor Charge-Backs	30.3		32.0		1	%	1	%
Total Gross-to-Net Sales Adjustments	1,145.9		1,137.2		21	%	23	%
Total Net Sales	$	4,200.7	$	3,901.3	79	%	77	%

The total dollar amount of WIC rebates in the United States decreased due to the loss of certain WIC contracts during late 2012.

28

Gross Profit

	Years Ended December 31,
(Dollars in millions)	2013			2012			% Change
Net Sales	$	4,200.7		$	3,901.3		8	%
Cost of Products Sold	1,532.8			1,485.3			3	%
Gross Profit	$	2,667.9		$	2,416.0		10	%
Gross Margin	63.5		%	61.9		%

Gross margin improvement versus the prior year was driven by pricing as well as strong productivity. In the fourth quarter of 2013, MJN saw a significant rise in dairy prices which we expect to have a negative impact on our gross margin for2014.

Expenses

	Years Ended December 31,						% of Net Sales
(Dollars in millions)	2013		2012		% Change		2013		2012
Selling, General and Administrative	$	918.0	$	877.8	5	%	22	%	23	%
Advertising and Promotion	645.1		552.8		17	%	15	%	14	%
Research and Development	102.4		95.4		7	%	2	%	2	%
Other Expenses/(Income)—net	77.8		20.0		289	%	2	%	1	%

Selling, General and Administrative Expenses

Selling, general and administrative expenses (“SG&A”) increased year over year due to higher sales force, performance-based compensation and marketing expenses. Such higher expenses were partially offset by the elimination of prior year expenses for IT/other separation costs related to the completion of our stand-alone operating structure, the relocation of our regional office in Asia and the implementation of our new business model in Europe.

Advertising and Promotion Expenses

Our advertising spending primarily includes television and other consumer media. Promotion activities primarily include product evaluation and education provided to health care professionals and consumers, where permitted by regulation. The increase in advertising and promotion expenses reflected demand-generation investments in support of our strategic growth initiatives.

Research and Development Expenses

Our R&D expenses include the continued investment in our innovation capability, product pipeline and quality compliance programs.

Other Expenses—net

	Years Ended December 31,
(In millions)	2013			2012
Foreign exchange (gains)/losses—net	$	9.3		$	(3.1	)
Administrative penalty (China)	33.4			—
Severance and other costs	2.2			8.0
Pension settlements and curtailments	29.3			15.2
Gain on sale of non-core intangible assets	—			(6.5		)
Legal settlements	7.0			—
Other—net	(3.4		)	6.4
Other expenses—net	$	77.8		$	20.0

        In 2013, we had higher cost related to pension settlements and curtailments as a result of higher lump-sum settlements made to retirees in the U.S. pension plan as compared to 2012. In addition, an administrative penalty was assessed by China’s NDRC in connection with the China Antitrust Review.

Earnings before Interest and Income Taxes

       Earnings before interest and income taxes (“EBIT”) from our three reportable segments, Asia, Latin America and North America/Europe, is reduced by Corporate and Other expenses. Corporate and Other consists of unallocated general and administrative expenses and global

29

business support activities, including R&D, marketing and supply chain costs; and income or expenses incurred within the operating segments that are not reflective of ongoing operations and affect the comparability of the operating segments’ results.

	Years Ended December 31,								% of Net Sales
(Dollars in millions)	2013			2012			% Change		2013		2012
Asia	$	795.8		$	725.3		10	%	37	%	37	%
Latin America	207.2			176.0			18	%	24	%	23	%
North America/Europe	248.5			246.1			1	%	21	%	21	%
Corporate and Other	(326.9		)	(277.4		)	(18	)%	n/a		n/a
EBIT	$	924.6		$	870.0		6	%	22	%	22	%

The Asia increase in EBIT was primarily related to sales growth and improved gross margin, partially offset by higher demand-generation investments.

The Latin America increase in EBIT was primarily related to sales growth and improved gross margin, partially offset by higher demand-generation investments.

The North America/Europe increase in EBIT was primarily related to an improved gross margin due to pricing and our new business model in Europe, offset by higher demand-generation investments.

Corporate and Other expenses increased compared to the prior year period primarily as a result of the $33.4 million charge related to the administrative penalty assessed by China’s NDRC in connection with the China Antitrust Review, increased pension settlement expense and current year foreign exchange transaction losses. These increased expenses were partially offset by the elimination of prior year IT/other separation costs related to the completion of our stand-alone operating structure, the prior year relocation of our regional office in Asia and the 2012 implementation of our new business model in Europe.

Interest Expense—net

Interest expense-net for the year ended December 31, 2013 totaled $50.6 million, down $14.4 million from the prior year. The decrease in interest expense is primarily a result of the July 2013 retirement of the short-term note payable incurred in connection with our 2012 acquisition in Argentina (the “Argentine Acquisition”), increased capitalization of interest expense associated with the construction of our new manufacturing and technology center in Singapore and higher interest income. The weighted-average interest rate on our long-term debt, including the impact of terminated interest rate swaps and the 2013 retirement of the note payable related to the Argentine Acquisition (the “Argentine Acquisition Note Payable”), was 4.2% and 4.5% for the years ended December 31, 2013 and 2012, respectively.

Income Taxes

        The effective tax rate (“ETR”) for the year ended December 31, 2013 and 2012 was 25.1% and 23.9%, respectively. The higher effective tax rate was primarily attributable to favorable adjustments in 2012 associated with prior years' tax filings and the 2013 administrative penalty related to the China antitrust review, which is non-deductible for tax purposes.

Net Earnings Attributable to Noncontrolling Interests

Net earnings attributable to noncontrolling interests consists of approximately 20%, 11% and 10% interest held by third parties in the our operating entities in Argentina, China and Indonesia, respectively.

Net Earnings Attributable to Shareholders

        For the foregoing reasons, net earnings attributable to shareholders for the year ended December 31, 2013 increased 7% to $649.5 million compared with the year ended December 31, 2012.

30

Results of Operations

Year Ended December 31, 2012 Compared to Year Ended December 31, 2011

Below is a summary of comparative results of operations for the years ended December 31, 2012 and 2011:

									% of Net Sales
(In millions, except per share data)	2012			2011			% Change		2012		2011
Net Sales	$	3,901.3		$	3,677.0		6	%
Earnings before Interest and Income Taxes	870.0			774.1			12	%	22	%	21	%
Interest Expense—net	65.0			52.2			25	%	1	%	1	%
Earnings before Income Taxes	805.0			721.9			12	%	21	%	20	%
Provision for Income Taxes	192.6			202.9			(5	)%	5	%	6	%
Effective Tax Rate	23.9		%	28.1		%
Net Earnings	612.4			519.0			18	%	16	%	14	%
Less: Net Earnings Attributable to Noncontrolling Interests	7.9			10.5			(25	)%	(1	)%	—	%
Net Earnings Attributable to Shareholders	604.5			$	508.5		19	%	15	%	14	%
Weighted-Average Common Shares— Diluted	204.3			205.0
Earnings per Common Share—Diluted	$	2.95		$	2.47		19	%

        The results for the years ended December 31, 2012 and 2011 included Specified Items and are listed in the table below:

	Years Ended December 31,
(In millions)	2012			2011
IT/other separation costs	$	19.9		$	74.7
Gain on sale of certain non-core intangible assets	(6.5		)	—
Severance and other costs	21.1			11.6
Legal, settlements and related costs	2.8			7.6
Specified Items before income taxes	$	37.3		$	93.9
Income tax impact on items above	(11.7		)	(29.3		)
Specified Items after taxes	$	25.6		$	64.6

        The decrease in specified items reflects the completion of our stand-alone operating infrastructure.

Net Sales

        Our net sales by reportable segment are shown in the table below:

	Years Ended December 31,						% Change Due to
(Dollars in millions)	2012		2011		% Change		Volume				Price/Mix		Foreign Exchange
Asia	$	1,967.0	$	1,827.8	8	%	—	%			7	%	1	%
Latin America	752.5		619.4		21	%	20	%	(1	)	7	%	(6	)%
North America/Europe	1,181.8		1,229.8		(4	)%	(7	)%			4	%	(1	)%
Net Sales	$	3,901.3	$	3,677.0	6	%	1	%			6	%	(1	)%

⁽¹⁾ Our acquisition in Argentina represented 10% of Latin America net sales increase.

Asia sales accounted for more than 50% of our net sales in 2012 and grew 8% year over year primarily as a result of price increases throughout the segment. Volume increased due to broad-based category growth but was offset in its entirety by market share loss in China that occurred towards the end of the second quarter. However, during the second half of 2012, we made significant progress in recovering this market share. In addition, although distributors’ inventory levels increased in China in the first half of 2012 as a result of the market share decline, by year end they had returned to levels similar to those seen at the beginning of the year.

Latin America sales increased 21%, of which 10% was due to the Argentine Acquisition. The increase in volume was driven by broad gains in market share across the segment. Price increases in Venezuela, Mexico and Brazil helped mitigate the impact of high inflation in these markets.

31

The decrease in sales in North America/Europe reflected lower U.S. market share as well as lower category consumption and births, partially offset by higher prices. Market share was lower in comparison to the prior year when we benefited from a competitor’s recall and due to the impact in 2012 of the unfounded media reports in December 2011 alleging product contamination in the United States. Investigating governmental agencies found no contamination in sealed containers of our product, but the resulting uncertainty caused some consumers to switch away from our brand.

        Our net sales by product category are shown in the table below:

	Years Ended December 31,
(Dollars in millions)	2012		2011		% Change
Infant Formula	$	2,295.5	$	2,188.7	5	%
Children’s Nutrition	1,487.0		1,394.4		7	%
Other	118.8		93.9		27	%
Net Sales	$	3,901.3	$	3,677.0	6	%

Infant formula accounts for approximately 90% of our sales in North America/Europe and approximately half of our sales in each of our Asia and Latin America segments.

        We recognize revenue net of various sales adjustments to arrive at net sales as reported on the statements of earnings. These adjustments are referred to as gross-to-net sales adjustments. The reconciliation of our gross sales to net sales is as follows:

	Years Ended December 31,				% of Gross Sales
(Dollars in millions)	2012		2011		2012		2011
Gross Sales	$	5,038.5	$	4,730.7	100	%	100	%
Gross-to-Net Sales Adjustments
WIC Rebates	730.0		700.7		14	%	15	%
Sales Discounts	191.9		149.8		4	%	3	%
Returns	82.5		81.8		2	%	2	%
Cash Discounts	45.2		47.5		1	%	1	%
Coupons and Other Adjustments	55.6		42.4		1	%	1	%
Prime Vendor Charge-Backs	32.0		31.5		1	%	—	%
Total Gross-to-Net Sales Adjustments	1,137.2		1,053.7		23	%	22	%
Total Net Sales	$	3,901.3	$	3,677.0	77	%	78	%

Total gross-to-net sales adjustments were consistent as a percentage of gross sales with the prior year. The total dollar amount of WIC rebates in the United States increased due to retail list price increases and changes in certain WIC contracts during 2012 and the second half of 2011.

Gross Profit

	Years Ended December 31,
(Dollars in millions)	2012			2011			% Change
Net Sales	$	3,901.3		$	3,677.0		6	%
Cost of Products Sold	1,485.3			1,362.3			9	%
Gross Profit	$	2,416.0		$	2,314.7		4	%
Gross Margin	61.9		%	63.0		%

The gross margin decline was attributable entirely to the North America/Europe segment and resulted from higher commodity costs, primarily dairy inputs, and unfavorable manufacturing variances attributed largely to lower production volumes. These factors were partially offset by increased prices and productivity gains.

Expenses

	Years Ended December 31,						% of Net Sales
(Dollars in millions)	2012		2011		% Change		2012		2011
Selling, General and Administrative	$	877.8	$	926.8	(5	)%	23	%	25	%
Advertising and Promotion	552.8		501.7		10	%	14	%	14	%
Research and Development	95.4		92.5		3	%	2	%	3	%
Other Expenses/(Income)—net	20.0		19.6		2	%	1	%	1	%

32

Selling, General and Administrative Expenses

SG&A decreased due to the completion of our stand-alone operating infrastructure and lower performance-based compensation expense, partially offset by an increase in sales force and distribution expenses supporting sales growth.

Advertising and Promotion Expenses

Our advertising spending primarily includes television and other consumer media. Promotion activities primarily include product evaluation and education provided to health care professionals and consumers, where permitted by regulation. The increase in advertising and promotion expenses reflected demand-generation investments in support of our strategic growth initiatives.

Research and Development Expenses

Our R&D expenses include the continued investment in our innovation capability, product pipeline and quality compliance programs.

Other Expenses—net

	Years Ended December 31,
(In millions)	2012			2011
Foreign exchange (gains)/losses—net	$	(3.1	)	$	(9.7	)
Severance and other costs	8.0			9.9
Pension settlements and curtailments	15.2			9.7
Gain on sale of non-core intangible assets	(6.5		)	—
Other—net	6.4			9.7
Other expenses—net	$	20.0		$	19.6

       In 2012, we had higher cost related topension settlements and curtailments primarily as a result of lump sum payments made to retirees in the U.S. pension plan.

Earnings before Interest and Income Taxes

EBIT from our three reportable segments, Asia, Latin America and North America/Europe, is reduced by Corporate and Other expenses. Corporate and Other consists of unallocated general and administrative expenses and global business support activities, including R&D, marketing and supply chain costs; and income or expenses incurred within the operating segments that are not reflective of ongoing operations and affect the comparability of the operating segments’ results.

	Years Ended December 31,								% of Net Sales
(Dollars in millions)	2012			2011			% Change		2012		2011
Asia	$	725.3		$	672.5		8	%	37	%	37	%
Latin America	176.0			139.1			27	%	23	%	22	%
North America/Europe	246.1			308.4			(20	)%	21	%	25	%
Corporate and Other	(277.4		)	(345.9		)	(20	)%	n/a		n/a
EBIT	$	870.0		$	774.1		12	%	22	%	21	%

The increase in EBIT for Asia was primarily related to sales growth and a higher gross margin, partially offset by higher expenses, such as advertising and promotion and sales force growth.

The increase in EBIT for Latin America was primarily related to sales growth, partially offset by higher expenses, such as advertising and promotion.

The North America/Europe decline in EBIT was primarily attributable to a decline in sales, along with a lower gross margin due to higher commodity costs, primarily dairy inputs, and unfavorable manufacturing variances attributed largely to lower production volumes in the United States.

Corporate and Other expenses decreased due to the completion of our stand-alone operating infrastructure and lower performance-based

compensation expense.

33

Interest Expense—net

Interest expense for the year ended December 31, 2012 primarily represented interest incurred on $1.5 billion of long-term notes and the short-term note payable related to our Argentine Acquisition. The increase in interest expense reflected the prior year's termination of our fixed-to-floating interest rate swaps and the Argentine Acquisition Note Payable. The weighted-average interest rate on our long-term debt, including the impact of the swaps and Argentine Acquisition Note Payable, was 4.5% and 4.0% for the years ended December 31, 2012 and 2011, respectively.

Income Taxes

The ETR for the year ended December 31, 2012 and 2011 was 23.9% and 28.1%, respectively. The ETR was primarily attributable to favorable adjustments associated with prior years’ tax filings, changes in management’s assertion that certain current and prior years’ foreign earnings and profits are permanently invested abroad and changes in the geographic earnings mix.

Net Earnings Attributable to Noncontrolling Interests

Net earnings attributable to noncontrolling interests consists of approximately 20%, 11% and 10% interest held by third parties in our operating entities in Argentina, China and Indonesia, respectively.

Net Earnings Attributable to Shareholders

For the foregoing reasons, net earnings attributable to shareholders for the year ended December 31, 2012 increased 19% to $604.5 million compared with the year ended December 31, 2011.

Liquidity and Capital Resources

Overview

Our primary sources of liquidity are cash on hand, cash from operations and available borrowings under our $500.0 million revolving credit facility. Cash flows from operating activities represent the inflow of cash from our customers net of the outflow of cash for raw material purchases, manufacturing, operating expenses, interest and taxes. Cash flows used in investing activities primarily represent capital expenditures for equipment, buildings and computer software and acquisitions. Cash flows used in financing activities primarily represent dividend payments, proceeds and repayments of short-term borrowings and share repurchases.

        Cash and cash equivalents totaled $1,050.8 million at December 31, 2013 of which $692.5 million was held outside of the United States. Cash and cash equivalents totaled $1,042.1 million as of December 31, 2012, of which $486.7 million was held outside of the United States.

        During 2013, we repatriated approximately $74 million of cash to the United States from multiple jurisdictions whose earnings and profits are not permanently invested abroad. During 2012, we repatriated approximately $660 million of cash to the United States from multiple jurisdictions of which approximately $409 million was repatriated as a return of basis.  We have no current plans to repatriate cash in a similar return of basis transaction.

        As a result of our evaluation of our global cash position, management has asserted that current and prior year earnings and profits in certain foreign jurisdictions are permanently invested abroad. We will continue to evaluate our global cash position and our determination as to whether earnings and profits of certain other foreign jurisdictions are permanently invested abroad. As of December 31, 2013, approximately $343 million of cash and cash equivalents were held by foreign subsidiaries whose undistributed earnings are considered permanently invested. Our intent is to invest these earnings in our foreign operations and our current plans do not demonstrate a need to repatriate them to fund our U.S. operations. If we decide at a later date to repatriate these earnings to the United States, we would be required to provide U.S. taxes on these amounts.

The declaration and payment of dividends is at the discretion of our board of directors and depends on many factors, including our financial condition, earnings, legal requirements, restrictions under the terms of our debt agreements and other relevant factors. Cash dividends paid for the years endedDecember 31, 2013,2012and2011were$267.7 million,$236.7 millionand$205.7 million, respectively.

Our board of directors previously authorized the repurchase of up to $300.0 million of our common stock (the “2010 Authorization”). The 2010 Authorization was primarily intended to offset the dilutive effect on earnings from stock-based compensation. The 2010 Authorization ends on May 1, 2015; however, during the year ended December 31, 2013, we completed all purchases remaining under the

34

2010 Authorization.From the date of such authorization throughDecember 31, 2013,4.2 million shares were repurchased at an average cost per share of $71.21.

        In September 2013, our board of directors approved a new share repurchase authorization of up to an additional$500.0 millionof our common stock (the "2013 Authorization"). The 2013 Authorization is intended to offset the dilutive effect on earnings per share from stock-based compensation and allow for opportunistic stock purchases to return capital to stockholders. The 2013 Authorization does not have an expiration date.From the date of such authorization through December 31, 2013, 0.1 million shares were repurchased at an average cost of $84.06. As ofDecember 31, 2013, we had $490.3 million available for further repurchases under the authorization.

Cash Flows

        We believe that cash on hand, cash from operations, and the available credit facility will be sufficient to support our working capital needs, pay our operating expenses, satisfy debt obligations, fund capital expenditures and make dividend payments.

	Years Ended December 31,
(Dollars in millions)	2013			2012			2011
Cash flow provided by/(used in):
Operating Activities
Net Earnings	$	654.9		$	612.4		$	519.0
Depreciation and Amortization	83.1			76.9			75.3
Other	87.7			72.5			28.0
Changes in Assets and Liabilities	0.3			(40.8		)	20.2
Pension and Other Post-Retirement Benefits Contributions	(19.4		)	(28.3		)	(9.7		)
Total Operating Activities	806.6			692.7			632.8
Investing Activities	(240.5		)	(228.8		)	(112.6		)
Financing Activities	(545.7		)	(267.5		)	(275.2		)
Effects of Changes in Exchange Rates on Cash and Cash Equivalents	(11.7		)	5.4			(0.3		)
Net Increase in Cash and Cash Equivalents	$	8.7		$	201.8		$	244.7

Year Ended December 31, 2013 Compared to Year Ended December 31, 2012

Cash flow provided from operating activities increased by $113.9 million in 2013 compared to 2012. Higher net earnings, along with lower cash paid for income taxes and performance-based compensation as well as lower cash contributions to our U.S. defined benefit pension plan partially offset a higher requirement for working capital, defined as accounts receivable plus inventory less accounts payable.

        Cash flow used in investing activities increased $11.7 million in 2013 compared to 2012 due primarily to higher capital expenditures partially offset by the Argentine Acquisition.

        Cash flow used in financing activities was $545.7 million for the year ended December 31, 2013, consisting primarily of $267.7 million of dividend payments, $165.4 million repayments of short-term borrowings and $106.0 million of treasury stock repurchases. Cash flow used in financing activities was $267.5 million for the year ended December 31, 2012, primarily from dividend payments of $236.7 million, treasury stock repurchases of $154.9 million and the Argentine Acquisition Note Payable of $52.6 million, offset by revolver borrowings of $161.0 million.

Year Ended December 31, 2012 Compared to Year Ended December 31, 2011

Cash flow provided from operating activities increased by $59.9 million in 2012 compared with 2011. Higher earnings and lower requirements for working capital were offset partially by higher cash paid for income taxes. The 2012 decrease in inventories reflected the impact from the December 2011 advance purchase of approximately $80 million for select dairy inputs.

        Cash flow used in investing activities increased $116.2 million in 2012 compared to 2011 due primarily to the Argentine Acquisition.

        Cash flow used in financing activities was $267.5 million for the year ended December 31, 2012, primarily from dividend payments of $236.7 million, treasury stock repurchases of $154.9 million and the Argentine Acquisition Note Payable of $52.6 million, offset by revolver borrowings of $161.0 million.

35

Capital Expenditures

        Capital expenditures and the cash outflow for capital expenditures were as follows:

(In millions)	Capital expenditures		Cash outflow for capital expenditures
Year ended December 31, 2013	$	251.1	$	240.4
Year ended December 31, 2012	170.3		124.4
Year ended December 31, 2011	121.6		109.5

Capital expenditures included investments primarily in a new spray dryer and research and development capabilities. In December 2011, we announced a three-year planned capital expenditure for a new manufacturing and technology center in Singapore. In 2013, we spent approximately $142 million for the second year of the capital expenditure in Singapore bringing our spending to date for the project to $220 million. In 2014, we expect capital expenditures to be approximately $180 million, including $35 million for the third year of the capital expenditure in Singapore, and continued emphasis on growth and innovation. We expect to fund capital expenditures from our cash flow generated by operations.

Revolving Credit Facility Agreement

In June 2011, the Company entered into a five-year revolving credit facility agreement (“Credit Facility”). Borrowings from the Credit Facility are to be used for working capital and other general corporate purposes. The Credit Facility is unsecured and repayable at maturity in June 2016, and subject to annual extensions if a sufficient number of lenders agree. The maximum amount of outstanding borrowings and letters of credit permitted at any one time under the Credit Facility is $500.0 million, which may be increased from time to time up to $750.0 million at our request and with the consent of the lenders, subject to satisfaction of customary conditions.

        The Credit Facility contains customary covenants, including covenants applicable to limiting liens, substantial asset sales and mergers. Most of these restrictions are subject to certain minimum thresholds and exceptions. The Credit Facility contains financial covenants whereby the ratio of consolidated total debt to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (“EBITDA”) cannot exceed 3.25 to 1.0, and the ratio of consolidated EBITDA to consolidated interest expense cannot be less than 3.0 to 1.0. We were in compliance with all financial covenants as of December 31, 2013.

        Borrowings under the Credit Facility bear interest at a rate that is determined as a base rate plus a margin. The base rate is either (a) LIBOR for a specified interest period, or (b) a floating rate based upon JPMorgan Chase Bank's prime rate, the Federal Funds rate or LIBOR. The margin is determined by reference to the Company's credit rating. The margin can range from 0.075% to 1.45% over the base rate. In addition, we incur an annual 0.2% facility fee on the entire facility commitment of $500.0 million.

        If our corporate credit rating falls below (i) Baa3 by Moody's Investors Service, Inc. (“Moody's”) and (ii) BBB- by Standard & Poor's Ratings Service (“S&P”), then Mead Johnson & Company shall automatically be deemed to guarantee the obligations under the Credit Facility. Moody's credit rating for MJN is currently Baa1. S&P's credit rating for MJN is currently BBB.

        As of December 31, 2013, we had no borrowings outstanding under our Credit Facility. As of December 31, 2012, we borrowed $161.0 million against our Credit Facility for general corporate purposes, including payment for acquisition debt obligations and funding of current and future capital expenditures.

Argentine Acquisition Note Payable

        On March 15, 2012, we completed the Argentine Acquisition (See “Item 8. Financial Statements - Note 8. Redeemable Noncontrolling Interest” for discussion of the Argentine Acquisition). Of the ARS850.7 million purchase price payable, ARS377.6 million was financed through a note payable. The remaining balance of the note payable was paid on July 10, 2013. Through March 15, 2013, the annual interest rate for the note payable was 14%. Effective as of March 16, 2013, the note was converted to U.S. dollar-denominated indebtedness, the annual interest rate was automatically reduced to 0.85%, and the note accrued interest at that rate through our final payment.

36

Long-Term Debt

        The components of our long-term debt are detailed in the table below:

Description	Principal Amount	Interest Rate	Maturity
2014 Notes	$500.0 million	3.50% fixed	November 1, 2014
2019 Notes	$700.0 million	4.90% fixed	November 1, 2019
2039 Notes	$300.0 million	5.90% fixed	November 1, 2039

        Our long-term debt has a principal value of $1,500 million, of which $500 million is considered current as it matures on November 1, 2014. As we plan to refinance a portion of our long-term notes in 2014, we entered into interest rate forward starting swaps with a combined notional value of $500 million.The forward starting rates of the swaps range from 3.79% to 3.94% and an effective date of October 31, 2014. The forward starting swaps effectively mitigate the interest rate exposure associated with our planned refinancing of a portion of our long-term debt.

        Our long-term debt may be prepaid at any time, in whole or in part, at a redemption price equal to the greater of par value or an amount calculated based upon the sum of the present values of the remaining scheduled payments. Upon a change of control, we may be required to repurchase the notes in an amount equal to 101% of the then outstanding principal amount plus accrued and unpaid interest. Interest on the notes are due semi-annually, and the notes are not subject to amortization.

        For additional information on our long-term debt, acquisition and interest rate swaps, see“Item 8. Financial Statements – Note 15. Debt and Note 16. Derivatives.”

Contractual Obligations

        As of December 31, 2013, our contractual obligations and other commitments were as follows:

	Payments due by December 31,
(In millions)	2014		2015		2016		2017		2018		Thereafter		Total
Operating lease obligations	$	36.4	$	29.5	$	20.8	$	15.5	$	14.3	$	22.3	$	138.8
Capital lease obligations	1.2		1.1		0.9		0.4		—		—		$	3.6
Purchase obligations	139.3		52.2		54.6		41.0		40.3		49.5		$	376.9
Short-term borrowings	2.0		—		—		—		—		—		$	2.0
Long-term debt	500.0		—		—		—		—		1,000.0		$	1,500.0
Interest payments	69.7		52.0		52.0		52.0		52.0		406.0		$	683.7
Total	$	748.6	$	134.8	$	128.3	$	108.9	$	106.6	$	1,477.8	$	2,705.0

        Our operating lease obligations are generally related to real estate leases for offices, manufacturing-related leases, and vehicle leases. Capital lease obligations relate to assets used for interplant transportation of materials and finished goods. Purchase obligations are for unconditional commitments related to a master service agreement with IBM for information technology, accounting and indirect procurement services; for the purchase of materials used in manufacturing; and for promotional services. The future interest payments include coupon payments on our long-term debt.

Additionally, liabilities for uncertain tax positions and pension and other post retirement benefits are excluded from the table above as we are unable to reasonably predict the ultimate amount or timing of a cash settlement of such liabilities. See“Item 8. Financial Statements – Note 4. Income Tax and Note 7. Employee Benefits” for more information.

Off-Balance Sheet Arrangements

        Pursuant to an Amended and Restated Tax Matters Agreement with BMS, we agreed to indemnify BMS for (i) any tax payable with respect to any separate tax return that we are required to file or cause to be filed, (ii) any tax incurred as a result of any gain that may be recognized by a member of the BMS affiliated group with respect to a transfer of certain foreign affiliates by us in preparation for our2009 initial public offering (“IPO”), and (iii) any tax arising from the failure or breach of any representation or covenant made by us which failure or breach results in the intended tax consequences of the split-off transaction not being achieved.

        We do not use off-balance sheet derivative financial instruments to hedge or partially hedge interest rate exposure nor do we maintain any other off-balance sheet arrangements for the purpose of credit enhancement, hedging transactions or other financial or investment purposes.

37

Significant Accounting Estimates

        In presenting our financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”), we are required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses and related disclosures.

        Some of the estimates and assumptions that we are required to make relate to matters that are inherently uncertain as they pertain to future events. We base these estimates and assumptions on historical experience or on various other factors that we believe to be reasonable and appropriate under the circumstances. On an on-going basis, we reconsider and evaluate our estimates and assumptions. Actual results may differ significantly from these estimates. Future results may differ from our estimates under different assumptions or conditions.

        We believe that the significant accounting estimates listed below involve our more significant judgments, assumptions and estimates and, therefore, could have the greatest potential impact on our financial statements.

        For information on our accounting policies, see“Item 8. Financial Statements – Note 2. Accounting Policies.”

Revenue Recognition

        We recognize revenue when substantially all the risks and rewards of ownership have transferred to the customer. Revenue is recognized on the date MJN’s products are received by the purchaser. Revenues are reduced at the time of recognition to reflect expected returns that are estimated based on historical experience and business trends. Additionally, provisions are made at the time of revenue recognition for discounts, WIC rebates and estimated sales allowances based on historical experience, updated for changes in facts and circumstances, as appropriate. Such provisions are recorded as a reduction of revenue. We offer sales incentives to customers and consumers through various programs consisting primarily of customer pricing allowances, merchandising funds and consumer coupons. Provisions are made at the time of revenue recognition for these items based on historical experience, updated for changes in facts and circumstances, as appropriate. Such provisions are recorded as a reduction of revenue.

        WIC Rebates—We participate on a competitive bidding basis in nutrition programs sponsored by states, tribal governments, the Commonwealth of Puerto Rico, and U.S. territories for WIC. Under these programs, we reimburse these entities for the difference between our wholesaler list price and the contract price on eligible products. We account for WIC rebates by establishing an accrual in an amount equal to our estimate of WIC rebate claims attributable to a sale. We determine our estimate of the WIC rebate accrual primarily based on historical experience regarding WIC rebates and current contract prices under the WIC programs. We consider levels of inventory in the distribution channel, new WIC contracts, terminated WIC contracts, changes in existing WIC contracts and WIC participation, and adjust the accrual periodically throughout the year to reflect actual expense. WIC rebate accruals were $199.7 million and $206.5 million at December 31, 2013 and 2012, respectively, and are included in accrued rebates and returns on our balance sheet. Rebates under the WIC program reduced revenues by $702.3 million, $730.0 million, and $700.7 million in the years ended December 31, 2013, 2012 and 2011, respectively.

        Sales Returns—We account for sales returns by establishing an accrual in an amount equal to our estimate of sales recorded for which the related products are expected to be returned. We determine our estimate of the sales return accrual primarily based on historical experience regarding sales returns, but also consider other factors that could impact sales returns such as discontinuations and new product introductions. Sales return accruals were $44.8 million and $46.4 million at December 31, 2013 and 2012, respectively, and are included in accrued rebates and returns on our balance sheet. Returns reduced sales by $81.0 million, $82.5 million, and $81.8 million for the years ended December 31, 2013, 2012 and 2011, respectively.

Income Taxes

        The ETR reflects statutory tax rates in the various jurisdictions in which we operate, including tax rulings and agreements, management’s assertion that certain foreign earnings and profits are permanently invested abroad and management’s estimate of appropriate reserves against uncertain tax positions. Significant judgment is required in determining the ETR and in evaluating the uncertainty in tax positions.

        The provision for income taxes has been determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of our assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable earnings in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when changes are enacted. The ultimate liability incurred by us may differ from the provision estimates based on a number of factors, including interpretations of tax laws and the resolution of examinations by the taxing authorities.

38

        Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment including the long-range forecast of future taxable earnings and the evaluation of tax planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made.

        Changes in uncertain tax positions and changes in valuation allowances could be material to our results of operations for any period, but are not expected to be material to our financial position.

Goodwill and Indefinite-lived Intangible Assets

Goodwill is not amortized but is tested for impairment annually and whenever events or changes in circumstances indicate that impairment may have occurred. We utilize a two-step quantitative assessment to test for impairment. The first step involves a comparison of the fair value of a reporting unit with its carrying value. If the carrying value of the reporting unit exceeds its fair value, the second step of the process involves a comparison of the implied fair value and carrying value of the goodwill of that reporting unit. If the carrying value of the goodwill of a reporting unit exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to the excess. In evaluating the recoverability of goodwill, it is necessary to estimate the fair value of reporting units, which is generally based on a discounted cash flow model. In making this assessment, the Company relies on a number of factors to discount anticipated future cash flows including operating results, business plans and present value techniques. Growth rates for sales and profits are determined using inputs from our annual planning process. We also make estimates of discount rates, perpetuity growth assumptions and other factors. Many of the factors used in assessing fair value are outside the control of the Company and it is reasonably likely that assumptions and estimates can change in future periods. These changes can result in future impairments. We completed the annual goodwill impairment assessment during the first quarter of 2013, 2012 and 2011 and no impairment of goodwill was required as we determined that the fair values of our reporting units were substantially in excess of respective carrying amounts. During the third quarter of 2013 we changed our annual impairment testing date from January 1 to July 1 to better align with the timing of our annual and long-term planning process, which is a significant input in the testing process. As a result, we completed impairment testing again in the third quarter of 2013 and no impairment of goodwill was required as we determined that the fair values of our reporting units were substantially in excess of respective carrying amounts.

As a result of our Argentine Acquisition in 2012 we recognized $172.8 million of goodwill as of the acquisition date, which represents a majority of our goodwill balance as of December 31, 2013. Although management currently believes operations in reporting units to which goodwill was allocated can support the value of recorded goodwill, a change in assumptions driven by macro-economic conditions or degradation in the Argentine consumer market that undermines the reporting unit's ability to achieve targeted profit levels may result in an impairment of the recorded goodwill.

Similarly, impairment testing of our other indefinite-lived intangible assets, primarily one trademark, requires a comparison of carrying value to fair value of that particular asset annually and whenever events or changes in circumstances indicate that impairment may have occurred. To test these assets for impairment, we estimate the fair value of each asset based on a discounted cash flow model using various inputs, including projected revenues, an assumed royalty rate, and a discount rate. Changes in these estimates and assumptions could impact the assessment of impairment in the future.

Pension and Other Post Retirement Benefits

        Our pension plans and post retirement benefit plans are accounted for using actuarial valuations. Management, in consultation with our actuaries, is required to make significant subjective judgments about a number of actuarial assumptions, including discount rates, long-term returns on plan assets, retirement, health care cost trend rates and mortality rates. Depending on the assumptions and estimates used, the pension and post retirement benefit expense could vary within a range of outcomes and have a material effect on projected benefit obligations. Our key assumptions used in calculating the cost of pension benefits are the discount rate and expected long term returns on plan assets. Actual results in any given year may differ from those estimated because of economic and other factors.

        The discount rate assumptions used to value the pension and post retirement benefit obligations reflect the yield to maturity of high quality corporate bonds that coincides with the cash flows of the plans’ estimated payouts. In developing the expected rate of return on pension plan assets, we estimate returns for individual asset classes with input from external advisors. We also consider long-term historical returns on the asset classes, the investment mix of plan assets, investment manager performance and projected future returns of the asset classes.

39

        Our principal pension plan is the Mead Johnson & Company Retirement Plan, LLC in the United States (“U.S. Pension Plan”), which is a frozen plan and represents approximately75%of our total pension assets and obligations. The assumptions used to determine net periodic benefit costs for the year are established at the beginning of the plan year and the assumptions used to determine benefit obligation are established as of the balance sheet date. The key assumptions for the U.S. Pension Plan were as follows:

Used to determine net periodic benefit cost for the years ended December 31,	2013		2012
Discount rate	3.00	%	3.75	%
Expected long-term return on plan assets	6.00	%	6.25	%

Used to determine benefit obligation as of December 31,	2013		2012
Discount rate	4.00	%	3.00	%

        The obligation for the U.S. Pension Plan decreased by $57.5 million during 2013, primarily due to the increase in the discount rate. The change in the discount rate assumption reflected higher corporate bond rates.

        The following table shows the impact on pension expense of hypothetical changes in the rates assumed for the U.S. pension plan:

		Increase/(Decrease) in Expense						Increase/(Decrease) in Obligation
(Dollars in millions)	Change in Rate	Increase in Rate			Decrease in Rate			Increase in Rate			Decrease in Rate
Impact of change in rates:
Discount rate	+/-100 basis points	$	1.7		$	(2.0	)	$	(23.0	)	$	27.3
Expected long-term rate of return on plan assets	+/-100 basis points	$	(2.3	)	$	2.3		N/A			N/A

       See“Item 8. Financial Statements – Note 7. Employee Benefits”for additional information on our pension and post retirement benefits.

Special Note Regarding Forward-Looking Statements

        This Annual Report on Form 10-K and other written and oral statements we make from time to time contain certain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these forward-looking statements by the fact they use words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. You can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on current expectations and involve inherent risks, uncertainties, and assumptions including factors that could delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations. These statements are likely to relate to, among other things, our goals, plans and projections regarding its financial position, results of operations, cash flows, market position, product development, product approvals, sales efforts, expenses, capital expenditures, performance or results of current and anticipated products and the outcome of contingencies such as legal proceedings and financial results, which are based on current expectations that involve inherent risks and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years. We have included important factors in the cautionary statements included in “Item 1A. Risk Factors,” that we believe could cause actual results to differ materially from any forward-looking statement.

        Although we believe we have been prudent in our plans and assumptions, we can give no assurance that any goal or plan set forth in forward-looking statements can be achieved and we caution readers not to place undue reliance on such statements, which speak only as of the date made. We undertake no obligation to release publicly any revisions to forward-looking statements as a result of new information, future events or otherwise.

Item 7A.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are exposed to certain market risks which exist as part of our on-going business operations. In addition to our costs for materials, compensation, media, distribution and other purchased services being subject to inflationary pressures, we are exposed to changes in currency exchange rates, price volatility for certain commodities and changes in interest rates. To reduce our exposure to these risks, we use a variety of contract techniques and financial instruments as described below. As a policy, we do not engage in speculative or leveraged transactions, nor do we hold or issue financial instruments for trading purposes.

40

Foreign Exchange Risk

        We are exposed to market risk due to changes in currency exchange rates. Our primary net foreign currency exposures are the Chinese renminbi, the Hong Kong dollar, the euro, the Philippine peso, the Malaysian ringitt and the Mexican peso. In addition to these primary exposures, as a global business, we are exposed to foreign currency translation risk in all countries in which we do business whose local reporting currency is not the U.S. dollar. Currency rates in smaller markets, such as Venezuela and Argentina, could also impact our results due to high volatility in exchange rates in such markets.

We use foreign currency contracts to hedge anticipated transactions on certain foreign currencies and designate these derivative instruments as foreign currency cash flow hedges when appropriate. If the derivative is designated as a cash flow hedge, the change in the fair value of the derivative is initially recorded in accumulated other comprehensive income(loss) and then recognized in our statement of earnings when the corresponding hedged item impacts our earnings. The foreign currency derivatives resulted in losses of $5.4 million,$0.8 million, and$2.9 millionin the years endedDecember 31, 2013,2012and2011, respectively. The impact of hedge ineffectiveness on earnings was not significant.

We enter into hedging and other foreign exchange management arrangements to reduce the risk of foreign currency exchange rate fluctuations on earnings to the extent that cost-effective derivative financial instruments or other non-derivative financial instrument approaches are available. The intent of gains and losses on hedging transactions is to offset the respective gains and losses on the underlying exposures being hedged. While we attempt to mitigate some of this risk with hedging and other activities, our business will nevertheless remain subject to substantial foreign exchange risk from foreign currency translation exposures that we will not be able to manage through effective hedging or the use of other financial instruments.

        We use foreign exchange forward contracts to hedge exposures and the total notional amount of these contracts was $201.4 million at December 31, 2013, representing a fair value asset of $3.7 million.

        The following table summarizes the foreign exchange forward contracts outstanding and the related weighted-average contract exchange rates as of December 31, 2013:

	Contract Amount (in millions)		Average Contractual Exchange Rate
Receive United States dollar/Pay Mexican peso	$	84.0	$	13.07
Receive United States dollar/Pay Philippine peso	$	62.4	$	43.48
Receive United States dollar/Pay Malaysian ringitt	$	55.0	$	3.18

        All of these derivatives were hedges of anticipated transactions and mature within 12 months. Assuming an unfavorable 10% change in year-end exchange rates, the fair value would have changed by $27.7 million and would have switched to a payable position. The unfavorable changes would generally have been offset by favorable changes in the values of the underlying exposures.

Venezuela Risk

We apply highly inflationary accounting to our business in Venezuela. Under highly inflationary accounting, the functional currency of the entity is aligned with the reporting currency of the Company. Exchange gains and losses from the remeasurement of monetary assets and liabilities are reflected in current earnings, rather than accumulated other comprehensive loss on the balance sheet. The impact of applying highly inflationary accounting for Venezuela on our consolidated financial statements is dependent upon movements in the official exchange rate, including devaluations, between the Bolivares Fuertes (“VEF”) and the U.S. dollar. The operating environment in Venezuela could include high inflation, governmental restrictions in the form of currency exchange, price and margin controls, and the possibility of further government actions such as further devaluations or other business intervention. In addition, the foreign exchange controls in Venezuela limit our ability to repatriate earnings and our Venezuela subsidiary’s ability to remit dividends and pay intercompany balances at any official exchange rate or at all.

Through December 31, 2013, the Venezuelan government had established one official exchange rate for qualifying dividends and imported goods and services, equal to 6.3 VEF to one U.S. dollar. Transactions at the official exchange rate are subject to CADIVI (Venezuelan government’s Foreign Exchange Administrative Commission) approval. In addition to the official exchange rate, there are and have been parallel exchange markets controlled by the Central Bank of Venezuela as the only legal intermediary to execute foreign exchange transactions outside of CADIVI. Through February 12, 2013, the parallel exchange program was SITME, which had a published rate of 5.3 VEF to one U.S. dollar. When the government devalued its currency in February, 2013, it also eliminated SITME, but established a new auction-based exchange rate market program, referred to as SICAD. Through December 31, 2013, the notional amount of transactions and regulations that has run through these programs has been limited, which essentially eliminates our ability to access any foreign exchange rate other than the official CADIVI rate to pay for imported goods and/or manage our local monetary asset balances. Accordingly, we measure all of our net monetary assets for our Venezuelan subsidiary using the official 6.3 exchange rate. As of December 31, 2013, our subsidiary had approximately $24 million of net monetary assets.

41

        In January, 2014, the Venezuelan government made a number of announcements related to the SICAD program, which could result in a devaluation of the rate at which our Venezuelan subsidiary is able to access U.S. dollars and the rate at which we translate results and balances denominated in VEF. This could have an unfavorable impact on our operating results. At this time, we are not able to predict the impact of these announcements and continue to monitor this situation, including the impact restrictions may have on our future business operations.

Commodity Risk

We purchase certain products in the normal course of business, including dairy, agricultural oils, and packaging materials, the costs of which are affected by global commodity changes. Therefore, we are exposed to price volatility related to market conditions outside of our control

        We employ various purchasing and pricing contract techniques in an effort to reduce volatility. Generally, these techniques include unit pricing that is based on an average of commodity prices over a contractually defined period of time, timing of purchases, and setting fixed prices with suppliers.Our intent is to utilize supplier volatility management tools when available. However, when such tools are unavailable or financially prohibitive through a supplier, we will utilize financial instruments. The company entered into non-fat dry milk futures contracts on November 26, 2013. The notional value of the hedge was 0.2 million pounds, representing a value of $0.3 million as of December 31, 2013which represents an insignificant portion of our total forecasted volume.

Interest Rate Risk

        We are exposed to changes in interest rates primarily as a result of our borrowing and investing activities used to maintain liquidity and fund business operations. Primary exposures include movements in U.S Treasury rates, LIBOR, and commercial paper rates. The nature and amount of our short-term and long-term debt can be expected to vary as a result of future business requirements, market conditions and other factors. Our debt obligations totaled$1.5 billion. For information on our debt obligations, see“Item 8. Financial Statements – Note 15. Debt.”

In addition, we used forward-starting interest rate swaps to hedge the interest rate volatilities on our planned refinancing of a portion of our long-term debt in 2014. The objective of these hedges is to offset the variability of future payments associated with the interest rate on our debt instruments. As of December 31, 2013, we had $500 million in aggregate notional amounts of forward-starting interest rate swaps outstanding. These hedges are designated as cash flow hedges. As of December 31, 2013, the fair value of the outstanding interest rate swaps was $19.4 million.

For information on interest rate swap activity, see“Item 8. Financial Statements – Note 16. Derivatives.”

42

Item 8.    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

INDEX TO FINANCIAL STATEMENTS

	Page
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	44
Audited Consolidated Financial Statements of Mead Johnson Nutrition Company:
Consolidated Statements of Earnings for the Years Ended December 31, 2013, 2012 and 2011	45
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2013, 2012 and 2011	46
Consolidated Balance Sheets as of December 31, 2013 and 2012	47
Consolidated Statements of Equity/(Deficit) and Redeemable Noncontrolling Interest for the Years Ended December 31, 2013, 2012 and 2011	48
Consolidated Statements of Cash Flows for the Years Ended December 31, 2013, 2012 and 2011	49
Notes to Financial Statements	50
Schedule II—Valuation and Qualifying Accounts	73

43

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders ofMead Johnson Nutrition CompanyGlenview, Illinois

We have audited the accompanying consolidated balance sheets of Mead Johnson Nutrition Company and subsidiaries (the “Company”) as of December 31, 2013 and 2012, and the related consolidated statements of earnings, comprehensive income, equity (deficit) and redeemable noncontrolling interest, and cash flows for each of the three years in the period ended December 31, 2013. Our audits also included the financial statement schedule listed in the Index at Item 8. These financial statements and financial statement schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on the financial statements and financial statement schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of Mead Johnson Nutrition Company and subsidiaries as of December 31, 2013 and 2012, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2013, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, such financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company's internal control over financial reporting as of December 31, 2013, based on the criteria established in Internal Control-Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 18, 2014 expressed an unqualified opinion on the Company's internal control over financial reporting.

/s/ DELOITTE & TOUCHE LLPChicago, IllinoisFebruary 18, 2014

44

CONSOLIDATED FINANCIAL STATEMENTS

OF MEAD JOHNSONNUTRITION COMPANY

CONSOLIDATED STATEMENTS OF EARNINGS(Dollars and shares in millions, except per share data)

	Years Ended December 31,
	2013		2012		2011
NET SALES	$	4,200.7	$	3,901.3	$	3,677.0
Cost of Products Sold	1,532.8		1,485.3		1,362.3
GROSS PROFIT	2,667.9		2,416.0		2,314.7
Expenses:
Selling, General and Administrative	918.0		877.8		926.8
Advertising and Promotion	645.1		552.8		501.7
Research and Development	102.4		95.4		92.5
Other Expenses – net	77.8		20.0		19.6
EARNINGS BEFORE INTEREST AND INCOME TAXES	924.6		870.0		774.1
Interest Expense – net	50.6		65.0		52.2
EARNINGS BEFORE INCOME TAXES	874.0		805.0		721.9
Provision for Income Taxes	219.1		192.6		202.9
NET EARNINGS	654.9		612.4		519.0
Less Net Earnings Attributable to Noncontrolling Interests	5.4		7.9		10.5
NET EARNINGS ATTRIBUTABLE TO SHAREHOLDERS	$	649.5	$	604.5	$	508.5
Earnings per Share – Basic
Net Earnings Attributable to Shareholders	$	3.20	$	2.96	$	2.48
Earnings per Share – Diluted
Net Earnings Attributable to Shareholders	$	3.19	$	2.95	$	2.47
Weighted-average Shares - Basic	202.4		203.6		204.3
Weighted-average Shares - Diluted	203.1		204.3		205.0

The accompanying notes are an integral part of these financial statements.

45

MEAD JOHNSON NUTRITION COMPANY

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Dollars in millions)

	Years Ended December 31,
	2013			2012			2011
NET EARNINGS	$	654.9		$	612.4		$	519.0
OTHER COMPREHENSIVE INCOME/(LOSS)
Foreign Currency Translation Adjustments
Translation Adjustments	(90.5		)	(8.4		)	(27.2		)
Tax Benefit/(Expense)	9.2			(13.0		)	4.7
Deferred Gains/(Losses) on Derivatives Qualifying as Hedges
Deferred Gains/(Losses) on Derivatives Qualifying as Hedges for the Period	24.2			(12.7		)	5.8
Reclassification Adjustment for Losses Included in Net Earnings	5.4			0.8			2.9
Tax Benefit/(Expense)	(10.1		)	3.5			(2.6		)
Pension and Other Post-Retirement Benefits
Deferred Gains/(Losses) on Pension and Other Post-Retirement Benefits	11.6			(58.5		)	(90.7		)
Reclassification Adjustment for Losses Included in Net Earnings	37.5			23.8			14.6
Tax Benefit/(Expense)	(16.1		)	10.6			24.1
OTHER COMPREHENSIVE LOSS	(28.8		)	(53.9		)	(68.4		)
COMPREHENSIVE INCOME	626.1			558.5			450.6
Less Comprehensive Income/(Loss) Attributable to Noncontrolling Interests	(6.9		)	7.9			10.6
COMPREHENSIVE INCOME ATTRIBUTABLE TO SHAREHOLDERS	$	633.0		$	550.6		$	440.0

The accompanying notes are an integral part of these financial statements.

46

MEAD JOHNSON NUTRITION COMPANYCONSOLIDATED BALANCE SHEETS(Dollars and shares in millions, except per share data)

	December 31,
	2013			2012
ASSETS
CURRENT ASSETS:
Cash and Cash Equivalents	$	1,050.8		$	1,042.1
Receivables – net of allowances of $6.5 and $7.6, respectively	384.4			364.6
Inventories	534.8			435.9
Deferred Income Taxes – net of valuation allowance	75.3			86.4
Income Taxes Receivable	15.9			26.0
Prepaid Expenses and Other Assets	56.9			60.0
Total Current Assets	2,118.1			2,015.0
Property, Plant, and Equipment – net	867.5			689.9
Goodwill	196.8			270.6
Other Intangible Assets – net	97.5			129.9
Deferred Income Taxes – net of valuation allowance	37.0			24.5
Other Assets	157.2			128.3
TOTAL	$	3,474.1		$	3,258.2
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Short-term Borrowings	$	2.0		$	161.0
Accounts Payable	566.8			508.5
Dividends Payable	69.3			61.3
Current Portion of Long-Term Debt	505.6			—
Note Payable	—			26.0
Accrued Expenses	220.0			220.4
Accrued Rebates and Returns	314.9			314.8
Deferred Income – current	46.6			36.1
Income Taxes – payable and deferred	56.1			41.8
Total Current Liabilities	1,781.3			1,369.9
Long-Term Debt	1,009.1			1,523.2
Deferred Income Taxes – noncurrent	15.3			15.9
Pension, Post Retirement and Post Employment Liabilities	161.8			188.8
Other Liabilities	156.4			95.1
Total Liabilities	3,123.9			3,192.9
COMMITMENTS AND CONTINGENCIES
REDEEMABLE NONCONTROLLING INTEREST	49.7			36.3
EQUITY
Shareholders’ Equity
Common Stock, $0.01 par value: 3,000 authorized, 206.8 and 206.0 issued, respectively	2.1			2.1
Additional Paid-in/(Distributed) Capital	(625.3		)	(676.6		)
Retained Earnings	1,470.4			1,124.8
Treasury Stock – at cost	(351.9		)	(244.6		)
Accumulated Other Comprehensive Loss	(203.5		)	(187.0		)
Total Shareholders’ Equity	291.8			18.7
Noncontrolling Interests	8.7			10.3
Total Equity	300.5			29.0
TOTAL	$	3,474.1		$	3,258.2

The accompanying notes are an integral part of these financial statements.

47

MEAD JOHNSON NUTRITION COMPANY

CONSOLIDATED STATEMENTS OF EQUITY/(DEFICIT) AND REDEEMABLE NONCONTROLLING INTEREST

(Dollars in millions)

	Common Stock		Additional Paid-in (Distributed) Capital			Retained Earnings			Treasury Stock			Accumulated Other Comprehensive Loss			Non- controlling Interests			Total  Equity/ (Deficit)			Redeemable Non- controlling Interest
Balance as of January 1, 2011	$	2.0	$	(775.6	)	$	474.0		$	(3.2	)	$	(64.6	)	$	9.1		$	(358.3	)	$	—
Stock-based Compensation Awards (includes excess tax benefits of $2.8)	0.1		47.2						(4.9		)							42.4
Treasury Stock Acquired									(81.6		)							(81.6		)
Distributions to Noncontrolling Interests															(8.6		)	(8.6		)
Cash Dividends Declared						(212.5		)										(212.5		)
Net Earnings						508.5									10.5			519.0
Other Comprehensive Income (Loss)												(68.5		)	0.1			(68.4		)
Balance as of December 31, 2011	$	2.1	$	(728.4	)	$	770.0		$	(89.7	)	$	(133.1	)	$	11.1		$	(168.0	)	$	—
Stock-based Compensation Awards (includes excess tax benefits of $11.8)	—		51.8						(15.2		)							36.6
Treasury Stock Acquired									(139.7		)							(139.7		)
Acquisition																		—			30.2
Distributions to Noncontrolling Interests															(7.6		)	(7.6		)
Cash Dividends Declared						(244.7		)										(244.7		)
Net Earnings						604.5									6.8			611.3			1.1
Redeemable Noncontrolling Interest Accretion						(5.0		)										(5.0		)	5.0
Other Comprehensive Income (Loss)												(53.9		)	—			(53.9		)
Balance as of December 31, 2012	$	2.1	$	(676.6	)	$	1,124.8		$	(244.6	)	$	(187.0	)	$	10.3		$	29.0		$	36.3
Stock-based Compensation Awards (includes excess tax benefits of $9.5)			56.6						(18.9		)							37.7
Treasury Stock Acquired									(88.4		)							(88.4		)
Distributions to Noncontrolling Interests															(8.3		)	(8.3		)	(1.2		)
Cash Dividends Declared						(275.7		)										(275.7		)
Net Earnings						649.5									4.6			654.1			0.8
Redeemable Noncontrolling Interest Accretion						(28.2		)										(28.2		)	28.2
Other Comprehensive Income (Loss)												(16.5		)	2.1			(14.4		)	(14.4		)
Other			(5.3		)													(5.3		)
Balance as of December 31, 2013	$	2.1	$	(625.3	)	$	1,470.4		$	(351.9	)	$	(203.5	)	$	8.7		$	300.5		$	49.7

The accompanying notes are an integral part of these consolidated financial statements.

48

MEAD JOHNSON NUTRITION COMPANYCONSOLIDATED STATEMENTS OF CASH FLOWS(Dollars in millions)

	Years Ended December 31,
	2013			2012			2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Earnings	$	654.9		$	612.4		$	519.0
Adjustments to Reconcile Net Earnings to Net Cash Provided by Operating Activities:
Depreciation and Amortization	83.1			76.9			75.3
Stock-Based Compensation Expense	32.6			32.2			39.9
Deferred Income Tax	7.0			17.1			(33.3		)
Gain on Sale of Intangible Assets	—			(6.5		)	—
Exchange Loss from Devaluation	2.2			—			—
Pension and Other Post Retirement Benefits Expense	43.1			27.9			19.1
Other	2.8			1.8			2.3
Change in Assets and Liabilities:
Receivables	(37.7		)	(8.5		)	(7.9		)
Inventories	(108.2		)	109.8			(183.3		)
Accounts Payable	56.0			(30.9		)	114.7
Accrued Expenses, Rebates and Returns	14.8			(6.3		)	50.0
Income Taxes Payable	27.0			(62.2		)	53.2
Other Assets and Liabilities	48.4			(42.7		)	(6.5		)
Pension and Other Post Retirement Benefits Contributions	(19.4		)	(28.3		)	(9.7		)
Net Cash Provided by Operating Activities	806.6			692.7			632.8
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for Capital Expenditures	(240.4		)	(124.4		)	(109.5		)
Proceeds from Sale of Property, Plant and Equipment	2.6			1.5			1.6
Proceeds from Sale of Intangible Assets	—			6.5			—
Investment in Other Companies	(2.7		)	(6.3		)	(4.7		)
Payment for Acquisition	—			(106.1		)	—
Net Cash Used in Investing Activities	(240.5		)	(228.8		)	(112.6		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Short-term Borrowings	6.9			391.2			72.0
Repayments of Short-term Borrowings	(165.4		)	(230.2		)	(73.2		)
Repayments of Notes Payable	(27.6		)	(52.6		)	—
Payments of Dividends	(267.7		)	(236.7		)	(205.7		)
Stock-Based Compensation Related Proceeds and Excess Tax Benefits	23.6			23.3			4.5
Purchases of Treasury Stock	(106.0		)	(154.9		)	(87.7		)
Proceeds from Termination of Interest Rate Swaps	—			—			23.5
Distributions to Noncontrolling Interests	(9.5		)	(7.6		)	(8.6		)
Net Cash Used in Financing Activities	(545.7		)	(267.5		)	(275.2		)
Effects of Changes in Exchange Rates on Cash and Cash Equivalents	(11.7		)	5.4			(0.3		)
NET INCREASE IN CASH AND CASH EQUIVALENTS	8.7			201.8			244.7
CASH AND CASH EQUIVALENTS:
Beginning of Period	1,042.1			840.3			595.6
End of Period	$	1,050.8		$	1,042.1		$	840.3

The accompanying notes are an integral part of these financial statements.

49

MEAD JOHNSON NUTRITION COMPANYNOTES TO CONSOLIDATED FINANCIAL STATEMENTSAS OF DECEMBER 31, 2013 AND 2012 AND FOR THE YEARS ENDEDDECEMBER 31, 2013, 2012 AND 2011

1. ORGANIZATION

        MeadJohnson Nutrition Company (“MJN” or the “Company”) manufactures, distributes and sells infant formula, children’s nutrition and other nutritional products. MJN has a broad product portfolio, which extends across routine and specialty infant formulas, children’s milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders. These products are generally sold to wholesalers, retailers and distributors and are promoted to healthcare professionals, and, where permitted by regulation and policy, directly to consumers. 

2. ACCOUNTING POLICIES

        Basis of Presentation—The financial statements present the results of operations, financial position, and cash flows of MJN and its majority-owned and controlled subsidiaries. Intercompany balances and transactions have been eliminated. The Company prepared the accompanying consolidated financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”). These financial statements consider subsequent events through the date of filing with the Securities and Exchange Commission.

In the Consolidated Statements of Cash Flows for the years ended December 31, 2012 and 2011, operating cash flow amounts reflected as pension and other postretirement benefit expense have been reclassified to conform to the presentation for the year ended December 31, 2013. These amounts were previously classified as a component of the change in other assets and liabilities.

        Use of Estimates—The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used in revenue recognition, including sales rebate and return accruals, impairment testing of goodwill and other indefinite-lived intangible assets, income tax assets and liabilities, income tax expense, and legal liabilities, as well as the accounting for stock-based compensation and retirement and post retirement benefits, including the actuarial assumptions. Actual results may or may not differ from estimated results.

        Fair Value Measurements—The fair value of financial assets and liabilities are classified in the fair value hierarchy as follows: Level 1—unadjusted quoted prices in active markets for identical assets or liabilities, Level 2—observable prices that are based on inputs not quoted on active markets, and Level 3—unobservable inputs that reflect estimates about the assumptions market participants would use in pricing the asset or liability.

        Revenue Recognition—MJN recognizes revenue when substantially all the risks and rewards of ownership have transferred to the customer. Revenue is recognized on the date MJN’s products are received by the purchaser. Revenues are reduced at the time of recognition to reflect expected returns that are estimated based on historical experience and business trends. Additionally, provisions are made at the time of revenue recognition for discounts, Women, Infants and Children (“WIC”) rebates and estimated sales allowances based on historical experience, updated for changes in facts and circumstances, as appropriate. Such provisions are recorded as a reduction of revenue. The Company offers sales incentives to customers and consumers through various programs consisting primarily of customer pricing allowances, merchandising funds and consumer coupons. Provisions are made at the time of revenue recognition for these items based on historical experience, updated for changes in facts and circumstances, as appropriate. Such provisions are recorded as a reduction of revenue.

        WIC rebate accruals were $199.7 million and $206.5 million at December 31, 2013 and 2012, respectively, and are included in accrued rebates and returns on the Company’s balance sheet. MJN participates on a competitive bidding basis in nutrition programs sponsored by states, tribal governments, the Commonwealth of Puerto Rico, and U.S. territories for WIC. Under these programs, MJN reimburses these entities for the difference between wholesaler list price and the contract price on eligible products. The Company accounts for WIC rebates by establishing an accrual in an amount equal to the Company’s estimate of WIC rebate claims attributable to a sale. MJN determines its estimate of the WIC rebate accrual primarily based on historical experience regarding WIC rebates and current contract prices under the WIC programs. The Company considers levels of inventory in the distribution channel, new WIC contracts, terminated WIC contracts, changes in existing WIC contracts and WIC participation, and adjusts the accrual periodically throughout the year to reflect actual expense. Rebates under the WIC program reduced revenues by $702.3 million, $730.0 million, and $700.7 million in the years ended December 31, 2013, 2012, and 2011, respectively.

        Sales return accruals were $44.8 million and $46.4 million at December 31, 2013 and 2012, respectively, and are included in accrued rebates and returns on the Company’s balance sheet. The Company accounts for sales returns by establishing an accrual in an amount equal

50

to its estimate of sales recorded for which the related products are expected to be returned. The Company determines its estimate of the sales return accrual primarily based on historical experience regarding sales returns, but also considers other factors that could impact sales returns such as discontinuations and new product introductions. Returns reduced sales by $81.0 million, $82.5 million, and $81.8 million for the years ended December 31, 2013, 2012 and 2011, respectively.

        Income Taxes—The provision for income taxes has been determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable earnings in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when changes are enacted.The ultimate liability incurred by the Company may differ from the provision estimates based on a number of factors, including interpretations of tax laws and the resolution of examinations by the taxing authorities.

        Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.The assessment of whether or not a valuation allowance is required often requires significant judgment including the long-range forecast of future taxable earnings and the evaluation of tax planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made.

        Uncertain tax positions that relate to deferred tax assets are recorded against deferred tax assets; otherwise, uncertain tax positions are recorded as either a current or noncurrent liability.

Cash and Cash Equivalents—Cash and cash equivalents consist of bank deposits, time deposits and money market funds. The Company maintains cash and cash equivalent balances in U.S. dollars and foreign currencies, which are subject to currency rate risk. Cash equivalents are primarily highly liquid investments with original maturities of 3 months or less at the time of purchase and are recorded at cost, which approximates fair value. Money market funds, which totaled $447.8 million and $520.7 million at December 31, 2013 and 2012, respectively, are classified as Level 2 in the fair value hierarchy.

        Inventory Valuation—Inventories are valued at the lower of cost or market. The Company determines cost on the basis of the average cost or first-in, first-out methods.

        Property, Plant and Equipment—Expenditures for additions and improvements, including capitalized interest, are recorded at cost. Depreciation is computed on a straight-line method based on the estimated useful lives of the related assets. The estimated useful lives of the major classes of depreciable assets are up to 50 years for buildings and 3 to 40 years for machinery, equipment, and fixtures. Maintenance and repair costs are expensed as incurred.

        Capitalized Software—Certain costs to obtain internal-use software for significant systems projects are capitalized and amortized on a straight-line basis over the estimated useful life of the software, which ranges from 3 to 7 years. Costs to obtain software for projects that are not significant are expensed as incurred.

        Impairment of Long-Lived Assets—The Company periodically evaluates whether current facts or circumstances indicate that the carrying value of its depreciable assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived asset, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. An estimate of the asset’s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company reports an asset to be disposed of at the lower of its cost less accumulated depreciation or its estimated net realizable value.

        Goodwill and Other Intangible Assets—During the third quarter of 2013 the Company changed its annual impairment testing date from January 1 to July 1, which did not result in any delay, acceleration or avoidance of an impairment charge. The Company believes that moving the goodwill impairment testing date to the third quarter is preferable because it better aligns with MJN’s annual and long-term planning timeline, which is a significant element in the testing process. The Company completed impairment testing in both the first and third quarters of 2013 and concluded that no impairment of goodwill exists (see Note 14).

The Company’s policy is to test Goodwill for impairment on an annual basis or when current facts or circumstances indicate that a potential impairment may exist. The Company compares the carrying value of a reporting unit, including goodwill, to the fair value of the unit. If the carrying amount of a reporting unit exceeds its fair value, the Company revalues all assets and liabilities of the reporting unit, excluding goodwill, to determine if the fair value of the net assets is greater than the net assets including goodwill. If the fair value of the net assets is less than the carrying amount of net assets including goodwill, impairment has occurred. The Company’s estimates of fair value are

51

primarily determined based on a discounted cash flow model. Growth rates for sales and profits are determined using inputs from the Company’s annual long-range planning process. The Company also makes estimates of discount rates, perpetuity growth assumptions, market comparables, and other factors. The Company completed its most recent goodwill impairment assessment during the third quarter and monitored for any potential impairment during the remainder of 2013. No impairment of goodwill was required in2013,2012or2011.

The Company evaluates the useful lives of its other intangible assets to determine if they are finite or indefinite-lived. Reaching a determination on useful life requires significant judgments and assumptions regarding the future effects of obsolescence, demand, competition, other economic factors (such as the stability of the industry, known technological advances, legislative action that results in an uncertain or changing regulatory environment, and expected changes in distribution channels), the level of required maintenance expenditures, and the expected lives of other related groups of assets. Intangible assets that are deemed to have definite lives are amortized on a straight-line basis, over their useful lives.

The Company’s indefinite-lived intangible assets are also tested for impairment annually and whenever events or changes in circumstances indicate that their carrying value may not be recoverable. Estimates of the fair value of indefinite-lived intangible assets is based on a discounted cash flow model using inputs which included projected revenues from the Company’s annual long-range plan, assumed royalty rates that could be payable if MJN did not own the brands, and a discount rate. The Company completed its most recent indefinite-lived intangible asset impairment assessment during the third quarter and monitored for any potential impairment during the remainder of 2013, determining that no impairment was required.

        Contingencies—In the ordinary course of business, the Company is subject to loss contingencies, such as lawsuits, investigations, government inquiries and claims, including, but not limited to, product liability claims, advertising disputes and inquiries, consumer fraud suits, other commercial disputes, premises claims and employment and environmental, health, and safety matters. The Company records accruals for such loss contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. The Company does not recognize gain contingencies until realized. Legal costs are expensed as incurred.

        Derivatives—Derivatives are used by the Company principally in the management of its foreign currency, interest rate and commodity pricing exposures. The Company records all derivatives on the balance sheet at fair value. The Company does not hold or issue derivatives for speculative purposes.

        The Company designates and assigns derivatives as hedges of forecasted transactions, specific assets or specific liabilities. When the hedged assets or liabilities are sold, extinguished or the forecasted transactions being hedged are no longer expected to occur, the Company immediately recognizes the gain or loss on the designated hedging financial instruments in the consolidated statements of earnings.

        If derivatives are designated as a cash flow hedge, the effective portion of changes in the fair value is temporarily reported in accumulated other comprehensive loss and is recognized in earnings when the hedged item affects earnings or is deemed ineffective; cash flows are classified consistent with the underlying hedged item. The Company assesses hedge effectiveness at inception and on a quarterly basis. These assessments determine whether derivatives designated as qualifying hedges continue to be highly effective in offsetting changes in the cash flows of hedged items. Any ineffective portion of the change in fair value is included in current period earnings. The Company will discontinue cash flow hedge accounting when the forecasted transaction is no longer probable of occurring on the originally forecasted date, or 60 days thereafter, or when the hedge is no longer effective.

        If derivatives are designated as a fair value hedge, both the changes in the fair value of the derivatives and of the hedged item attributable to the hedged risk are recognized in the consolidated statements of earnings; cash flows are classified consistent with the underlying hedged item.

        Pension and Other Post Retirement Benefits—The funded status of the Company’s defined pension and post retirement benefit plans is measured as the difference between the fair value of the plan assets and the benefit obligation. For the defined benefit plans, the benefit obligation is the projected benefit obligation; for any other defined benefit post retirement plans, the benefit obligation is the accumulated post retirement benefit obligation. The net over- or under-funded status is recognized as an asset or a liability on the balance sheet. Any unrecognized actuarial gain or loss, or service cost or benefit is reported as a component of accumulated other comprehensive loss.

        Shipping and Handling Costs—The Company typically does not charge customers for shipping and handling costs. Shipping and handling costs, including warehousing expenses, were $119.1 million, $115.6 million, and $104.3 million in the years ended December 31, 2013, 2012, and 2011, respectively, and are included in selling, general and administrative expenses.

        Advertising Costs—Advertising costs are expensed as incurred and were $226.7 million, $180.3 million, and $180.6 million in the years ended December 31, 2013, 2012, and 2011, respectively.

        Research and Development—Research and development costs are expensed as incurred.

52

        Foreign Currency Translation—The statements of earnings of the Company’s foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using average exchange rates for the period. The net assets of the Company’s foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using exchange rates as of the balance sheet date. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in accumulated other comprehensive income (loss).

Recently Adopted Accounting Standards—In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, requiring entities to provide information about the amounts reclassified out of accumulated other comprehensive income by component. For significant reclassifications related to net income, the ASU required disclosure in the consolidated statement of earnings or within the footnotes. For other amounts, the ASU required a cross-reference to other disclosures that provide additional detail about those amounts. This ASU did not change the current requirements for reporting the consolidated statement of earnings or other comprehensive income in the financial statements. The Company adopted the required financial reporting presentation effective January 1, 2013.

Recently Issued Accounting Standards—In March 2013, the FASB issued ASU No. 2013-05, Foreign Currency Matters (Topic 830), clarifying the applicable guidance for the release of the cumulative translation adjustment. ASU 2013-05 is effective for the Company in the period beginning January 1, 2014. The Company does not expect the adoption of this update to have a material impact on the consolidated financial statements.   

In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or Tax Credit Carryforward Exists. ASU 2013-11 requires that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, with certain exceptions. ASU 2013-11 is effective for the Company in the period beginning January 1, 2014 and the Company does not anticipate that the adoption of this standard to have a material impact on its consolidated financial statements.

3. EARNINGS PER SHARE

        The numerator for basic and diluted earnings per share is net earnings attributable to shareholders reduced by dividends and undistributed earnings attributable to unvested shares. The denominator for basic earnings per share is the weighted-average number of shares outstanding during the period. The denominator for diluted earnings per share is the weighted-average shares outstanding adjusted for the effect of dilutive stock options and performance share awards.

        The following table presents the calculation of basic and diluted earnings per share:

	Years Ended December 31,
(In millions, except per share data)	2013			2012			2011
Basic earnings per share:
Weighted-average shares outstanding	202.4			203.6			204.3
Net earnings attributable to shareholders	$	649.5		$	604.5		$	508.5
Dividends and undistributed earnings attributable to unvested shares	(1.2		)	(1.4		)	(1.4		)
Net earnings attributable to shareholders used for basic earnings per share calculation	$	648.3		$	603.1		$	507.1
Net earnings attributable to shareholders per share	$	3.20		$	2.96		$	2.48
Diluted earnings per share:
Weighted-average shares outstanding	202.4			203.6			204.3
Incremental shares outstanding assuming the exercise/vesting of dilutive stock options/performance shares	0.7			0.7			0.7
Weighted-average shares — diluted	203.1			204.3			205.0
Net earnings attributable to shareholders	$	649.5		$	604.5		$	508.5
Dividends and undistributed earnings attributable to unvested shares	(1.2		)	(1.4		)	(1.4		)
Net earnings attributable to shareholders used for diluted earnings per share calculation	$	648.3		$	603.1		$	507.1
Net earnings attributable to shareholders per share	$	3.19		$	2.95		$	2.47

Potential shares outstanding from all stock-based awards were 2.8 million, 2.7 million and 2.9 million as of December 31, 2013, 2012 and 2011, respectively, of which 2.1 million, 2.0 million and 2.2 million were not included in the diluted earnings per share calculation for the years ended December 31,2013, 2012 and 2011, respectively. 

53

4. INCOME TAXES

       The components of earnings before income taxes were:

	Years Ended December 31,
(In millions)	2013		2012		2011
U.S.	$	90.2	$	131.8	$	153.7
Non-U.S.	783.8		673.2		568.2
Total	$	874.0	$	805.0	$	721.9

        The above amounts are categorized based on the applicable taxing authorities.

        The provision (benefit) for income taxes consisted of:

	Years Ended December 31,
(In millions)	2013			2012			2011
Current:
U.S. federal	$	79.1		$	37.1		$	81.3
U.S. states	2.4			(1.3		)	10.7
Non-U.S.	130.6			139.7			144.2
Total current income tax expense	212.1			175.5			236.2
Deferred:
U.S. federal	(23.5		)	15.8			(5.2		)
U.S. states	0.3			(3.3		)	(4.4		)
Non-U.S.	30.2			4.6			(23.7		)
Total deferred income tax expense	7.0			17.1			(33.3		)
Total	$	219.1		$	192.6		$	202.9

        Effective Tax Rate—MJN’s provision for income taxes in the years ended December 31, 2013, 2012 and 2011 was different from the amount computed by applying the statutory U.S. federal income tax rate to earnings before income taxes as a result of the following:

(Dollars in millions)	2013					2012					2011
U.S. statutory rate	$	305.9		35.0	%	$	281.7		35.0	%	$	252.6		35.0	%
State and local taxes	1.3			0.2		0.8			0.1		3.7			0.5
Foreign income taxed at different rates	(25.6		)	(2.9	)	(67.7		)	(8.4	)	(42.1		)	(5.8	)
Repatriation of foreign income	9.4			1.1		21.6			2.7		21.8			3.0
Tax rulings and agreements	(121.9		)	(13.9	)	(46.4		)	(5.8	)	(51.9		)	(7.2	)
Reversal of deferred tax on prior years' unremitted foreign earnings due to a permanent reinvestment assertion	(8.2		)	(0.9	)	(8.7		)	(1.1	)	—			—
Administrative penalty related to China antitrust review	8.3			1.0		—			—		—			—
Unrecognized tax benefits and related interest/penalties	38.1			4.4		13.1			1.6		7.3			1.0
Other	11.8			1.1		(1.8		)	(0.2	)	11.5			1.6
Total provision / effective tax rate	$	219.1		25.1	%	$	192.6		23.9	%	$	202.9		28.1	%

   The Company negotiated a tax ruling effective from January 1, 2010, under which certain profits in the Netherlands are exempt from taxation through the year ending December 31, 2019. This ruling was superseded by a subsequent tax agreement effective July 26, 2012, whereby the Company and the Dutch tax authorities agreed to the appropriate remuneration attributable to Dutch manufacturing activities through the year ending December 31, 2019.

In addition, the Company negotiated a tax ruling effective from January 1, 2013, under which certain profits in Singapore are eligible for favorable taxation through the year ending December 31, 2027.

54

        Deferred Taxes and Valuation Allowance—The components of current and noncurrent deferred income tax assets (liabilities) were:

	December 31,
(In millions)	2013			2012
Deferred tax assets:
Accrued expenses	$	33.5		$	28.0
Accrued rebates and returns	42.2			44.5
Pension, post retirement and post employment liabilities	58.1			65.3
Stock-based compensation	20.2			18.3
Obsolescence reserves and other inventory items	7.9			6.3
Net operating loss carryforwards	13.5			17.2
Other—net	6.7			23.2
Valuation allowance	(7.3		)	(6.1		)
Total deferred tax assets	174.8			196.7
Deferred tax liabilities:
Depreciation and amortization	(68.5		)	(76.5		)
Unremitted earnings and cumulative foreign currency translation adjustments	(9.7		)	(26.1		)
Total deferred tax liabilities	(78.2		)	(102.6		)
Deferred tax assets—net	$	96.6		$	94.1
Recognized as:
Net deferred income taxes—current	74.9			85.5
Net deferred income taxes—noncurrent	21.7			8.6
Total	$	96.6		$	94.1

   As ofDecember 31, 2013, the Company had definite-lived and indefinite-lived gross foreign net operating loss (“NOL”) carryforwards of$49.0 million.Indefinite-lived NOL carryforwards totaled $22.3 million with the remainder being definite-lived. An immaterial amount of these definite-lived NOL carryforwards will begin to expire in2014, with the remainder of the definite-lived NOL carryforwards to expire no later than2031. The valuation allowance recorded for NOL carryforwards is$5.0 millionas ofDecember 31, 2013.

As of December 31, 2013, the Company had various definite-lived U.S. state tax credit carryforwards of $6.9 million net of federal benefit. An immaterial amount of these state tax credit carryforwards will begin to expire in 2016, with the remainder of the state tax credit carryforwards to expire no later than 2023. The valuation allowance recorded for state tax credit carryforwards is $2.3 million, net of federal benefit as of December 31, 2013.

        Income taxes paid net of refunds were $159.3 million, $226.8 million, and $174.3 million in the years ended December 31,2013, 2012, and 2011, respectively. The income taxes were paid to federal, state and foreign taxing authorities and BMS pursuant to the terms of the Amended and Restated Tax Matters Agreement.

        As ofDecember 31, 2013, U.S. taxes have not been provided on approximately$1.4 billionof foreign earnings as these undistributed earnings have been permanently invested offshore. If, in the future, these earnings were to be repatriated to the U.S. additional tax provisionswould be required. It is impracticable to determine a precise estimate of the additional provision required. However, the maximum potential estimated U.S. tax liability would be$494 millionif these earnings were to be repatriated to the United States in such a manner that the entire amount of foreign earnings would be subject to the U.S. statutory tax rate with no U.S. tax relief for foreign taxes already paid.  However, the Company has no plans to repatriate these foreign earnings.

        The Company’s tax returns are routinely audited by federal, state and foreign tax authorities and these tax audits are at various stages of completion at any given time. The Internal Revenue Service (“IRS”) has completed examinations of the Company’s U.S. income tax filings through December 31, 2007. At December 31, 2013, the Company’s 2011 income tax return was under IRS examination. At December 31, 2013, tax years remaining open to examination outside the U.S. include 2003 and forward.

55

        A reconciliation of the Company’s changes in gross uncertain tax positions is as follows:

	Years Ended December 31,
(In millions)	2013			2012			2011
Balance at January 1:	$	64.7		$	29.7		$	13.6
Increases based on current year tax positions	23.8			17.8			14.6
Decreases based on current year tax positions	—			—			—
Increases based on prior year tax positions	18.9			21.4			1.7
Decreases based on prior year tax positions	—			—			(0.3		)
Settlements	—			—			(0.1		)
Lapse of statute of limitations	(3.8		)	(5.2		)	—
Cumulative translation adjustment	(1.0		)	1.0			0.2
Balance at December 31:	$	102.6		$	64.7		$	29.7

        Uncertain tax positions have been recorded as part ofother liabilitieswith a reversal of up to$10 millionreasonably possible in the next 12 months due to the expiration of statutes of limitations. The amounts of uncertain tax positions that, if recognized, would impact the effective tax rate were$48.6 million,$18.9 million, and$10.9 millionas of December 31, 2013, 2012 and 2011, respectively.The Company believes that it has provided adequately for all uncertain tax positions. It is reasonably possible that new issues may be raised by tax authorities and that these issues may require increases in the balance of uncertain tax positions.

        Interest and penalties related to uncertain tax positions were $14.8 million and $11.2 million, as of December 31, 2013, and 2012, respectively, and are included as a component of other liabilities. The Company classifies interest and penalties related to uncertain tax positions as a component of provision for income taxes. The amount of interest and penalties included as a component of provision for income taxes was $3.0 million, $5.0 million and $0.6 million for the years ended December 31, 2013, 2012 and 2011, respectively.

On December 18, 2009, the Company and Bristol-Myers Squibb Company (“BMS”) entered into an Amended and Restated Tax Matters Agreement in anticipation of the separation from BMS. Under the Amended and Restated Tax Matters Agreement, BMS agreed to indemnify the Company for (i) any tax attributable to a MJN legal entity for any taxable period ending on or before December 31, 2008, (ii) any tax arising solely as a result of MJN’s 2009 initial public offering (“IPO”) and the restructuring preceding the IPO, and (iii) any transaction tax associated with the separation transaction. The Company agreed to indemnify BMS for (i) any tax payable with respect to any separate return that the Company is required to file or cause to be filed, (ii) any tax incurred as a result of any gain which may be recognized by a member of the BMS affiliated group with respect to a transfer of certain foreign affiliates by the Company in preparation for the IPO, and (iii) any tax arising from the failure or breach of any representation or covenant made by the Company which failure or breach results in the intended tax consequences of the separation transaction not being achieved.Additionally,under the Amended and Restated Tax Matters Agreement, the Company continues to maintain responsibility for any tax positions which may existfor any taxable period ending after December 31, 2008.

5. SEGMENT INFORMATION

        MJN operates infourgeographic operating segments: Asia, Europe, Latin America and North America. In the fourth quarter of 2013, the Company revised its reportable segments. Previously the Company presented two reportable segments: Asia/Latin America and North America/Europe. In the fourth quarter of 2013, the Company expanded the number of reportable segments tothreeas it separated the Asia/Latin America segment into two reportable segments: Asia and Latin America. The North America/Europe reportable segment remains unchanged. This change in segment reporting presentation does not change any consolidated totals. The Company made this segment reporting change because it believes that the new presentation will provide investors with greater insight into the Company's consolidated results and operating performance. Prior year comparative information has been revised to conform to the current reportable segment presentation.

Corporate and Other consists of unallocated general and administrative expenses; global business support activities, including research and development, marketing and supply chain costs; and income or expenses incurred within the operating segments that are not reflective of ongoing operations and affect the comparability of the operating segments’ results. The Company’s products are sold principally to wholesalers, retailers and distributors. One customer in the North America/Europe and Latin America segments accounted for 10%, 11% and 12% of the Company’s gross sales for each year ended December 31, 2013, 2012, and 2011; a second customer in the Asia segment accounted for 16%, 15%, and 14% of the Company’s gross sales for the years ended December 31, 2013, 2012, and 2011, respectively.

56

        The Company's segment, product and geographic results consisted of:

(In millions)	Net Sales		Earnings Before Interest and Income Taxes			Year-End Assets		Payments for Capital Expenditures		Depreciation and Amortization
Year ended December 31, 2013
Asia	$	2,179.3	$	795.8		$	1,390.7	$	168.1	$	19.4
Latin America	861.4		207.2			716.9		33.3		10.5
North America/Europe	1,160.0		248.5			798.5		31.6		29.1
Total operating segments	4,200.7		1,251.5			2,906.1		233.0		59.0
Corporate and Other	—		(326.9		)	568.0		7.4		24.1
Total	$	4,200.7	$	924.6		$	3,474.1	$	240.4	$	83.1
Year ended December 31, 2012
Asia	$	1,967.0	$	725.3		$	1,097.3	$	87.4	$	16.9
Latin America	752.5		176.0			712.8		10.7		8.9
North America/Europe	1,181.8		246.1			740.5		22.3		27.4
Total operating segments	3,901.3		1,147.4			2,550.6		120.4		53.2
Corporate and Other	—		(277.4		)	707.6		4.0		23.7
Total	$	3,901.3	$	870.0		$	3,258.2	$	124.4	$	76.9
Year ended December 31, 2011
Asia	$	1,827.8	$	672.5		$	1,008.6	$	34.0	$	17.2
Latin America	619.4		139.1			467.4		12.0		7.6
North America/Europe	1,229.8		308.4			764.0		33.4		30.7
Total operating segments	3,677.0		1,120.0			2,240.0		79.4		55.5
Corporate and Other	—		(345.9		)	526.8		30.1		19.8
Total	$	3,677.0	$	774.1		$	2,766.8	$	109.5	$	75.3

Net Sales (in millions)	Infant Formula		Children’s Nutrition		Other		Total
Year ended December 31, 2013	$	2,459.7	$	1,653.3	$	87.7	$	4,200.7
Year ended December 31, 2012	$	2,295.5	$	1,487.0	$	118.8	$	3,901.3
Year ended December 31, 2011	$	2,188.7	$	1,394.4	$	93.9	$	3,677.0

Geographic (in millions)	United States		China/ Hong Kong		Mexico		Singapore	Other		Total
Year ended December 31, 2013
Net Sales	$	948.2	$	1,315.8	$	328.2	28.0	$	1,580.5	$	4,200.7
Long-Lived Assets	446.6		64.7		134.8		245.9	427.0		1,319.0
Year ended December 31, 2012
Net Sales	$	990.1	$	1,160.1	$	317.2	22.5	$	1,411.4	$	3,901.3
Long-Lived Assets	456.0		65.1		180.1		104.9	437.1		1,243.2
Year ended December 31, 2011
Net Sales	$	1,019.7	$	1,083.5	$	321.0	20.8	$	1,232.0	$	3,677.0
Long-Lived Assets	457.3		60.7		171.6		1.3	169.7		860.6

6. EMPLOYEE STOCK BENEFIT PLANS

        MJN 2009 Stock Award and Incentive Plan—The MJN 2009 Amended and Restated Stock Award and Incentive Plan (“Award and Incentive Plan”) provides for the grant of stock options, performance share awards, restricted stock units and other stock-based awards. Executive officers and other key employees of MJN, and non-employee directors and others who provide substantial services to MJN, are eligible to be granted awards under the Award and Incentive Plan. Twenty-five million shares of stock were approved and registered with the Securities and Exchange Commission (the “SEC”) for grants to participants under the Award and Incentive Plan. Shares used for awards assumed in an acquisition or combination will not count against the shares reserved under the Award and Incentive Plan. The shares reserved may be used for any type of award under the Award and Incentive Plan. Stock-based compensation expense is based on awards ultimately expected to vest. Forfeitures are estimated based on the historical experience of participants in the Award and Incentive Plan since its inception in February of 2009.

        MJN may grant options to purchase common stock at no less than 100% of the closing market price on the date the option is granted. Stock options generally become exercisable in installments of either 25% per year on each of the first through the fourth anniversaries of the

57

grant date or 33% per year on each of the first through the third anniversaries of the grant date. Stock options have a maximum term of 10 years. Generally, MJN will issue shares for the stock option exercises from treasury stock, if available, or will issue new shares.

        MJN may also grant performance share awards, which are granted in the form of a target number of performance shares to be earned and have a three-year performance cycle consisting of three one-year performance periods. The performance share awards have annual goals set at the beginning of each performance period, at which time the awards are considered granted. The maximum payout is 200%. If targets are not met for a performance period, no payment is made under the plan for that annual period.

        MJN may also grant restricted stock units under the Award and Incentive Plan. Restrictions generally expire over a 1- to 5-year period from the date of grant. Stock-based compensation expense is recognized over the restricted period. A restricted stock unit is a right to receive stock at the end of the specified vesting period. A restricted stock unit has non-forfeitable rights to dividend equivalent payments and has no voting rights.

        MJN Stock Options—The fair value of stock options granted in 2013, 2012, and 2011 was estimated on the date of grant using the Black-Scholes option pricing model. No stock options with market conditions were granted in 2013, 2012 or 2011. The following assumptions were used in the valuations:

	2013		2012		2011
	Black-Scholes Model		Black-Scholes Model		Black-Scholes Model
Expected volatility	27.0	%	26.9	%	26.7	%
Risk-free interest rate	0.9	%	1.2	%	2.6	%
Dividend yield	1.9	%	1.6	%	1.7	%
Expected life	5.3 years		6.0 years		6.0 years

        The 2013 and 2012 expected volatility assumption required in the Black-Scholes model was calculated based principally on the Company’s historical volatility, and to a lesser extent, on implied volatility from publicly-traded options on the Company’s stock.As MJN has not yet accumulated six years of historical stock trading data, the full history of MJN over the period of February 2009 through December 2013 is used to calculate the expected volatility assumption required in the Black-Scholes model. The 2011 expected volatility assumption required in the Black-Scholes model was calculated based on an equal weighting between the Company’s historical volatility and implied volatility from publicly-traded options on the Company’s stock.

        The risk-free interest rate assumption in the Black-Scholes model is based upon the U.S. Treasury yield curve in effect at the time of grant. The dividend yield assumption is based on MJN’s expectation of dividend payouts. The expected life is based on the vesting period and the contractual term for each grant, or for each vesting tranche for awards with graded vesting. The selection of this approach was based on MJN’s assessment that this simplified method is appropriate given the terms of the stock option granted and given that there is not sufficient historical stock option exercise experience upon which to estimate expected terms.        

        Stock option activities were as follows:

	Shares (in thousands)	Weighted Average Exercise Price of Shares		Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in millions)
Balance—January 1, 2011	1,404	$	34.36	8.6	$	48.2
Granted	558	59.18
Exercised	(140)	31.65			$	5.2
Forfeited or expired	(33)	45.03
Balance—December 31, 2011	1,789	42.12		8.1	$	47.6
Granted	491	78.12
Exercised	(325)	35.60			$	11.6
Forfeited or expired	(53)	57.50
Balance—December 31, 2012	1,902	52.11		7.7	$	99.2
Granted	485	74.76
Exercised	(377)	36.06			$	17.6
Forfeited or expired	(51)	73.57
Balance—December 31, 2013	1,959	60.12		7.4	$	46.3
Vested—December 31, 2013	1,119	50.24		6.5	$	37.5
Vested and expected to vest—December 31, 2013	1,940	59.98		7.4	$	46.1

58

        The weighted-average grant date fair value of stock options granted is $15.08, $17.55 and $14.73 for 2013, 2012 and 2011 respectively.

        Cash proceeds received from options exercised during the years ended December 31,2013,2012and2011were$13.6 million,$11.6 millionand$4.5 million, respectively. The tax benefit realized from stock options exercised was$5.9 millionin2013,$4.8 million in 2012and$1.8 millionin2011.

        At December 31, 2013, total unrecognized compensation cost related to stock options of $7.4 million is expected to be recognized over a weighted average period of 1.8 years.

        MJN Performance Share Awards—The fair value of performance share awards is based on the closing trading price of MJN’s stock on the date of the grant, discounted using the risk-free interest rate as the awards do not participate in dividends. Information related to performance share awards activity is summarized as follows:

Grant Date	Performance Cycle Measurement Date	Shares Granted and Earned (in thousands)	Weighted- Average Grant- Date Fair Value		Performance Shares Outstanding at December 31, 2013
February 27, 2013	Annually on 12/31	203	$	72.30	143
March 2, 2012	Annually on 12/31	418	$	67.22	197
March 2, 2011	Annually on 12/31	275	$	57.03	79

        Shares granted and earned in the table above assumes 100% plan performance adjusted for the actual plan achievement level for completed performance periods. At December 31, 2013, total unrecognized compensation cost related to the performance share awards granted of $6.5 million is expected to be recognized over a weighted average period of 1.5 years.

        MJN Restricted Stock Units—The fair value of restricted stock units is determined based on the closing trading price of MJN’s common stock on the grant date. A summary of restricted stock unit activity is as follows:

	Shares (in thousands)		Weighted- Average Grant Date Fair Value
Nonvested restricted stock units—January 1, 2011	588		$	35.15
Granted	134		59.40
Vested	(170	)	44.44
Forfeited	(19	)	40.39
Nonvested restricted stock units—December 31, 2011	533		38.09
Granted	146		76.98
Vested	(146	)	32.28
Forfeited	(19	)	47.57
Nonvested restricted stock units—December 31, 2012	514		50.24
Granted	133		74.85
Vested	(189	)	39.14
Forfeited	(35	)	62.68
Nonvested restricted stock units—December 31, 2013	423		61.59

        At December 31, 2013, total unrecognized compensation cost related to nonvested restricted stock units was $12.8 million and is expected to be recognized over a weighted average period of 2.5 years.

        Stock-Based Compensation Expense—The following table summarizes stock-based compensation expense related to MJN stock options, MJN performance share awards and MJN restricted stock units for the years ended December 31, 2013, 2012, and 2011:

	Years Ended December 31,
(In millions)	2013			2012			2011
Stock options	$	6.5		$	7.5		$	5.9
Performance share awards	16.1			16.1			22.8
Restricted stock units	10.0			8.6			11.2
Total pre-tax stock-based compensation expense	$	32.6		$	32.2		$	39.9
Net tax benefit related to stock-based compensation expense	$	(11.4	)	$	(9.8	)	$	(14.1	)

59

        Stock-based compensation expense was recognized in the consolidated statements of earnings as follows:

	Years Ended December 31,
(Dollars in millions)	2013		2012		2011
Cost of products sold	$	3.0	$	3.0	$	4.0
Selling, general and administrative	26.6		26.2		31.9
Research and development	3.0		3.0		4.0
Total stock-based compensation expense	$	32.6	$	32.2	$	39.9

        There were no costs related to stock-based compensation that were capitalized.

7. EMPLOYEE BENEFITS

Pension and Other Post Retirement Benefits

        Pension—The principal pension plan is the Mead Johnson & Company Retirement Plan in the United States (U.S. Pension Plan) which represents approximately 75% of the Company’s total pension assets and obligations. The benefits of this plan are frozen as of February 9, 2014 and benefits are no longer accrued for service.

        Other post retirement benefits—The Company also provides comprehensive medical and group life benefits for substantially all U.S. and Canadian retirees who elect to participate in its comprehensive medical and group life plans. The retiree medical plan is contributory and participation is limited to those employees who participate in the U.S. Pension Plan. Contributions are adjusted periodically and vary by date of retirement. The retiree life insurance plan is non-contributory.

Changes in benefit obligations, plan assets, funded status and amounts recognized in the balance sheet were as follows:

	Pension Benefits						Other Benefits
(In millions)	2013			2012			2013			2012
Beginning benefit obligations	$	463.6		$	402.7		$	35.1		$	30.2
Service cost—benefits earned during the year	5.2			3.9			1.1			1.0
Interest cost on projected benefit obligations	14.4			15.6			1.3			1.3
Actuarial assumptions (gains) losses	(25.7		)	72.2			(3.8		)	2.6
Settlements and curtailments	(50.4		)	(30.9		)	—			—
Benefits paid	(2.8		)	(2.2		)	(1.3		)	(0.1		)
Exchange rate changes	(0.3		)	2.3			0.2			0.1
Benefit obligations at end of year	$	404.0		$	463.6		$	32.6		$	35.1
Beginning fair value of plan assets	$	312.1		$	280.7		$	—		$	—
Actual return on plan assets	(1.4		)	32.8			—			—
Employer contributions	18.5			28.2			0.9			0.1
Settlements	(50.4		)	(29.3		)	—			—
Benefits paid	(2.8		)	(2.2		)	(1.3		)	(0.1		)
Exchange rate changes	0.1			1.9			0.4			—
Fair value of plan assets at end of year	$	276.1		$	312.1		$	—		$	—
Underfunded status at end of year	$	(127.9	)	$	(151.5	)	$	(32.6	)	$	(35.1	)
Amounts in the consolidated balance sheets include:
Other assets	$	1.3		$	2.2		$	—		$	—
Pension, post retirement and post employment liabilities	(129.2		)	(153.7		)	(32.6		)	(35.1		)
Balance in the consolidated balance sheet at end of year	$	(127.9	)	$	(151.5	)	$	(32.6	)	$	(35.1	)
Amounts in accumulated other comprehensive loss include:
Net actuarial loss	$	197.7		$	242.6		$	11.8		$	17.3
Prior service (benefit)	1.2			—			(0.3		)	(0.5		)
Transition obligation	0.1			0.2			—			—
Balance in accumulated other comprehensive loss at end of year	$	199.0		$	242.8		$	11.5		$	16.8
Accumulated benefit obligation	$	375.7		$	428.0		$	32.6		$	35.1

60

        The Company’s defined benefit pension and post retirement benefit plans with an accumulated benefit obligation in excess of plan assets were as follows:

	Years Ended December 31,
(In millions)	2013		2012
Projected benefit obligation	$	366.3	$	449.3
Accumulated benefit obligation	356.1		430.2
Fair value of plan assets	210.8		263.1

        The net periodic benefit cost of the Company’s defined benefit pension and post retirement benefit plans includes:

	Pension Benefits									Other Benefits
	Years Ended December 31,									Years Ended December 31,
(In millions)	2013			2012			2011			2013			2012			2011
Service cost — benefits earned during the period	$	5.2		$	3.9		$	3.5		$	1.1		$	1.0		$	0.9
Interest cost on projected benefit obligations	14.4			15.6			17.0			1.3			1.3			1.3
Expected return on plan assets	(16.4		)	(16.2		)	(18.2		)	—			—			—
Amortization of net actuarial loss	6.6			5.3			3.3			1.7			1.9			1.7
Amortization of prior service (benefit)	—			—			—			(0.2		)	(0.2		)	(0.2		)
Amortization of transition cost	0.1			0.1			0.1			—			—			—
Sub-total	$	9.9		$	8.7		$	5.7		$	3.9		$	4.0		$	3.7
Settlements and curtailments	29.3			15.2			9.7			—			—			—
Total net periodic benefit cost	$	39.2		$	23.9		$	15.4		$	3.9		$	4.0		$	3.7

        The estimated net actuarial loss and prior service cost that will be amortized from accumulated other comprehensive loss into net periodic benefit cost in 2014 are:

(In millions)	Pension Benefits		Other Benefits
Amortization of net actuarial loss	$	5.2	$	1.1
Amortization of prior service (benefit)	0.1		(0.1		)
Amortization of transition cost	0.1		—
	$	5.4	$	1.0

Actuarial assumptions

        Weighted-average assumptions used to determine benefit obligations are established as of the balance sheet date and were as follows:

	Pension Benefits				Other Benefits
	December 31,				December 31,
	2013		2012		2013		2012
Discount rate	4.08	%	3.21	%	4.98	%	3.75	%
Rate of compensation increase	3.22	%	3.58	%	3.08	%	3.48	%

        The discount rate was determined based on the yield to maturity of high-quality corporate bonds and considering the duration of the pension plan obligations. The Citigroup Pension Discount Curve is used in developing the discount rate for the U.S. Pension Plan.

        Weighted-average assumptions used to determine net periodic benefit cost are established at the beginning of the plan year and were as follows:

	Pension Benefits						Other Benefits
	Years Ended December 31,						Years Ended December 31,
	2013		2012		2011		2013		2012		2011
Discount rate	3.26	%	4.03	%	5.59	%	3.75	%	4.29	%	5.28	%
Expected long term return on plan assets	5.22	%	5.65	%	6.91	%	—	%	—	%	—	%
Rate of compensation increase	3.59	%	4.00	%	4.02	%	3.48	%	3.94	%	3.94	%

61

        The yield on high-quality corporate bonds that matches the duration of the benefit obligations was used in determining the discount rate. The Citigroup Pension Discount Curve is used in developing the discount rate for the U.S. plans. The expected long-term return on plan assets was determined based on the target asset allocation, expected rate of return by each asset class, and estimated future inflation.

        For the U.S. Pension Plan, the expected long-term return on plan assets assumption to be used to determine net periodic benefit cost for the year ending December 31, 2014 is 7.00%. The expected long-term return on plan assets was determined based on the Company’s target asset allocation, expected rate of return by each asset class, and estimated future inflation. The Company anticipates moving towards an asset mix that is more heavily focused on equity securities in 2014.

        Gains and losses have resulted from changes in actuarial assumptions, such as changes in the discount rate, and from differences between assumed and actual experience, such as differences between actual and assumed returns on plan assets. These gains and losses are adjusted for the difference between the fair value and the market-related value of the plan assets and are amortized to the extent they exceed 10% of the higher of the market-related value or the projected benefit obligation for each respective plan. The majority of the remaining actuarial losses are amortized over the life expectancy of the plans’ participants for the frozen U.S. plans and expected remaining service periods for the other plans.

        Assumed health care cost trend rates were as follows:

	December 31,
	2013		2012		2011
Health care cost trend rate assumed for next year	6.9	%	7.8	%	7.4	%
Rate to which the cost trend rate is assumed to decline (the ultimate trend rate)	4.9	%	4.9	%	5.0	%
Year that the rate reaches the ultimate trend rate	2023		2023		2017

        Assumed health care cost trend rates affect the amounts reported for the retiree medical plans. A one-percentage-point change in assumed health care cost trend rates would have the following effects:

(In millions)	1-Percentage-Point Increase		1-Percentage-Point Decrease
Effect on total of service and interest cost	$	—	$	—
Increase/(decrease) in post retirement benefit obligation	0.2		0.3

Plan assets

        The Company’s investment strategy for the U.S. Pension Plan assets consists of a mix of equities and fixed income in order to achieve returns over a market cycle which reduces contribution and expense at an acceptable level of risk. The target asset allocation as ofDecember 31, 2013was40%public equity and60%fixed income. Cash flow (i.e., cash contributions, benefit payments) was used to rebalance back to the targets as necessary. Investments are well diversified within each of the two major asset categories. All of the U.S. equity investments are actively managed. Investment strategies for international pension plans are typically similar, although the asset allocations are usually more conservative.

        The fair values of the Company’s pension plan assets by asset category were as follows:

	December 31, 2013						December 31, 2012
(In millions)	Total		Level 1		Level 2		Total		Level 1		Level 2
Cash and cash equivalents	$	13.0	$	13.0	$	—	$	11.4	$	11.4	$	—
Equity securities:
U.S. large-cap	16.3		—		16.3		13.6		—		13.6
U.S. mid-cap growth	3.1		—		3.1		2.8		—		2.8
U.S. small-cap growth	0.1		—		0.1		1.5		—		1.5
Emerging markets	2.8		—		2.8		3.1		—		3.1
Real estate investment trusts	5.6		—		5.6		13.4		—		13.4
International large-cap value	37.0		8.5		28.5		28.3		—		28.3
Hedge fund	17.4		—		17.4		15.7		—		15.7
Fixed income securities:
Government bonds	72.8		—		72.8		83.5		—		83.5
Corporate bonds	101.7		—		101.7		138.8		—		138.8
Emerging markets	6.3		—		6.3		—		—		—
Total	$	276.1	$	21.5	$	254.6	$	312.1	$	11.4	$	300.7

62

        Level 1 cash and cash equivalents, which excluded money market funds, are recorded at closing prices in active markets. Level 2 money market, equity, and fixed income funds are recorded at the net asset values per share, which were determined based on quoted market prices of the underlying assets contained within the funds. The Level 2 hedge fund is recorded at the net asset value per share, which was derived from the underlying funds’ net asset values per share; this diversified hedge fund may be redeemed quarterly with 60 days notice.

Contributions

        In 2014, the funding policy for the pension plans is to contribute amounts to provide for current service and to fund past service liability. MJN contributed $18.5 million, $28.2 million and $9.5 million to the pension plans in 2013, 2012 and 2011, respectively. The Company is not required to make any contributions to its pension plans in 2014 and does not foresee making a discretionary contribution. There will be no cash funding for other post retirement benefits in 2014, except funding to cover benefit payments.

Estimated Future Benefit Payments

        The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

(In millions)	Pension Benefits		Other Benefits
2014	$	29.3	$	0.8
2015	29.5		1.0
2016	29.5		1.1
2017	30.8		1.1
2018	29.7		1.3
Years 2019 - 2023	147.8		6.5

Defined Contribution Benefits

        Employees who meet certain eligibility requirements may participate in various defined contribution plans. Total cost recognized for all defined contribution benefit plans were $19.9 million, $21.3 million and $19.3 million for the years ended December 31, 2013, 2012, and 2011, respectively.

8.REDEEMABLE NONCONTROLLING INTEREST

On March 15, 2012, the Company acquired 80% of the outstanding capital stock of Nutricion para el Conosur S.A. which manufactures, distributes and sells infant formula and children’s nutrition products in Argentina under the SanCor Bebé and Bebé Plus brands (the “Argentine Acquisition”). Under the terms of an agreement related to the Argentine Acquisition, the noncontrolling interest owner has the right to require MJN to purchase (the “Put Right”) its remaining 20% interest or to sell (the “Call Right”) up to an additional 20% of the outstanding capital stock of Nutricion para el Conosur S.A. The Put Right is exercisable from September 15, 2015 to September 15, 2018 and the decision to exercise is not within the control of MJN. The price paid upon exercise will be determined based on established multiples of sales and earnings of the acquired business and is currently estimated to equate to fair value at the earliest exercise date. As a result of the Put Right, the noncontrolling interest is presented as redeemable noncontrolling interest outside of equity on the balance sheet. Accretion to the redemption value of the Put Right is being recognized through equity using an interest method over the period from March 15, 2012 to September 15, 2015.

9. NONCONTROLLING INTERESTS

Net earnings attributable to noncontrolling interests consists of approximately 20%, 11% and 10% interests held by third parties in operating entities in Argentina, China and Indonesia, respectively. 

63

10. OTHER EXPENSES—NET

        The components of other expenses—net were:

	Years Ended December 31,
(In millions)	2013			2012			2011
Foreign exchange (gains)/losses—net	$	9.3		$	(3.1	)	$	(9.7	)
Administrative penalty (China)	33.4			—			—
Severance and other costs	2.2			8.0			9.9
Pension settlements and curtailments	29.3			15.2			9.7
Gain on sale of non-core intangible assets	—			(6.5		)	—
Legal settlements	7.0			—			—
Other—net	(3.4		)	6.4			9.7
Other expenses—net	$	77.8		$	20.0		$	19.6

11. RECEIVABLES

        The major categories of receivables were as follows:

	December 31,
(In millions)	2013			2012
Trade receivables	$	335.7		$	330.0
Miscellaneous receivables	55.2			42.2
Less allowances	(6.5		)	(7.6		)
Receivables—net	$	384.4		$	364.6

12. INVENTORIES

        The major categories of inventories were as follows:

(In millions)	December 31, 2013		December 31, 2012
Finished goods	$	312.7	$	264.6
Work in process	82.5		56.9
Raw and packaging materials	139.6		114.4
Inventories	$	534.8	$	435.9

13. LONG-LIVED ASSETS

Property, Plant, and Equipment

The major categories of property, plant, and equipment were as follows: 

(In millions)	December 31, 2013			December 31, 2012
Land	$	12.6		$	6.0
Buildings	550.8			506.0
Machinery, equipment, and fixtures	650.3			595.7
Construction in progress	260.9			150.4
Accumulated depreciation	(607.1		)	(568.2		)
Property, plant, and equipment—net	$	867.5		$	689.9

        Depreciation expense was $63.7 million, $55.8 million and $57.2 million for the years ended December 31, 2013, 2012 and 2011, respectively, and is primarily included in costs of products sold. Interest capitalized during the year was $5.7 million, $0.6 million and $0.2 million for the years ended December 31, 2013, 2012 and 2011, respectively.

64

        The Company’s liability for asset retirement obligations was $3.6 million and $3.3 million at December 31, 2013 and 2012.

Other Intangible Assets

The gross carrying value and accumulated amortization by class of intangible assets were as follows: 

	As of December 31, 2013							As of December 31, 2012
(In millions)	Gross Carrying Amount		Accumulated Amortization			Net Book Value		Gross Carrying Amount		Accumulated Amortization			Net Book Value
Indefinite-lived intangible assets
Trademark(1) .	$	34.5	$	—		$	34.5	$	45.3	$	—		$	45.3
Non-compete agreement(1) .	6.8		—			6.8		8.9		—			8.9
Total	41.3		—			41.3		54.2		—			54.2
Amortizable intangible assets
Computer software	132.8		(79.3		)	53.5		132.2		(60.2		)	72.0
Distributor-customer relationship(2) 10 year life	3.3		(0.6		)	2.7		4.4		(0.7		)	3.7
Total	136.1		(79.9		)	56.2		136.6		(60.9		)	75.7
Total other intangible assets	$	177.4	$	(79.9	)	$	97.5	$	190.8	$	(60.9	)	$	129.9

⁽¹⁾Changes in balances result from currency translation.

⁽²⁾Changes in balances result from currency translation and amortization.

        Amortization expense for other intangible assets was $19.4 million, $21.1 million and $18.1 million for the years ended December 31, 2013, 2012 and 2011, respectively.

        Expected amortization expense related to intangible assets is as follows:

(In millions) Years Ending December 31,
2014	$	16.0
2015	15.0
2016	12.3
2017	9.4
2018	1.8
Later years	1.7

Non-Cash Activity

Additions to long-lived assets not yet paid were $89.5 million, $78.7 million and $32.8 million for the years ended December 31, 2013, 2012 and 2011, respectively.

14.GOODWILL

The Company tests goodwill for impairment on an annual basis and whenever an event occurs or circumstances change that would, more likely than not, reduce the fair value of a reporting unit below its carrying amount. Historically, the Company’s policy was to perform the annual impairment test for goodwill as of January 1 of each year. The Company completed its annual impairment test in the first quarter of 2013 in accordance with this policy and concluded that no impairment existed. During the third quarter of 2013 the Company changed its annual impairment testing date from January 1 to July 1 of each fiscal year to better align with the timing of its annual and long-term planning process, which is a significant input in the testing process. Accordingly, the Company believes this change is preferable. This change did not delay, accelerate or avoid an impairment charge. As a result of this change, impairment testing was completed during the third quarter of 2013 and the Company concluded that no impairment existed. This change was applied prospectively beginning July 1, 2013 and had no impact on the consolidated financial statements. The change was not applied retrospectively as it is impracticable to do so because retrospective application would have required the application of significant estimates and assumptions without the use of hindsight.

For the year ended December 31,2013, the change in the carrying amount of goodwill by reportable segment, was primarily driven by the cumulative impact due to a correction of the currency denomination of the goodwill related to two reporting units. The revision had the impact of decreasing the Company’s total value of goodwill and decreasing the total currency translation adjustment included in the accumulated other comprehensive loss section of shareholders’ equity and other comprehensive income.

65

For the year ended December 31,2013 and 2012, the change in the carrying amount of goodwill by reportable segment, including the cumulative impact of the revisions described above, was as follows:

(In millions)	Asia		Latin America			North America/ Europe			Total
Balance as of January 1, 2012	$	—	$	115.8		$	1.7		$	117.5
Acquisition	—		155.5			17.3			172.8
Translation adjustments	—		(17.7		)	(2.0		)	(19.7		)
Balance as of December 31, 2012	—		253.6			17.0			270.6
Redenomination	—		(42.5		)	2.0			(40.5		)
Translation adjustments	—		(33.3		)	—			(33.3		)
Balance as of December 31, 2013	$	—	$	177.8		$	19.0		$	196.8

A portion of the goodwill from the acquisition of Nutricion para el Conosur S.A. was attributed to the North America/Europe segment in consideration of expected benefits to be derived from the acquisition. As of December 31, 2013, the Company had no accumulated impairment loss.

15.DEBT

Short-Term Borrowings

Outstanding Borrowings

As of December 31, 2013, the Company’s short-term borrowings were $2.0 million and consisted of borrowings made by the Company’s subsidiary in Argentina. These short-term borrowings had a weighted-average interest rate of 22.00% as of December 31, 2013. The Company intends to repay these borrowings within 12 months and has the ability to do so.

As of December 31, 2012, the Company’s short-term borrowings totaled $161.0 million and were primarily from its 5-year revolving credit facility agreement (“Credit Facility”).

Five-Year Revolving Credit Facility Agreement

Borrowings from the Credit Facility are used for working capital and other general corporate purposes. The Credit Facility is unsecured, repayable at maturity in June 2016 and can be extended annually if a sufficient number of lenders agree. The maximum amount of outstanding borrowings and letters of credit permitted at any one time under the Credit Facility is $500.0 million, which may be increased from time to time up to $750.0 million at the Company’s request and with the consent of the lenders, subject to satisfaction of customary conditions. The Credit Facility contains financial covenants, whereby the ratio of consolidated total debt to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (“EBITDA”) cannot exceed 3.25 to 1.0, and the ratio of consolidated EBITDA to consolidated interest expense cannot be less than 3.0 to 1.0. The Company was in compliance with these covenants as of December 31, 2013.

Borrowings under the Credit Facility bear interest at a rate that is determined as a base rate plus a margin. The base rate is either (a) LIBOR for a specified interest period, or (b) a floating rate based upon JPMorgan Chase Bank’s prime rate, the Federal Funds rate or LIBOR. The margin is determined by reference to the Company’s credit rating. The margin can range from 0.075% to 1.45% over the base rate. In addition, the Company incurs an annual 0.2% facility fee on the entire facility commitment of $500.0 million.

As of December 31, 2013, the Company did not have any borrowings outstanding from the Credit Facility. For the year ended December 31,2013, borrowings from the Credit Facility had a weighted-average interest rate of 1.52%.

Note Payable

On March 15, 2012, the Company acquired 80% of the outstanding capital stock of Nutricion para el Conosur S.A. See Note 8 for discussion of the acquisition. Of the ARS850.7 million purchase price, ARS377.6 million was financed through a note payable. The remaining balance of the note payable was paid on July 10, 2013.

66

Long-Term Debt

The components of long-term debt were as follows: 

(Dollars in millions)	December 31, 2013			December 31, 2012
Principal Value:
3.50% Notes due 2014	$	500.0		$	500.0
4.90% Notes due 2019	700.0			700.0
5.90% Notes due 2039	300.0			300.0
Subtotal	1,500.0			1,500.0
Adjustments to Principal Value:
Unamortized basis adjustment for terminated interest rate swaps	16.7			26.0
Unamortized bond discount	(2.0		)	(2.8		)
Less amount due within one year	505.6			—
Long-term debt	$	1,009.1		$	1,523.2

       The notes may be prepaid at any time, in whole or in part, at a redemption price equal to the greater of par value or an amount calculated based upon the sum of the present values of the remaining scheduled payments. Upon a change of control, the Company may be required to repurchase the notes in an amount equal to 101% of the then outstanding principal amount plus accrued and unpaid interest. Interest on the notes are due semi-annually, and the notes are not subject to amortization.

       The Company’s long-term debt has a principal value of $1,500 million, of which $500 million is considered short-term as it matures on November 1, 2014. MJN plans to refinance a portion of these notes in 2014. The Company determined the fair value of its long-term debt based on current market yields in the secondary market, classified as Level 2. As of December 31, 2013 fair value of the Company's long-term debt was $1,611.1 million.

The components of interest expense-net were as follows: 

	Years Ended December 31,
(In millions)	2013			2012			2011
Interest expense	$59.2			$70.9			$	60.2
Interest income	(8.6		)	(5.9		)	(8.0		)
Interest expense-net	$50.6			$65.0			$	52.2
Interest payments, net of amounts related to interest rate swaps	$	72.0		$	74.9		$	61.4

See Note 16 for discussion on the Company’s derivatives.

16. DERIVATIVES

        The Company is exposed to market risk due to changes in foreign currency exchange rates, commodities pricing and interest rates. To manage that risk, the Company enters into certain derivative financial instruments, when available on a cost-effective basis, to hedge its underlying economic exposure. The Company does not enter into derivatives for speculative purposes. These financial instruments are classified as Level 2 of the fair value hierarchy at December 31, 2013 and 2012, and there were no transfers between levels in the fair value hierarchy during the periods then ended.

        The following table summarizes the fair value of the Company's outstanding derivatives, all of which are cash flow hedges:

		December 31,
(In millions)	Balance Sheet Location	2013			2012
Cash flow hedges:
Foreign exchange contracts	Other assets	$	4.2		$	—
Interest rate forward swaps	Other assets	19.9			—
Foreign exchange contracts	Accrued expenses	(0.5		)	(5.1		)
Net asset/(liability) of derivatives designated as hedging items		$	23.6		$	(5.1	)

        The Company’s derivative financial instruments present certain market and counterparty risks; however, concentration of counterparty risk is mitigated as the Company deals with a variety of major banks worldwide whose long-term debt is rated A- or higher by Standard & Poor’s Rating Service, Fitch Ratings, or Moody’s Investors Service, Inc. In addition, only conventional derivative financial instruments are

67

used. The Company would not be materially impacted if any of the counterparties to the derivative financial instruments outstanding atDecember 31, 2013failed to perform according to the terms of its agreement.Based upon the risk profile of the Company's portfolio, MJN does not require collateral or any other form of securitization to be furnished by the counterparties to its derivative financial instruments.

Cash Flow Hedges

    As of December 31, 2013 and 2012 all of the Company’s cash flow hedges qualify as hedges of forecasted cash flows and the effective portion of changes in fair value are temporarily reported in accumulated other comprehensive income (loss). During the period that the underlying hedged transaction impacts earnings, the effective portion of the changes in the fair value of the cash flow hedges are recognized within earnings. The Company assesses effectiveness at inception and on a quarterly basis. These assessments determine whether derivatives designated as qualifying hedges continue to be highly effective in offsetting changes in the cash flows of hedged items. Any ineffective portion of the change in fair value is included in current period earnings.

        The Company will discontinue cash flow hedge accounting when the forecasted transaction is no longer probable of occurring on the originally forecasted date, or 60 days thereafter, or when the hedge is no longer effective. For the years ended December 31, 2013, 2012, and 2011, the Company did not discontinue any cash flow hedges.

Foreign Exchange Contracts

        The Company uses foreign exchange contracts to hedge forecasted transactions, primarily foreign currency denominated intercompany purchases anticipated in the next1.5years and designates these derivative instruments as foreign currency cash flow hedges when appropriate.When the underlying intercompany purchases impact the Company’s consolidated earnings, the effective portion of the hedge is recognized within cost of products sold. For the years ended December 31, 2013, 2012 and 2011, ineffectiveness related to the Company’s foreign exchange hedges on earnings was insignificant.

        The table below summarizes the Company’s outstanding foreign exchange forward contracts at December 31, 2013. The fair value of foreign exchange forward contracts should be viewed in relation to the fair value of the underlying hedged transactions and the overall reduction in exposure to fluctuations in foreign currency exchange rates.

(Dollars in millions)	Weighted-average Forward Rate	Notional Amount		Fair Value Asset		Maturity
Foreign exchange contracts:
Cash flow hedges:
Mexican peso	13.07	84.0		0.7		2014
Malaysian ringgit	3.18	55.0		2.0		2014
Philippine peso	43.48	62.4		1.0		2014
Total foreign exchange contracts		$	201.4	$	3.7

        The change in accumulated other comprehensive income (loss) and the impact on earnings from foreign exchange contracts that qualified as cash flow hedges for the years ended December 31, 2013 and 2012, were as follows:

(In millions)	2013			2012
Balance—January 1	$	(4.1	)	$	4.3
Derivatives qualifying as cash flow hedges deferred in other comprehensive income	4.8			(12.7		)
Derivatives qualifying as cash flow hedges reclassified to cost of products sold (effective portion)	5.4			0.8
Change in deferred taxes	(2.9		)	3.5
Balance—December 31	$	3.2		$	(4.1	)

AtDecember 31, 2013,the portion of changes in cash flow hedges deferred into other comprehensive income that is expected to be reclassified into earnings within the next 12 months was $3.2 million.

Interest Rate Forward Swaps

During the fourth quarter of 2013 the Company entered into interest rate forward starting swaps with a combined notional value of $500.0 million. The forward starting rates of the swaps range from 3.79% to 3.94% and have an effective date of October 31, 2014. The forward starting swaps effectively mitigate the interest rate exposure associated with the Company’s planned refinancing of a portion of long-term debt in 2014, which is an anticipated transaction as a portion of MJN’s existing long-term debt will mature in 2014. These derivative instruments were designated as cash flow hedges at inception and were highly effective in offsetting fluctuations in the benchmark interest rate. As of December 31, 2013, all forward swaps were outstanding and had a fair value of $19.4 million, recognized in accumulated other comprehensive income. When the forward swaps are settled, which would be on or about the time of the issuance of long-term debt, any gain

68

or loss on the settlement will be recorded to accumulated other comprehensive income (loss) and will be amortized over the life of the notes. There was an immaterial amount of ineffectiveness related to the forward swaps which was recognized as a benefit within other expenses-net.

Commodity Hedge

During the fourth quarter of 2013, the Company began utilizing commodity hedges to minimize the variability in cash flows due to fluctuations in market prices of the Company’s non-fat dry milk purchases. The maturities of the commodity contracts are scheduled to match the pricing terms of the Company’s existing bulk purchase agreements. When the underlying non-fat dry milk purchases impact the Company’s consolidated earnings, the effective portion of the hedge is recognized within cost of products sold.

As of December 31, 2013, the Company had commodity contracts outstanding with a notional of 0.2 million pounds of forecasted non-fat dry milk purchases, representing a value of $0.3 million and an insignificant portion of the Company’s total forecasted volume. The effective portion of the hedge, which was recorded at fair value as a component of accumulated other comprehensive income, as well as the ineffective portion recognized within other income and expense were immaterial as of December 31, 2013 and for the period then ended.

Fair Value Hedges

Interest Rate Swaps

In November 2009, the Company executed several interest rate swaps to convert $700.0 million of the Company’s newly-issued fixed rate debt to be paid in 2014 and 2019 to variable rate debt. In November 2010, the Company terminated $200.0 million notional amount of fixed-to-floating interest rate swaps for cash of $15.6 million. In July 2011, the Company terminated the remaining $500.0 million notional amount of fixed-to-floating interest rate swaps for cash of $23.5 million. The related basis adjustments of the underlying hedged items are being recognized as a reduction of interest expense over the remaining life of the underlying debt. The Company had no interest rate swaps outstanding at December 31, 2013.

        (Gain) loss on marked to market of fair value hedges during the years ended December 31, 2013, 2012, and 2011 was as follows:

	(Gain) Loss on Marked to Market Swaps							(Gain) Loss on Marked to Market of Hedged Items
(In millions)	2013		2012		2011			2013		2012		2011
Interest expense—net	$	—	$	—	$	(4.2	)	$	—	$	—	$	4.2

        The impact on earnings from interest rate swaps that qualified as fair value hedges was as follows:

(In millions)	2013			2012			2011
Recognized in interest expense	$	—		$	—		$	(6.3	)
Amortization of basis adjustment for terminated interest rate swaps recognized in interest expense	(9.2		)	(9.3		)	(5.5		)
Total	$	(9.2	)	$	(9.3	)	$	(11.8	)

        See Note 15 for discussion on the Company’s debt.

Other Financial Instruments

The Company does not hedge the interest rate risk associated with money market funds, which totaled $447.8 million and $520.7 million as of December 31, 2013 and 2012, respectively. Money market funds are classified as Level 2 in the fair value hierarchy and are included in cash and cash equivalents on the balance sheet.  The money market funds have quoted market prices that are generally equivalent to par.

69

17. EQUITY

        Changes in common shares and treasury stock were as follows:

(In millions)	Common Shares Issued	Treasury Stock	Cost of Treasury Stock
Balance as of January 1, 2011	204.8	0.1	$	3.2
Stock-based compensation	0.3	—	4.9
Treasury stock purchases	—	1.3	81.6
Balance as of December 31, 2011	205.1	1.4	$	89.7
Stock-based compensation	0.9	0.2	15.2
Treasury stock purchases	—	1.9	139.7
Balance as of December 31, 2012	206.0	3.5	$	244.6
Stock-based compensation	0.8	0.2	18.9
Treasury stock purchases	—	1.1	88.4
Balance as of December 31, 2013	206.8	4.8	$	351.9

The Company may use either authorized and unissued shares or treasury shares to meet share requirements resulting from the exercise of stock options and vesting of performance share awards and restricted stock units. Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized using the first-in first-out method.

On March 16, 2010, MJN’s board of directors approved the repurchase of up to $300.0 million of the Company’s common stock. From the date of such authorization through December 31, 2013, 4.2 million shares were repurchased at an average cost per share of $71.21. As of December 31, 2013, the Company has completed all purchases remaining under this authorization.

On September 10, 2013, MJN’s board of directors approved a new share repurchase authorization of up to an additional $500.0 million of the Company’s common stock. From the date of such authorization through December 31, 2013, 0.1 million shares were repurchased at an average cost of $84.06. As of December 31, 2013, the Company had $490.3 million available under this authorization.

Changes in accumulated other comprehensive loss by component were as follows:

(In millions)	Foreign Currency Translation Adjustments			Deferred Gains/(Losses) on Derivatives Qualifying as Hedges			Pension and Other Post-retirement Benefits			Total			Noncontrolling Interest				Redeemable Noncontrolling Interest
Balance as of January 1, 2013	$	(14.6	)	$	(4.1	)	$	(168.3	)	$	(187.0	)	$	(0.2	)		$	—
Deferred Gains/(Losses)	(79.4		)	24.2			11.6			(43.6		)	3.3			1	(14.4		)	1
Reclassification Adjustment for   (Gains)/Losses Included in Net   Earnings	—			5.4			37.5			42.9			—				—
Tax Benefit/(Expense)	10.4			(10.1		)	(16.1		)	(15.8		)	(1.2		)		—
Balance as of December 31, 2013	$	(83.6	)	$	15.4		$	(135.3	)	$	(203.5	)	$	1.9			$	(14.4	)

1 Represents foreign currency translation adjustments.

70

Reclassification adjustments out of accumulated other comprehensive loss were as follows:

	December 31, 2013
	Affected Statement of Earnings Lines
(In millions)	Cost of Products Sold			Selling, General and Administrative			Research and Development			Other Expenses/ (Income) - Net			Tax Benefit/(Expense)		Net
Deferred Gains/(Losses) on Derivatives Qualifying as Hedges:
Forward Exchange Contracts	$	(5.4	)										$	1.6	$	(3.8	)
Pension and Other Postretirement Benefit Plans:
Actuarial Gains/(Losses)	(2.8		)	(4.7		)	(0.9		)				2.9		(5.5		)
Prior Service Benefits	0.1			0.1											0.2
Settlements										(29.3		)	11.0		(18.3		)
Total Reclassifications	$	(8.1	)	$	(4.6	)	$	(0.9	)	$	(29.3	)	$	15.5	$	(27.4	)

Dividends declared per share were $1.36, $1.20 and $1.04 for the years ended December 31, 2013,2012and2011, respectively.

18. LEASES

        Minimum rental commitments under all non-cancelable operating leases, primarily real estate leases for offices, manufacturing-related leases and vehicle leases, in effect at December 31, 2013, are:

(In millions) Years Ending December 31,
2014	$	36.4
2015	29.5
2016	20.8
2017	15.5
2018	14.3
Later Years	22.3
Total Minimum Payments	$	138.8

        Operating lease rental expenses were $39.7 million, $37.4 million and $35.5 million in the years ended December 31, 2013, 2012, and 2011, respectively. At December 31, 2013 and 2012, MJN had capital lease obligations outstanding in the amount of $2.9 million and $2.7 million, respectively.

19.CONTINGENCIES

In the ordinary course of business, the Company is subject to lawsuits, investigations, government inquiries and claims, including, but not limited to, product liability claims, advertising disputes and inquiries, consumer fraud suits, other commercial disputes, premises claims and employment and environmental, health, and safety matters.

The Company was served with a lawsuit filed on October 16, 2012 in St. Clair County (Illinois) Circuit Court under the caption Shelby Schrack, et al. v. Mead Johnson Nutrition Company and Mead Johnson & Company, which lawsuit alleges that certain bacteria in powdered formula were responsible for the death of one infant and serious illness in two others and seeks unspecified monetary damages. These events were widely publicized in December 2011 and January 2012. The infants allegedly consumed formula from batches that were extensively tested by the Company, the Centers for Disease Control (“CDC”) and the U.S. FDA. These tests detected no bacteria in our infant formula. The CDC further noted that while these bacteria have sometimes been found in formula, they also exist in the environment and may potentially cause illness through person to person contact or through contamination of infant feedings at the point of use. The Company believes that the claims in this matter are without merit. Nevertheless, in November 2013, the Company and the plaintiffs agreed to settle the disputed claims asserted in this litigation, and on December 12, 2013, the Company obtained court approval of the proposed settlement and release of all such claims. The settlement did not materially affect the Company’s consolidated financial position, results of operations or cash flows.

71

The Company records accruals for contingencies when it is probable that a liability will be incurred and the loss can be reasonably estimated. Although the Company cannot predict with certainty the final resolution of lawsuits, investigations and claims asserted against the Company, MJN does not believe any currently pending legal proceeding to which the Company is a party will have a material effect on the Company’s business or financial condition, although an unfavorable outcome in excess of amounts recognized as of December 31, 2013, with respect to one or more of these proceedings could have a material effect on the Company’s results of operations and cash flows for the periods in which a loss is recognized.

The Company incurred costs for an administrative penalty assessed by China's National Development and Reform Commission ("NDRC") in connection with the NDRC’s antitrust review of the infant formula industry’s resale pricing practices (the “China Antitrust Review”) and was resolved during the third quarter of 2013. In connection with the China Antitrust Review, the NDRC assessed an administrative penalty of $33.4 million against the Company, which penalty was paid during the third quarter and is non-deductible for tax purposes.

Following an SEC request for documents relating to certain business activities of the Company’s local subsidiary in China, the Company is continuing an internal investigation of such business activities. The Company’s investigation is focused on certain expenditures that were made in connection with the promotion of the Company’s products or may have otherwise been made. Certain of such expenditures were made in violation of Company policies and may have been made in violation of applicable U.S. and/or local laws, including the U.S. Foreign Corrupt Practices Act (the “FCPA”).  The investigation is being conducted by outside legal counsel and overseen by a committee of independent members of the Company’s board of directors. The status and results of the investigation are being discussed with the SEC and other governmental authorities.  At this time, the Company is unable to predict the scope, timing or outcome of this ongoing matter or any regulatory or legal actions that may be commenced related to this matter.  If a violation of the FCPA or other laws is determined to have occurred, the Company could become subject to monetary penalties as well as civil and criminal sanctions.

20. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

Dollars in Millions, Except Per Share Data	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Year
2013:
Net sales	$	1,037.9	$	1,055.3	$	1,046.8	$	1,060.7	$	4,200.7
Gross profit	$	647.0	$	670.9	$	681.3	$	668.7	$	2,667.9
Net earnings	$	174.5	$	163.6	$	160.0	$	156.8	$	654.9
Net earnings attributable to shareholders	$	172.5	$	162.2	$	161.6	$	153.2	$	649.5
Basic earnings per share	$	0.85	$	0.80	$	0.80	$	0.76	$	3.20
Diluted earnings per share	$	0.85	$	0.80	$	0.79	$	0.75	$	3.19
2012:
Net sales	$	986.6	$	1,012.3	$	921.3	$	981.1	$	3,901.3
Gross profit	$	613.1	$	640.0	$	563.8	$	599.1	$	2,416.0
Net earnings	$	169.8	$	171.1	$	139.2	$	132.3	$	612.4
Net earnings attributable to shareholders	$	164.2	$	165.8	$	140.3	$	134.2	$	604.5
Basic earnings per share	$	0.80	$	0.81	$	0.69	$	0.66	$	2.96
Diluted earnings per share	$	0.80	$	0.81	$	0.69	$	0.66	$	2.95

72

SCHEDULE II

MEAD JOHNSON NUTRITION COMPANYVALUATION AND QUALIFYING ACCOUNTS

Description	Balance at beginning of period		Provisions for bad debts		Bad debts written off			Other			Balance at end of period
(In millions)
Allowances for Doubtful Accounts
For the year ended December 31, 2013	$	7.6	$	0.6	$	(0.2	)	$	(1.5	)	$	6.5
For the year ended December 31, 2012	6.3		1.5		(0.4		)	0.2			7.6
For the year ended December 31, 2011	8.3		0.2		—			(2.2		)	6.3

Description	Balance at beginning of period		Provision for valuation allowance		Release of valuation allowance/ other			Balance at end of period
(In millions)
Valuation Allowance on Deferred Tax Assets
For the year ended December 31, 2013	$	6.1	$	3.8	$	(2.6	)	$	7.3
For the year ended December 31, 2012	7.0		1.1		(2.0		)	6.1
For the year ended December 31, 2011	3.3		3.7		—			7.0

73

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

        None.

Item 9A.    CONTROLS AND PROCEDURES.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and the Chief Financial Officer (our principal executive officer and principal financial officer, respectively), we have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of December 31, 2013. Based upon that evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that, as of December 31, 2013, the Company’s disclosure controls and procedures were effective in ensuring information required to be disclosed by the Company in reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Management’s Annual Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting. Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, management assessed the effectiveness of internal control over financial reporting as of December 31, 2013, based on the framework in Internal Control-Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that assessment, management has concluded that our internal control over financial reporting was effective at December 31, 2013, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Due to its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

Deloitte & Touche LLP, our independent registered public accounting firm, has audited our financial statements included in this Annual Report on Form 10-K and has issued its attestation report on the effectiveness of our internal control over financial reporting as of December 31, 2013, which appears below.

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders ofMead Johnson Nutrition Company:

We have audited the internal control over financial reporting of Mead Johnson Nutrition Company and subsidiaries (the “Company”) as of December 31, 2013, based on criteria established in Internal Control - Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed by, or under the supervision of, the company's principal executive and principal financial officers, or persons performing similar functions, and effected by the company's board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the

74

company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2013, based on the criteria established in Internal Control - Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements and financial statement schedule as of and for the year ended December 31, 2013 of the Company and our report dated February 18, 2014 expressed an unqualified opinion on those financial statements and financial statement schedule.

/s/ DELOITTE & TOUCHE LLP
Chicago, Illinois
February 18, 2014

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting during the quarter ended December 31, 2013, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9B.    OTHER INFORMATION.

        None.

75

PART III

Item 10.    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

The information required by this Item 10 is set forth under the headings “Directors, Executive Officers and Corporate Governance – Board of Directors,” “Directors, Executive Officers and Corporate Governance – Code of Ethics,” “Directors, Executive Officers and Corporate Governance – Committees of the Board of Directors,” “Directors, Executive Officers and Corporate Governance – Executive Officers” and “Section 16(a) Beneficial Ownership Reporting Compliance” in our 2014 Proxy Statement to be filed with the SEC in connection with the solicitation of proxies for our 2014 Annual Meeting of Stockholders (the “2014 Proxy Statement”) and is incorporated herein by reference. The 2014 Proxy Statement will be filed with the SEC within 120 days after the end of our 2013 fiscal year.

Item 11.    EXECUTIVE COMPENSATION.

The information required by this Item 11 is set forth under the headings “Directors, Executive Officers and Corporate Governance - Compensation Committee Interlocks and Insider Participation,” “Executive Compensation – Compensation and Management Development Committee Report,” “Executive Compensation” and “Directors, Executive Officers and Corporate Governance – Compensation of Directors” in our 2014 Proxy Statement and is incorporated herein by reference.

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The information required by this Item 12 is set forth under the headings “Security Ownership of Certain Beneficial Owners and Management” and “Securities Authorized for Issuance under Equity Compensation Plans” in our 2014 Proxy Statement and is incorporated herein by reference.

Item 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

The information required by this Item 13 is set forth under the headings “Review, Approval or Ratification of Transactions with Related Persons” and “Directors, Executive Officers and Corporate Governance – Board of Directors – Director Independence” in our 2014 Proxy Statement and is incorporated herein by reference.

Item 14.    PRINCIPAL ACCOUNTANT FEES AND SERVICES.

The information required by this Item is set forth under the headings “Audit Related Matters - Fees Paid to Independent Registered Public Accounting Firm” and “Audit Related Matters - Pre-approval of Audit and Permissible Non-Audit Services” in our 2014 Proxy Statement and is incorporated herein by reference.

PART IV

Item 15.    EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

The financial statements and schedule filed as part of this Annual Report on Form 10-K are listed in the accompanying Index to Financial Statements in “Item 8. Financial Statements and Supplementary Data.” The exhibits filed as a part of this Annual Report on Form 10-K are listed in the Exhibit Index immediately following the signature page to this report.

76

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		MEAD JOHNSON NUTRITION COMPANY
Date:	February 18, 2014	By:	/s/ Tom De Weerdt
			Tom De Weerdt
			Vice President, Corporate Controller

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.

Date:	February 18, 2014	By:	/s/ Peter Kasper Jakobsen
			Peter Kasper Jakobsen
			President, Chief Executive Officer and Director
			(Principal Executive Officer)
Date:	February 18, 2014	By:	/s/ Peter G. Leemputte
			Peter G. Leemputte
			Executive Vice President and Chief Financial Officer
			(Principal Financial Officer)
Date:	February 18, 2014	By:	/s/ Tom De Weerdt
			Tom De Weerdt
			Vice President, Corporate Controller
			(Principal Accounting Officer)
Date:	February 18, 2014	By:	/s/ James M. Cornelius
			James M. Cornelius
			Chairman of the Board of Directors
Date:	February 18, 2014	By:	/s/ Steven M. Altschuler, M.D.
			Steven M. Altschuler, M.D.
			Director
Date:	February 18, 2014	By:	/s/ Howard B. Bernick
			Howard B. Bernick
			Director

77

Date:	February 18, 2014	By:	/s/ Kimberly A. Casiano
			Kimberly A. Casiano
			Director
Date:	February 18, 2014	By:	/s/ Anna C. Catalano
			Anna C. Catalano
			Director
Date:	February 18, 2014	By:	/s/ Celeste A. Clark, Ph.D.
			Celeste A. Clark, Ph.D.
			Director
Date:	February 18, 2014	By:	/s/ Stephen W. Golsby
			Stephen W. Golsby
			Director
Date:	February 18, 2014	By:	/s/ Peter G. Ratcliffe
			Peter G. Ratcliffe
			Director
Date:	February 18, 2014	By:	/s/ Elliott Sigal, M.D., Ph.D.
			Elliott Sigal, M.D., Ph.D.
			Director
Date:	February 18, 2014	By:	/s/ Robert S. Singer
			Robert S. Singer
			Director

78

EXHIBIT INDEX

Exhibit Number	Description
3	Articles of Incorporation and Bylaws
3.1	Second Amended and Restated Certificate of Incorporation of Mead Johnson Nutrition Company (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed on January 8, 2010)
3.2	Amended and Restated By-laws of Mead Johnson Nutrition Company (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed on January 30, 2012)
4	Instruments defining the rights of the security holders, including indentures
4.1	Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Amendment No. 1 to Registration Statement on Form S-1 (Registration No. 333-156298) filed on January 14, 2009)
4.2	Indenture, dated as of November 1, 2009, by and between Mead Johnson Nutrition Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed on November 12, 2009)
4.3	First Supplemental Indenture, dated as of November 5, 2009, by and among Mead Johnson Nutrition Company, Mead Johnson & Company and The Bank of New York Mellon Trust Company, N.A., as trustee (including forms of the 3.50% Notes due 2014, 4.90% Notes due 2019 and 5.90% Notes due 2039 Notes) (incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K filed on November 12, 2009)
10	Material Contracts
10.1	Separation Agreement by and between Bristol-Myers Squibb Company and Mead Johnson Nutrition Company, dated January 31, 2009 (incorporated by reference to Exhibit 10.1 to Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed on March 27, 2009)
10.2	Employee Matters Agreement between Bristol-Myers Squibb Company and Mead Johnson Nutrition Company, dated January 31, 2009 (incorporated by reference to Exhibit 10.2 to Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed on March 27, 2009)
10.3	Second Amended and Restated Transitional Services Agreement between Bristol-Myers Squibb Company and Mead Johnson Nutrition, dated December 18, 2009 (incorporated by reference to Exhibit 10.4 to Annual Report on Form 10-K for the fiscal year ended December 31, 2009 filed on February 25, 2010)
10.4	Amended and Restated Tax Matters Agreement between Bristol-Myers Squibb Company and Mead Johnson Nutrition Company dated December 18, 2009 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on December 23, 2009)
10.5	Five Year Revolving Credit Facility Agreement, dated as of June 17, 2011, among Mead Johnson Nutrition Company, Mead Johnson & Company, LLC, the borrowing subsidiaries, the lenders named therein, Bank of America, N.A., The Bank of Tokyo-Mitsubishi UFJ, Ltd. and Royal Bank of Canada, as Co-Documentation Agents, Citibank, N.A., as Syndication Agent, and JP Morgan Chase Bank, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2011 filed on July 28, 2011)
10.6†	Supply Agreement by and between Mead Johnson & Company and Martek Biosciences Corporation, dated as of January 1, 2006 (incorporated by reference to Exhibit 10.18 to Registration Statement on Form S-1 (Registration No. 333-156298) filed on December 19, 2008)
10.7†	Amendment No. 1 to Supply Agreement by and between Mead Johnson & Company, LLC and Martek Biosciences Corporation, made and entered into effective as of June 1, 2010 (incorporated by reference to Exhibit 10.1 to quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2010 filed on July 29, 2010)
10.8*	Mead Johnson Nutrition Company 2009 Amended and Restated Stock Award and Incentive Plan (incorporated by reference to Addendum A to Definitive Proxy Statement on Schedule 14A filed on April 2, 2010)
10.9*	Mead Johnson Nutrition Company 2009 Senior Executive Performance Incentive Plan (As Amended and Restated Effective as of January 1, 2011) (incorporated by reference to Exhibit 10.9 to Annual Report on Form 10-K for the fiscal year ended December 31, 2012 filed on February 21, 2013)
10.10*	Mead Johnson & Company Benefit Equalization Plan-Retirement Plan (incorporated by reference to Exhibit 10.31 to Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed on March 27, 2009)
10.11*	Mead Johnson & Company Benefit Equalization Plan-Retirement Savings Plan (incorporated by reference to Exhibit 10.32 to Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed on March 27, 2009)

79

10.12*	Mead Johnson & Company Key International Pension Plan (incorporated by reference to Exhibit 10.33 to Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed on March 27, 2009)
10.13*	Mead Johnson & Company, LLC Senior Executive Severance Plan (as amended and restated effective as of January 1, 2011)
10.14*	Mead Johnson & Company, LLC Executive Change in Control Severance Plan (as amended and restated effective as of September 13, 2011)
10.15*	Form of Nonqualified Stock Option Agreement (incorporated by reference to Exhibit 10.34 to Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed on March 27, 2009)
10.16*	Form of Performance Shares Agreement (incorporated by reference to Exhibit 10.35 to Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed on March 27, 2009)
10.17*	Form of Director Restricted Stock Units Agreement (incorporated by reference to Exhibit 10.36 to Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed on March 27, 2009)
10.18*	Form of Employee Restricted Stock Units Agreement (incorporated by reference to Exhibit 10.37 to Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed on March 27, 2009)
10.19*	Form of Restricted Stock Units Agreement (incorporated by reference to Exhibit 10.5 to Current Report on Form 8-K filed on December 23, 2009)
10.20*	Form of 2013 Nonqualified Stock Option Agreement (incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2013 filed on April 25, 2013)
10.21*	Form of 2013 Employee Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2013 filed on April 25, 2013)
10.22*	Form of 2013 Non-Employee Director Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.3 to Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2013 filed on April 25, 2013)
10.23*	Form of 2013 Performance Share Award Agreement (incorporated by reference to Exhibit 10.4 to Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2013 filed on April 25, 2013)
21	Subsidiaries of the Registrant
21.1	Subsidiaries of the Registrant
23	Consents of experts and counsel
23.1	Consent of Deloitte & Touche LLP
31	Rule 13a-14(a)/15d-14(a) Certifications
31.1	Certification of the Chief Executive Officer
31.2	Certification of the Chief Financial Officer
32	Section 1350 Certifications
32.1	Certification of the Chief Executive Officer
32.2	Certification of the Chief Financial Officer
101	Interactive Data File
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document

† Confidential treatment has been granted for certain portions which are omitted in the copy of the exhibit electronically filed with the SEC. The omitted information has been filed separately with the SEC pursuant to our application for confidential treatment.

* Compensatory plan or arrangement.

80

EX-10.13

Exhibit 10.13

Amended and Restated

Mead Johnson & Company, LLC

Senior Executive Severance Plan

and

Summary Plan Description

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Contents

________________________________________________________________________________

Introduction and Highlights            1

Eligibility to Participate                2

Eligibility for Severance Benefits            3

Severance Payments and Benefits            5

Amendment and Plan Termination            9

Additional Plan Information            10

Code Section 409A                12

Administrative Information About Your Plan        14

Your Rights and Privileges Under ERISA        16

Other Administrative Facts            17

Glossary                        18

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Introduction and Highlights

________________________________________________________________________________________________________

Mead Johnson & Company, LLC (the "Company") adopted the Mead Johnson & Company, LLC Senior Executive Severance Plan (the "Plan") effective as of December 23, 2009 for eligible executive level employees of the Company and its participating subsidiaries and affiliates ("Participating Employers"). The purpose of the Plan is to provide equitable treatment for terminated eligible employees in concert with the Company's values and culture, provide financial support for such employees seeking new employment, and recognize such employees' contributions to the Company. The Company further believes that the Plan will aid the Company in attracting and retaining highly qualified executive level employees who are essential to its success.

The Plan has been amended and restated, to reflect certain changes in the bonus provisions and to make other technical and conforming changes. This document sets out the Plan's provisions as of January 1, 2011, which is the effective date of the amendment and restatement of the Plan. This document serves as the Plan's official document and summary plan description. It replaces and supersedes any plan document, summary, or description you may have previously received regarding the Company's severance benefits as they apply to you. The Glossary at the end of this document defines the capitalized terms used in the Plan or tells you where in this document to find a term's meaning. When you encounter a capitalized term, turn to the Glossary to find its meaning.

You are eligible to receive Severance Pay and other benefits under the Plan if (i) you meet the applicable eligibility criteria, (ii) your employment terminates under circumstances which entitle you to benefits, (iii) you timely sign and return an Executive Separation Agreement & General Release, and (iv) the Executive Separation Agreement & General Release has become effective, all as described below. The “Release Requirements” will be considered satisfied as of a specified date if the requirements set forth in paragraphs (iii) and (iv) are met as of such date.

Severance Pay is based on your position and is equal to a multiple of your base salary. You will also be entitled to payment of a pro-rated portion of your Bonus. As set forth below, certain benefits coverage may continue to be available for a specified time period after your Termination Date. You will also be entitled to Basic Severance Pay equal to four weeks of your base salary without regard to whether you satisfy the Release Requirements.

1

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Eligibility to Participate

________________________________________________________________________________________________________

You are eligible to participate in the Plan only if you are an active, full-time or part-time executive level employee of the Company or a Participating Employer with a salary grade of 18 or above and if you are either employed in the U.S. or a U.S. expatriate at a Company or Participating Employer location abroad.

Who Is Not Eligible to Participate

Notwithstanding any other Plan provision, you are not eligible to participate in the Plan and will be excluded from coverage under the Plan if you are:

(A) an employee who is a party to an individual arrangement or a written employment agreement providing severance payments other than pursuant to the Plan;

(B) employed at a salary grade that is not eligible to participate in the Plan; or

(C) covered by a local practice outside the U.S. that provides for severance payments and/or benefits in connection with a voluntary or involuntary termination of employment that are greater than the severance payments and/or benefits set forth in the Plan.

You will not be entitled to Severance Pay or other benefits under the Plan (including Basic Severance Pay) if you are entitled to severance pay or benefits under the Executive Change in Control Severance Plan.

2

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Eligibility for Severance Benefits

________________________________________________________________________________________________________

Right To Severance Payments And Benefits

You will be eligible to receive severance payments and benefits from the Company as set forth in the Severance Payments and Benefits Section of this Plan if your Termination Date occurs for any one or more of the following reasons:

(A) Your employment is terminated involuntarily by the Company or a Participating Employer, other than for Cause; or

(B) You voluntarily terminate your employment for Good Reason.

To qualify for severance payments and benefits under the Plan upon voluntary termination for Good Reason, you must notify the Company in writing of termination for Good Reason, specifying the event constituting Good Reason, within 10 business days after the occurrence of the event that you believe constitutes Good Reason. Failure for any reason to give written notice of termination of employment for Good Reason in accordance with the foregoing will be deemed a waiver of the right to voluntarily terminate your employment for that Good Reason event. The Company will have a period of 30 days after receipt of your notice in which to cure the Good Reason. If the Good Reason is cured within this period, you will not be entitled to severance payments and benefits under the Plan. If the Company waives its right to cure or does not, within the 30 day period, cure the Good Reason, you will be entitled to severance payments and benefits under the Plan subject to the terms and conditions hereof, and your actual Termination Date will be determined in the sole discretion of the Company, but in no event will it be later than 30 calendar days from the date the Company waives its right to cure or the end of the 30-day period in which to cure the Good Reason, whichever is earlier.

Ineligibility for Severance Benefits

Notwithstanding any other provision of the Plan, you will not be eligible for severance payments and benefits under the Plan if your Termination Date occurs by reason of any of the following:

• Voluntary termination or voluntary retirement other than for Good Reason;

• Mandatory retirement from employment in accordance with Company policy or statutory requirements;

• Disability (as defined in the Company's Long-Term Disability Plan);

• For Cause; or

• Refusal to accept a transfer to a position with the Company or a Participating Employer, as applicable, for which you are qualified, as determined by the Company, by reason of your knowledge, training, and experience, provided that the transfer would not constitute Good Reason for a voluntary termination.

Cause

"Cause" means the following:

(A) Failure or refusal by you to substantially perform your duties with the Company or a Participating Employer (except where the failure results from incapacity due to Disability); or

(B) Severe misconduct or activity deemed detrimental to the interests of the Company or a Participating Employer. This may include, but is not limited to, the following: acts involving dishonesty, violation of the Company's or a Participating Employer's written policies (such as those related to alcohol or drugs, etc.), violation of safety rules, disorderly conduct, discrimination and/or discriminatory harassment, unauthorized disclosure of the Company's or a Participating Employer's confidential information, or the entry of a plea of nolo contendere to, or the conviction of, a crime.

"Cause" will be interpreted by the Compensation Committee (or its designee) in its sole discretion and such interpretation will be conclusive and binding on all parties.

3

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Good Reason

"Good Reason" means the occurrence of any one or more of the following events which occur without your express written consent:

(A) A material reductionin your base salary;

(B) A reduction in your grade level (e.g., the Company changes your job level from a 18 to a 17), resulting in a material diminution of your authority, duties, or responsibilities;

(C) A change in the principal location of your job or office, such that you will be based at a location that is 50 miles or more further (determined in accordance with the Company's relocation policy) from your principal job or office location immediately prior to the proposed change in your job or office.

4

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Severance Payments and Benefits

________________________________________________________________________________________________________

Under the Plan, you are eligible to receive Basic Severance Pay, Severance Pay and benefits as set forth below, provided you meet the eligibility criteria for severance payments and benefits described in the previous Section and this Section.

Cash Severance Payments

________________________________________________________________________________________________________

Basic Severance Pay

If you are eligible for severance benefits, as defined by the Plan, you will be entitled to Basic Severance Pay, subject to the terms and conditions of the Plan, equal to four weeks of your Base Salary. Basic Severance Pay is not subject to the Release Requirements and will be made at regular payroll intervals according to your pay schedule prior to your Termination Date.

Severance Pay

If you are eligible for severance benefits, as defined by the Plan, you will be entitled to Severance Pay, subject to the terms and conditions of the Plan. Your Severance Pay will consist of (A) a pro-rata portion of your Bonus (the “Bonus Portion”), plus (B) cash severance payments (the “Cash Portion”) determined in accordance with the following schedule:

Tier	Amount of Cash Portion of Severance Pay
Tier 1 (Chief Executive Officer)	Two times Base Salary
Tier 2 (Chief Financial Officer and Region Presidents)	One and one-half times Base Salary
Tier 3 (Senior Executives in Grade 18 and abovenot in Tier 1 or Tier 2)	One to one and one-half times Base Salary*

* Determination of whether the amount is one or one and one-half times Base Salary shall be made by the Compensation Committee (or its designee).

Any Severance Pay to which you are entitled is in addition to, and not in lieu of, any Basic Severance Pay to which you may be entitled under the Plan.

Payment of the Bonus Portion of your Severance Pay will be made in a lump sum at the time that annual incentive bonuses are paid to similarly-situated employees of the Company or Participating Employers who have not terminated employment, including, if applicable, after any required actions, including certification of applicable performance targets, are taken by the Compensation Committee; provided that the Release Requirements are satisfied as of the Payment Start Date (or, if earlier, the date on which annual incentive bonuses are otherwise paid to similarly-situated employees of the Company or Participating Employers who have not terminated employment).

Payments of the Cash Portion of your Severance Pay will begin as of the date that is 60 days after your Termination Date (the “Payment Start Date”) provided that the Release Requirements are satisfied as of such date. Thereafter, payment of the Cash Portion of your Severance Pay will be made in substantially equal installments over the Severance Pay Period at regular payroll intervals according to your pay schedule prior to your Termination Date (unless otherwise required under Code Section 409A); provided, however, that if you are entitled to the Cash Portion of your Severance Pay and you obtain new employment after your Termination Date, all remaining payments of the Cash Portion of your Severance Pay, if any, will be paid to you in a lump sum

5

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

payment to the extent that such remaining payments are not subject to Code Section 409A. You are required to notify the Company within 10 days after you obtain other employment after your Termination Date. Your “Severance Pay Period” shall mean the period of time included in the severance multiplier (i.e., 2 years for Tier 1, 18 months for Tier 2 and one year for Tier 3). If the Release Requirements are not satisfied as of the Payment Start Date, you will not receive any Severance Pay (or other benefits) under the Plan (other than Basic Severance Pay if you are entitled to such payments).

Notwithstanding the foregoing, if a payment of Basic Severance Pay or Severance Pay is a direct payment or a substitute or replacement for a right to payment that constitutes nonqualified deferred compensation within the meaning of Code Section 409A, including, to the extent applicable, amounts payable under another plan or agreement between the employee and the Company (the “Protected Amount”) and if the Protected Amount is payable upon termination of employment, then the Basic Severance Pay and Severance Pay shall be paid at the same time and in the same form as the Protected Amount.

No Duplication of Benefits/No Substitution

Nothing in the Plan, a change in control plan or agreement, an offer letter or letter agreement from the Company or a Participating Employer, a prevailing practice of the Company or a Participating Employer, or any oral statement made by or on behalf of the Company or a Participating Employer will entitle you to receive duplicate benefits in connection with a voluntary or involuntary termination of employment. For example, you are not eligible for payments and benefits under both this Plan and a change in control letter agreement between you and the Company. The Company's (or any Participating Employer's) obligation of the Company to make payments under the Plan will be expressly conditioned upon you not receiving duplicate payments. In addition, if you are entitled to Severance Pay under the Plan, you will not receive payment of your Bonus for the year in which your Termination Date occurs (other than the Bonus Portion of your Severance Pay).

To the extent that any amounts would otherwise be payable (or benefits would otherwise be provided) to an employee under another plan of the Company or a Participating Employer (or their affiliates) or an agreement with an employee and the Company or a Participating Employer (or their affiliates), including a change in control plan or agreement, an offer letter or letter agreement, or to the extent that an employee who is eligible for benefits under the Plan moves between Tiers, and to the extent that such other payments or benefits or the severance payments and benefits provided under this Plan are subject to Code Section 409A, the Plan shall be administered to ensure that no payment or benefit under the Plan will be (i) accelerated in violation of Code Section 409A or (ii) further deferred in violation of Code Section 409A.

Offset for U.S. Expatriates

The amount of the total Severance Pay to which you are entitled under the Plan will be reduced (but not below zero) for U.S. expatriates by a amount equal to any (i) payments of severance required to be paid by law in any country other than the U.S. and (ii) tax equalization payments due to the Company or a Participating Employer, and the payments and benefits under the Plan are conditioned upon any such payments required to be paid by law and/or tax equalization payments due being offset. Any offset shall be applied in a manner consistent with Code Section 409A to the extent that either the Severance Pay or the payments described in paragraphs (i) or (ii) next above are subject to Code Section 409A.

Debt owed to the Company or a Participating Employer

If you owe the Company or a Participating Employer money for any reason, the Company or Participating Employer may offset the amount of the debt from your Basic Severance Pay and/or Severance Pay to the extent permitted by law; provided, however, that, any such offset shall be applied in a manner consistent with Code Section 409A to the extent that the Basic Severance Pay or Severance Pay is subject to Code Section 409A.

6

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Continuation of Employee Benefits/Special Benefits

________________________________________________________________________________________________________

During your Severance Pay Period (and from and after your Termination Date), you are not considered an employee of the Company or a Participating Employer for any purpose -- including eligibility under any Company employee benefit plan. The following benefits, however, will continue to be available as outlined below

Health Care Plans

If you and your dependents were enrolled in the Company's medical and/or dental plan on your Termination Date, this coverage will continue until the end of the month in which you are no longer employed with the Company or a Participating Employer, as applicable. At termination of employment, you and your enrolled eligible dependents will be offered the opportunity to elect to continue your current plan coverage beyond the end of the month in which you are no longer employed with the Company under one of two options. The option that applies to you will depend upon whether or not the Release Requirements have been satisfied as of the Payment Start Date.

Option I applies to you if the Release Requirements are satisfied as of the Payment Start Date. Under Option I, your eligibility for Company subsidized medical and/or dental plan coverage will continue for you and your family until the earliest of (i) the end of your Severance Pay Period, (ii) the date you begin new employment, or (iii) the date that COBRA coverage would otherwise end by its terms, provided, in any case, that you timely elect COBRA continuation coverage for you and your family on the forms provided to you. (Option I continuation coverage is COBRA continuation coverage, but its cost is subsidized by the Company to the same extent as coverage for similarly situated active employees and their families from time to time.) Please remember that your eligible dependents will be able to continue their medical and/or dental coverage under Option I only if you are also entitled to continue coverage under this option.

Option II applies to you if the Release Requirements are not satisfied as of the Payment Start Date. Option II provides for the continuation of medical and/or dental plan coverage as required under COBRA. Under COBRA you are required to pay the full cost of coverage for you and your covered dependents plus a 2% administrative fee. The COBRA continuation period begins as of the first day following the month in which your Termination Date occurs. As with Option 1, you are only entitled to COBRA continuation coverage if you timely elect the coverage on forms provided to you.

If Option I applies to you, then after your Company-subsidized continuation coverage ends, you can continue COBRA coverage, if any. In any event, any medical and/or dental coverage that continues during your Severance Pay Period is also applied toward the maximum continuation period and does not extend the COBRA continuation coverage period.

Detailed information about the two benefit continuation options described above will be mailed to your home at the time of termination.

Note that if you are eligible for severance benefits but not eligible to retire¹, you may qualify for the "Rule of 70" benefits under the group health plan. More information regarding this benefit is included in the summary plan description for the health plan.

Life Insurance

Your level of employee life insurance coverage as of your Termination Date will continue at the same level until the end of the month in which your Termination Date occurs. Thereafter, if the Release Requirements are satisfied by the Payment Start Date, Company-provided life insurance coverage equal to one times your Base Salary at your Termination Date will be continued until the earlier of (i) the end of your Severance Pay Period or (ii) the date you begin new employment.

If you are have survivor income coverage or dependent life insurance coverage under the Company's life insurance plan as of your Termination Date, that coverage will end on the last day of the month in which your Termination Date occurs. When your employment terminates, you may have the opportunity to elect to convert all or part of any terminating life insurance coverage to an individual policy with the insurer. Those conversion rights, if any, are determined under the terms of the life insurance plan.

_______________________

¹     To be eligible to retire, you must be at least age 55 with 10 years of service or age 65.

7

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Employee Assistance Program (EAP)

You may continue to participate in the Company's employee assistance program (EAP) during the Severance Pay Period, as long as you remain eligible for benefits under the Company's medical plan. If you elect COBRA continuation coverage, you may continue to participate in the EAP. You will receive additional information regarding participation at the time of your termination.

Outplacement

You will be eligible for outplacement services with one of the Company's preferred providersin accordance with the Company's outplacement services that are in effect for employees at your level as of your Termination Date for up to 12 months following your Payment Start Date; provided, however, that no outplacement services will be provided unless the Release Requirements are satisfied as of your Payment Start Date.

Other Benefits

Accrued and unused vacation days (including banked vacation), long-term performance awards, vesting and exercising of stock options, vesting of restricted stock and restricted stock units, and bonus payments will be determined in accordance with the applicable Company plans, programs and/or policies. All other benefits coverage and eligibility to participate in the Company's benefit plans will end as of your Termination Date except as otherwise expressly provided by the terms of the applicable benefit plans

Notwithstanding the foregoing, if you are entitled to Severance Pay under the Plan, you will not receive payment of any portion of your Bonus for the year in which your Termination Date occurs (other than the Bonus Portion of your Severance Pay); and

• The benefits that will end include, but are not limited to:

• Contributions to the Dependent Care Reimbursement Account;

• Contributions to the Company's Retirement Savings Plan;

• Earning additional service for vesting and benefit accrual purposes under the Company's Retirement Plan; and

• Participation in the Company's disability plans.

8

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Amendment and Plan Termination

________________________________________________________________________________________________________

The Company reserves the right to terminate or amend the Plan, in whole or in part, at any time in the Company's sole discretion. The Company reserves the right to implement changes even if the changes have not been reprinted or substituted in this document.

9

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Additional Plan Information

________________________________________________________________________________________________________

Employment Status

The Plan does not constitute a contract of employment, and nothing in the Plan provides or may be construed to provide that participation in the Plan is a guarantee of continued employment with the Company, a Participating Employer, or any of their respective affiliates.

Withholding of Taxes

The Company will withhold from any amounts payable under the Plan all Federal, state, local or other taxes that are legally required to be withheld from your severance payments.

No Effect on Other Benefits

Neither the provisions of this Plan nor the severance payments and benefits provided for under the Plan will reduce any amounts otherwise payable to you under any incentive, retirement, stock option, stock bonus, stock ownership, group insurance or other benefit plan.

Validity and Severability

The invalidity or unenforceability of any provision of the Plan will not affect the validity or enforceability of any other provision of the Plan, which will remain in full force and effect, and any prohibition or unenforceability in any jurisdiction will not invalidate that provision, or render it unenforceable, in any other jurisdiction.

Unfunded Obligation

All severance payments and benefits under the Plan constitute unfunded obligations of the Company and the Participating Employers. Severance payments will be made, as due, from the general funds of the Company or the Participating Employers. The Plan constitutes solely an unsecured promise by the Company and the Participating Employers to provide severance benefits to you to the extent provided in the Plan. For avoidance of doubt, any medical, dental or life insurance coverage to which you may be entitled under the Plan will be provided under other applicable employee benefit plans of the Company.

Type of Plan and Governing Law

This plan is designed to qualify as a severance pay arrangement within the meaning of Section 3(2)(B)(i) of ERISA and is intended to be excepted from the definitions of "employee pension benefit plan" and "pension plan" set forth under Section 3(2) of ERISA and is intended to meet the descriptive requirements of a plan constituting a "severance pay plan" within the meaning of the regulations published by the Secretary of Labor. The Plan and all rights under it will be governed and construed in accordance with ERISA and, to the extent not preempted by Federal law, with the laws of the state of Illinois.

Assignment

The Plan will inure to the benefit of and will be enforceable by your personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If you should die while any amount is still payable to you under the Plan had you continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of the Plan to your estate. Your rights under the Plan will not otherwise be transferable or subject to lien or attachment.

Other Benefits

Nothing in this document is intended to guarantee that benefit levels or costs will remain unchanged in the future in any other plan, program or arrangement of the Company. The Company and its affiliates and subsidiaries reserve the right to terminate, amend, modify, suspend, or discontinue any other plan, program or arrangement of the Company or its subsidiaries or affiliates in accordance with the terms of that plan, program or arrangement and applicable law.

10

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Oral Statements

The provisions of this document supersede any oral statements made by any employee, officer, or Board member of the Company or any Participating Employer regarding eligibility, severance payments and benefits.

Successors and Assigns

This Plan will be binding upon and inure to the benefit of the Company and its successors and assigns and will be binding upon and insure to the benefit of you and your legal representatives, heirs and legatees.

11

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Code Section 409A

________________________________________________________________________________________________________

Exemption

It is intended that payments of Basic Severance Pay and Severance Pay under the Plan will be exempt from Code Section 409A to the extent payments (i) do not exceed two times the lesser of (1) the employee's total annual compensation based on the employee's annual rate of pay for the prior taxable year (adjusted for any increase that was expected to continue indefinitely) or (2) the limitation under Code Section 401(a)(17) for the year in which the employee has a separation from service within the meaning of Code Section 409A and Treasury regulation Section 1.409A-1(h) ($245,000 in 2010 (2x = $490,000)), and (ii) are paid in full no later than December 31 of the second year following a separation from service or to the extent that such payments otherwise fit within an exemption provided by Code Section 409A or applicable guidance. Similarly, other benefits provided under the Plan are intended to be exempt from Code Section 409A to the extent an applicable exemption is applicable.

Specified Employees

In general, Code Section 409A prohibits certain payments of nonqualified deferred compensation (within the meaning of Code Section 409A) to “Specified Employees” (generally defined as an officer of the Company who is one of the top 50 highest paid employees as determined by the Company) within 6 months following the Specified Employee's separation from service. This rule does not apply to amounts which are exempt from the requirements of Code Section 409A. To comply with this rule and notwithstanding any other provision of the Plan to the contrary, if any payment or benefit under the Plan is subject to Code Section 409A, and if such payment or benefit is to be paid or provided on account of the employee's Termination Date and if the employee is a Specified Employee (within the meaning of Code Section 409A(a)(2)(B)) and if any such payment or benefit is required to be made or provided prior to the first day of the seventh month following the employee's Termination Date, such payment or benefit shall be delayed until the first day of the seventh month following the Executive's separation from service and shall at that time be paid on a lump sum (or, in the case of a non-cash benefit, shall be provided in a manner that is consistent with Code Section 409A). Any amount that would have been paid or provided during this six month period will be paid on the first business day of the seventh month following the separation from service, or, if earlier, the date of the individual's death.

Statement of Intent

To the fullest extent possible, amounts and other benefits payable under the Plan are intended to be exempt from the definition of "nonqualified deferred compensation" under Code Section 409A in accordance with one or more exemptions available under the final Treasury regulations promulgated under Code Section 409A. To the extent that any such amount or benefit is or becomes subject to Code Section 409A, this Plan is intended to comply with the applicable requirements of Code Section 409A with respect to those amounts or benefits so as to avoid the imposition of taxes and penalties. This Plan will be interpreted and administered to the extent possible in a manner consistent with the foregoing statement of intent.

If you notify the Company (specifying the reasons for your position) that you believe that any provision of this Plan or of any payment to be made or benefit granted under this Plan would cause you to incur any additional tax, penalty or interest under Code Section 409A and if the Company concurs, or if the Company (without any obligation whatsoever to do so) independently makes such a determination, the Company will, after consulting with you and to the extent permitted by law, reform the provision to try to comply with Code Section 409A or to be exempt from Code Section 409A to the extent possible without thereby creating other liability, including liability for any other Plan participant. The Company in its sole discretion may modify the timing of payments and benefits under the Plan for the sole purpose of exempting those payments and benefits from Code Section 409A. To the extent that any payment or benefit under the Plan is modified to comply with Code Section 409A or to be exempt from Code Section 409A, the modification or exemption will be made in good faith and will, to the maximum extent reasonably possible, maintain the original intent and economic benefit to you and the Company of the applicable payment or benefit without violating the provisions of Code Section 409A.

12

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

In no event whatsoever will the Company be liable for any additional tax, interest or penalties that may be imposed on you by Code Section 409A or any damages for failing to comply with Code Section 409A.

13

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Administrative Information About Your Plan

________________________________________________________________________________________________________

Employer Identification Number

________________________________________________________________________________________________________

Mead Johnson & Company, LLC's employer identification number is 35-1140848.

Claim for Benefits

________________________________________________________________________________________________________

If you believe that you are entitled to payments and benefits under the Plan that are not provided to you, or you disagree with any other action taken by the Plan Administrator with respect to the Plan, then you may submit a claim to the Plan Administrator in writing. A claim must be made in writing and submitted within 6 months of your Termination Date. In the event you make a claim for benefits beyond 6 months of your Termination Date, then you are expressly precluded from receiving any severance payments and/or benefits under the Plan.

Claims Review Procedures

You will be notified in writing by the Plan Administrator if your claim under the Plan is denied.

If a claim for benefits under the Plan is denied in full or in part, you Or your duly authorized representative. may appeal the decision to the Plan Administrator.

To appeal a decision, you* must submit a written document through the U.S. Postal Service or other courier service appealing the denial of the claim within 60 days after you receive notice of the claim denial described above. You* may also include information or other documentation in support of your claim.

You* will be notified of a decision within 90 days (which may be extended to 180 days, if required) of the date your appeal is received. This notice will include the reasons for the denial and the specific provision(s) on which the denial is based, a description of any additional information needed to resubmit the claim, and an explanation of the claims review procedure. If the Plan Administrator requires an extension of time to respond to your appeal, you* will receive notice of the reason for the extension within the initial 90-day period and a date by which you can expect a decision.

If the original denial is upheld on first appeal, you* may request a review of this decision. You* may submit a written request for reconsideration to the Plan Administrator (as listed below) within 60 days after receiving the denial.

You* can review all plan documents in preparing your appeal and you* may have a qualified person represent you* during the appeal process. Any documents or records that support your position must be submitted with your appeal letter.

The case will be reviewed, and you* will receive written notice of the decision within 60 days (which may be extended to 120 days, if required). The written notice will include the specific reasons for the decision and specific reference to the Plan provision(s) on which the decision is based.

Any decision on final appeal will be final, conclusive and binding upon all parties. If the final appeal is denied, however, you will be advised of your right to file a claim in court. It is the Company's intent that in any challenge to a denial of benefits on final appeal under these procedures, the court of law or a professional arbitrator conducting the review will apply to a deferential ("arbitrary and capricious") standard and not a de novo review.

_______________________

* Or your duly authorized representative.

14

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Legal Action

You may not bring a lawsuit to recover benefits under the Plan until you have exhausted the internal administrative process described above. No legal action may be commenced at all unless commenced no later than 1 year following the issuance of a final decision on the claim for benefits, or the expiration of the appeal decision period if no decision is issued. This one-year statute of limitations on suits for all benefits will apply in any forum where you may initiate such a suit.

Participating Employers

________________________________________________________________________________________________________

A complete list of Mead Johnson & Company, LLC affiliates, subsidiaries or divisions that participate in the Plan may be obtained from the Plan Administrator by written request. (See the chart at the end of this Section for the name and address of the Plan Administrator.)

Plan Administrator

________________________________________________________________________________________________________

The administration of the Plan is the responsibility of the Plan Administrator. The Plan Administrator has the discretionary authority and responsibility for, among other things, determining eligibility for benefits and construing and interpreting the terms of the Plan. In addition, the Plan Administrator has the authority, at its discretion, to delegate its responsibility to others. The chart at the end of this Section contains the name and address of the Plan Administrator. Notwithstanding the foregoing, if and to the extent required by applicable law, the rules of any applicable securities exchange on which the shares of MJN common stock is traded or MJN's by-laws or articles of incorporation, the Plan will be administered by the MJN Board or the Compensation Committee.

15

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Your Rights and Privileges Under ERISA

________________________________________________________________________________________________________

As a participant in the Plan, you are entitled to certain rights and protection under Employee Retirement Income Security Act of 1974 ("ERISA"). ERISA provides that you shall be entitled to:

Receive Information About Your Plan and Benefits

Examine, without charge, at the Company's offices and at other specified locations all documents governing the plan filed by the plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration.

Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the plan and updated summary plan description. The administrator may make a reasonable charge for the copies.

Prudent Actions by Plan Fiduciaries

In addition to creating certain rights for you, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan. The people who operate your plan, called "fiduciaries" of the plan, have a duty to do so prudently and in the interest of you and other plan participants and beneficiaries. No one, including your employer, or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a welfare benefit or exercising your rights under ERISA.

Enforce Your Rights

If your claim for a welfare benefit is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules.

Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request a copy of plan documents or the latest annual report from the plan and do not receive them within 30 days, you may file suit in a Federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the administrator.

If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in a state or Federal court. In addition, if you disagree with the plan's decision or lack thereof concerning the qualified status of a medical child support order, you may file suit in a Federal court.

If it should happen that plan fiduciaries misuse the plan's money, or if you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a Federal court. The court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous.

Assistance with Your Questions

If you have any questions about your plan, you should contact the Plan Administrator. If you have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210.

You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration at 1-866-444-EBSA (3272) or accessing their website at http://www.dol.gov/ebsa.

16

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Other Administrative Facts

________________________________________________________________________________________________________

Name of Plan	Amended and Restated Mead Johnson & Company, LLC Senior Executive Severance Plan, a component plan of the Mead Johnson & Company, LLC Welfare Benefit Plan
Type of Plan	"Welfare" plan
Plan Records	Kept on a calendar-year basis
Plan Year	January 1 - December 31
Plan Funding	Company and Participating Employers provide severance benefits from general assets.
Plan Sponsor	Mead Johnson & Company, LLC
Plan Number	501
Plan Administrator and Named Fiduciary	Mead Johnson & Company, LLC 2701 Patriot Blvd. 4th Floor Glenview, IL 60026
Agent for Service of Legal Process on the Plan	Mead Johnson & Company, LLC c/o Senior Vice President and General Counsel 2701 Patriot Boulevard Glenview, IL 60026 Mead Johnson & Company, LLC c/o Senior Vice President, Human Resources 2701 Patriot Blvd. 4th Floor Glenview, IL 60026
Trustee	Not applicable
Insurance Company	Not applicable

17

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Glossary

________________________________________________________________________________________________________

It is important to know about the following terms as they apply to the Plan.

Base Salary	Your annual base rate of salary in effect as of the effective date of your Termination Date (determined without regard to any reduction in your rate of base salary under circumstances that constitute Good Reason), including salary reductions under Code Sections 132(f), 125, 137, or 401(k), and excluding overtime, bonuses, income from stock options, stock grants, dividend equivalents, benefits-in-kind, allowances (including, but not limited to, car values, vacation bonuses, food coupons) or other incentives, and any other forms of extra compensation. No foreign service or expatriate allowances shall be included in determining base salary or the amount of severance payments payable under the Plan.
Basic Severance Pay	Basic Severance Pay is the minimum cash severance payments to which you are entitled under the Plan, as described in the Severance Payments and Benefits Section, under the subheading “Cash Severance Payments”.
Bonus	The annual incentive bonus to which you would have been entitled for the year in which your Termination Date occurs as determined under the Company's or Participating Employer's annual incentive bonus plan had your Termination Date not occurred, based on satisfaction of applicable performance criteria.
Bonus Portion	The Bonus Portion of your Severance Pay as defined in the Severance Payments and Benefits Section, under the subheading “Cash Severance Payments”.
Cash Portion	The Cash Portion of your Severance Pay as defined in the Severance Payments and Benefits Section, under the subheading “Cash Severance Payments”.
Cause	Cause is defined in the Eligibility For Severance Benefits Section, under the subheading, "Cause".
COBRA	The continuation coverage provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, a amended. It is a federal law allowing certain individuals, under certain circumstances, to continue group health coverage that would otherwise end due to certain qualifying events, including termination of employment.
Code	The Internal Revenue Code of 1986, as amended, which is the Federal tax code.
Company	Mead Johnson & Company, LLC.
Compensation Committee	The Compensation Committee of the Board of Directors of MJN.
Disability	Disability is defined in the Eligibility for Severance Benefits Section, under the subheading “Ineligibility for Severance Benefits”.
ERISA	The Employee Retirement Income Security Act of 1974, as amended, which is a Federal employee benefits law.
Executive Change in Control Severance Plan	The Amended and Restated Mead Johnson & Company, LLC Executive Change in Control Severance Plan.

18

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

Executive Separation Agreement & General Release	An Executive Separation Agreement & General Release in a form determined by the Company which an employee is required to execute and which must become effective as a condition of severance pay and benefits under the Plan. The Agreement will include, but is not limited to: a general release of claims against the Company, its subsidiaries, its affiliates and their respective officers, directors, employees and agents; certain restrictive covenants and obligations including, but not be limited to, non-competition and non-solicitation covenants for a period of one-year following the Termination Date; and agreements not to make use of confidential or proprietary information of the Company, its subsidiaries or its affiliates, not to disparage or encourage or induce others to disparage the Company, its subsidiaries, its affiliates or their respective products, and to cooperate with the Company, its subsidiaries and its affiliates concerning legal matters.
Good Reason	Good Reason is defined in the Eligibility for Severance Benefits Section, under the subheading "Good Reason".
MJN	Mead Johnson Nutrition Company.
MJN Board	The Board of Directors of MJN.
Participating Employer	A subsidiary or affiliate of the Company that participates in the Plan.
Payment Start Date	Payment Start Date is defined in the Severance Payments and Benefits Section, under the subheading “Cash Severance Payments”.
Plan	The Amended and Restated Mead Johnson & Company, LLC Senior Executive Severance Plan, as set forth in this document and as it may be amended from time to time.
Protected Amount	Protected Amount is defined in the Severance Payment and Benefits Section, under the subheading “Cash Severance Payments”.
Release Requirements	Release Requirements is defined in the Introduction and Highlights Section.
Retirement Savings Plan	The Mead Johnson & Company, LLC Retirement Savings Plan.
Severance Pay	Severance Pay is the cash severance benefits to which you are entitled under the Plan (which includes the Bonus Portion and the Cash Portion), as described in the Severance Payments and Benefits Section, under the subheading “Cash Severance Payments”.
Severance Pay Period	Severance Pay Period is defined in the Severance Payments and Benefits Section, under the subheading “Cash Severance Payments”.
Specified Employee	Specified Employee is defined in the Code Section 409A Section, under the subheading "Specified Employees".
Termination Date	The date on which your employment with the Company, the Participating Employers and their respective affiliates terminates for any reason. To the extent that any payments or benefits under the Plan are subject to Code Section 409A, the determination of whether your Termination Date has occurred (or whether you have otherwise had a termination of employment) shall be made in accordance with the provisions of Code Section 409A and the guidance issued thereunder without application of any alternative levels of reductions of bona fide services permitted thereunder.

19

Amended and Restated Senior Executive Severance Plan & SPD - Effective January 1, 2011                 Mead Johnson & Company, LLC

EX-10.14

Exhibit 10.14

Mead Johnson & Company, LLC

Second Amended and Restated

Executive Change in Control

Severance Plan

and

Summary Plan Description

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Contents

Introduction and Highlights                1

Eligibility to Participate                    2

Eligibility for Severance Benefits                3

Severance Payments and Benefits                7

Continuation of Employee Benefits/Special Benefits        8

Amendment and Plan Termination                13

Additional Plan Information                14

Section 409A                        15

Administrative Information About Your Plan            17

Your Rights and Privileges Under ERISA            19

Other Administrative Facts                21

Glossary                            22

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Introduction and Highlights

Mead Johnson & Company, LLC (the "Company") adopted the Mead Johnson & Company, LLC Executive Change in Control Severance Plan (the "Plan") effective as of December 23, 2009 for eligible executive level employees of the Company and its subsidiaries and affiliates. The purpose of the Plan is to encourage eligible executives to remain employed by the Company and/or its subsidiaries and affiliates and to provide such eligible executives with additional protections in the event their employment is terminated in connection with a Change in Control. The Company further believes that the Plan will aid the Company in attracting and retaining highly qualified executive level employees who are essential to its success.

The Plan has been amended and restated to clarify certain provisions and provide enhanced alternatives for Plan participants. This document sets out the Plan's provisions as of September 13, 2011 which is the effective date of the amendment and restatement of the Plan. This document serves as the Plan's official document and summary plan description. It replaces and supersedes any plan document, summary, or description you may have previously received regarding the Company's severance benefits as they apply to you following a change in control, other than as described herein. The Glossary at the end of this document defines the capitalized terms used in the Plan or tells you where in this document to find a term's meaning. When you encounter a capitalized term, turn to the Glossary to find its meaning.

You are eligible to receive Severance Pay and other benefits under the Plan if (i) you are selected for participation in the Plan by the Compensation Committee (or its designee), (ii) your employment terminates in a Qualifying Termination, (iii) you timely sign and return an Executive Separation Agreement & General Release, and (iv) the Executive Separation Agreement & General Release has become effective as described below. The “Release Requirements” will be considered satisfied as of a specified date if the requirements set forth in paragraphs (iii) and (iv) are met as of such date.

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Eligibility to Participate

You are eligible to participate in the Plan only if (and during the period that) your role for MJN is a Participating Executive Role.

Who Is Not Eligible to Participate

Notwithstanding any other Plan provision, you are not eligible to participate in the Plan and will be excluded from coverage under the Plan if you are an employee who is a party to an individual arrangement or a written employment agreement providing severance payments other than pursuant to the Plan. You will not be entitled to Severance Pay or other benefits under the Senior Executive Severance Plan if you are entitled to benefits under the Plan.

2

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Eligibility for Severance Benefits

Right To Severance Payments And Benefits

You will be eligible to receive severance payments and benefits from the Company as set forth in the Severance Payments and Benefits Section of this Plan if your Termination Date occurs as the result of a Qualifying Termination. For purposes of the Plan, your Termination Date will be considered to have occurred as the result of a “Qualifying Termination” if your Termination Date occurs during the Protected Period for any one or more of the following reasons:

(A) Your employment is terminated involuntarily by the Company other than for Cause; or

(B) You voluntarily terminate your employment for Good Reason.

To qualify for severance payments and benefits under the Plan upon voluntary termination for Good Reason, you must notify the Company in writing of termination for Good Reason, specifying the event constituting Good Reason, within 90 days after you first become aware of the event that you believe constitutes Good Reason. Failure for any reason to give written notice of termination of employment for Good Reason in accordance with the foregoing will be deemed a waiver of the right to terminate your employment for that Good Reason event. The Company will have a period of 30 days after receipt of your notice in which to cure the Good Reason. If the Good Reason is cured within this period, you will not be entitled to severance payments and benefits under the Plan. If the Company waives its right to cure or does not, within the 30 day period, cure the Good Reason, you may terminate your employment for Good Reason within 30 days following the earlier of the date on which the Company waives its right to cure or the end of the cure period. If you do not terminate your employment within such 30 day period, you will waive your right to terminate your employment for that Good Reason event.

Ineligibility for Severance Benefits

Notwithstanding any other provision of the Plan, you will not be eligible for severance payments and benefits under the Plan if your Termination Date occurs for any reason other than a Qualifying Termination, including if your Termination Date occurs as the result of any of the following:

• Voluntary termination or voluntary retirement other than for Good Reason;

• Mandatory retirement from employment in accordance with Company policy or statutory requirements;

• Disability (as defined in the Company's Long-Term Disability Plan);

• For Cause; or

• Termination other than during the Protected Period.

3

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Cause

"Cause" means the following

(A) Willful and continued failure by you to substantially perform your duties with the Company or MJN (except where the failure results from incapacity due to Disability) for a period of 30 consecutive days after a written demand for substantial performance is delivered to you by the Board, which demand specifically identifies the manner in which the Board believes that you have not substantially performed your duties;

(B) Willful engaging by you in conduct which is demonstrably and materially injurious to the Company or its subsidiaries or affiliates, monetarily or otherwise;

(C) You are convicted of, or have entered a plea of nolo contendere to, a felony.

For purposes of paragraphs (A) and (B) next above, no act, or failure to act, on your part shall be deemed “willful” unless done, or omitted to be done, by you not in good faith and without reasonable belief that your act, or failure to act, was in the best interest of the Company. "Cause" will be interpreted by the Compensation Committee (or its designee) in its sole discretion and such interpretation will be conclusive and binding on all parties.

Good Reason

"Good Reason" means the occurrence of any one or more of the following events which occur without your express written consent:

(A) the assignment to you of any duties materially inconsistent with your status as an officer of MJN (e.g., no longer reporting to the CEO) or a substantial adverse alteration in the nature or status of your authorities, duties or responsibilities from those in effect immediately prior to the Change in Control (e.g., reduction in signing authority);

(B) a material adverse change in your reporting relationships;

(C) a material reduction by the Company in your base salary or bonus from the levels in effect immediately prior to a Change in Control or as the same may be increased from time to time after a Change in Control;

(D) the relocation of your principal place of employment to a location more than 50 miles from the location of such place of employment immediately prior to a Change in Control, except for required travel on the Company's business to an extent substantially consistent with your business travel obligations prior to the Change in Control or, if you have consented to a relocation, the failure by the Company to provide you with all of the benefits of the Company's relocation policy as in operation immediately prior to a Change in Control;

(E) the failure of the Company to pay to you any material amount or portion of your compensation or to pay to you any portion of an installment of deferred compensation under any deferred compensation program of the Company within seven days of the date on which such compensation was due; or

(F) the failure by the Company to continue in effect any compensation or benefit plan which is material to your compensation and in which you participated immediately prior to the Change in Control, unless an equitable arrangement (embodied in an ongoing substitute or alternative plan) has been made with respect to such plan, or the failure by the Company to continue your participation therein (or in such substitute or alternative plan) on a basis not materially less favorable, both in terms of the amounts of benefits provided and the level of your participation relative to other participants, as existed at the time of the Change in Control.

4

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Change in Control

For purposes of the Plan, a “Change in Control” shall be deemed to have occurred upon the first to occur of any of the following:

(A) Any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) (a “Person”) shall have become the direct or indirect beneficial owner of thirty percent (30%) or more of (i) the then outstanding shares of common stock of MJN (the “Outstanding MJN Common Shares”) or (ii) the combined voting power of the then outstanding voting securities of MJN entitled to vote generally in the election of directors (the “Outstanding MJN Voting Securities”)(other than, in each case, in connection with a merger or consolidation as a result of which (1) MJN becomes a direct or indirect wholly-owned subsidiary of a holding company, (2) the direct or indirect holders of the common stock and the voting securities of such holding company immediately following the transaction are substantially the same as the holders of the Outstanding MJN Common Shares and the Outstanding MJN Voting Securities, as the case may be, immediately prior to the transaction, and (3) immediately following the transaction no Person is the beneficial owner, directly or indirectly, of thirty percent (30%) or more of the common stock or the voting securities of such holding company);

(B) The consummation of a reorganization, merger, statutory share exchange, consolidation, or similar transaction involving MJN or any of its subsidiaries, the sale or other disposition of all or substantially all of the assets of MJN and its subsidiaries (taken as a whole), or the acquisition of assets or stock of another entity by MJN or any of its subsidiaries (each a “Business Combination”), in each case, unless, following such Business Combination, (i) all or substantially all of the individuals and entities that were the beneficial owners of the Outstanding MJN Common Shares and the Outstanding MJN Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than fifty percent (50%) of the then outstanding shares of common stock (or, for a non-corporate entity, equivalent securities) and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of members of the board of directors (or, for a non-corporate entity, equivalent governing body), as the case may be, of the entity surviving or resulting from such Business Combination (including an entity that, as a result of such transaction, owns all or substantially all of the common stock or the voting securities of MJN or all or substantially all of MJN's assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership immediately prior to such Business Combination of the Outstanding MJN Common Shares and the Outstanding MJN Voting Securities, as the case may be, (ii) no Person (excluding MJN or any employee benefit plan (or related trust) of MJN or such entity surviving or resulting from such Business Combination) beneficially owns, directly or indirectly, thirty percent (30%) or more of, respectively, the then outstanding shares of common stock (or, for a non-corporate entity, equivalent securities) of the entity surviving or resulting from such Business Combination (or any parent thereof) or the combined voting power of the then outstanding voting securities of such entity (or any parent thereof) entitled to vote generally in the election of members of the board of directors (or, for a non-corporate entity, equivalent governing body) and (iii) at least a majority of the members of the board of directors (or, for a non-corporate entity, equivalent governing body) of the entity surviving or resulting from such Business Combination (or any parent thereof) were members of the MJN Board at the time of the execution of the initial agreement or action of the MJN Board providing for such Business Combination;

5

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

(C) The stockholders of MJN approve a plan of complete liquidation or dissolution of MJN; or

(D) There shall have been a change in the composition of the MJN Board within a two (2) year period such that a majority of the MJN Board does not consist of directors who were serving at the beginning of such period together with directors whose initial nomination for election by MJN stockholders or, if earlier, initial appointment to the MJN Board was approved by the vote of two-thirds of the directors then still in office who were in office at the beginning of the two (2) year period together with the directors who were previously so approved (either by a specific vote of approval or by approval of MJN's proxy statement in which such person was named as a nominee for election as a director).

6

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Severance Payments and Benefits

Cash Severance Payments

If your Termination Date occurs as the result of a Qualifying Termination, then, subject to the terms and conditions of the Plan, you will be entitled to a cash severance benefit (“Severance Pay”) in accordance with the following:

Tier	Amount of Severance Pay
Tier 1 (Chief Executive Officer)	Three times Base Salary and Bonus
Tier 2 (Management Committee))	Two times Base Salary and Bonus
Tier 3 (Designated eligible employees not in Tier 1 or Tier 2)	One or One and one half times Base Salary (as determined by the Compensation Committee) and Bonus

Payments of Severance Pay will be made in a lump sum as of the date that is 60 days after your Termination Date (the “Payment Start Date”) provided that the Release Requirements are satisfied as of such date. If the Release Requirements are not satisfied as of the Payment Start Date, you will not receive any Severance Pay (or other benefits) under the Plan.

Notwithstanding the foregoing, if a payment of Severance Pay is a direct payment or a substitute or replacement for a right to payment that constitutes nonqualified deferred compensation within the meaning of Code Section 409A, including, to the extent applicable, amounts payable under the Senior Executive Severance Plan or another plan or agreement between the employee and the Company (the “Protected Amount”) and if the Protected Amount is payable upon termination of employment, and if a Change in Control does not constitute a change in control event within the meaning of Code Section 409A, then the Severance Pay shall be paid at the same time and in the same form as the Protected Amount.

No Duplication of Benefits/No Substitution

Nothing in the Plan, a change in control plan or agreement, an offer letter or letter agreement from the Company or any of its subsidiaries or affiliates, a prevailing practice of the Company or any of its subsidiaries or affiliates, or any oral statement made by or on behalf of the Company or any of its subsidiaries or affiliates will entitle you to receive duplicate benefits in connection with a voluntary or involuntary termination of employment. For example, you are not eligible for payments and benefits under both this Plan and a change in control letter agreement between you and the Company. The Company's obligation to make payments under the Plan will be expressly conditioned upon you not receiving duplicate payments. In addition, if you are entitled to Severance Pay under the Plan, you will not receive payment of your Bonus for the year in which your Termination Date occurs.

To the extent that any amounts would otherwise be payable (or benefits would otherwise be provided) to an employee under another plan of the Company or its subsidiaries or affiliates or an agreement with an employee and the Company or its subsidiaries or affiliates, including a change in control plan or agreement, an offer letter or letter agreement, or to the extent that an employee who is eligible for benefits under the Plan moves between Tiers, and to the extent that such other payments or benefits or the severance payments and benefits provided under this Plan are subject to Code Section 409A, the Plan shall be administered to ensure that no payment or benefit under the Plan will be (i) accelerated in violation of Code Section 409A or (ii) further deferred in violation of Code Section 409A.

7

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Continuation of Employee Benefits/Special Benefits

During your Severance Pay Period (and from and after your Termination Date), you are not considered an employee of the Company or any of its subsidiaries or affiliates for any purpose -- including eligibility under any Company employee benefit plan. The following benefits, however, will continue to be available as outlined below:

Health Care Plans

If you and your dependents were enrolled in the Company's medical and/or dental plan on your Termination Date, this coverage will continue until the end of the month in which you are no longer employed with the Company. At termination of employment, you and your enrolled eligible dependents will be offered the opportunity to elect to continue your current plan coverage beyond the end of the month in which you are no longer employed with the Company under one of two options. The option that applies to you will depend upon whether or not the Release Requirements have been satisfied as of the Payment Start Date.

Option I applies to you if the Release Requirements are satisfied as of the Payment Start Date. Under Option I, your eligibility for Company subsidized medical and/or dental plan coverage will continue for you and your family until the earliest of (i) the end of your Severance Pay Period, (ii) the date you begin new employment, or (iii) the date that COBRA coverage would otherwise end by its terms, provided, in any case, that you timely elect COBRA continuation coverage for you and your family on the forms provided to you. (Option I continuation coverage is COBRA continuation coverage, but its cost is subsidized by the Company to the same extent as coverage for similarly situated active employees and their families from time to time.) Please remember that your eligible dependents will be able to continue their medical and/or dental coverage under Option I only if you are also entitled to continue coverage under this option.

Option II applies to you if the Release Requirements are not satisfied as of the Payment Start Date. Option II provides for the continuation of medical and/or dental plan coverage as required under COBRA. Under COBRA you are required to pay the full cost of coverage for you and your covered dependents plus a 2% administrative fee. The COBRA continuation period begins as of the first day following the month in which your Termination Date occurs. As with Option 1, you are only entitled to COBRA continuation coverage if you timely elect the coverage on forms provided to you.

If Option I applies to you, then after your Company-subsidized continuation coverage ends, you can continue COBRA coverage, if any. In any event, any medical and/or dental coverage that continues during your Severance Pay Period is also applied toward the maximum continuation period and does not extend the COBRA continuation coverage period.

Detailed information about the two benefit continuation options described above will be mailed to your home at the time of termination.

Note that if you are eligible for severance benefits but not eligible to retire,¹ you may qualify for the "Rule of 70" benefits under the group health plan. More information regarding this benefit is included in the summary plan description for the health plan.

_______________________

¹  To be eligible to retire, you must be at least age 55 with 10 years of service or age 65.

8

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Life Insurance

Your level of employee life insurance coverage as of your Termination Date will continue at the same level until the end of the month in which your Termination Date occurs. Thereafter, if the Release Requirements are satisfied by the Payment Start Date, Company-provided life insurance coverage equal to one times your Base Salary at your Termination Date will be continued until the earlier of (i) the end of your Severance Pay Period or (ii) the date you begin new employment.

If you have survivor income coverage or dependent life insurance coverage under the Company's life insurance plan as of your Termination Date, that coverage will end on the last day of the month in which your Termination Date occurs. When your employment terminates, you may have the opportunity to elect to convert all or part of any terminating life insurance coverage to an individual policy with the insurer. Those conversion rights, if any, are determined under the terms of the life insurance plan.

Employee Assistance Program (EAP)

You may continue to participate in the Company's employee assistance program (EAP) during the Severance Pay Period, as long as you remain eligible for benefits under the Company's medical plan. If you elect COBRA continuation coverage, you may continue to participate in the EAP. You will receive additional information regarding participation at the time of your termination.

Outplacement

You will be eligible for outplacement services in accordance with the Company's outplacement services that are in effect for employees at your level as of your Termination Date for up to 12 months following the Payment Start Date; provided, however, that no outplacement services will be provided unless the Release Requirements are satisfied as of the Payment Start Date.

Financial Planning Assistance

You will be eligible for financial planning assistance up to a maximum $15,000; provided, however, that no financial planning assistance will be provided unless the Release Requirements are satisfied as of the Payment Start Date. The assistance may be provided as an in-kind benefit or through a reimbursement arrangement, as determined by the Company. In any event, any expenses that you incur for financial planning assistance (including pursuant to an in-kind arrangement) must be incurred within the first twelve months following your Termination Date. In addition, to the extent that any such financial planning assistance is taxable to you (whether provided as a in-kind benefit or a reimbursement), the amount of the financial planning assistance that will be provided to you during one calendar year may not affect the amount of financial planning assistance that is to be provided to you in any subsequent calendar year, your right to receive financial planning assistance shall not be subject to liquidation or exchange for any other benefit and if the assistance is provided through a reimbursement arrangement, the reimbursement will be made on or before the last day of your taxable year following the year in which the expense was incurred.

Expatriation/Repatriation Benefits

You will be entitled to expatriation and/or repatriation benefits in accordance with the Company's Expatriate policy for a period of three months following your Termination Date.

Enhanced Supplemental Retirement Benefits

Supplemental Retirement Benefit

9

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

You will be entitled to a lump sum cash payment (the “Supplemental Retirement Benefit”) in an amount (if any, but not less than zero) equal to the actuarial present value of:

(A) the BEP Benefit, if any, to which you are entitled under the Benefit Equalization Plan-Retirement Plan as of your Termination Date calculated (i) without regard to the reduction provided in the BEP Benefit formula for the benefit payable under the Retirement Plan (the “Gross BEP Benefit”), and (ii) for purposes of calculating the Gross BEP Benefit, as if your Severance Pay had been taken into account as Final Average Compensation under the Retirement Plan for the Severance Pay Period; MINUS

(B) your accrued benefit under the Retirement Plan determined as of your Termination Date; MINUS;

(C) your BEP Benefit determined as of your Termination Date.

All determinations of your accrued benefit under the Retirement Plan and/or the benefit to which you would have been entitled under the Retirement Plan taking into account the foregoing provisions shall be determined in accordance with the terms of the Retirement Plan, including by application of any actuarial assumptions applicable under the Retirement Plan. All determinations of your Supplemental Retirement Benefit, BEP Benefit, your Gross BEP Benefit and any benefit to which you would have been entitled under the Benefit Equalization Plan taking into account the foregoing provisions shall be determined in accordance with the Benefit Equalization Plan, including by application of any actuarial assumption applicable under the Benefit Equalization Plan. The Supplemental Retirement Benefit will be made in a lump sum as of the Payment Start Date provided that the Release Requirements are satisfied as of such date. If the Release Requirements are not satisfied as of the Payment Start Date, you will not receive the Supplemental Retirement Benefit (or Severance Pay or any other benefits) under the Plan.

In addition to the foregoing and notwithstanding the provisions of the Benefit Equalization Plan-Retirement Plan, (i) your BEP Benefit will be fully vested upon your Qualifying Termination, and (ii) your BEP Benefit will be paid to you in a lump sum as of the Payment Start Date notwithstanding your payment elections under the Benefit Equalization Plan-Retirement Plan provided that (1) the Change in Control is a change in control event within the meaning of Section 409A of the Code, and (2) a lump sum payment of your BEP Benefit as of the Payment Start Date would be permitted without violating the provisions of Section 409A of the Code. Unless both of the requirements of paragraphs (1) and (2) above are satisfied, your BEP Benefit will be paid at the time and in the form determined under the Benefit Equalization Plan-Retirement Plan without regard to the provisions of paragraph (2) above.

Supplemental Retirement Savings Plan Benefit

You will be entitled to a lump sum cash payment (the “Supplemental Retirement Savings Plan Benefit”) in an amount (if any, but not less than zero) equal to the sum of:

(A) the amount of the Employing Company Contributions which would have been credited to you under the Retirement Savings Plan for the Severance Period if (i) you had continued in employment with the Company through the last day of the Severance Period, (ii) the Severance Payment had been taken into account under Retirement Savings Plan as benefit eligible compensation or wages ratably over the Severance Period and if the Severance Payment had been the only benefit eligible compensation or wages you received during such period, and (iii) you had contributed at the maximum rate permitted under the Retirement Savings Plan during the Severance Period; PLUS

(B) the amount of Employer Credits which would have been credited to you under the Benefit Equalization Plan-Retirement Savings Plan for the Severance Period if (i) you had continued in employment with the Company through the last day of the Severance Period, (ii) the Severance Payment had been taken into account under Benefit Equalization Plan-Retirement Savings Plan as compensation for purposes of Employer Credits ratably over the Severance Period and if the Severance Payment had been the only compensation you received during such period, and (iii) you had contributed at the maximum rate permitted under the Benefit Equalization Plan-Retirement Savings Plan during the Severance Period.

10

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

All determinations of the benefits to which you would have been entitled under the Retirement Savings Plan and/or the Benefit Equalization Plan-Retirement Savings Plan shall be determined in accordance with the terms of the Retirement Savings Plan and the Benefit Equalization Plan-Retirement Savings Plan, as applicable. The Supplemental Retirement Savings Plan Benefit will be made in a lump sum as of the Payment Start Date provided that the Release Requirements are satisfied as of such date. If the Release Requirements are not satisfied as of the Payment Start Date, you will not receive the Supplemental Retirement Savings Plan Benefit (or Severance Pay or any other benefits) under the Plan.

In no event shall the amount of your Supplemental Retirement Plan Benefit be contingent on the amount of your actual contributions to the Retirement Savings Plan and/or whether or to what extent you actually made contributions to the Retirement Savings Plan.

In addition to the foregoing and notwithstanding the provisions of the Benefit Equalization Plan-Retirement Savings Plan, (i) your Account Balance will be fully vested upon your Qualifying Termination, and (ii) your Account Balance will be paid to you in a lump sum as of the Payment Start Date notwithstanding your payment elections under the Benefit Equalization Plan-Retirement Savings Plan provided that (1) the Change in Control is a change in control event within the meaning of Section 409A of the Code, and (2) a lump sum payment of your Account Balance as of the Payment Start Date would be permitted without violating the provisions of Section 409A of the Code. Unless both of the requirements of paragraphs (1) and (2) above are satisfied, your Account Balance will be paid at the time and in the form determined under the Benefit Equalization Plan-Retirement Savings Plan without regard to the provisions of paragraph (2) above.

Other Benefits

Accrued and unused vacation days (including banked vacation), long-term performance awards, vesting and exercising of stock options, vesting of restricted stock and restricted stock units, and bonus payments will be determined in accordance with the applicable Company plans, programs and/or policies. All other benefits coverage and eligibility to participate in the Company's benefit plans will end as of your Termination Date except as otherwise expressly provided by the terms of the applicable benefit plans

Notwithstanding the foregoing, if you are entitled to Severance Pay under the Plan, you will not receive payment of any portion of your Bonus for the year in which your Termination Date occurs.

The benefits that will end include, but are not limited to:

• Contributions to the Dependent Care Reimbursement Account;

• Contributions to the Company's Retirement Savings Plan;

• Earning additional service for vesting and benefit accrual purposes under the Company's Retirement Plan; and

• Participation in the Company's disability plans.

11

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Reduction of Payments and Benefits in Certain Circumstances

If (A) any payment or benefit to which you are entitled from the Company and/or any affiliate of the Company under the Plan or otherwise (collectively, “Payments”) are subject to an Excise Tax, and (B) reduction of the Payments to the amount necessary to avoid the application of the Excise Tax would result in you retaining an amount that is greater than the amount you would retain if the Payments were made without such reduction but after the application of the Excise Tax, then, in accordance with the following, you may elect to have the Payments reduced to the extent required to avoid application of the Excise Tax. The determination of whether the Payments would result in the application of the Excise Tax, and the amount of reduction that is necessary so that no such Excise Tax is applied, shall be made by the independent accounting firm selected by the Company. To the extent that you elect to have any of the Payments reduced, you shall be treated as having forfeited such Payments and you will have no further rights to them.

Any reductions in your Payments shall be made in the following order:

(i) first, by reducing Payments (other than Low Ratio Benefits) that are not subject to section 409A of the Code (in the order that you elect);

(ii) next, if further reduction is necessary, from Payments (other than Low Ratio Benefits) that are subject to section 409A of the Code, which Payments shall be reduced in the order of lowest to highest value and if more than one Payment has the same value, the reduction shall be in the order that such Payments would have been paid or provided beginning with the last such Payment to be paid or provided and ending with the first such Payment to be paid or provided and if the Payments would have been provided at the same time, the reduction will be made first from cash benefits and next from non-cash benefits;

(iii) next, if further reduction is necessary, from Low Ratio Benefits that are subject to section 409A of the Code, which Low Ratio Benefits shall be reduced in the order of lowest to highest value and if a Low Ratio Benefit has the same value, the reduction shall be in the order that such Low Ratio Benefits would be paid or provided beginning with the last Low Ratio Benefits to be paid or provided and ending with the first such Low Ratio Benefit to be paid or provided and if the Low Ratio Benefits would have been provided at the same time, the reduction will be made first from cash benefits and next from non-cash benefits; and

(iv) finally, if further reduction is necessary, from Low Ratio Benefits that are not subject to section 409A of the Code (in the order that you elect).

12

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Amendment and Plan Termination

The Company reserves the right to terminate or amend the Plan, in whole or in part, at any time in the Company's sole discretion. The Company reserves the right to implement changes even if the changes have not been reprinted or substituted in this document. Notwithstanding the foregoing, the Plan may not be amended during the Protected Period in a manner that reduces payments or benefits to be provided to any person who was eligible to participate in the Plan on the date of a Change in Control.

13

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Additional Plan Information

Employment Status

The Plan does not constitute a contract of employment, and nothing in the Plan provides or may be construed to provide that participation in the Plan is a guarantee of continued employment with the Company or any of its subsidiaries or affiliates.

Withholding of Taxes

The Company will withhold from any amounts payable under the Plan all Federal, state, local or other taxes that are legally required to be withheld from your severance payments.

No Effect on Other Benefits

Neither the provisions of this Plan nor the severance payments and benefits provided for under the Plan will reduce any amounts otherwise payable to you under any incentive, retirement, stock option, stock bonus, stock ownership, group insurance or other benefit plan.

Validity and Severability

The invalidity or unenforceability of any provision of the Plan will not affect the validity or enforceability of any other provision of the Plan, which will remain in full force and effect, and any prohibition or unenforceability in any jurisdiction will not invalidate that provision, or render it unenforceable, in any other jurisdiction.

Unfunded Obligation

All severance payments and benefits under the Plan constitute unfunded obligations of the Company. Severance payments will be made, as due, from the general funds of the Company. The Plan constitutes solely an unsecured promise by the Company to provide severance benefits to you to the extent provided in the Plan. For avoidance of doubt, any medical, dental or life insurance coverage to which you may be entitled under the Plan will be provided under other applicable employee benefit plans of the Company.

Type of Plan and Governing Law

This plan is designed to qualify as a severance pay arrangement within the meaning of Section 3(2)(B)(i) of ERISA and is intended to be excepted from the definitions of "employee pension benefit plan" and "pension plan" set forth under Section 3(2) of ERISA and is intended to meet the descriptive requirements of a plan constituting a "severance pay plan" within the meaning of the regulations published by the Secretary of Labor. The Plan and all rights under it will be governed and construed in accordance with ERISA and, to the extent not preempted by Federal law, with the laws of the state of Illinois.

14

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Section 409A

Exemption

It is intended that payments of Severance Pay under the Plan will be exempt from Code Section 409A to the extent payments (i) do not exceed two times the lesser of (1) the employee's total annual compensation based on the employee's annual rate of pay for the prior taxable year (adjusted for any increase that was expected to continue indefinitely) or (2) the limitation under Code Section 401(a)(17) for the year in which the employee has a separation from service within the meaning of Code Section 409A and Treasury regulation Section 1.409A-1(h) ($245,000 in 2010 (2x = $490,000)), and (ii) are paid in full no later than December 31 of the second year following a separation from service or to the extent that such payments otherwise fit within an exemption provided by Code Section 409A or applicable guidance. Similarly, other benefits provided under the Plan are intended to be exempt from Code Section 409A to the extent an exemption is applicable.

Specified Employees

In general, Code Section 409A prohibits certain payments of nonqualified deferred compensation (within the meaning of Code Section 409A) to “Specified Employees” (generally defined as an officer of the Company who is one of the top 50 highest paid employees as determined by the Company) within 6 months following the Specified Employee's separation from service. This rule does not apply to amounts which are exempt from the requirements of Code Section 409A. To comply with this rule and notwithstanding any other provision of the Plan to the contrary, if any payment or benefit under the Plan is subject to Code Section 409A, and if such payment or benefit is to be paid or provided on account of the employee's Termination Date and if the employee is a Specified Employee (within the meaning of Code Section 409A(a)(2)(B)) and if any such payment or benefit is required to be made or provided prior to the first day of the seventh month following the employee's Termination Date, such payment or benefit shall be delayed until the first day of the seventh month following the employee's separation from service and shall at that time be paid in a lump sum (or, in the case of a non-cash benefit, shall be provided in a manner that is consistent with Code Section 409A). Any amount that would have been paid or provided during this six month period will be paid on the first business day of the seventh month following the separation from service, or, if earlier, the date of the individual's death.

Statement of Intent

To the fullest extent possible, amounts and other benefits payable under the Plan are intended to be exempt from the definition of "nonqualified deferred compensation" under Code Section 409A in accordance with one or more exemptions available under the final Treasury regulations promulgated under Code Section 409A. To the extent that any such amount or benefit is or becomes subject to Code Section 409A, this Plan is intended to comply with the applicable requirements of Code Section 409A with respect to those amounts or benefits so as to avoid the imposition of taxes and penalties. This Plan will be interpreted and administered to the extent possible in a manner consistent with the foregoing statement of intent.

If you notify the Company (specifying the reasons for your position) that you believe that any provision of this Plan or of any payment to be made or benefit granted under this Plan would cause you to incur any additional tax, penalty or interest under Code Section 409A and if the Company concurs, or if the Company (without any obligation whatsoever to do so) independently makes such a determination, the Company will, after consulting with you and to the extent permitted by law, reform the provision to try to comply with Code Section 409A or to be exempt from Code Section 409A to the extent possible without thereby creating other liability, including liability for any other Plan participant. The Company in its sole discretion may modify the timing of payments and benefits under the Plan for the sole purpose of exempting those payments and benefits from Code Section 409A. To the extent that any payment or benefit under the Plan is modified to comply with Code Section 409A or to be exempt from Code Section 409A, the modification or exemption will be made in good faith and will, to the maximum extent reasonably possible, maintain the original intent and economic benefit to you and the Company of the applicable payment or benefit without violating the provisions of Code Section 409A.

15

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

In no event whatsoever will the Company be liable for any additional tax, interest or penalties that may be imposed on you by Code Section 409A or any damages for failing to comply with Code Section 409A.

Assignment

The Plan will inure to the benefit of and will be enforceable by your personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If you should die while any amount is still payable to you under the Plan had you continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of the Plan to your estate. Your rights under the Plan will not otherwise be transferable or subject to lien or attachment.

Other Benefits

Nothing in this document is intended to guarantee that benefit levels or costs will remain unchanged in the future in any other plan, program or arrangement of the Company. The Company and its affiliates and subsidiaries reserve the right to terminate, amend, modify, suspend, or discontinue any other plan, program or arrangement of the Company or its subsidiaries or affiliates in accordance with the terms of that plan, program or arrangement and applicable law.

Oral Statements

The provisions of this document supersede any oral statements made by any employee, officer, or Board member of the Company or any of its subsidiaries or affiliates regarding eligibility, severance payments and benefits.

Successors and Assigns

This Plan will be binding upon and inure to the benefit of the Company and its successors and assigns and will be binding upon and insure to the benefit of you and your legal representatives, heirs and legatees.

16

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Administrative Information About Your Plan

Employer Identification Number

The Company's employer identification number is 35-1140848.

Claim for Benefits

If you believe that you are entitled to payments and benefits under the Plan that are not provided to you, or you disagree with any other action taken by the Plan Administrator with respect to the Plan, then you may submit a claim to the Plan Administrator in writing. A claim must be made in writing and submitted within 6 months of your Termination Date. In the event you make a claim for benefits beyond 6 months of your Termination Date, then you are expressly precluded from receiving any severance payments and/or benefits under the Plan.

Claims Review Procedures

You will be notified in writing by the Plan Administrator if your claim under the Plan is denied.

If a claim for benefits under the Plan is denied in full or in part, you Or your duly authorized representative. may appeal the decision to the Plan Administrator.

To appeal a decision, you* must submit a written document through the U.S. Postal Service or other courier service appealing the denial of the claim within 60 days after you receive notice of the claim denial described above. You* may also include information or other documentation in support of your claim.

You* will be notified of a decision within 90 days (which may be extended to 180 days, if required) of the date your appeal is received. This notice will include the reasons for the denial and the specific provision(s) on which the denial is based, a description of any additional information needed to resubmit the claim, and an explanation of the claims review procedure. If the Plan Administrator requires an extension of time to respond to your appeal, you* will receive notice of the reason for the extension within the initial 90-day period and a date by which you can expect a decision.

If the original denial is upheld on first appeal, you* may request a review of this decision. You* may submit a written request for reconsideration to the Plan Administrator (as listed on the last page of this Section) within 60 days after receiving the denial.

You* can review all plan documents in preparing your appeal and you* may have a qualified person represent you* during the appeal process. Any documents or records that support your position must be submitted with your appeal letter.

The case will be reviewed, and you* will receive written notice of the decision within 60 days (which may be extended to 120 days, if required). The written notice will include the specific reasons for the decision and specific reference to the Plan provision(s) on which the decision is based.

Any decision on final appeal will be final, conclusive and binding upon all parties. If the final appeal is denied, however, you will be advised of your right to file a claim in court. It is the Company's intent that in any challenge to a denial of benefits on final appeal under these procedures, the court of law or a professional arbitrator conducting the review will apply to a deferential ("arbitrary and capricious") standard and not a de novo review.

_______________________

* Or your duly authorized representative.

17

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Legal Action

You may not bring a lawsuit to recover benefits under the Plan until you have exhausted the internal administrative process described above. No legal action may be commenced at all unless commenced no later than 1 year following the issuance of a final decision on the claim for benefits, or the expiration of the appeal decision period if no decision is issued. This one-year statute of limitations on suits for all benefits will apply in any forum where you may initiate such a suit.

Plan Administrator

The administration of the Plan is the responsibility of the Plan Administrator. The Plan Administrator has the discretionary authority and responsibility for, among other things, determining eligibility for benefits and construing and interpreting the terms of the Plan. In addition, the Plan Administrator has the authority, at its discretion, to delegate its responsibility to others. The chart at the end of this Section contains the name and address of the Plan Administrator. Notwithstanding the foregoing, if and to the extent required by applicable law, the rules of any applicable securities exchange on which the shares of MJN common stock is traded or MJN's by-laws or articles of incorporation, the Plan will be administered by the MJN Board or the Compensation Committee.

18

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Your Rights and Privileges Under ERISA

As a participant in the Plan, you are entitled to certain rights and protection under the Employee Retirement Income Security Act of 1974 ("ERISA"). ERISA provides that you shall be entitled to:

Receive Information About Your Plan and Benefits

• Examine, without charge, at the Company's offices and at other specified locations all documents governing the plan filed by the plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration.

• Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the plan and updated summary plan description. The administrator may make a reasonable charge for the copies.

Prudent Actions by Plan Fiduciaries

In addition to creating certain rights for you, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan. The people who operate your plan, called "fiduciaries" of the plan, have a duty to do so prudently and in the interest of you and other plan participants and beneficiaries. No one, including your employer, or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a welfare benefit or exercising your rights under ERISA.

Enforce Your Rights

If your claim for a welfare benefit is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules.

Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request a copy of plan documents or the latest annual report from the plan and do not receive them within 30 days, you may file suit in a Federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the administrator.

If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in a state or Federal court. In addition, if you disagree with the plan's decision or lack thereof concerning the qualified status of a medical child support order, you may file suit in a Federal court.

If it should happen that plan fiduciaries misuse the plan's money, or if you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a Federal court. The court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous.

Assistance with Your Questions

If you have any questions about your plan, you should contact the Plan Administrator. If you have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210.

19

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration at 1-866-444-EBSA (3272) or accessing their website at http://www.dol.gov/ebsa.

20

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Other Administrative Facts

Severance Plan
Name of Plan	Mead Johnson & Company, LLC Executive Change in Control Severance Plan, a component plan of the Mead Johnson & Company, LLC Welfare Benefit Plan
Type of Plan	"Welfare" plan
Plan Records	Kept on a calendar-year basis
Plan Year	January 1 - December 31
Plan Funding	Company provides severance benefits from general assets.
Plan Sponsor	Mead Johnson & Company, LLC
Plan Number	501
Plan Administrator and Named Fiduciary	Mead Johnson & Company, LLC 2701 Patriot Blvd. 4th Floor Glenview, IL 60026
Agent for Service of Legal Process on the Plan	Mead Johnson & Company, LLC c/o Senior Vice President and General Counsel 2701 Patriot Blvd. 4th Floor Glenview, IL 60026
Trustee	Not applicable
Insurance Company	Not applicable

21

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Glossary

It is important to know about the following terms as they apply to the Plan.

Account Balance	Account Balance has the meaning set forth in the Benefit Equalization Plan-Retirement Savings Plan.
Base Salary	Your annual base rate of salary in effect as of your Termination Date (determined without regard to any reduction in your rate of base salary under circumstances that constitute an event of Good Reason), including salary reductions under Code Sections 132(f), 125, 137, or 401(k), and excluding overtime, bonuses, income from stock options, stock grants, dividend equivalents, benefits-in-kind, allowances (including, but not limited to, car values, vacation bonuses, food coupons) or other incentives, and any other forms of extra compensation. No foreign service or expatriate allowances shall be included in determining base salary or the amount of severance payments payable under the Plan.
Benefit Equalization Plan-Retirement Plan	The Mead Johnson & Company Benefit Equalization Plan-Retirement Plan.
Benefit Equalization Plan-Retirement Savings Plan	The Mead Johnson & Company Benefit Equalization Plan-Retirement Savings Plan.
BEP Benefit	BEP Benefit has the meaning set forth in the Benefit Equalization Plan-Retirement Plan.
Board	The Board of Directors of the Company.
Bonus	Your target annual incentive bonus for the year in which your Termination Date occurs as determined under the Company's annual incentive bonus plan (and determined without regard to any reduction in your target annual bonus under circumstances that constitute an event of Good Reason).
Business Combination	Business Combination is defined in the Eligibility for Benefits Section, under the subheading “Change in Control”.
Cause	Cause is defined in the Eligibility For Severance Benefits Section, under the subheading "Cause".
Change in Control	Change in Control is defined in the Eligibility for Severance Benefits Section, under the subheading “Change in Control”.
COBRA	The continuation coverage provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended. It is a federal law allowing certain individuals, under certain circumstances, to continue group health coverage that would otherwise end due to certain qualifying events, including termination of employment.
Code	The Internal Revenue Code of 1986, as amended, which is the Federal tax code.
Company	Mead Johnson & Company, LLC.

22

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Compensation Committee	The Compensation and Management Development Committee of the MJN Board.
Disability	Disability is defined in the Eligibility for Severance Benefits Section, under the subheading “Ineligibility for Severance Benefits”.
Employer Credits	Employer Credits has the meaning set forth in the Benefit Equalization Plan-Retirement Savings Plan.
Employing Company Contributions	Employing Company Contributions has the meaning set forth in the Retirement Savings Plan.
ERISA	The Employee Retirement Income Security Act of 1974, as amended, which is a Federal employee benefits law.
Executive Separation Agreement & General Release	An Executive Separation Agreement & General Release in a form determined by the Company which an employee is required to execute and which must become effective as a condition of severance pay and benefits under the Plan. The Agreement will include, but is not limited to: a general release of claims against the Company, its subsidiaries, its affiliates and their respective officers, directors, employees and agents; certain restrictive covenants and obligations including, but not limited to, non-competition and non-solicitation covenants for a period of one-year following the Termination Date; and agreements not to make use of confidential or proprietary information of the Company, its subsidiaries or its affiliates, not to disparage or encourage or induce others to disparage the Company, its subsidiaries or its affiliates or their respective products, and to cooperate with the Company, its subsidiaries and its affiliates concerning legal matters.
Good Reason	Good Reason is defined in the Eligibility for Severance Benefits Section, under the subheading "Good Reason".
Gross BEP Benefit	Gross BEP Benefit is defined in the Continuation of Employee Benefits/Special Benefits Section, under the subheading “Supplemental Retirement Benefit”.
Excise Tax	An excise tax imposed under section 4999 of the Code or any similar federal or state law.
Low Ratio Benefit	A payment or benefit which is taken into account for purposes of calculating an Excise Tax and which has a value for purposes of calculating the Excise Tax that is less than the actual value of such payment or benefit such that the ratio of the value of the payment or benefit for purposes of calculating the Excise Tax to the actual value of the payment or benefit is less than one hundred percent (100%).
MJN	Mead Johnson Nutrition Company.
MJN Board	The Board of Directors of MJN.
Outstanding MJN Common Shares	Outstanding MJN Common Shares is defined in the Eligibility for Benefits Section, under the subheading “Change in Control”.
Outstanding MJN Voting Securities	Outstanding MJN Voting Stock is defined in the Eligibility for Benefits Section, under the subheading “Change in Control”.

23

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Payments	Payments is defined in the Severance Payments and Benefits Section, under the subheading “Reduction of Payments and Benefits in Certain Cases”.
Payment Start Date	Payment Start Date is defined in the Severance Payments and Benefits Section, under the subheading “Cash Severance Payments”.
Person	Person is defined in the Eligibility for Benefits Section, under the subheading “Change in Control”.
Plan	The Mead Johnson & Company, LLC Executive Change in Control Severance Plan, as set forth in this document and as it may be amended from time to time.
Protected Amount	Protected Amount is defined in the Severance Payments and Benefits Section, under the subheading “Cash Severance Payments”.
Protected Period	The two year period beginning on the date of a Change in Control.
Qualifying Termination	Qualifying Termination is defined in the Eligibility for Severance Benefits Section, under the subheading “Right to Severance Payments and Benefits”.
Release Requirements	Release Requirements is defined in the Introduction and Highlights Section.
Retirement Plan	The Mead Johnson & Company, LLC Retirement Plan.
Retirement Savings Plan	The Mead Johnson & Company, LLC Retirement Savings Plan.
Senior Executive Severance Plan	Mead Johnson & Company, LLC Senior Executive Severance Plan.
Severance Pay	Severance Pay is the cash severance benefits to which you are entitled under the Plan, as described in the Severance Payments and Benefits Section, under the subheading “Cash Severance Payments”.
Severance Pay Period	The number of years (or years and months) of Base Salary and Bonus included in your Severance Pay (i.e., 3 years for Tier 1, 2 years for Tier 2, and one year for Tier 3).
Specified Employee	Specified Employee is defined in the Section 409A Section, under the subheading "Specified Employees".
Supplemental Retirement Benefit	Supplemental Retirement Benefit is defined in the Continuation of Employee Benefits/Special Benefits Section, under the subheading “Supplemental Retirement Benefit”.
Supplemental Retirement Savings Plan Benefit	Supplemental Retirement Savings Plan Benefit is defined in the Continuation of Employee Benefits/Special Benefits Section, under the subheading “Supplemental Retirement Savings Plan Benefit”.

24

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

Termination Date The date on which your employment with the Company, its subsidiaries and its affiliates terminates for any reason. To the extent that any payments or benefits under the Plan are subject to Code Section 409A, the determination of whether your Termination Date has occurred (or whether you have otherwise had a termination of employment) shall be made in accordance with the provisions of Code Section 409A and the guidance issued thereunder without application of any alternative levels of reductions of bona fide services permitted thereunder.

25

Executive Change in Control Severance Plan & SPD - Second Amended and Restated          Mead Johnson & Company, LLC

EX-21.1

EXHIBIT 21.1

Mead Johnson Nutrition Company Subsidiaries as of December 31, 2013

Entity Name	Jurisdiction
Mead Johnson Nutrition Argentina S.A.	Argentina
Mead Johnson Nutrition S.R L.	Argentina
Mead Johnson Nutrition (Australia) Pty Ltd	Australia
Mead Johnson Nutrition (Belgium) BVBA	Belgium
Apenas Boa Nutrição Indústria de Alimentos Ltda. (Only Good Nutrition Indústria de Alimentos Ltda.)	Brazil
Mead Johnson do Brasil Comércio e Importação de Produtos de Nutrição Ltda.	Brazil
Mead Johnson Nutrition (Canada) Co.	Canada
Mead Johnson Nutritionals (China) Limited	China
Mead Johnson Pediatric Nutrition Institute (China) Ltd.	China
Mead Johnson Pediatric Nutrition Technology (Guanghzou) Ltd.	China
Mead Johnson Nutrition (Colombia) Ltda.	Colombia
Mead Johnson Nutrition (Ecuador) Cia. Ltda.	Ecuador
Mead Johnson Nutrition (France) S.A.S.	France
MJN Holdings (Gibraltar) Limited	Gibraltar
Mead Johnson A.E.B.E.	Greece
Mead Johnson Nutrition (Hong Kong) Limited	Hong Kong
Mead Johnson Nutrition (India) Private Limited	India
PT Mead Johnson Indonesia	Indonesia
Mead Johnson Nutrition (Italia) S.r.l.	Italy
Mead Johnson Nutrition (Malaysia) Sdn. Bhd.	Malaysia
Manufactura MJN, S. de R.L. de C.V.	Mexico
Mead Johnson Nutricionales de Mexico, S. de R.L. de C.V.	Mexico
Servicios Nutricionales Mead Johnson, S. de R.L. de C.V.	Mexico
GMK Holdings B.V.	Netherlands
Mead Johnson B.V.	Netherlands
Mead Johnson Nutrition Americas B.V.	Netherlands
Mead Johnson One C.V.	Netherlands
Mead Johnson Two C.V.	Netherlands
Mead Johnson Three C.V.	Netherlands
MJN Global Holdings B.V.	Netherlands
MJN Holdings (Asia) B.V.	Netherlands
MJN Holdings (Netherlands) B.V.	Netherlands
MJN Holdings International B.V.	Netherlands
MJN Innovation Services B.V.	Netherlands
Mead Johnson Nutrition (Panama), S. de R.L.	Panama
Mead Johnson Nutrition (Peru) S.r.l.	Peru
2309 Realty Corporation	Philippines
Mead Johnson Nutrition (Philippines), Inc.	Philippines
Sphinx Holdings Company, Inc.	Philippines
Mead Johnson Nutrition (Poland) Sp. z o.o.	Poland

Limited Liability Company "Mead Johnson Nutrition"	Russia
Mead Johnson Nutrition (Asia Pacific) Pte. Ltd.	Singapore
Mead Johnson Nutrition (Singapore) Pte. Ltd.	Singapore
Mead Johnson Nutrition Holdings (Singapore) Pte. Ltd.	Singapore
Mead Johnson Nutrition International Holdings Pte. Ltd.	Singapore
Mead Johnson Nutrition (Spain), S.L.	Spain
Mead Johnson Nutrition (Sweden) AB	Sweden
Mead Johnson Nutrition (Taiwan) Ltd.	Taiwan
Mead Johnson Nutrition (Thailand) Ltd.	Thailand
Mead Johnson Nutrition (UK) Ltd	United Kingdom
Blisa, L.L.C.	Delaware, U.S.A.
Mead Johnson & Company, LLC	Delaware, U.S.A.
Mead Johnson Nutrition (Dominicana) S.A.	Delaware, U.S.A.
Mead Johnson Nutrition (Puerto Rico) Inc.	Delaware, U.S.A.
Mead Johnson Nutrition (Venezuela) LLC	Delaware, U.S.A.
Mead Johnson Nutrition Nominees LLC	Delaware, U.S.A.
MJN Asia Pacific Holdings, LLC	Delaware, U.S.A.
MJN U.S. Holdings LLC	Delaware, U.S.A.
Mead Johnson Nutrition Venezuela, S.C.A.	Venezuela
Mead Johnson Nutrition (Vietnam) Company Limited	Vietnam

EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statements Nos. 333-160201 and 333-164606 on Form S-8, of our reports dated February 18, 2014, relating to the consolidated financial statements and financial statement schedule of Mead Johnson Nutrition Company and subsidiaries (the “Company”), and the effectiveness of the Company's internal control over financial reporting, appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2013.

/s/ DELOITTE & TOUCHE LLP

Chicago, IllinoisFebruary 18, 2014

EX-31.1

EXHIBIT 31.1

Certification of the Chief Executive Officer

I, Peter Kasper Jakobsen, certify that:

1.    I have reviewed this Annual Report on Form 10-K of Mead Johnson Nutrition Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	February 18, 2014	By:	/s/ Peter Kasper Jakobsen
			Peter Kasper Jakobsen
			President and Chief Executive Officer

EX-31.2

EXHIBIT 31.2

Certification of the Chief Financial Officer

I, Peter G. Leemputte, certify that:

1.    I have reviewed this Annual Report on Form 10-K of Mead Johnson Nutrition Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	February 18, 2014	By:	/s/ Peter G. Leemputte
			Peter G. Leemputte
			Executive Vice President and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

I, Peter Kasper Jakobsen, Chief Executive Officer of Mead Johnson Nutrition Company, certify that (i) Mead Johnson Nutrition Company’s Annual Report on Form 10-K for the year ended December 31, 2013, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in Mead Johnson Nutrition Company’s Annual Report on Form 10-K for the year ended December 31, 2013, fairly presents, in all material respects, the financial condition and results of operations of Mead Johnson Nutrition Company.

Date:	February 18, 2014	By:	/s/ Peter Kasper Jakobsen
			Peter Kasper Jakobsen
			President and Chief Executive Officer

EX-32.2

EXHIBIT 32.2

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

I, Peter G. Leemputte, Chief Financial Officer of Mead Johnson Nutrition Company, certify that (i) Mead Johnson Nutrition Company’s Annual Report on Form 10-K for the year ended December 31, 2013, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in Mead Johnson Nutrition Company’s Annual Report on Form 10-K for the year ended December 31, 2013, fairly presents, in all material respects, the financial condition and results of operations of Mead Johnson Nutrition Company.

Date:	February 18, 2014	By:	/s/ Peter G. Leemputte
			Peter G. Leemputte
			Executive Vice President and Chief Financial Officer

XML

LONG LIVED ASSETS (Tables)

12 Months Ended

Dec. 31, 2013

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

The major categories of property, plant, and equipment were as follows: 

(In millions)	December 31, 2013			December 31, 2012
Land	$	12.6		$	6.0
Buildings	550.8			506.0
Machinery, equipment, and fixtures	650.3			595.7
Construction in progress	260.9			150.4
Accumulated depreciation	(607.1		)	(568.2		)
Property, plant, and equipment—net	$	867.5		$	689.9

Schedule of gross carrying value and accumulated amortization by class of intangible assets

The gross carrying value and accumulated amortization by class of intangible assets were as follows: 

	As of December 31, 2013							As of December 31, 2012
(In millions)	Gross Carrying Amount		Accumulated Amortization			Net Book Value		Gross Carrying Amount		Accumulated Amortization			Net Book Value
Indefinite-lived intangible assets
Trademark(1) .	$	34.5	$	—		$	34.5	$	45.3	$	—		$	45.3
Non-compete agreement(1) .	6.8		—			6.8		8.9		—			8.9
Total	41.3		—			41.3		54.2		—			54.2
Amortizable intangible assets
Computer software	132.8		(79.3		)	53.5		132.2		(60.2		)	72.0
Distributor-customer relationship(2) 10 year life	3.3		(0.6		)	2.7		4.4		(0.7		)	3.7
Total	136.1		(79.9		)	56.2		136.6		(60.9		)	75.7
Total other intangible assets	$	177.4	$	(79.9	)	$	97.5	$	190.8	$	(60.9	)	$	129.9

Schedule of Expected Amortization Expense [Table Text Block]

Expected amortization expense related to intangible assets is as follows:

(In millions) Years Ending December 31,
2014	$	16.0
2015	15.0
2016	12.3
2017	9.4
2018	1.8
Later years	1.7

XML

SEGMENT INFORMATION (Details 2) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
SEGMENT INFORMATION
NET SALES	$ 1,060.7	$ 1,046.8	$ 1,055.3	$ 1,037.9	$ 981.1	$ 921.3	$ 1,012.3	$ 986.6	$ 4,200.7	$ 3,901.3	$ 3,677.0
Infant Formula
SEGMENT INFORMATION
NET SALES									2,459.7	2,295.5	2,188.7
Children's Nutrition
SEGMENT INFORMATION
NET SALES									1,653.3	1,487.0	1,394.4
Other.
SEGMENT INFORMATION
NET SALES									$ 87.7	$ 118.8	$ 93.9

XML

ACCOUNTING POLICIES (Details 3) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]
Cash-flow hedge discontinuation number of days from original forecasted transaction date	60 days
Shipping and handling costs
Shipping and handling costs, including warehousing expenses	$ 119.1	$ 115.6	$ 104.3
Advertising Costs
Advertising costs	$ 226.7	$ 180.3	$ 180.6

XML

DERIVATIVES AND OTHER FINANCIAL INSTRUMENTS (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended		12 Months Ended						12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013 Commodity Option [Member] lb	Dec. 31, 2013 Mexican peso	Dec. 31, 2013 Malaysia, Ringgits	Dec. 31, 2013 Philippine peso	Dec. 31, 2013 Interest Rate Swaps	Nov. 30, 2009 Interest Rate Swaps	Dec. 31, 2013 Cash flow hedges D	Dec. 31, 2013 Cash flow hedges Foreign Currency Forward Contract	Dec. 31, 2013 Designated as hedging instruments Cash flow hedges Other assets	Dec. 31, 2012 Designated as hedging instruments Cash flow hedges Other assets	Dec. 31, 2013 Designated as hedging instruments Cash flow hedges Accrued expenses	Dec. 31, 2012 Designated as hedging instruments Cash flow hedges Accrued expenses	Dec. 31, 2013 Designated as hedging instruments Interest Rate Swaps Other assets	Dec. 31, 2012 Designated as hedging instruments Interest Rate Swaps Other assets	Dec. 31, 2013 Lower limit Interest Rate Swaps	Dec. 31, 2013 Upper limit Interest Rate Swaps
Derivative disclosures
No transfers between levels in fair value hierarchy	$ 0
Derivative, Nonmonetary Notional Amount, Mass			200,000
Derivative, Amount of Hedged Item							500.0	700.0
Cash flow hedges											4.2	0	(0.5)	(5.1)	19.9	0
Net asset/(liability) of derivatives designated as hedging instruments	23.6	(5.1)
Number of days from originally forecasted transaction date to discontinue cash flow hedge accounting									60
Maximum duration of foreign exchange contracts used to hedge intercompany purchases (in months)										1 year 6 months
Weighted average Forward Rate (in foreign currency)				13.07	3.18	43.48
Notional value	201.4		0.3	84.0	55.0	62.4
Derivative Asset, Fair Value, Gross Asset	$ 3.7			$ 0.7	$ 2.0	$ 1.0
Derivative, Maturity Date				Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014
Derivative, Forward Interest Rate																	3.79%	3.94%

XML

SEGMENT INFORMATION (Details 3) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
SEGMENT INFORMATION
NET SALES	$ 1,060.7	$ 1,046.8	$ 1,055.3	$ 1,037.9	$ 981.1	$ 921.3	$ 1,012.3	$ 986.6	$ 4,200.7	$ 3,901.3	$ 3,677.0
Long-Lived Assets	1,319.0				1,243.2				1,319.0	1,243.2	860.6
United States
SEGMENT INFORMATION
NET SALES									948.2	990.1	1,019.7
Long-Lived Assets	446.6				456.0				446.6	456.0	457.3
China / Hong Kong
SEGMENT INFORMATION
NET SALES									1,315.8	1,160.1	1,083.5
Long-Lived Assets	64.7				65.1				64.7	65.1	60.7
Mexico
SEGMENT INFORMATION
NET SALES									328.2	317.2	321.0
Long-Lived Assets	134.8				180.1				134.8	180.1	171.6
SINGAPORE
SEGMENT INFORMATION
NET SALES									28.0	22.5	20.8
Long-Lived Assets	245.9				104.9				245.9	104.9	1.3
Other
SEGMENT INFORMATION
NET SALES									1,580.5	1,411.4	1,232.0
Long-Lived Assets	$ 427.0				$ 437.1				$ 427.0	$ 437.1	$ 169.7

XML

ACCOUNTING POLICIES (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue Recognition
WIC rebate accruals	$ 199.7	$ 206.5
Reduction in revenue due to rebates under the WIC program	702.3	730.0	700.7
Sales return accruals	44.8	46.4
Reduction in sales due to sales returns	81.0	82.5	81.8
Cash and Cash Equivalents
Maximum Term of Original Maturity to Classify Instruments as Cash and Cash Equivalents(months)	3 months
Money market funds, classified as Level Two	$ 447.8	$ 520.7

XML

SEGMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2013

Segment Reporting [Abstract]

Schedule of net sales and earnings before interest and income taxes for by reportable segments

(In millions)	Net Sales		Earnings Before Interest and Income Taxes			Year-End Assets		Payments for Capital Expenditures		Depreciation and Amortization
Year ended December 31, 2013
Asia	$	2,179.3	$	795.8		$	1,390.7	$	168.1	$	19.4
Latin America	861.4		207.2			716.9		33.3		10.5
North America/Europe	1,160.0		248.5			798.5		31.6		29.1
Total operating segments	4,200.7		1,251.5			2,906.1		233.0		59.0
Corporate and Other	—		(326.9		)	568.0		7.4		24.1
Total	$	4,200.7	$	924.6		$	3,474.1	$	240.4	$	83.1
Year ended December 31, 2012
Asia	$	1,967.0	$	725.3		$	1,097.3	$	87.4	$	16.9
Latin America	752.5		176.0			712.8		10.7		8.9
North America/Europe	1,181.8		246.1			740.5		22.3		27.4
Total operating segments	3,901.3		1,147.4			2,550.6		120.4		53.2
Corporate and Other	—		(277.4		)	707.6		4.0		23.7
Total	$	3,901.3	$	870.0		$	3,258.2	$	124.4	$	76.9
Year ended December 31, 2011
Asia	$	1,827.8	$	672.5		$	1,008.6	$	34.0	$	17.2
Latin America	619.4		139.1			467.4		12.0		7.6
North America/Europe	1,229.8		308.4			764.0		33.4		30.7
Total operating segments	3,677.0		1,120.0			2,240.0		79.4		55.5
Corporate and Other	—		(345.9		)	526.8		30.1		19.8
Total	$	3,677.0	$	774.1		$	2,766.8	$	109.5	$	75.3

Schedule of net sales by product line

Net Sales (in millions)	Infant Formula		Children’s Nutrition		Other		Total
Year ended December 31, 2013	$	2,459.7	$	1,653.3	$	87.7	$	4,200.7
Year ended December 31, 2012	$	2,295.5	$	1,487.0	$	118.8	$	3,901.3
Year ended December 31, 2011	$	2,188.7	$	1,394.4	$	93.9	$	3,677.0

Schedule of net sales and long-lived assets by geographic region

Geographic (in millions)	United States		China/ Hong Kong		Mexico		Singapore	Other		Total
Year ended December 31, 2013
Net Sales	$	948.2	$	1,315.8	$	328.2	28.0	$	1,580.5	$	4,200.7
Long-Lived Assets	446.6		64.7		134.8		245.9	427.0		1,319.0
Year ended December 31, 2012
Net Sales	$	990.1	$	1,160.1	$	317.2	22.5	$	1,411.4	$	3,901.3
Long-Lived Assets	456.0		65.1		180.1		104.9	437.1		1,243.2
Year ended December 31, 2011
Net Sales	$	1,019.7	$	1,083.5	$	321.0	20.8	$	1,232.0	$	3,677.0
Long-Lived Assets	457.3		60.7		171.6		1.3	169.7		860.6

XML

EQUITY (Details) (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended								12 Months Ended					12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended						46 Months Ended	4 Months Ended	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013 Redeemable Noncontrolling Interest	Dec. 31, 2012 Redeemable Noncontrolling Interest	Dec. 31, 2013 Accumulated Translation Adjustment [Member]	Dec. 31, 2012 Accumulated Translation Adjustment [Member]	Dec. 31, 2013 Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	Dec. 31, 2012 Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	Dec. 31, 2013 Accumulated Defined Benefit Plans Adjustment [Member]	Dec. 31, 2012 Accumulated Defined Benefit Plans Adjustment [Member]	Dec. 31, 2013 Noncontrolling Interests	Dec. 31, 2012 Noncontrolling Interests	Dec. 31, 2013 Common Stock	Dec. 31, 2012 Common Stock	Dec. 31, 2011 Common Stock	Dec. 31, 2013 Treasury Stock	Dec. 31, 2012 Treasury Stock	Dec. 31, 2011 Treasury Stock	Dec. 31, 2013 March Two Thousand Ten Repurchase [Member] Treasury Stock	Dec. 31, 2013 September Two Thousand Thirteen Repurchase [Member] Treasury Stock	Dec. 31, 2013 Selling, General and Administrative Expenses [Member]	Dec. 31, 2013 Selling, General and Administrative Expenses [Member] Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	Dec. 31, 2013 Selling, General and Administrative Expenses [Member] Accumulated Defined Benefit Plans Adjustment [Member]	Dec. 31, 2013 Foreign Exchange [Member] Selling, General and Administrative Expenses [Member] Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	Dec. 31, 2013 Cost of products sold Selling, General and Administrative Expenses [Member]	Dec. 31, 2013 Cost of products sold Selling, General and Administrative Expenses [Member] Accumulated Defined Benefit Plans Adjustment [Member]	Dec. 31, 2013 Selling, General and Administrative Expenses [Member]	Dec. 31, 2013 Selling, General and Administrative Expenses [Member] Accumulated Defined Benefit Plans Adjustment [Member]	Dec. 31, 2013 Research and Development Expense [Member] Selling, General and Administrative Expenses [Member]	Dec. 31, 2013 Research and Development Expense [Member] Selling, General and Administrative Expenses [Member] Accumulated Defined Benefit Plans Adjustment [Member]	Dec. 31, 2013 Other expenses - net [Member] Selling, General and Administrative Expenses [Member]	Dec. 31, 2013 Other expenses - net [Member] Selling, General and Administrative Expenses [Member] Accumulated Defined Benefit Plans Adjustment [Member]
Changes in common shares and treasury stock
Common stock issued, balance at beginning of period				206.0					206.0													206.0	205.1	204.8
Treasury stock balance at beginning of period																									3.5	1.4	0.1
Stock-based compensation																						0.8	0.9	0.3	0.2	0.2	0
Treasury stock purchases																						0	0	0	1.1	1.9	1.3
Common stock issued, balance at end of period	206.8				206.0				206.8	206.0												206.8	206.0	205.1
Treasury stock balance at end of period																									4.8	3.5	1.4
Balance, beginning of period (in dollars )				$ 244.6					$ 244.6																$ 244.6	$ 89.7	$ 3.2
Stock-based compensation (in dollars )																									18.9	15.2	4.9
Treasury stock purchases (in dollars )																									88.4	139.7	81.6
Balance, end of period (in dollars )	351.9				244.6				351.9	244.6															351.9	244.6	89.7
Shares authorized to be repurchased (in dollars)																												300.0	500.0
Shares repurchased, shares																												4.2	0.1
Shares repurchased, average cost per share																												$ 71.21	$ 84.06
Remaining repurchased available under the authorization (in dollars)																													490.3
Accumulated Other Comprehensive Loss	(203.5)				(187.0)				(203.5)	(187.0)				(83.6)	(14.6)	15.4	(4.1)	(135.3)	(168.3)
Stockholders Equity Noncontrolling Interest Accumulated Other Comprehensive Income																				1.9	(0.2)
Redeemable noncontrolling interest accumlated other comprehensive income loss												(14.4)	0
Other Comprehensive Income (Loss), before Reclassifications, before Tax									(43.6)			(14.4)		(79.4)		24.2		11.6		3.3
Cost of Goods Sold									42.9			0		0		5.4		37.5		0
Tax Benefit/(Expense)									9.2	(13.0)	4.7	0		10.4						(1.2)
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax									2.9	(3.5)						10.1
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax									(16.1)	10.6	24.1							(16.1)
Other Comprehensive Income (Loss), Tax									(15.8)
Reclassification Adjustment for Losses Included in Net Earnings									(1,532.8)	(1,485.3)	(1,362.3)																						(5.4)	8.1
Income Tax Expense (Benefit)									219.1	192.6	202.9																			15.5	1.6										11.0
NET EARNINGS	156.8	160.0	163.6	174.5	132.3	139.2	171.1	169.8	654.9	612.4	519.0																			(27.4)	(3.8)	(18.3)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Gain (Loss), before Tax									(37.5)	(23.8)	(14.6)																								(2.8)		(4.7)		(0.9)
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net (Gain) Loss, Tax																																2.9
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net (Gain) Loss, Net of Tax																																(5.5)
Other Comprehensive (Income) Loss, Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax																																			0.1		0.1
Other Comprehensive Income (Loss), Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service (Cost) Credit, Net of Tax																																0.2
Selling, General and Administrative Expense									918.0	877.8	926.8																									(4.6)
Research and Development Expense									102.4	95.4	92.5																											(0.9)
Other Expenses—net									$ 77.8	$ 20.0	$ 19.6																													$ (29.3)	$ (29.3)
Common Stock, Dividends, Per Share, Declared									$ 1.36	$ 1.20	$ 1.04

XML

EMPLOYEE STOCK BENEFIT PLANS (Details 2) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock-based compensation expense
Allocated Share-based Compensation Expense (pre-tax)	$ 32.6	$ 32.2	$ 39.9
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	0
Cost of products sold
Stock-based compensation expense
Allocated Share-based Compensation Expense (pre-tax)	3.0	3.0	4.0
Selling, general and administrative
Stock-based compensation expense
Allocated Share-based Compensation Expense (pre-tax)	26.6	26.2	31.9
Research and Development Expense [Member]
Stock-based compensation expense
Allocated Share-based Compensation Expense (pre-tax)	$ 3.0	$ 3.0	$ 4.0

XML

SELECTED QUARTERLY FINANCIAL DATA(UNAUDITED) (Details) (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Quarterly Financial Information Disclosure [Abstract]
NET SALES	$ 1,060.7	$ 1,046.8	$ 1,055.3	$ 1,037.9	$ 981.1	$ 921.3	$ 1,012.3	$ 986.6	$ 4,200.7	$ 3,901.3	$ 3,677.0
Gross Profit	668.7	681.3	670.9	647.0	599.1	563.8	640.0	613.1	2,667.9	2,416.0	2,314.7
Net Earnings	156.8	160.0	163.6	174.5	132.3	139.2	171.1	169.8	654.9	612.4	519.0
Net earnings attributable to shareholders	$ 153.2	$ 161.6	$ 162.2	$ 172.5	$ 134.2	$ 140.3	$ 165.8	$ 164.2	$ 649.5	$ 604.5	$ 508.5
Net Earnings Attributable to Shareholders (in dollars per share)	$ 0.76	$ 0.80	$ 0.80	$ 0.85	$ 0.66	$ 0.69	$ 0.81	$ 0.80	$ 3.20	$ 2.96	$ 2.48	$ 2.48
Net Earnings Attributable to Shareholders (in dollars per share - diluted)	$ 0.75	$ 0.79	$ 0.80	$ 0.85	$ 0.66	$ 0.69	$ 0.81	$ 0.80	$ 3.19	$ 2.95	$ 2.47

XML

Schedule II Valuation and Qualifying Accounts (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Valuation Allowance of Deferred Tax Assets [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Balance	$ 6.1	$ 7.0	$ 3.3
Valuation Allowances and Reserves, Charged to Cost and Expense	3.8	1.1	3.7
Valuation Allowances and Reserves, Adjustments	(2.6)	(2.0)	0
Valuation Allowances and Reserves, Balance	7.3	6.1	7.0
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Balance	7.6	6.3	8.3
Valuation Allowances and Reserves, Charged to Cost and Expense	0.6	1.5	0.2
Valuation Allowances and Reserves, Deductions	(0.2)	(0.4)	0
Valuation Allowances and Reserves, Adjustments	(1.5)	0.2	(2.2)
Valuation Allowances and Reserves, Balance	$ 6.5	$ 7.6	$ 6.3

XML

DERIVATIVES AND OTHER FINANCIAL INSTRUMENTS (Details 2) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Interest rate swap fair value hedges
Beginning balance	$ (4.1)	$ 4.3
Derivatives qualifying as cash flow hedges deferred in other comprehensive income	24.2	(12.7)	5.8
Reclassification Adjustment for Losses Included in Net Earnings	5.4	0.8	2.9
Change in deferred taxes	(2.9)	3.5
Ending balance	3.2	(4.1)	4.3
Cash flow hedge included within accumulated other comprehensive income (loss) expected to be reclassified within the next twelve months	3.2
Foreign Exchange Contracts
Interest rate swap fair value hedges
Derivatives qualifying as cash flow hedges deferred in other comprehensive income	4.8	(12.7)
Interest Rate Swaps
Interest rate swap fair value hedges
Derivatives qualifying as cash flow hedges deferred in other comprehensive income	$ 19.4

XML

EQUITY

12 Months Ended

Dec. 31, 2013

Equity [Abstract]

EQUITY

EQUITY

        Changes in common shares and treasury stock were as follows:

(In millions)	Common Shares Issued	Treasury Stock	Cost of Treasury Stock
Balance as of January 1, 2011	204.8	0.1	$	3.2
Stock-based compensation	0.3	—	4.9
Treasury stock purchases	—	1.3	81.6
Balance as of December 31, 2011	205.1	1.4	$	89.7
Stock-based compensation	0.9	0.2	15.2
Treasury stock purchases	—	1.9	139.7
Balance as of December 31, 2012	206.0	3.5	$	244.6
Stock-based compensation	0.8	0.2	18.9
Treasury stock purchases	—	1.1	88.4
Balance as of December 31, 2013	206.8	4.8	$	351.9

The Company may use either authorized and unissued shares or treasury shares to meet share requirements resulting from the exercise of stock options and vesting of performance share awards and restricted stock units. Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized using the first-in first-out method.

On March 16, 2010, MJN’s board of directors approved the repurchase of up to $300.0 million of the Company’s common stock. From the date of such authorization through December 31, 2013, 4.2 million shares were repurchased at an average cost per share of $71.21. As of December 31, 2013, the Company has completed all purchases remaining under this authorization.

On September 10, 2013, MJN’s board of directors approved a new share repurchase authorization of up to an additional $500.0 million of the Company’s common stock. From the date of such authorization through December 31, 2013, 0.1 million shares were repurchased at an average cost of $84.06. As of December 31, 2013, the Company had $490.3 million available under this authorization.

Changes in accumulated other comprehensive loss by component were as follows:

(In millions)	Foreign Currency Translation Adjustments			Deferred Gains/(Losses) on Derivatives Qualifying as Hedges			Pension and Other Post-retirement Benefits			Total			Noncontrolling Interest				Redeemable Noncontrolling Interest
Balance as of January 1, 2013	$	(14.6	)	$	(4.1	)	$	(168.3	)	$	(187.0	)	$	(0.2	)		$	—
Deferred Gains/(Losses)	(79.4		)	24.2			11.6			(43.6		)	3.3			1	(14.4		)	1
Reclassification Adjustment for   (Gains)/Losses Included in Net   Earnings	—			5.4			37.5			42.9			—				—
Tax Benefit/(Expense)	10.4			(10.1		)	(16.1		)	(15.8		)	(1.2		)		—
Balance as of December 31, 2013	$	(83.6	)	$	15.4		$	(135.3	)	$	(203.5	)	$	1.9			$	(14.4	)

1 Represents foreign currency translation adjustments.

Reclassification adjustments out of accumulated other comprehensive loss were as follows:

	December 31, 2013
	Affected Statement of Earnings Lines
(In millions)	Cost of Products Sold			Selling, General and Administrative			Research and Development			Other Expenses/ (Income) - Net			Tax Benefit/(Expense)		Net
Deferred Gains/(Losses) on Derivatives Qualifying as Hedges:
Forward Exchange Contracts	$	(5.4	)										$	1.6	$	(3.8	)
Pension and Other Postretirement Benefit Plans:
Actuarial Gains/(Losses)	(2.8		)	(4.7		)	(0.9		)				2.9		(5.5		)
Prior Service Benefits	0.1			0.1											0.2
Settlements										(29.3		)	11.0		(18.3		)
Total Reclassifications	$	(8.1	)	$	(4.6	)	$	(0.9	)	$	(29.3	)	$	15.5	$	(27.4	)

Dividends declared per share were $1.36, $1.20 and $1.04 for the years ended December 31, 2013,2012and2011, respectively.

XML

INCOME TAXES (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Components of earnings before income taxes
U.S	$ 90.2	$ 131.8	$ 153.7
Non-U.S.	783.8	673.2	568.2
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest	874.0	805.0	721.9
U.S. federal	79.1	37.1	81.3
U.S. states	2.4	(1.3)	10.7
Non-U.S.	130.6	139.7	144.2
Current Income Tax Expense (Benefit)	212.1	175.5	236.2
U.S. federal	(23.5)	15.8	(5.2)
U.S. states	0.3	(3.3)	(4.4)
Non-U.S.	30.2	4.6	(23.7)
Deferred Income Tax Expense (Benefit)	7.0	17.1	(33.3)
Income Tax Expense (Benefit)	219.1	192.6	202.9
Provision for income taxes
U.S. statutory rate	305.9	281.7	252.6
State and local taxes	1.3	0.8	3.7
Foreign income taxed at different rates	(25.6)	(67.7)	(42.1)
Repatriation of foreign income	9.4	21.6	21.8
Tax rulings	(121.9)	(46.4)	(51.9)
Reversal of deferred tax on prior years' unremitted earnings due to reinvestment assertion	(8.2)	(8.7)	0
Administrative penalty related to China antitrust review	8.3	0	0
Unrecognized taxbenefits and related interest penalties	38.1	13.1	7.3
Other	$ 11.8	$ (1.8)	$ 11.5
Effective income tax rate reconciliation
U.S. statutory rate (as a percent)	35.00%	35.00%	35.00%
State and local taxes (as a percent)	0.20%	0.10%	0.50%
Foreign income taxed at different rates (as a percent)	(2.90%)	(8.40%)	(5.80%)
Repatriation of foreign income (as a percent)	1.10%	2.70%	3.00%
Tax rulings (as a percent)	(13.90%)	(5.80%)	(7.20%)
Reversal of deferred tax on prior years' due to reinvestmt assertion (as a percent)	(0.90%)	(1.10%)	0.00%
Effective Income Tax Rate Reconciliation change admin penalty China	1.00%	0.00%	0.00%
Effective Income Tax Rate Reconciliation Unrecognized tax benefits and related interest penalties	4.40%	1.60%	1.00%
Other (as a percent)	1.10%	(0.20%)	1.60%
Effective tax rate (as a percent)	25.10%	23.90%	28.10%

XML

DERIVATIVES AND OTHER FINANCIAL INSTRUMENTS (Tables)

12 Months Ended

Dec. 31, 2013

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of fair value of outstanding derivatives

		December 31,
(In millions)	Balance Sheet Location	2013			2012
Cash flow hedges:
Foreign exchange contracts	Other assets	$	4.2		$	—
Interest rate forward swaps	Other assets	19.9			—
Foreign exchange contracts	Accrued expenses	(0.5		)	(5.1		)
Net asset/(liability) of derivatives designated as hedging items		$	23.6		$	(5.1	)

Schedule Of Outstanding Foreign Exchange Forward Contracts

(Dollars in millions)	Weighted-average Forward Rate	Notional Amount		Fair Value Asset		Maturity
Foreign exchange contracts:
Cash flow hedges:
Mexican peso	13.07	84.0		0.7		2014
Malaysian ringgit	3.18	55.0		2.0		2014
Philippine peso	43.48	62.4		1.0		2014
Total foreign exchange contracts		$	201.4	$	3.7

Schedule of change in accumulated other comprehensive income (loss) and the impact on earnings from foreign exchange contracts

(In millions)	2013			2012
Balance—January 1	$	(4.1	)	$	4.3
Derivatives qualifying as cash flow hedges deferred in other comprehensive income	4.8			(12.7		)
Derivatives qualifying as cash flow hedges reclassified to cost of products sold (effective portion)	5.4			0.8
Change in deferred taxes	(2.9		)	3.5
Balance—December 31	$	3.2		$	(4.1	)

Schedule of impact on earnings from interest rate swaps

	(Gain) Loss on Marked to Market Swaps							(Gain) Loss on Marked to Market of Hedged Items
(In millions)	2013		2012		2011			2013		2012		2011
Interest expense—net	$	—	$	—	$	(4.2	)	$	—	$	—	$	4.2

        The impact on earnings from interest rate swaps that qualified as fair value hedges was as follows:

(In millions)	2013			2012			2011
Recognized in interest expense	$	—		$	—		$	(6.3	)
Amortization of basis adjustment for terminated interest rate swaps recognized in interest expense	(9.2		)	(9.3		)	(5.5		)
Total	$	(9.2	)	$	(9.3	)	$	(11.8	)

        See Note 15 for discussion on the Company’s debt.

XML

CONTINGENCIES (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013 Proceeding	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]
Administrative penalty (China)	$ 33.4	$ 0	$ 0
Minimum number of proceedings that could have a material impact	1

XML

RECEIVABLES (Tables)

12 Months Ended

Dec. 31, 2013

Receivables Abstract [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

	December 31,
(In millions)	2013			2012
Trade receivables	$	335.7		$	330.0
Miscellaneous receivables	55.2			42.2
Less allowances	(6.5		)	(7.6		)
Receivables—net	$	384.4		$	364.6

XML

INCOME TAXES (Details 3) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Reconciliation of the Company's changes in gross uncertain tax positions
Gross reserve for uncertain tax positions related to foreign and domestic matters, including penalties and interest	$ 102.6	$ 64.7	$ 29.7	$ 13.6
Increases based on current year tax positions	23.8	17.8	14.6
Decreases based on current year tax positions	0	0	0
Increases based on prior year tax positions	18.9	21.4	1.7
Decreases based on prior year tax positions	0	0	(0.3)
Settlements	0	0	(0.1)
Lapse of statute of limitations	(3.8)	(5.2)	0
Cumulative translation adjustment	(1.0)	1.0	0.2
Unrecognized Tax Benefits reversing within 12 months	10
Amounts of uncertain tax positions that, if recognized, would impact effective tax rate	48.6	18.9	10.9
Interest and penalties related to uncertain tax positions, included in other liabilities	14.8	11.2
Amount of interest and penalties included as a component of provision for income taxes	$ 3.0	$ 5.0	$ 0.6

XML

GOODWILL (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Details of goodwill
Goodwill at the beginning of the period	$ 270.6	$ 117.5
Acquisition		172.8
Goodwill, Other Changes	(40.5)
Translation adjustments	(33.3)	(19.7)
Goodwill at the end of the period	196.8	270.6
Latin America
Details of goodwill
Goodwill at the beginning of the period	253.6	115.8
Acquisition		155.5
Goodwill, Other Changes	(42.5)
Translation adjustments	(33.3)	(17.7)
Goodwill at the end of the period	177.8	253.6
North America/Europe
Details of goodwill
Goodwill at the beginning of the period	17.0	1.7
Acquisition		17.3
Goodwill, Other Changes	2.0
Translation adjustments	0	(2.0)
Goodwill at the end of the period	19.0	17.0
Asia [Member]
Details of goodwill
Goodwill at the beginning of the period	0	0
Acquisition		0
Goodwill, Other Changes	0
Translation adjustments	0	0
Goodwill at the end of the period	$ 0	$ 0

XML

OTHER EXPENSES-NET (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
ScheduleOfOtherIncomeAndOtherExpenseNet [Line Items]
Foreign exchange (gains)/losses-net	$ 9.3	$ (3.1)	$ (9.7)
Administrative penalty (China)	33.4	0	0
Severance and other costs	2.2	8.0	9.9
Pension settlements and curtailments	29.3	15.2	9.7
Gain on sale of non-strategic intangible asset		(6.5)	0
Legal Fees	7.0	0	0
Other net	(3.4)	6.4	9.7
Other Expenses/(Income)—net	77.8	20.0	19.6
Total operating segments
ScheduleOfOtherIncomeAndOtherExpenseNet [Line Items]
Gain on sale of non-strategic intangible asset	$ 0

XML

ACCOUNTING POLICIES (Details 2)	12 Months Ended
	Dec. 31, 2013
Buildings
Capital Assets and Depreciation
Estimated useful life, property, plant and equipment (in years)	50 years
Lower limit
Finite-Lived Intangible Assets, Net [Abstract]
Estimated useful life, capitalized software (in years)	3 years
Lower limit | Machinery, equipment, and fixtures
Capital Assets and Depreciation
Estimated useful life, property, plant and equipment (in years)	3 years
Upper limit
Finite-Lived Intangible Assets, Net [Abstract]
Estimated useful life, capitalized software (in years)	7 years
Upper limit | Machinery, equipment, and fixtures
Capital Assets and Depreciation
Estimated useful life, property, plant and equipment (in years)	40 years

XML

ORGANIZATION

12 Months Ended

Dec. 31, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION

ORGANIZATION

        MeadJohnson Nutrition Company (“MJN” or the “Company”) manufactures, distributes and sells infant formula, children’s nutrition and other nutritional products. MJN has a broad product portfolio, which extends across routine and specialty infant formulas, children’s milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders. These products are generally sold to wholesalers, retailers and distributors and are promoted to healthcare professionals, and, where permitted by regulation and policy, directly to consumers.

XML

RECEIVABLES (Details) (USD $) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Receivables Abstract [Abstract]
Trade receivables	$ 335.7	$ 330.0
Miscellaneous receivables	55.2	42.2
Less allowances	(6.5)	(7.6)
Receivables, Net	$ 384.4	$ 364.6

XML

EQUITY (Tables)

12 Months Ended

Dec. 31, 2013

Accumulated Other Comprehensive Income (Loss) [Line Items]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Changes in accumulated other comprehensive loss by component were as follows:

(In millions)	Foreign Currency Translation Adjustments			Deferred Gains/(Losses) on Derivatives Qualifying as Hedges			Pension and Other Post-retirement Benefits			Total			Noncontrolling Interest				Redeemable Noncontrolling Interest
Balance as of January 1, 2013	$	(14.6	)	$	(4.1	)	$	(168.3	)	$	(187.0	)	$	(0.2	)		$	—
Deferred Gains/(Losses)	(79.4		)	24.2			11.6			(43.6		)	3.3			1	(14.4		)	1
Reclassification Adjustment for   (Gains)/Losses Included in Net   Earnings	—			5.4			37.5			42.9			—				—
Tax Benefit/(Expense)	10.4			(10.1		)	(16.1		)	(15.8		)	(1.2		)		—
Balance as of December 31, 2013	$	(83.6	)	$	15.4		$	(135.3	)	$	(203.5	)	$	1.9			$	(14.4	)

1 Represents foreign currency translation adjustments.

Reclassification adjustments out of accumulated other comprehensive loss were as follows:

	December 31, 2013
	Affected Statement of Earnings Lines
(In millions)	Cost of Products Sold			Selling, General and Administrative			Research and Development			Other Expenses/ (Income) - Net			Tax Benefit/(Expense)		Net
Deferred Gains/(Losses) on Derivatives Qualifying as Hedges:
Forward Exchange Contracts	$	(5.4	)										$	1.6	$	(3.8	)
Pension and Other Postretirement Benefit Plans:
Actuarial Gains/(Losses)	(2.8		)	(4.7		)	(0.9		)				2.9		(5.5		)
Prior Service Benefits	0.1			0.1											0.2
Settlements										(29.3		)	11.0		(18.3		)
Total Reclassifications	$	(8.1	)	$	(4.6	)	$	(0.9	)	$	(29.3	)	$	15.5	$	(27.4	)

Schedule of changes in common shares and treasury stock

Changes in common shares and treasury stock were as follows:

(In millions)	Common Shares Issued	Treasury Stock	Cost of Treasury Stock
Balance as of January 1, 2011	204.8	0.1	$	3.2
Stock-based compensation	0.3	—	4.9
Treasury stock purchases	—	1.3	81.6
Balance as of December 31, 2011	205.1	1.4	$	89.7
Stock-based compensation	0.9	0.2	15.2
Treasury stock purchases	—	1.9	139.7
Balance as of December 31, 2012	206.0	3.5	$	244.6
Stock-based compensation	0.8	0.2	18.9
Treasury stock purchases	—	1.1	88.4
Balance as of December 31, 2013	206.8	4.8	$	351.9

XML

Schedule II Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2013

Valuation and Qualifying Accounts [Abstract]

Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]

SCHEDULE II

MEAD JOHNSON NUTRITION COMPANYVALUATION AND QUALIFYING ACCOUNTS

Description	Balance at beginning of period		Provisions for bad debts		Bad debts written off			Other			Balance at end of period
(In millions)
Allowances for Doubtful Accounts
For the year ended December 31, 2013	$	7.6	$	0.6	$	(0.2	)	$	(1.5	)	$	6.5
For the year ended December 31, 2012	6.3		1.5		(0.4		)	0.2			7.6
For the year ended December 31, 2011	8.3		0.2		—			(2.2		)	6.3

Description	Balance at beginning of period		Provision for valuation allowance		Release of valuation allowance/ other			Balance at end of period
(In millions)
Valuation Allowance on Deferred Tax Assets
For the year ended December 31, 2013	$	6.1	$	3.8	$	(2.6	)	$	7.3
For the year ended December 31, 2012	7.0		1.1		(2.0		)	6.1
For the year ended December 31, 2011	3.3		3.7		—			7.0

XML

SELECTED QUARTERLY FINANCIAL DATA(UNAUDITED)

12 Months Ended

Dec. 31, 2013

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information [Text Block]

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

Dollars in Millions, Except Per Share Data	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Year
2013:
Net sales	$	1,037.9	$	1,055.3	$	1,046.8	$	1,060.7	$	4,200.7
Gross profit	$	647.0	$	670.9	$	681.3	$	668.7	$	2,667.9
Net earnings	$	174.5	$	163.6	$	160.0	$	156.8	$	654.9
Net earnings attributable to shareholders	$	172.5	$	162.2	$	161.6	$	153.2	$	649.5
Basic earnings per share	$	0.85	$	0.80	$	0.80	$	0.76	$	3.20
Diluted earnings per share	$	0.85	$	0.80	$	0.79	$	0.75	$	3.19
2012:
Net sales	$	986.6	$	1,012.3	$	921.3	$	981.1	$	3,901.3
Gross profit	$	613.1	$	640.0	$	563.8	$	599.1	$	2,416.0
Net earnings	$	169.8	$	171.1	$	139.2	$	132.3	$	612.4
Net earnings attributable to shareholders	$	164.2	$	165.8	$	140.3	$	134.2	$	604.5
Basic earnings per share	$	0.80	$	0.81	$	0.69	$	0.66	$	2.96
Diluted earnings per share	$	0.80	$	0.81	$	0.69	$	0.66	$	2.95

XML

EMPLOYEE STOCK BENEFIT PLANS (Details) (USD $) In Millions, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares approved	25,000,000
Percentage of market price at which executive officers and key employees may be granted options to purchase common stock	100.00%
Term of awards	3 years
Assumptions used to calculate fair value of stock options
Expected volatility (as a percent)	27.00%	26.90%	26.70%
Risk-free interest rate (as a percent)	0.90%	1.20%	2.60%
Dividend yield (as a percent)	1.90%	1.60%	1.70%
Expected life (in years)	5 years 3 months 20 days	6 years	6 years
Stock option, Shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,959,000	1,902,000	1,789,000	1,404,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	485,000	491,000	558,000
Exercised (in shares)	(377,000)	(325,000)	(140,000)
Forfeited or expired (in shares)	(51,000)	(53,000)	(33,000)
Vested (in shares)	1,119,000
Vested and expected to vest (in shares)	1,940,000
Stock option, Weighted Average Exercise Price of Shares
Balance at the beginning of the period (in dollars per share)	$ 52.11	$ 42.12	$ 34.36
Granted (in dollars per share)	$ 74.76	$ 78.12	$ 59.18
Exercised (in dollars per share)	$ 36.06	$ 35.60	$ 31.65
Forfeited or expired (in dollars per share)	$ 73.57	$ 57.50	$ 45.03
Balance at the end of the period (in dollars per share)	$ 60.12	$ 52.11	$ 42.12	$ 34.36
Vested (in dollars per share)	$ 50.24
Vested and expected to vest (in dollars per share)	$ 59.98
Stock option, Average Remaining Contractual Term (in years)
Balance at the end of the period (in years)	7 years 4 months 24 days	7 years 8 months 15 days	8 years 1 month 6 days	8 years 7 months 9 days
Vested (in years)	6 years 6 months
Vested and expected to vest (in years)	7 years 4 months 24 days
Stock option, Aggregate Intrinsic Value
Outstanding options	$ 46.3	$ 99.2	$ 47.6	$ 48.2
Exercised options	17.6	11.6	5.2
Vested options	37.5
Vested and expected to vest options	46.1
Weighted-Average Grant Date Fair Value (in dollars per share)	$ 15.08	$ 17.55	$ 14.73
Cash proceeds received from options exercised	13.6	11.6	4.5
Tax benefit realized from stock options exercised	5.9	4.8	1.8
Performance Share Awards
Shares Granted and Earned	203,000	418,000	275,000
Weighted-Average Grant- Date Fair Value (in dollars per share)	$ 72.30	$ 67.22	$ 57.03
Shares outstanding at period end	143,000	197,000	79,000
Percentage of plan performance assumed	100.00%
Nonvested restricted stock units, Shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	423,000	514,000	533,000	588,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	133,000	146,000	134,000
Vested (in shares)	(189,000)	(146,000)	(170,000)
Forfeited (in shares)	(35,000)	(19,000)	(19,000)
Nonvested restricted stock units, Weighted-Average Grant Date Fair Value
Nonvested at the beginning of the period (in dollars per share)	$ 50.24	$ 38.09	$ 35.15
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	$ 74.85	$ 76.98	$ 59.40
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$ 39.14	$ 32.28	$ 44.44
Forfeited (in dollars per share)	$ 62.68	$ 47.57	$ 40.39
Nonvested at the end of the period (in dollars per share)	$ 61.59	$ 50.24	$ 38.09	$ 35.15
Allocated Share-based Compensation Expense (pre-tax)	32.6	32.2	39.9
Stock-based compensation expense
Allocated Share-based Compensation Expense (pre-tax)	32.6	32.2	39.9
Net tax benefit related to stock-based compensation expense	(11.4)	(9.8)	(14.1)
Upper limit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of awards	5 years
Percentage payout based on targets met	200.00%
Lower limit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of awards	1 year
Percentage payout based on targets met	0.00%
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Under one of the company's vesting schedules, percentage of stock options exercisable on each of the first through the fourth anniversaries of the grant date	25.00%
Under the second of two vesting schedules, percentage of stock options exercisable on each of the first through the third anniversaries of the grant date	33.00%
Term of awards	10 years
Stock option, Aggregate Intrinsic Value
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	7.4
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	1 year 9 months 18 days
Nonvested restricted stock units, Weighted-Average Grant Date Fair Value
Allocated Share-based Compensation Expense (pre-tax)	6.5	7.5	5.9
Stock-based compensation expense
Allocated Share-based Compensation Expense (pre-tax)	6.5	7.5	5.9
Performance share awards
Stock option, Aggregate Intrinsic Value
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	6.5
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	1 year 6 months
Nonvested restricted stock units, Weighted-Average Grant Date Fair Value
Allocated Share-based Compensation Expense (pre-tax)	16.1	16.1	22.8
Stock-based compensation expense
Allocated Share-based Compensation Expense (pre-tax)	16.1	16.1	22.8
Restricted stock units
Stock option, Aggregate Intrinsic Value
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	12.8
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	2 years 6 months
Nonvested restricted stock units, Weighted-Average Grant Date Fair Value
Allocated Share-based Compensation Expense (pre-tax)	10.0	8.6	11.2
Stock-based compensation expense
Allocated Share-based Compensation Expense (pre-tax)	$ 10.0	$ 8.6	$ 11.2

XML

LEASES (Tables)

12 Months Ended

Dec. 31, 2013

Leases [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

(In millions) Years Ending December 31,
2014	$	36.4
2015	29.5
2016	20.8
2017	15.5
2018	14.3
Later Years	22.3
Total Minimum Payments	$	138.8

XML

ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation—The financial statements present the results of operations, financial position, and cash flows of MJN and its majority-owned and controlled subsidiaries. Intercompany balances and transactions have been eliminated. The Company prepared the accompanying consolidated financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”). These financial statements consider subsequent events through the date of filing with the Securities and Exchange Commission.

Reclassification, Policy [Policy Text Block]

In the Consolidated Statements of Cash Flows for the years ended December 31, 2012 and 2011, operating cash flow amounts reflected as pension and other postretirement benefit expense have been reclassified to conform to the presentation for the year ended December 31, 2013. These amounts were previously classified as a component of the change in other assets and liabilities.

Use of Estimates

Use of Estimates—The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used in revenue recognition, including sales rebate and return accruals, impairment testing of goodwill and other indefinite-lived intangible assets, income tax assets and liabilities, income tax expense, and legal liabilities, as well as the accounting for stock-based compensation and retirement and post retirement benefits, including the actuarial assumptions. Actual results may or may not differ from estimated results.

Fair Value Measurements

Fair Value Measurements—The fair value of financial assets and liabilities are classified in the fair value hierarchy as follows: Level 1—unadjusted quoted prices in active markets for identical assets or liabilities, Level 2—observable prices that are based on inputs not quoted on active markets, and Level 3—unobservable inputs that reflect estimates about the assumptions market participants would use in pricing the asset or liability.

Revenue Recognition

Revenue Recognition—MJN recognizes revenue when substantially all the risks and rewards of ownership have transferred to the customer. Revenue is recognized on the date MJN’s products are received by the purchaser. Revenues are reduced at the time of recognition to reflect expected returns that are estimated based on historical experience and business trends. Additionally, provisions are made at the time of revenue recognition for discounts, Women, Infants and Children (“WIC”) rebates and estimated sales allowances based on historical experience, updated for changes in facts and circumstances, as appropriate. Such provisions are recorded as a reduction of revenue. The Company offers sales incentives to customers and consumers through various programs consisting primarily of customer pricing allowances, merchandising funds and consumer coupons. Provisions are made at the time of revenue recognition for these items based on historical experience, updated for changes in facts and circumstances, as appropriate. Such provisions are recorded as a reduction of revenue.

        WIC rebate accruals were $199.7 million and $206.5 million at December 31, 2013 and 2012, respectively, and are included in accrued rebates and returns on the Company’s balance sheet. MJN participates on a competitive bidding basis in nutrition programs sponsored by states, tribal governments, the Commonwealth of Puerto Rico, and U.S. territories for WIC. Under these programs, MJN reimburses these entities for the difference between wholesaler list price and the contract price on eligible products. The Company accounts for WIC rebates by establishing an accrual in an amount equal to the Company’s estimate of WIC rebate claims attributable to a sale. MJN determines its estimate of the WIC rebate accrual primarily based on historical experience regarding WIC rebates and current contract prices under the WIC programs. The Company considers levels of inventory in the distribution channel, new WIC contracts, terminated WIC contracts, changes in existing WIC contracts and WIC participation, and adjusts the accrual periodically throughout the year to reflect actual expense. Rebates under the WIC program reduced revenues by $702.3 million, $730.0 million, and $700.7 million in the years ended December 31, 2013, 2012, and 2011, respectively.

        Sales return accruals were $44.8 million and $46.4 million at December 31, 2013 and 2012, respectively, and are included in accrued rebates and returns on the Company’s balance sheet. The Company accounts for sales returns by establishing an accrual in an amount equal to its estimate of sales recorded for which the related products are expected to be returned. The Company determines its estimate of the sales return accrual primarily based on historical experience regarding sales returns, but also considers other factors that could impact sales returns such as discontinuations and new product introductions. Returns reduced sales by $81.0 million, $82.5 million, and $81.8 million for the years ended December 31, 2013, 2012 and 2011, respectively.

Income Taxes

Income Taxes—The provision for income taxes has been determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable earnings in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when changes are enacted.The ultimate liability incurred by the Company may differ from the provision estimates based on a number of factors, including interpretations of tax laws and the resolution of examinations by the taxing authorities.

        Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.The assessment of whether or not a valuation allowance is required often requires significant judgment including the long-range forecast of future taxable earnings and the evaluation of tax planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made.

        Uncertain tax positions that relate to deferred tax assets are recorded against deferred tax assets; otherwise, uncertain tax positions are recorded as either a current or noncurrent liability.

Cash and Cash Equivalents

Cash and Cash Equivalents—Cash and cash equivalents consist of bank deposits, time deposits and money market funds. The Company maintains cash and cash equivalent balances in U.S. dollars and foreign currencies, which are subject to currency rate risk. Cash equivalents are primarily highly liquid investments with original maturities of 3 months or less at the time of purchase and are recorded at cost, which approximates fair value. Money market funds, which totaled $447.8 million and $520.7 million at December 31, 2013 and 2012, respectively, are classified as Level 2 in the fair value hierarchy.

Inventory Valuation

        Inventory Valuation—Inventories are valued at the lower of cost or market. The Company determines cost on the basis of the average cost or first-in, first-out methods.

Property, Plant and Equipment

        Property, Plant and Equipment—Expenditures for additions and improvements, including capitalized interest, are recorded at cost. Depreciation is computed on a straight-line method based on the estimated useful lives of the related assets. The estimated useful lives of the major classes of depreciable assets are up to 50 years for buildings and 3 to 40 years for machinery, equipment, and fixtures. Maintenance and repair costs are expensed as incurred.

Capitalized Software

        Capitalized Software—Certain costs to obtain internal-use software for significant systems projects are capitalized and amortized on a straight-line basis over the estimated useful life of the software, which ranges from 3 to 7 years. Costs to obtain software for projects that are not significant are expensed as incurred.

Impairment of Long-Lived Assets

       Impairment of Long-Lived Assets—The Company periodically evaluates whether current facts or circumstances indicate that the carrying value of its depreciable assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived asset, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. An estimate of the asset’s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company reports an asset to be disposed of at the lower of its cost less accumulated depreciation or its estimated net realizable value.

Goodwill

       Goodwill and Other Intangible Assets—During the third quarter of 2013 the Company changed its annual impairment testing date from January 1 to July 1, which did not result in any delay, acceleration or avoidance of an impairment charge. The Company believes that moving the goodwill impairment testing date to the third quarter is preferable because it better aligns with MJN’s annual and long-term planning timeline, which is a significant element in the testing process. The Company completed impairment testing in both the first and third quarters of 2013 and concluded that no impairment of goodwill exists (see Note 14).

The Company’s policy is to test Goodwill for impairment on an annual basis or when current facts or circumstances indicate that a potential impairment may exist. The Company compares the carrying value of a reporting unit, including goodwill, to the fair value of the unit. If the carrying amount of a reporting unit exceeds its fair value, the Company revalues all assets and liabilities of the reporting unit, excluding goodwill, to determine if the fair value of the net assets is greater than the net assets including goodwill. If the fair value of the net assets is less than the carrying amount of net assets including goodwill, impairment has occurred. The Company’s estimates of fair value are primarily determined based on a discounted cash flow model. Growth rates for sales and profits are determined using inputs from the Company’s annual long-range planning process. The Company also makes estimates of discount rates, perpetuity growth assumptions, market comparables, and other factors. The Company completed its most recent goodwill impairment assessment during the third quarter and monitored for any potential impairment during the remainder of 2013. No impairment of goodwill was required in2013,2012or2011.

The Company evaluates the useful lives of its other intangible assets to determine if they are finite or indefinite-lived. Reaching a determination on useful life requires significant judgments and assumptions regarding the future effects of obsolescence, demand, competition, other economic factors (such as the stability of the industry, known technological advances, legislative action that results in an uncertain or changing regulatory environment, and expected changes in distribution channels), the level of required maintenance expenditures, and the expected lives of other related groups of assets. Intangible assets that are deemed to have definite lives are amortized on a straight-line basis, over their useful lives.

The Company’s indefinite-lived intangible assets are also tested for impairment annually and whenever events or changes in circumstances indicate that their carrying value may not be recoverable. Estimates of the fair value of indefinite-lived intangible assets is based on a discounted cash flow model using inputs which included projected revenues from the Company’s annual long-range plan, assumed royalty rates that could be payable if MJN did not own the brands, and a discount rate. The Company completed its most recent indefinite-lived intangible asset impairment assessment during the third quarter and monitored for any potential impairment during the remainder of 2013, determining that no impairment was required.

Contingencies

        Contingencies—In the ordinary course of business, the Company is subject to loss contingencies, such as lawsuits, investigations, government inquiries and claims, including, but not limited to, product liability claims, advertising disputes and inquiries, consumer fraud suits, other commercial disputes, premises claims and employment and environmental, health, and safety matters. The Company records accruals for such loss contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. The Company does not recognize gain contingencies until realized. Legal costs are expensed as incurred.

Derivatives

        Derivatives—Derivatives are used by the Company principally in the management of its foreign currency, interest rate and commodity pricing exposures. The Company records all derivatives on the balance sheet at fair value. The Company does not hold or issue derivatives for speculative purposes.

        The Company designates and assigns derivatives as hedges of forecasted transactions, specific assets or specific liabilities. When the hedged assets or liabilities are sold, extinguished or the forecasted transactions being hedged are no longer expected to occur, the Company immediately recognizes the gain or loss on the designated hedging financial instruments in the consolidated statements of earnings.

        If derivatives are designated as a cash flow hedge, the effective portion of changes in the fair value is temporarily reported in accumulated other comprehensive loss and is recognized in earnings when the hedged item affects earnings or is deemed ineffective; cash flows are classified consistent with the underlying hedged item. The Company assesses hedge effectiveness at inception and on a quarterly basis. These assessments determine whether derivatives designated as qualifying hedges continue to be highly effective in offsetting changes in the cash flows of hedged items. Any ineffective portion of the change in fair value is included in current period earnings. The Company will discontinue cash flow hedge accounting when the forecasted transaction is no longer probable of occurring on the originally forecasted date, or 60 days thereafter, or when the hedge is no longer effective.

        If derivatives are designated as a fair value hedge, both the changes in the fair value of the derivatives and of the hedged item attributable to the hedged risk are recognized in the consolidated statements of earnings; cash flows are classified consistent with the underlying hedged item.

Pension and Other Post Retirement Benefits

        Pension and Other Post Retirement Benefits—The funded status of the Company’s defined pension and post retirement benefit plans is measured as the difference between the fair value of the plan assets and the benefit obligation. For the defined benefit plans, the benefit obligation is the projected benefit obligation; for any other defined benefit post retirement plans, the benefit obligation is the accumulated post retirement benefit obligation. The net over- or under-funded status is recognized as an asset or a liability on the balance sheet. Any unrecognized actuarial gain or loss, or service cost or benefit is reported as a component of accumulated other comprehensive loss.

Shipping and Handling Costs

       Shipping and Handling Costs—The Company typically does not charge customers for shipping and handling costs. Shipping and handling costs, including warehousing expenses, were $119.1 million, $115.6 million, and $104.3 million in the years ended December 31, 2013, 2012, and 2011, respectively, and are included in selling, general and administrative expenses.

Advertising Costs

        Advertising Costs—Advertising costs are expensed as incurred and were $226.7 million, $180.3 million, and $180.6 million in the years ended December 31, 2013, 2012, and 2011, respectively.

Research and Development

        Research and Development—Research and development costs are expensed as incurred.

Foreign Currency Translation

        Foreign Currency Translation—The statements of earnings of the Company’s foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using average exchange rates for the period. The net assets of the Company’s foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using exchange rates as of the balance sheet date. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in accumulated other comprehensive income (loss).

Recently Adopted Accounting Standards and Recently Issued Accounting Standards

Recently Adopted Accounting Standards—In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, requiring entities to provide information about the amounts reclassified out of accumulated other comprehensive income by component. For significant reclassifications related to net income, the ASU required disclosure in the consolidated statement of earnings or within the footnotes. For other amounts, the ASU required a cross-reference to other disclosures that provide additional detail about those amounts. This ASU did not change the current requirements for reporting the consolidated statement of earnings or other comprehensive income in the financial statements. The Company adopted the required financial reporting presentation effective January 1, 2013.

Recently Issued Accounting Standards—In March 2013, the FASB issued ASU No. 2013-05, Foreign Currency Matters (Topic 830), clarifying the applicable guidance for the release of the cumulative translation adjustment. ASU 2013-05 is effective for the Company in the period beginning January 1, 2014. The Company does not expect the adoption of this update to have a material impact on the consolidated financial statements.   

In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or Tax Credit Carryforward Exists. ASU 2013-11 requires that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, with certain exceptions. ASU 2013-11 is effective for the Company in the period beginning January 1, 2014 and the Company does not anticipate that the adoption of this standard to have a material impact on its consolidated financial statements.

XML

EARNINGS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2013

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following table presents the calculation of basic and diluted earnings per share:

	Years Ended December 31,
(In millions, except per share data)	2013			2012			2011
Basic earnings per share:
Weighted-average shares outstanding	202.4			203.6			204.3
Net earnings attributable to shareholders	$	649.5		$	604.5		$	508.5
Dividends and undistributed earnings attributable to unvested shares	(1.2		)	(1.4		)	(1.4		)
Net earnings attributable to shareholders used for basic earnings per share calculation	$	648.3		$	603.1		$	507.1
Net earnings attributable to shareholders per share	$	3.20		$	2.96		$	2.48
Diluted earnings per share:
Weighted-average shares outstanding	202.4			203.6			204.3
Incremental shares outstanding assuming the exercise/vesting of dilutive stock options/performance shares	0.7			0.7			0.7
Weighted-average shares — diluted	203.1			204.3			205.0
Net earnings attributable to shareholders	$	649.5		$	604.5		$	508.5
Dividends and undistributed earnings attributable to unvested shares	(1.2		)	(1.4		)	(1.4		)
Net earnings attributable to shareholders used for diluted earnings per share calculation	$	648.3		$	603.1		$	507.1
Net earnings attributable to shareholders per share	$	3.19		$	2.95		$	2.47

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net Earnings	$ 654.9	$ 612.4	$ 519.0
Adjustments to Reconcile Net Earnings to Net Cash Provided by Operating Activities:
Depreciation and Amortization	83.1	76.9	75.3
Stock-Based Compensation Expense	32.6	32.2	39.9
Deferred Income Tax	7.0	17.1	(33.3)
Gain on Sale of Intangible Assets	0	(6.5)	0
Exchange Loss from Devaluation	2.2	0	0
Pension and Other Post Retirement Benefits Expense	43.1	27.9	19.1
Other	2.8	1.8	2.3
Receivables	(37.7)	(8.5)	(7.9)
Inventories	(108.2)	109.8	(183.3)
Accounts Payable	56.0	(30.9)	114.7
Accrued Expense, Rebates and Returns	14.8	(6.3)	50.0
Income Taxes Payable	27.0	(62.2)	53.2
Other Assets and Liabilities	48.4	(42.7)	(6.5)
Pension and Other Post Retirement Benefits Contributions	(19.4)	(28.3)	(9.7)
Net Cash Provided by Operating Activities	806.6	692.7	632.8
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for Capital Expenditures	(240.4)	(124.4)	(109.5)
Proceeds from Sale of Property, Plant and Equipment	2.6	1.5	1.6
Proceeds from Sale of Intangible Assets	0	6.5	0
Investment in Other Companies	(2.7)	(6.3)	(4.7)
Payment for Acquisition	0	(106.1)	0
Net Cash Used in Investing Activities	(240.5)	(228.8)	(112.6)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Short-term Borrowings	6.9	391.2	72.0
Repayments of Short-term Borrowings	(165.4)	(230.2)	(73.2)
Repayments of Notes Payable	(27.6)	(52.6)	0
Payments of Dividends	(267.7)	(236.7)	(205.7)
Stock-based-compensation-related Proceeds and Excess Tax Benefits	23.6	23.3	4.5
Purchases of Treasury Stock	(106.0)	(154.9)	(87.7)
Proceeds from Termination of Interest Rate Swaps	0	0	23.5
Distributions to Noncontrolling Interests	(9.5)	(7.6)	(8.6)
Net Cash Used in Financing Activities	(545.7)	(267.5)	(275.2)
Effects of Changes in Exchange Rates on Cash and Cash Equivalents	(11.7)	5.4	(0.3)
NET INCREASE IN CASH AND CASH EQUIVALENTS	8.7	201.8	244.7
CASH AND CASH EQUIVALENTS:
Beginning of Period	1,042.1	840.3	595.6
End of Period	$ 1,050.8	$ 1,042.1	$ 840.3

XML

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2013

Income Tax Disclosure [Abstract]

Schedule of components of earnings before income taxes

The components of earnings before income taxes were:

	Years Ended December 31,
(In millions)	2013		2012		2011
U.S.	$	90.2	$	131.8	$	153.7
Non-U.S.	783.8		673.2		568.2
Total	$	874.0	$	805.0	$	721.9

        The above amounts are categorized based on the applicable taxing authorities.

Summary of components of provision (benefit) for income taxes attributable to operations

The provision (benefit) for income taxes consisted of:

	Years Ended December 31,
(In millions)	2013			2012			2011
Current:
U.S. federal	$	79.1		$	37.1		$	81.3
U.S. states	2.4			(1.3		)	10.7
Non-U.S.	130.6			139.7			144.2
Total current income tax expense	212.1			175.5			236.2
Deferred:
U.S. federal	(23.5		)	15.8			(5.2		)
U.S. states	0.3			(3.3		)	(4.4		)
Non-U.S.	30.2			4.6			(23.7		)
Total deferred income tax expense	7.0			17.1			(33.3		)
Total	$	219.1		$	192.6		$	202.9

Schedule of effective income tax rate reconciliation

Effective Tax Rate—MJN’s provision for income taxes in the years ended December 31, 2013, 2012 and 2011 was different from the amount computed by applying the statutory U.S. federal income tax rate to earnings before income taxes as a result of the following:

(Dollars in millions)	2013					2012					2011
U.S. statutory rate	$	305.9		35.0	%	$	281.7		35.0	%	$	252.6		35.0	%
State and local taxes	1.3			0.2		0.8			0.1		3.7			0.5
Foreign income taxed at different rates	(25.6		)	(2.9	)	(67.7		)	(8.4	)	(42.1		)	(5.8	)
Repatriation of foreign income	9.4			1.1		21.6			2.7		21.8			3.0
Tax rulings and agreements	(121.9		)	(13.9	)	(46.4		)	(5.8	)	(51.9		)	(7.2	)
Reversal of deferred tax on prior years' unremitted foreign earnings due to a permanent reinvestment assertion	(8.2		)	(0.9	)	(8.7		)	(1.1	)	—			—
Administrative penalty related to China antitrust review	8.3			1.0		—			—		—			—
Unrecognized tax benefits and related interest/penalties	38.1			4.4		13.1			1.6		7.3			1.0
Other	11.8			1.1		(1.8		)	(0.2	)	11.5			1.6
Total provision / effective tax rate	$	219.1		25.1	%	$	192.6		23.9	%	$	202.9		28.1	%

   The Company negotiated a tax ruling effective from January 1, 2010, under which certain profits in the Netherlands are exempt from taxation through the year ending December 31, 2019. This ruling was superseded by a subsequent tax agreement effective July 26, 2012, whereby the Company and the Dutch tax authorities agreed to the appropriate remuneration attributable to Dutch manufacturing activities through the year ending December 31, 2019.

Summary of components of current and noncurrent deferred income tax assets (liabilities)

Deferred Taxes and Valuation Allowance—The components of current and noncurrent deferred income tax assets (liabilities) were:

	December 31,
(In millions)	2013			2012
Deferred tax assets:
Accrued expenses	$	33.5		$	28.0
Accrued rebates and returns	42.2			44.5
Pension, post retirement and post employment liabilities	58.1			65.3
Stock-based compensation	20.2			18.3
Obsolescence reserves and other inventory items	7.9			6.3
Net operating loss carryforwards	13.5			17.2
Other—net	6.7			23.2
Valuation allowance	(7.3		)	(6.1		)
Total deferred tax assets	174.8			196.7
Deferred tax liabilities:
Depreciation and amortization	(68.5		)	(76.5		)
Unremitted earnings and cumulative foreign currency translation adjustments	(9.7		)	(26.1		)
Total deferred tax liabilities	(78.2		)	(102.6		)
Deferred tax assets—net	$	96.6		$	94.1
Recognized as:
Net deferred income taxes—current	74.9			85.5
Net deferred income taxes—noncurrent	21.7			8.6
Total	$	96.6		$	94.1

   As ofDecember 31, 2013, the Company had definite-lived and indefinite-lived gross foreign net operating loss (“NOL”) carryforwards of$49.0 million.Indefinite-lived NOL carryforwards totaled $22.3 million with the remainder being definite-lived. An immaterial amount of these definite-lived NOL carryforwards will begin to expire in2014, with the remainder of the definite-lived NOL carryforwards to expire no later than2031. The valuation allowance recorded for NOL carryforwards is$5.0 millionas ofDecember 31, 2013.

As of December 31, 2013, the Company had various definite-lived U.S. state tax credit carryforwards of $6.9 million net of federal benefit. An immaterial amount of these state tax credit carryforwards will begin to expire in 2016, with the remainder of the state tax credit carryforwards to expire no later than 2023. The valuation allowance recorded for state tax credit carryforwards is $2.3 million, net of federal benefit as of December 31, 2013.

        Income taxes paid net of refunds were $159.3 million, $226.8 million, and $174.3 million in the years ended December 31,2013, 2012, and 2011, respectively. The income taxes were paid to federal, state and foreign taxing authorities and BMS pursuant to the terms of the Amended and Restated Tax Matters Agreement.

        As ofDecember 31, 2013, U.S. taxes have not been provided on approximately$1.4 billionof foreign earnings as these undistributed earnings have been permanently invested offshore. If, in the future, these earnings were to be repatriated to the U.S. additional tax provisionswould be required. It is impracticable to determine a precise estimate of the additional provision required. However, the maximum potential estimated U.S. tax liability would be$494 millionif these earnings were to be repatriated to the United States in such a manner that the entire amount of foreign earnings would be subject to the U.S. statutory tax rate with no U.S. tax relief for foreign taxes already paid.  However, the Company has no plans to repatriate these foreign earnings.

        The Company’s tax returns are routinely audited by federal, state and foreign tax authorities and these tax audits are at various stages of completion at any given time. The Internal Revenue Service (“IRS”) has completed examinations of the Company’s U.S. income tax filings through December 31, 2007. At December 31, 2013, the Company’s 2011 income tax return was under IRS examination. At December 31, 2013, tax years remaining open to examination outside the U.S. include 2003 and forward.

Schedule of reconciliation of changes in uncertain tax positions

A reconciliation of the Company’s changes in gross uncertain tax positions is as follows:

	Years Ended December 31,
(In millions)	2013			2012			2011
Balance at January 1:	$	64.7		$	29.7		$	13.6
Increases based on current year tax positions	23.8			17.8			14.6
Decreases based on current year tax positions	—			—			—
Increases based on prior year tax positions	18.9			21.4			1.7
Decreases based on prior year tax positions	—			—			(0.3		)
Settlements	—			—			(0.1		)
Lapse of statute of limitations	(3.8		)	(5.2		)	—
Cumulative translation adjustment	(1.0		)	1.0			0.2
Balance at December 31:	$	102.6		$	64.7		$	29.7

        Uncertain tax positions have been recorded as part ofother liabilitieswith a reversal of up to$10 millionreasonably possible in the next 12 months due to the expiration of statutes of limitations. The amounts of uncertain tax positions that, if recognized, would impact the effective tax rate were$48.6 million,$18.9 million, and$10.9 millionas of December 31, 2013, 2012 and 2011, respectively.The Company believes that it has provided adequately for all uncertain tax positions. It is reasonably possible that new issues may be raised by tax authorities and that these issues may require increases in the balance of uncertain tax positions.

        Interest and penalties related to uncertain tax positions were $14.8 million and $11.2 million, as of December 31, 2013, and 2012, respectively, and are included as a component of other liabilities. The Company classifies interest and penalties related to uncertain tax positions as a component of provision for income taxes. The amount of interest and penalties included as a component of provision for income taxes was $3.0 million, $5.0 million and $0.6 million for the years ended December 31, 2013, 2012 and 2011, respectively.

On December 18, 2009, the Company and Bristol-Myers Squibb Company (“BMS”) entered into an Amended and Restated Tax Matters Agreement in anticipation of the separation from BMS. Under the Amended and Restated Tax Matters Agreement, BMS agreed to indemnify the Company for (i) any tax attributable to a MJN legal entity for any taxable period ending on or before December 31, 2008, (ii) any tax arising solely as a result of MJN’s 2009 initial public offering (“IPO”) and the restructuring preceding the IPO, and (iii) any transaction tax associated with the separation transaction. The Company agreed to indemnify BMS for (i) any tax payable with respect to any separate return that the Company is required to file or cause to be filed, (ii) any tax incurred as a result of any gain which may be recognized by a member of the BMS affiliated group with respect to a transfer of certain foreign affiliates by the Company in preparation for the IPO, and (iii) any tax arising from the failure or breach of any representation or covenant made by the Company which failure or breach results in the intended tax consequences of the separation transaction not being achieved.Additionally,under the Amended and Restated Tax Matters Agreement, the Company continues to maintain responsibility for any tax positions which may existfor any taxable period ending after December 31, 2008.

XML

GOODWILL (Tables)

12 Months Ended

Dec. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Change in carrying amount of goodwill by reportable segment

For the year ended December 31,2013 and 2012, the change in the carrying amount of goodwill by reportable segment, including the cumulative impact of the revisions described above, was as follows:

(In millions)	Asia		Latin America			North America/ Europe			Total
Balance as of January 1, 2012	$	—	$	115.8		$	1.7		$	117.5
Acquisition	—		155.5			17.3			172.8
Translation adjustments	—		(17.7		)	(2.0		)	(19.7		)
Balance as of December 31, 2012	—		253.6			17.0			270.6
Redenomination	—		(42.5		)	2.0			(40.5		)
Translation adjustments	—		(33.3		)	—			(33.3		)
Balance as of December 31, 2013	$	—	$	177.8		$	19.0		$	196.8

XML

SEGMENT INFORMATION (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013 Segment	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting [Abstract]
Number of geographic operating segments									4
Number of reportable segments									3
Concentration Risk
Net Sales	$ 1,060.7	$ 1,046.8	$ 1,055.3	$ 1,037.9	$ 981.1	$ 921.3	$ 1,012.3	$ 986.6	$ 4,200.7	$ 3,901.3	$ 3,677.0
Earnings Before Interest and Income Taxes									924.6	870.0	774.1
Assets	3,474.1				3,258.2				3,474.1	3,258.2	2,766.8
Payments for Capital Expenditures									240.4	124.4	109.5
Depreciation and Amortization									83.1	76.9	75.3
North America Europe and Latin America [Member] [Member] | Customer one
Concentration Risk
Percentage of the entity's gross sales									10.00%	11.00%	12.00%
North America/Europe
Concentration Risk
Net Sales									1,160.0	1,181.8	1,229.8
Earnings Before Interest and Income Taxes									248.5	246.1	308.4
Assets	798.5				740.5				798.5	740.5	764.0
Payments for Capital Expenditures									31.6	22.3	33.4
Depreciation and Amortization									29.1	27.4	30.7
Total operating segments
Concentration Risk
Net Sales									4,200.7	3,901.3	3,677.0
Earnings Before Interest and Income Taxes									1,251.5	1,147.4	1,120.0
Assets	2,906.1				2,550.6				2,906.1	2,550.6	2,240.0
Payments for Capital Expenditures									233.0	120.4	79.4
Depreciation and Amortization									59.0	53.2	55.5
Corporate And Other
Concentration Risk
Net Sales									0	0	0
Earnings Before Interest and Income Taxes									(326.9)	(277.4)	(345.9)
Assets	568.0				707.6				568.0	707.6	526.8
Payments for Capital Expenditures									7.4	4.0	30.1
Depreciation and Amortization									24.1	23.7	19.8
Asia [Member]
Concentration Risk
Net Sales									2,179.3	1,967.0	1,827.8
Earnings Before Interest and Income Taxes									795.8	725.3	672.5
Assets	1,390.7				1,097.3				1,390.7	1,097.3	1,008.6
Payments for Capital Expenditures									168.1	87.4	34.0
Depreciation and Amortization									19.4	16.9	17.2
Asia [Member] | Customer two
Concentration Risk
Percentage of the entity's gross sales									16.00%	15.00%	14.00%
Latin America
Concentration Risk
Net Sales									861.4	752.5	619.4
Earnings Before Interest and Income Taxes									207.2	176.0	139.1
Assets	716.9				712.8				716.9	712.8	467.4
Payments for Capital Expenditures									33.3	10.7	12.0
Depreciation and Amortization									$ 10.5	$ 8.9	$ 7.6

XML

DERIVATIVES AND OTHER FINANCIAL INSTRUMENTS (Details 3) (USD $) In Millions, unless otherwise specified	12 Months Ended					1 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013 Interest Rate Swaps	Nov. 30, 2009 Interest Rate Swaps	Jul. 31, 2011 Interest Rate Swaps Terminated contracts	Nov. 30, 2010 Interest Rate Swaps Terminated contracts	Dec. 31, 2013 Fair value hedges	Dec. 31, 2012 Fair value hedges	Dec. 31, 2011 Fair value hedges	Dec. 31, 2013 Fair value hedges Interest Rate Swaps	Dec. 31, 2012 Fair value hedges Interest Rate Swaps	Dec. 31, 2011 Fair value hedges Interest Rate Swaps
Interest rate swap fair value hedges
Notional Amount of Underlying Debt				$ 500.0	$ 700.0
Notional amount	201.4					500.0	200.0
Cash received						23.5	15.6
(Gain) loss on marked to market of swaps								0	0	(4.2)
(Gain) loss on marked to market of hedged items	0	0	4.2
Derivative, Gain on Derivative											0	0	6.3
Amortization of basis adjustment for terminated interest rate swaps recognized in interest expense											(9.2)	(9.3)	(5.5)
Recognized in interest expense											9.2	9.3	11.8
Money market funds, classified as Level Two	$ 447.8	$ 520.7

XML

CONSOLIDATED STATEMENTS OF EARNINGS (USD $) In Millions, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
NET SALES	$ 4,200.7	$ 3,901.3	$ 3,677.0
Cost of Products Sold	1,532.8	1,485.3	1,362.3
GROSS PROFIT	2,667.9	2,416.0	2,314.7
Expenses:
Selling, General and Administrative Expense	918.0	877.8	926.8
Advertising and Promotion	645.1	552.8	501.7
Research and Development Expense	102.4	95.4	92.5
Other Expenses—net	77.8	20.0	19.6
EARNINGS BEFORE INTEREST AND INCOME TAXES	924.6	870.0	774.1
Interest Expense-net	50.6	65.0	52.2
EARNINGS BEFORE INCOME TAXES	874.0	805.0	721.9
Provision for Income Taxes	219.1	192.6	202.9
NET EARNINGS	654.9	612.4	519.0
Less Net Earnings Attributable to Noncontrolling Interests	5.4	7.9	10.5
Net earnings attributable to shareholders	$ 649.5	$ 604.5	$ 508.5
Earnings per Share-Basic
Net Earnings Attributable to Shareholders (in dollars per share)	$ 3.20	$ 2.96	$ 2.48
Earnings per Share-Diluted
Net Earnings Attributable to Shareholders (in dollars per share - diluted)	$ 3.19	$ 2.95	$ 2.47
Weighted Average Number of Shares Outstanding, Basic [Abstract]
Weighted Average Number of Shares Issued, Basic	202.4	203.6	204.3
Weighted Average Number of Shares Outstanding, Basic	203.1	204.3	205.0

XML

SELECTED QUARTERLY FINANCIAL DATA(UNAUDITED) (Tables)

12 Months Ended

Dec. 31, 2013

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information [Table Text Block]

Dollars in Millions, Except Per Share Data	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Year
2013:
Net sales	$	1,037.9	$	1,055.3	$	1,046.8	$	1,060.7	$	4,200.7
Gross profit	$	647.0	$	670.9	$	681.3	$	668.7	$	2,667.9
Net earnings	$	174.5	$	163.6	$	160.0	$	156.8	$	654.9
Net earnings attributable to shareholders	$	172.5	$	162.2	$	161.6	$	153.2	$	649.5
Basic earnings per share	$	0.85	$	0.80	$	0.80	$	0.76	$	3.20
Diluted earnings per share	$	0.85	$	0.80	$	0.79	$	0.75	$	3.19
2012:
Net sales	$	986.6	$	1,012.3	$	921.3	$	981.1	$	3,901.3
Gross profit	$	613.1	$	640.0	$	563.8	$	599.1	$	2,416.0
Net earnings	$	169.8	$	171.1	$	139.2	$	132.3	$	612.4
Net earnings attributable to shareholders	$	164.2	$	165.8	$	140.3	$	134.2	$	604.5
Basic earnings per share	$	0.80	$	0.81	$	0.69	$	0.66	$	2.96
Diluted earnings per share	$	0.80	$	0.81	$	0.69	$	0.66	$	2.95

XML

CONSOLIDATED STATEMENTS OF EQUITY/(DEFICIT) AND REDEEMABLE NONCONTROLLING INTEREST (USD $) In Millions, unless otherwise specified	Total	Redeemable Noncontrolling Interest	Common Stock	Additional Paid-in (Distributed) Capital	Retained Earnings	Treasury Stock	Accumulated Other Comprehensive Loss	Noncontrolling Interests
Redeemable Noncontrolling Interest, BALANCE at Dec. 31, 2010	$ 0
BALANCE at Dec. 31, 2010	(358.3)		2.0	(775.6)	474.0	(3.2)	(64.6)	9.1
Increase (Decrease) in Stockholders' Equity
Stock-based Compensation Awards	42.4		0.1	47.2		(4.9)
Treasury Stock Acquired	(81.6)					(81.6)
Distributions to Noncontrolling Interests	(8.6)							(8.6)
Cash Dividends Declared	(212.5)				(212.5)
Net Earnings	519.0				508.5			10.5
Other Comprehensive Income/(Loss)	(68.4)						(68.5)	0.1
Increase (Decrease) in Temporary Equity
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	8.6							8.6
Redeemable Noncontrolling Interest, BALANCE at Dec. 31, 2011	0
BALANCE at Dec. 31, 2011	(168.0)		2.1	(728.4)	770.0	(89.7)	(133.1)	11.1
Increase (Decrease) in Stockholders' Equity
Stock-based Compensation Awards	36.6		0	51.8		(15.2)
Treasury Stock Acquired	(139.7)					(139.7)
Distributions to Noncontrolling Interests	(7.6)							(7.6)
Cash Dividends Declared	(244.7)				(244.7)
Net Earnings	611.3				604.5			6.8
Equity Impact of Redeemable Noncontrolling Interest Accretion	5.0				5.0
Other Comprehensive Income/(Loss)	(53.9)						(53.9)	0
Increase (Decrease) in Temporary Equity
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	7.6							7.6
Acquisition		30.2
Net earnings of redeemable noncontrolling interest		1.1
Redeemable Noncontrolling Interest Accretion		5.0
Redeemable Noncontrolling Interest, BALANCE at Dec. 31, 2012	36.3
BALANCE at Dec. 31, 2012	29.0		2.1	(676.6)	1,124.8	(244.6)	(187.0)	10.3
Increase (Decrease) in Stockholders' Equity
Stock-based Compensation Awards	37.7			56.6		(18.9)
Treasury Stock Acquired	(88.4)					(88.4)
Distributions to Noncontrolling Interests	(8.3)	(1.2)						(8.3)
Cash Dividends Declared	(275.7)				(275.7)
Net Earnings	654.1				649.5			4.6
Equity Impact of Redeemable Noncontrolling Interest Accretion	28.2				28.2
Other Comprehensive Income/(Loss)	(28.8)	(14.4)					(16.5)	2.1
Other Comprehensive Income Loss net of tax excl RNCI	(14.4)
OtherComprehensiveIncomeLossOther	(5.3)			(5.3)
Increase (Decrease) in Temporary Equity
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	8.3	1.2						8.3
Net earnings of redeemable noncontrolling interest		0.8
Redeemable Noncontrolling Interest Accretion		28.2
Redeemable Noncontrolling Interest, BALANCE at Dec. 31, 2013	49.7	49.7
BALANCE at Dec. 31, 2013	$ 300.5		$ 2.1	$ (625.3)	$ 1,470.4	$ (351.9)	$ (203.5)	$ 8.7

XML

REDEEMABLE NONCONTROLLING INTEREST (Details)	Mar. 15, 2012 Nutricion para el Conosur S.A.	Dec. 31, 2013 Put Option [Member]	Dec. 31, 2013 Call Option [Member]
Business Acquisition [Line Items]
Percentage of outstanding shares of capital stock acquired	80.00%
Noncontrolling interests (as a percent)		20.00%	20.00%

XML

PENSION AND OTHER POST RETIREMENT BENEFIT PLANS (Tables)

12 Months Ended

Dec. 31, 2013

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Schedule of changes in benefit obligations, plan assets, funded status and amounts recognized in the balance sheet

	Pension Benefits						Other Benefits
(In millions)	2013			2012			2013			2012
Beginning benefit obligations	$	463.6		$	402.7		$	35.1		$	30.2
Service cost—benefits earned during the year	5.2			3.9			1.1			1.0
Interest cost on projected benefit obligations	14.4			15.6			1.3			1.3
Actuarial assumptions (gains) losses	(25.7		)	72.2			(3.8		)	2.6
Settlements and curtailments	(50.4		)	(30.9		)	—			—
Benefits paid	(2.8		)	(2.2		)	(1.3		)	(0.1		)
Exchange rate changes	(0.3		)	2.3			0.2			0.1
Benefit obligations at end of year	$	404.0		$	463.6		$	32.6		$	35.1
Beginning fair value of plan assets	$	312.1		$	280.7		$	—		$	—
Actual return on plan assets	(1.4		)	32.8			—			—
Employer contributions	18.5			28.2			0.9			0.1
Settlements	(50.4		)	(29.3		)	—			—
Benefits paid	(2.8		)	(2.2		)	(1.3		)	(0.1		)
Exchange rate changes	0.1			1.9			0.4			—
Fair value of plan assets at end of year	$	276.1		$	312.1		$	—		$	—
Underfunded status at end of year	$	(127.9	)	$	(151.5	)	$	(32.6	)	$	(35.1	)
Amounts in the consolidated balance sheets include:
Other assets	$	1.3		$	2.2		$	—		$	—
Pension, post retirement and post employment liabilities	(129.2		)	(153.7		)	(32.6		)	(35.1		)
Balance in the consolidated balance sheet at end of year	$	(127.9	)	$	(151.5	)	$	(32.6	)	$	(35.1	)
Amounts in accumulated other comprehensive loss include:
Net actuarial loss	$	197.7		$	242.6		$	11.8		$	17.3
Prior service (benefit)	1.2			—			(0.3		)	(0.5		)
Transition obligation	0.1			0.2			—			—
Balance in accumulated other comprehensive loss at end of year	$	199.0		$	242.8		$	11.5		$	16.8
Accumulated benefit obligation	$	375.7		$	428.0		$	32.6		$	35.1

Schedule of accumulated benefit obligation in excess of plan assets

	Years Ended December 31,
(In millions)	2013		2012
Projected benefit obligation	$	366.3	$	449.3
Accumulated benefit obligation	356.1		430.2
Fair value of plan assets	210.8		263.1

Schedule of net periodic benefit cost

	Pension Benefits									Other Benefits
	Years Ended December 31,									Years Ended December 31,
(In millions)	2013			2012			2011			2013			2012			2011
Service cost — benefits earned during the period	$	5.2		$	3.9		$	3.5		$	1.1		$	1.0		$	0.9
Interest cost on projected benefit obligations	14.4			15.6			17.0			1.3			1.3			1.3
Expected return on plan assets	(16.4		)	(16.2		)	(18.2		)	—			—			—
Amortization of net actuarial loss	6.6			5.3			3.3			1.7			1.9			1.7
Amortization of prior service (benefit)	—			—			—			(0.2		)	(0.2		)	(0.2		)
Amortization of transition cost	0.1			0.1			0.1			—			—			—
Sub-total	$	9.9		$	8.7		$	5.7		$	3.9		$	4.0		$	3.7
Settlements and curtailments	29.3			15.2			9.7			—			—			—
Total net periodic benefit cost	$	39.2		$	23.9		$	15.4		$	3.9		$	4.0		$	3.7

Schedule of net actuarial loss and prior service cost that will be amortized from accumulated other comprehensive income into net periodic benefit cost in 2012

(In millions)	Pension Benefits		Other Benefits
Amortization of net actuarial loss	$	5.2	$	1.1
Amortization of prior service (benefit)	0.1		(0.1		)
Amortization of transition cost	0.1		—
	$	5.4	$	1.0

Schedule of weighted-average assumptions used to determine benefit obligations and net periodic benefit cost

	Pension Benefits				Other Benefits
	December 31,				December 31,
	2013		2012		2013		2012
Discount rate	4.08	%	3.21	%	4.98	%	3.75	%
Rate of compensation increase	3.22	%	3.58	%	3.08	%	3.48	%

        The discount rate was determined based on the yield to maturity of high-quality corporate bonds and considering the duration of the pension plan obligations. The Citigroup Pension Discount Curve is used in developing the discount rate for the U.S. Pension Plan.

        Weighted-average assumptions used to determine net periodic benefit cost are established at the beginning of the plan year and were as follows:

	Pension Benefits						Other Benefits
	Years Ended December 31,						Years Ended December 31,
	2013		2012		2011		2013		2012		2011
Discount rate	3.26	%	4.03	%	5.59	%	3.75	%	4.29	%	5.28	%
Expected long term return on plan assets	5.22	%	5.65	%	6.91	%	—	%	—	%	—	%
Rate of compensation increase	3.59	%	4.00	%	4.02	%	3.48	%	3.94	%	3.94	%

Schedule of assumed health care cost trend rates

	December 31,
	2013		2012		2011
Health care cost trend rate assumed for next year	6.9	%	7.8	%	7.4	%
Rate to which the cost trend rate is assumed to decline (the ultimate trend rate)	4.9	%	4.9	%	5.0	%
Year that the rate reaches the ultimate trend rate	2023		2023		2017

Schedule of effect of one-percentage-point change in assumed health care cost trend rates

(In millions)	1-Percentage-Point Increase		1-Percentage-Point Decrease
Effect on total of service and interest cost	$	—	$	—
Increase/(decrease) in post retirement benefit obligation	0.2		0.3

Schedule of fair values of the pension plan assets by asset category

	December 31, 2013						December 31, 2012
(In millions)	Total		Level 1		Level 2		Total		Level 1		Level 2
Cash and cash equivalents	$	13.0	$	13.0	$	—	$	11.4	$	11.4	$	—
Equity securities:
U.S. large-cap	16.3		—		16.3		13.6		—		13.6
U.S. mid-cap growth	3.1		—		3.1		2.8		—		2.8
U.S. small-cap growth	0.1		—		0.1		1.5		—		1.5
Emerging markets	2.8		—		2.8		3.1		—		3.1
Real estate investment trusts	5.6		—		5.6		13.4		—		13.4
International large-cap value	37.0		8.5		28.5		28.3		—		28.3
Hedge fund	17.4		—		17.4		15.7		—		15.7
Fixed income securities:
Government bonds	72.8		—		72.8		83.5		—		83.5
Corporate bonds	101.7		—		101.7		138.8		—		138.8
Emerging markets	6.3		—		6.3		—		—		—
Total	$	276.1	$	21.5	$	254.6	$	312.1	$	11.4	$	300.7

Schedule of estimated future benefit payments expected to be paid

(In millions)	Pension Benefits		Other Benefits
2014	$	29.3	$	0.8
2015	29.5		1.0
2016	29.5		1.1
2017	30.8		1.1
2018	29.7		1.3
Years 2019 - 2023	147.8		6.5

XML

OTHER INTANGIBLE ASSETS (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Other intangible assets
Total	$ 41.3	$ 54.2
Indefinite-lived intangible assets zero amortization	0	0
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	136.1	136.6
Accumulated Amortization	(79.9)	(60.9)
Net Book Value	56.2	75.7
Total other intangible assets, Gross Carrying Amount	177.4	190.8
Total other intangible assets, Net Book Value	97.5	129.9
Amortization expense for other intangible assets	19.4	21.1	18.1
Computer software
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	132.8	132.2
Accumulated Amortization	(79.3)	(60.2)
Net Book Value	53.5	72.0
Distributor-customer relationship
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	3.3	4.4
Accumulated Amortization	(0.6)	(0.7)
Net Book Value	2.7	3.7
Trademark
Other intangible assets
Total	34.5	45.3
Indefinite-lived intangible assets zero amortization	0	0
Non-compete agreement
Other intangible assets
Total	6.8	8.9
Indefinite-lived intangible assets zero amortization	$ 0	$ 0

XML

GOODWILL

12 Months Ended

Dec. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL

GOODWILL

The Company tests goodwill for impairment on an annual basis and whenever an event occurs or circumstances change that would, more likely than not, reduce the fair value of a reporting unit below its carrying amount. Historically, the Company’s policy was to perform the annual impairment test for goodwill as of January 1 of each year. The Company completed its annual impairment test in the first quarter of 2013 in accordance with this policy and concluded that no impairment existed. During the third quarter of 2013 the Company changed its annual impairment testing date from January 1 to July 1 of each fiscal year to better align with the timing of its annual and long-term planning process, which is a significant input in the testing process. Accordingly, the Company believes this change is preferable. This change did not delay, accelerate or avoid an impairment charge. As a result of this change, impairment testing was completed during the third quarter of 2013 and the Company concluded that no impairment existed. This change was applied prospectively beginning July 1, 2013 and had no impact on the consolidated financial statements. The change was not applied retrospectively as it is impracticable to do so because retrospective application would have required the application of significant estimates and assumptions without the use of hindsight.

For the year ended December 31,2013, the change in the carrying amount of goodwill by reportable segment, was primarily driven by the cumulative impact due to a correction of the currency denomination of the goodwill related to two reporting units. The revision had the impact of decreasing the Company’s total value of goodwill and decreasing the total currency translation adjustment included in the accumulated other comprehensive loss section of shareholders’ equity and other comprehensive income.

For the year ended December 31,2013 and 2012, the change in the carrying amount of goodwill by reportable segment, including the cumulative impact of the revisions described above, was as follows:

(In millions)	Asia		Latin America			North America/ Europe			Total
Balance as of January 1, 2012	$	—	$	115.8		$	1.7		$	117.5
Acquisition	—		155.5			17.3			172.8
Translation adjustments	—		(17.7		)	(2.0		)	(19.7		)
Balance as of December 31, 2012	—		253.6			17.0			270.6
Redenomination	—		(42.5		)	2.0			(40.5		)
Translation adjustments	—		(33.3		)	—			(33.3		)
Balance as of December 31, 2013	$	—	$	177.8		$	19.0		$	196.8

A portion of the goodwill from the acquisition of Nutricion para el Conosur S.A. was attributed to the North America/Europe segment in consideration of expected benefits to be derived from the acquisition. As of December 31, 2013, the Company had no accumulated impairment loss.

XML

OTHER EXPENSES-NET (Tables)

12 Months Ended

Dec. 31, 2013

Other Income and Expenses [Abstract]

Components of other expenses/(income) net

The components of other expenses—net were:

	Years Ended December 31,
(In millions)	2013			2012			2011
Foreign exchange (gains)/losses—net	$	9.3		$	(3.1	)	$	(9.7	)
Administrative penalty (China)	33.4			—			—
Severance and other costs	2.2			8.0			9.9
Pension settlements and curtailments	29.3			15.2			9.7
Gain on sale of non-core intangible assets	—			(6.5		)	—
Legal settlements	7.0			—			—
Other—net	(3.4		)	6.4			9.7
Other expenses—net	$	77.8		$	20.0		$	19.6

XML

DERIVATIVES AND OTHER FINANCIAL INSTRUMENTS

12 Months Ended

Dec. 31, 2013

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVES AND OTHER FINANCIAL INSTRUMENTS

DERIVATIVES

        The Company is exposed to market risk due to changes in foreign currency exchange rates, commodities pricing and interest rates. To manage that risk, the Company enters into certain derivative financial instruments, when available on a cost-effective basis, to hedge its underlying economic exposure. The Company does not enter into derivatives for speculative purposes. These financial instruments are classified as Level 2 of the fair value hierarchy at December 31, 2013 and 2012, and there were no transfers between levels in the fair value hierarchy during the periods then ended.

        The following table summarizes the fair value of the Company's outstanding derivatives, all of which are cash flow hedges:

		December 31,
(In millions)	Balance Sheet Location	2013			2012
Cash flow hedges:
Foreign exchange contracts	Other assets	$	4.2		$	—
Interest rate forward swaps	Other assets	19.9			—
Foreign exchange contracts	Accrued expenses	(0.5		)	(5.1		)
Net asset/(liability) of derivatives designated as hedging items		$	23.6		$	(5.1	)

        The Company’s derivative financial instruments present certain market and counterparty risks; however, concentration of counterparty risk is mitigated as the Company deals with a variety of major banks worldwide whose long-term debt is rated A- or higher by Standard & Poor’s Rating Service, Fitch Ratings, or Moody’s Investors Service, Inc. In addition, only conventional derivative financial instruments are used. The Company would not be materially impacted if any of the counterparties to the derivative financial instruments outstanding atDecember 31, 2013failed to perform according to the terms of its agreement.Based upon the risk profile of the Company's portfolio, MJN does not require collateral or any other form of securitization to be furnished by the counterparties to its derivative financial instruments.

Cash Flow Hedges

    As of December 31, 2013 and 2012 all of the Company’s cash flow hedges qualify as hedges of forecasted cash flows and the effective portion of changes in fair value are temporarily reported in accumulated other comprehensive income (loss). During the period that the underlying hedged transaction impacts earnings, the effective portion of the changes in the fair value of the cash flow hedges are recognized within earnings. The Company assesses effectiveness at inception and on a quarterly basis. These assessments determine whether derivatives designated as qualifying hedges continue to be highly effective in offsetting changes in the cash flows of hedged items. Any ineffective portion of the change in fair value is included in current period earnings.

        The Company will discontinue cash flow hedge accounting when the forecasted transaction is no longer probable of occurring on the originally forecasted date, or 60 days thereafter, or when the hedge is no longer effective. For the years ended December 31, 2013, 2012, and 2011, the Company did not discontinue any cash flow hedges.

Foreign Exchange Contracts

        The Company uses foreign exchange contracts to hedge forecasted transactions, primarily foreign currency denominated intercompany purchases anticipated in the next1.5years and designates these derivative instruments as foreign currency cash flow hedges when appropriate.When the underlying intercompany purchases impact the Company’s consolidated earnings, the effective portion of the hedge is recognized within cost of products sold. For the years ended December 31, 2013, 2012 and 2011, ineffectiveness related to the Company’s foreign exchange hedges on earnings was insignificant.

        The table below summarizes the Company’s outstanding foreign exchange forward contracts at December 31, 2013. The fair value of foreign exchange forward contracts should be viewed in relation to the fair value of the underlying hedged transactions and the overall reduction in exposure to fluctuations in foreign currency exchange rates.

(Dollars in millions)	Weighted-average Forward Rate	Notional Amount		Fair Value Asset		Maturity
Foreign exchange contracts:
Cash flow hedges:
Mexican peso	13.07	84.0		0.7		2014
Malaysian ringgit	3.18	55.0		2.0		2014
Philippine peso	43.48	62.4		1.0		2014
Total foreign exchange contracts		$	201.4	$	3.7

        The change in accumulated other comprehensive income (loss) and the impact on earnings from foreign exchange contracts that qualified as cash flow hedges for the years ended December 31, 2013 and 2012, were as follows:

(In millions)	2013			2012
Balance—January 1	$	(4.1	)	$	4.3
Derivatives qualifying as cash flow hedges deferred in other comprehensive income	4.8			(12.7		)
Derivatives qualifying as cash flow hedges reclassified to cost of products sold (effective portion)	5.4			0.8
Change in deferred taxes	(2.9		)	3.5
Balance—December 31	$	3.2		$	(4.1	)

AtDecember 31, 2013,the portion of changes in cash flow hedges deferred into other comprehensive income that is expected to be reclassified into earnings within the next 12 months was $3.2 million.

Interest Rate Forward Swaps

During the fourth quarter of 2013 the Company entered into interest rate forward starting swaps with a combined notional value of $500.0 million. The forward starting rates of the swaps range from 3.79% to 3.94% and have an effective date of October 31, 2014. The forward starting swaps effectively mitigate the interest rate exposure associated with the Company’s planned refinancing of a portion of long-term debt in 2014, which is an anticipated transaction as a portion of MJN’s existing long-term debt will mature in 2014. These derivative instruments were designated as cash flow hedges at inception and were highly effective in offsetting fluctuations in the benchmark interest rate. As of December 31, 2013, all forward swaps were outstanding and had a fair value of $19.4 million, recognized in accumulated other comprehensive income. When the forward swaps are settled, which would be on or about the time of the issuance of long-term debt, any gain or loss on the settlement will be recorded to accumulated other comprehensive income (loss) and will be amortized over the life of the notes. There was an immaterial amount of ineffectiveness related to the forward swaps which was recognized as a benefit within other expenses-net.

Commodity Hedge

During the fourth quarter of 2013, the Company began utilizing commodity hedges to minimize the variability in cash flows due to fluctuations in market prices of the Company’s non-fat dry milk purchases. The maturities of the commodity contracts are scheduled to match the pricing terms of the Company’s existing bulk purchase agreements. When the underlying non-fat dry milk purchases impact the Company’s consolidated earnings, the effective portion of the hedge is recognized within cost of products sold.

As of December 31, 2013, the Company had commodity contracts outstanding with a notional of 0.2 million pounds of forecasted non-fat dry milk purchases, representing a value of $0.3 million and an insignificant portion of the Company’s total forecasted volume. The effective portion of the hedge, which was recorded at fair value as a component of accumulated other comprehensive income, as well as the ineffective portion recognized within other income and expense were immaterial as of December 31, 2013 and for the period then ended.

Fair Value Hedges

Interest Rate Swaps

In November 2009, the Company executed several interest rate swaps to convert $700.0 million of the Company’s newly-issued fixed rate debt to be paid in 2014 and 2019 to variable rate debt. In November 2010, the Company terminated $200.0 million notional amount of fixed-to-floating interest rate swaps for cash of $15.6 million. In July 2011, the Company terminated the remaining $500.0 million notional amount of fixed-to-floating interest rate swaps for cash of $23.5 million. The related basis adjustments of the underlying hedged items are being recognized as a reduction of interest expense over the remaining life of the underlying debt. The Company had no interest rate swaps outstanding at December 31, 2013.

        (Gain) loss on marked to market of fair value hedges during the years ended December 31, 2013, 2012, and 2011 was as follows:

	(Gain) Loss on Marked to Market Swaps							(Gain) Loss on Marked to Market of Hedged Items
(In millions)	2013		2012		2011			2013		2012		2011
Interest expense—net	$	—	$	—	$	(4.2	)	$	—	$	—	$	4.2

        The impact on earnings from interest rate swaps that qualified as fair value hedges was as follows:

(In millions)	2013			2012			2011
Recognized in interest expense	$	—		$	—		$	(6.3	)
Amortization of basis adjustment for terminated interest rate swaps recognized in interest expense	(9.2		)	(9.3		)	(5.5		)
Total	$	(9.2	)	$	(9.3	)	$	(11.8	)

        See Note 15 for discussion on the Company’s debt.

Other Financial Instruments

The Company does not hedge the interest rate risk associated with money market funds, which totaled $447.8 million and $520.7 million as of December 31, 2013 and 2012, respectively. Money market funds are classified as Level 2 in the fair value hierarchy and are included in cash and cash equivalents on the balance sheet.  The money market funds have quoted market prices that are generally equivalent to par.

XML

DEBT (Details) In Millions, unless otherwise specified	3 Months Ended	12 Months Ended		1 Months Ended		12 Months Ended
	Dec. 31, 2013 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Mar. 31, 2012 Nutricion para el Conosur S.A. ARS	Mar. 15, 2012 Nutricion para el Conosur S.A. ARS	Dec. 31, 2013 Lower limit	Dec. 31, 2013 Upper limit
Line of credit facility disclosures
Short-term borrowings	$ 2.0	$ 2.0	$ 161.0
Short term borrowings interest rate at end of period	22.00%	22.00%
Term of credit facility	5
Line of Credit Facility, Expiration Date		Jun. 30, 2016
Line of credit, maximum amount of outstanding borrowings and letters of credit permitted at any one time	500.0	500.0
Line of credit, potential maximum with Company's request and lender consent	750.0	750.0
Credit Facility covenant, consolidated total debt to consolidated EBITDA ratio, numerator(cannot exceed)		3.25
Credit Facility covenant, consolidated total debt to consolidated EBITDA ratio, denominator		1.0
Credit Facility covenant, consolidated EBITDA to consolidated interest expense ratio, numerator (cannot be less)		3.0
Credit Facility covenant, consolidated EBITDA to consolidated interest expense ratio, denominator		1.0
Description of interest rate basis		LIBOR
Range of margin added to base rate (as a percent)						0.075%	1.45%
Credit facility, commitment fee percentage		0.20%
Credit facility weighted average interest rate (as a percent)		1.52%
Percentage of outstanding shares of capital stock acquired					80.00%
Purchase price allocation, Total consideration transferred				850.7
Note payable, acquisition date					377.6

XML

CONSOLIDATED STATEMENTS OF EQUITY/ AND REDEEMABLE NONCONTROLLING INTEREST Consolidated Statements of Equity/ and Redeemable Noncontrolling Interest (parenthetical) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements Of Equity deficit And Redeemable Noncontrolling Interest Parenthetical [Abstract]
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation	$ 9.5	$ 11.8	$ 2.8

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
NET EARNINGS	$ 654.9	$ 612.4	$ 519.0
Foreign Currency Translation Adjustments
Translation Adjustments	(90.5)	(8.4)	(27.2)
Tax Benefit/(Expense)	9.2	(13.0)	4.7
Deferred Gains/(Losses) on Derivatives Qualifying as Hedges
Deferred Gains/(Losses) on Derivatives Qualifying as Hedges for the Period	24.2	(12.7)	5.8
Reclassification Adjustment for Losses Included in Net Earnings	5.4	0.8	2.9
Tax Benefit/(Expense)	(10.1)	3.5	(2.6)
Pension and Other Post Retirement Benefits
Deferred Gains/(Losses) on Pension and Other Postretirement Benefits	11.6	(58.5)	(90.7)
Reclassification Adjustment for Losses Included in Net Earnings	37.5	23.8	14.6
Tax Benefit/(Expense)	(16.1)	10.6	24.1
OTHER COMPREHENSIVE INCOME/(LOSS)	(28.8)	(53.9)	(68.4)
COMPREHENSIVE INCOME	626.1	558.5	450.6
Less Comprehensive Income Attributable to Noncontrolling Interests	(6.9)	7.9	10.6
COMPREHENSIVE INCOME ATTRIBUTABLE TO SHAREHOLDERS	$ 633.0	$ 550.6	$ 440.0

XML

NONCONTROLLING INTERESTS

12 Months Ended

Dec. 31, 2013

Noncontrolling Interest [Abstract]

NONCONTROLLING INTERESTS

NONCONTROLLING INTERESTS

Net earnings attributable to noncontrolling interests consists of approximately 20%, 11% and 10% interests held by third parties in operating entities in Argentina, China and Indonesia, respectively.

XML

Document and Entity Information (USD $) In Billions, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Feb. 10, 2014	Jun. 28, 2013
Entity Information [Line Items]
Entity Registrant Name	Mead Johnson Nutrition Co
Entity Central Index Key	0001452575
Document Type	10-K
Document Period End Date	Dec. 31, 2013
Entity Well-known Seasoned Issuer	Yes
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q4
Entity Voluntary Filers	No
Entity Public Float			$ 16.0
Entity Common Stock, Shares Outstanding		201,660,776

XML

OTHER EXPENSES-NET

12 Months Ended

Dec. 31, 2013

Other Income and Expenses [Abstract]

Other Expense/(Income)-Net

OTHER EXPENSES—NET

        The components of other expenses—net were:

	Years Ended December 31,
(In millions)	2013			2012			2011
Foreign exchange (gains)/losses—net	$	9.3		$	(3.1	)	$	(9.7	)
Administrative penalty (China)	33.4			—			—
Severance and other costs	2.2			8.0			9.9
Pension settlements and curtailments	29.3			15.2			9.7
Gain on sale of non-core intangible assets	—			(6.5		)	—
Legal settlements	7.0			—			—
Other—net	(3.4		)	6.4			9.7
Other expenses—net	$	77.8		$	20.0		$	19.6

XML

CONSOLIDATED BALANCE SHEETS (USD $) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS:
Cash and Cash Equivalents	$ 1,050.8	$ 1,042.1
Receivables-net of allowances of $6.5 and $7.6, respectively	384.4	364.6
Inventories	534.8	435.9
Deferred Income Taxes-net of valuation allowance	75.3	86.4
Income Taxes Receivable	15.9	26.0
Prepaid Expenses and Other Assets	56.9	60.0
Total Current Assets	2,118.1	2,015.0
Property, Plant, and Equipment-net	867.5	689.9
Goodwill	196.8	270.6
Other Intangible Assets-net	97.5	129.9
Deferred Income Taxes-net of valuation allowance	37.0	24.5
Other Assets	157.2	128.3
TOTAL	3,474.1	3,258.2
CURRENT LIABILITIES:
Short-term Borrowings	2.0	161.0
Accounts Payable	566.8	508.5
Dividends Payable	69.3	61.3
Long-term Debt, Current Maturities	505.6	0
Note Payable	0	26.0
Accrued Expenses	220.0	220.4
Accrued Rebates and Returns	314.9	314.8
Deferred Income-current	46.6	36.1
Income Taxes-payable and deferred	56.1	41.8
Total Current Liabilities	1,781.3	1,369.9
Long-Term Debt	1,009.1	1,523.2
Deferred Income Taxes-noncurrent	15.3	15.9
Pension, Post Retirement and Post Employment Liabilities	161.8	188.8
Other Liabilities	156.4	95.1
Total Liabilities	3,123.9	3,192.9
COMMITMENTS AND CONTINGENCIES
REDEEMABLE NONCONTROLLING INTEREST	49.7	36.3
Shareholders' Equity
Common Stock, $0.01 par value: 3,000 authorized, 206.8 and 206.0 issued, respectively	2.1	2.1
AdditionalPaidinDistributedCapital	(625.3)	(676.6)
Retained Earnings	1,470.4	1,124.8
Treasury Stock-at cost	(351.9)	(244.6)
Accumulated Other Comprehensive Loss	(203.5)	(187.0)
Total Shareholders' Equity/(Deficit)	291.8	18.7
Noncontrolling Interests	8.7	10.3
Total Equity/(Deficit)	300.5	29.0
TOTAL	$ 3,474.1	$ 3,258.2

XML

INCOME TAXES

12 Months Ended

Dec. 31, 2013

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

       The components of earnings before income taxes were:

	Years Ended December 31,
(In millions)	2013		2012		2011
U.S.	$	90.2	$	131.8	$	153.7
Non-U.S.	783.8		673.2		568.2
Total	$	874.0	$	805.0	$	721.9

        The above amounts are categorized based on the applicable taxing authorities.

        The provision (benefit) for income taxes consisted of:

	Years Ended December 31,
(In millions)	2013			2012			2011
Current:
U.S. federal	$	79.1		$	37.1		$	81.3
U.S. states	2.4			(1.3		)	10.7
Non-U.S.	130.6			139.7			144.2
Total current income tax expense	212.1			175.5			236.2
Deferred:
U.S. federal	(23.5		)	15.8			(5.2		)
U.S. states	0.3			(3.3		)	(4.4		)
Non-U.S.	30.2			4.6			(23.7		)
Total deferred income tax expense	7.0			17.1			(33.3		)
Total	$	219.1		$	192.6		$	202.9

        Effective Tax Rate—MJN’s provision for income taxes in the years ended December 31, 2013, 2012 and 2011 was different from the amount computed by applying the statutory U.S. federal income tax rate to earnings before income taxes as a result of the following:

(Dollars in millions)	2013					2012					2011
U.S. statutory rate	$	305.9		35.0	%	$	281.7		35.0	%	$	252.6		35.0	%
State and local taxes	1.3			0.2		0.8			0.1		3.7			0.5
Foreign income taxed at different rates	(25.6		)	(2.9	)	(67.7		)	(8.4	)	(42.1		)	(5.8	)
Repatriation of foreign income	9.4			1.1		21.6			2.7		21.8			3.0
Tax rulings and agreements	(121.9		)	(13.9	)	(46.4		)	(5.8	)	(51.9		)	(7.2	)
Reversal of deferred tax on prior years' unremitted foreign earnings due to a permanent reinvestment assertion	(8.2		)	(0.9	)	(8.7		)	(1.1	)	—			—
Administrative penalty related to China antitrust review	8.3			1.0		—			—		—			—
Unrecognized tax benefits and related interest/penalties	38.1			4.4		13.1			1.6		7.3			1.0
Other	11.8			1.1		(1.8		)	(0.2	)	11.5			1.6
Total provision / effective tax rate	$	219.1		25.1	%	$	192.6		23.9	%	$	202.9		28.1	%

   The Company negotiated a tax ruling effective from January 1, 2010, under which certain profits in the Netherlands are exempt from taxation through the year ending December 31, 2019. This ruling was superseded by a subsequent tax agreement effective July 26, 2012, whereby the Company and the Dutch tax authorities agreed to the appropriate remuneration attributable to Dutch manufacturing activities through the year ending December 31, 2019.

In addition, the Company negotiated a tax ruling effective from January 1, 2013, under which certain profits in Singapore are eligible for favorable taxation through the year ending December 31, 2027.

        Deferred Taxes and Valuation Allowance—The components of current and noncurrent deferred income tax assets (liabilities) were:

	December 31,
(In millions)	2013			2012
Deferred tax assets:
Accrued expenses	$	33.5		$	28.0
Accrued rebates and returns	42.2			44.5
Pension, post retirement and post employment liabilities	58.1			65.3
Stock-based compensation	20.2			18.3
Obsolescence reserves and other inventory items	7.9			6.3
Net operating loss carryforwards	13.5			17.2
Other—net	6.7			23.2
Valuation allowance	(7.3		)	(6.1		)
Total deferred tax assets	174.8			196.7
Deferred tax liabilities:
Depreciation and amortization	(68.5		)	(76.5		)
Unremitted earnings and cumulative foreign currency translation adjustments	(9.7		)	(26.1		)
Total deferred tax liabilities	(78.2		)	(102.6		)
Deferred tax assets—net	$	96.6		$	94.1
Recognized as:
Net deferred income taxes—current	74.9			85.5
Net deferred income taxes—noncurrent	21.7			8.6
Total	$	96.6		$	94.1

   As ofDecember 31, 2013, the Company had definite-lived and indefinite-lived gross foreign net operating loss (“NOL”) carryforwards of$49.0 million.Indefinite-lived NOL carryforwards totaled $22.3 million with the remainder being definite-lived. An immaterial amount of these definite-lived NOL carryforwards will begin to expire in2014, with the remainder of the definite-lived NOL carryforwards to expire no later than2031. The valuation allowance recorded for NOL carryforwards is$5.0 millionas ofDecember 31, 2013.

As of December 31, 2013, the Company had various definite-lived U.S. state tax credit carryforwards of $6.9 million net of federal benefit. An immaterial amount of these state tax credit carryforwards will begin to expire in 2016, with the remainder of the state tax credit carryforwards to expire no later than 2023. The valuation allowance recorded for state tax credit carryforwards is $2.3 million, net of federal benefit as of December 31, 2013.

        Income taxes paid net of refunds were $159.3 million, $226.8 million, and $174.3 million in the years ended December 31,2013, 2012, and 2011, respectively. The income taxes were paid to federal, state and foreign taxing authorities and BMS pursuant to the terms of the Amended and Restated Tax Matters Agreement.

        As ofDecember 31, 2013, U.S. taxes have not been provided on approximately$1.4 billionof foreign earnings as these undistributed earnings have been permanently invested offshore. If, in the future, these earnings were to be repatriated to the U.S. additional tax provisionswould be required. It is impracticable to determine a precise estimate of the additional provision required. However, the maximum potential estimated U.S. tax liability would be$494 millionif these earnings were to be repatriated to the United States in such a manner that the entire amount of foreign earnings would be subject to the U.S. statutory tax rate with no U.S. tax relief for foreign taxes already paid.  However, the Company has no plans to repatriate these foreign earnings.

        The Company’s tax returns are routinely audited by federal, state and foreign tax authorities and these tax audits are at various stages of completion at any given time. The Internal Revenue Service (“IRS”) has completed examinations of the Company’s U.S. income tax filings through December 31, 2007. At December 31, 2013, the Company’s 2011 income tax return was under IRS examination. At December 31, 2013, tax years remaining open to examination outside the U.S. include 2003 and forward.

        A reconciliation of the Company’s changes in gross uncertain tax positions is as follows:

	Years Ended December 31,
(In millions)	2013			2012			2011
Balance at January 1:	$	64.7		$	29.7		$	13.6
Increases based on current year tax positions	23.8			17.8			14.6
Decreases based on current year tax positions	—			—			—
Increases based on prior year tax positions	18.9			21.4			1.7
Decreases based on prior year tax positions	—			—			(0.3		)
Settlements	—			—			(0.1		)
Lapse of statute of limitations	(3.8		)	(5.2		)	—
Cumulative translation adjustment	(1.0		)	1.0			0.2
Balance at December 31:	$	102.6		$	64.7		$	29.7

        Uncertain tax positions have been recorded as part ofother liabilitieswith a reversal of up to$10 millionreasonably possible in the next 12 months due to the expiration of statutes of limitations. The amounts of uncertain tax positions that, if recognized, would impact the effective tax rate were$48.6 million,$18.9 million, and$10.9 millionas of December 31, 2013, 2012 and 2011, respectively.The Company believes that it has provided adequately for all uncertain tax positions. It is reasonably possible that new issues may be raised by tax authorities and that these issues may require increases in the balance of uncertain tax positions.

        Interest and penalties related to uncertain tax positions were $14.8 million and $11.2 million, as of December 31, 2013, and 2012, respectively, and are included as a component of other liabilities. The Company classifies interest and penalties related to uncertain tax positions as a component of provision for income taxes. The amount of interest and penalties included as a component of provision for income taxes was $3.0 million, $5.0 million and $0.6 million for the years ended December 31, 2013, 2012 and 2011, respectively.

On December 18, 2009, the Company and Bristol-Myers Squibb Company (“BMS”) entered into an Amended and Restated Tax Matters Agreement in anticipation of the separation from BMS. Under the Amended and Restated Tax Matters Agreement, BMS agreed to indemnify the Company for (i) any tax attributable to a MJN legal entity for any taxable period ending on or before December 31, 2008, (ii) any tax arising solely as a result of MJN’s 2009 initial public offering (“IPO”) and the restructuring preceding the IPO, and (iii) any transaction tax associated with the separation transaction. The Company agreed to indemnify BMS for (i) any tax payable with respect to any separate return that the Company is required to file or cause to be filed, (ii) any tax incurred as a result of any gain which may be recognized by a member of the BMS affiliated group with respect to a transfer of certain foreign affiliates by the Company in preparation for the IPO, and (iii) any tax arising from the failure or breach of any representation or covenant made by the Company which failure or breach results in the intended tax consequences of the separation transaction not being achieved.Additionally,under the Amended and Restated Tax Matters Agreement, the Company continues to maintain responsibility for any tax positions which may existfor any taxable period ending after December 31, 2008.

XML

EARNINGS PER SHARE

12 Months Ended

Dec. 31, 2013

Earnings Per Share [Abstract]

EARNINGS PER SHARE

EARNINGS PER SHARE

        The numerator for basic and diluted earnings per share is net earnings attributable to shareholders reduced by dividends and undistributed earnings attributable to unvested shares. The denominator for basic earnings per share is the weighted-average number of shares outstanding during the period. The denominator for diluted earnings per share is the weighted-average shares outstanding adjusted for the effect of dilutive stock options and performance share awards.

        The following table presents the calculation of basic and diluted earnings per share:

	Years Ended December 31,
(In millions, except per share data)	2013			2012			2011
Basic earnings per share:
Weighted-average shares outstanding	202.4			203.6			204.3
Net earnings attributable to shareholders	$	649.5		$	604.5		$	508.5
Dividends and undistributed earnings attributable to unvested shares	(1.2		)	(1.4		)	(1.4		)
Net earnings attributable to shareholders used for basic earnings per share calculation	$	648.3		$	603.1		$	507.1
Net earnings attributable to shareholders per share	$	3.20		$	2.96		$	2.48
Diluted earnings per share:
Weighted-average shares outstanding	202.4			203.6			204.3
Incremental shares outstanding assuming the exercise/vesting of dilutive stock options/performance shares	0.7			0.7			0.7
Weighted-average shares — diluted	203.1			204.3			205.0
Net earnings attributable to shareholders	$	649.5		$	604.5		$	508.5
Dividends and undistributed earnings attributable to unvested shares	(1.2		)	(1.4		)	(1.4		)
Net earnings attributable to shareholders used for diluted earnings per share calculation	$	648.3		$	603.1		$	507.1
Net earnings attributable to shareholders per share	$	3.19		$	2.95		$	2.47

Potential shares outstanding from all stock-based awards were 2.8 million, 2.7 million and 2.9 million as of December 31, 2013, 2012 and 2011, respectively, of which 2.1 million, 2.0 million and 2.2 million were not included in the diluted earnings per share calculation for the years ended December 31,2013, 2012 and 2011, respectively.

XML

DEBT

12 Months Ended

Dec. 31, 2013

Debt Disclosure [Abstract]

DEBT

DEBT

Short-Term Borrowings

Outstanding Borrowings

As of December 31, 2013, the Company’s short-term borrowings were $2.0 million and consisted of borrowings made by the Company’s subsidiary in Argentina. These short-term borrowings had a weighted-average interest rate of 22.00% as of December 31, 2013. The Company intends to repay these borrowings within 12 months and has the ability to do so.

As of December 31, 2012, the Company’s short-term borrowings totaled $161.0 million and were primarily from its 5-year revolving credit facility agreement (“Credit Facility”).

Five-Year Revolving Credit Facility Agreement

Borrowings from the Credit Facility are used for working capital and other general corporate purposes. The Credit Facility is unsecured, repayable at maturity in June 2016 and can be extended annually if a sufficient number of lenders agree. The maximum amount of outstanding borrowings and letters of credit permitted at any one time under the Credit Facility is $500.0 million, which may be increased from time to time up to $750.0 million at the Company’s request and with the consent of the lenders, subject to satisfaction of customary conditions. The Credit Facility contains financial covenants, whereby the ratio of consolidated total debt to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (“EBITDA”) cannot exceed 3.25 to 1.0, and the ratio of consolidated EBITDA to consolidated interest expense cannot be less than 3.0 to 1.0. The Company was in compliance with these covenants as of December 31, 2013.

Borrowings under the Credit Facility bear interest at a rate that is determined as a base rate plus a margin. The base rate is either (a) LIBOR for a specified interest period, or (b) a floating rate based upon JPMorgan Chase Bank’s prime rate, the Federal Funds rate or LIBOR. The margin is determined by reference to the Company’s credit rating. The margin can range from 0.075% to 1.45% over the base rate. In addition, the Company incurs an annual 0.2% facility fee on the entire facility commitment of $500.0 million.

As of December 31, 2013, the Company did not have any borrowings outstanding from the Credit Facility. For the year ended December 31,2013, borrowings from the Credit Facility had a weighted-average interest rate of 1.52%.

Note Payable

On March 15, 2012, the Company acquired 80% of the outstanding capital stock of Nutricion para el Conosur S.A. See Note 8 for discussion of the acquisition. Of the ARS850.7 million purchase price, ARS377.6 million was financed through a note payable. The remaining balance of the note payable was paid on July 10, 2013.

Long-Term Debt

The components of long-term debt were as follows: 

(Dollars in millions)	December 31, 2013			December 31, 2012
Principal Value:
3.50% Notes due 2014	$	500.0		$	500.0
4.90% Notes due 2019	700.0			700.0
5.90% Notes due 2039	300.0			300.0
Subtotal	1,500.0			1,500.0
Adjustments to Principal Value:
Unamortized basis adjustment for terminated interest rate swaps	16.7			26.0
Unamortized bond discount	(2.0		)	(2.8		)
Less amount due within one year	505.6			—
Long-term debt	$	1,009.1		$	1,523.2

       The notes may be prepaid at any time, in whole or in part, at a redemption price equal to the greater of par value or an amount calculated based upon the sum of the present values of the remaining scheduled payments. Upon a change of control, the Company may be required to repurchase the notes in an amount equal to 101% of the then outstanding principal amount plus accrued and unpaid interest. Interest on the notes are due semi-annually, and the notes are not subject to amortization.

       The Company’s long-term debt has a principal value of $1,500 million, of which $500 million is considered short-term as it matures on November 1, 2014. MJN plans to refinance a portion of these notes in 2014. The Company determined the fair value of its long-term debt based on current market yields in the secondary market, classified as Level 2. As of December 31, 2013 fair value of the Company's long-term debt was $1,611.1 million.

The components of interest expense-net were as follows: 

	Years Ended December 31,
(In millions)	2013			2012			2011
Interest expense	$59.2			$70.9			$	60.2
Interest income	(8.6		)	(5.9		)	(8.0		)
Interest expense-net	$50.6			$65.0			$	52.2
Interest payments, net of amounts related to interest rate swaps	$	72.0		$	74.9		$	61.4

See Note 16 for discussion on the Company’s derivatives.

XML

RECEIVABLES

12 Months Ended

Dec. 31, 2013

us gaap loans notes trade and other receivables disclosure text block [Abstract]

Receivables

RECEIVABLES

        The major categories of receivables were as follows:

	December 31,
(In millions)	2013			2012
Trade receivables	$	335.7		$	330.0
Miscellaneous receivables	55.2			42.2
Less allowances	(6.5		)	(7.6		)
Receivables—net	$	384.4		$	364.6

XML

PENSION AND OTHER POST RETIREMENT BENEFIT PLANS

12 Months Ended

Dec. 31, 2013

General Discussion of Pension and Other Postretirement Benefits [Abstract]

PENSION AND OTHER POST RETIREMENT BENEFIT PLANS

EMPLOYEE BENEFITS

Pension and Other Post Retirement Benefits

        Pension—The principal pension plan is the Mead Johnson & Company Retirement Plan in the United States (U.S. Pension Plan) which represents approximately 75% of the Company’s total pension assets and obligations. The benefits of this plan are frozen as of February 9, 2014 and benefits are no longer accrued for service.

        Other post retirement benefits—The Company also provides comprehensive medical and group life benefits for substantially all U.S. and Canadian retirees who elect to participate in its comprehensive medical and group life plans. The retiree medical plan is contributory and participation is limited to those employees who participate in the U.S. Pension Plan. Contributions are adjusted periodically and vary by date of retirement. The retiree life insurance plan is non-contributory.

Changes in benefit obligations, plan assets, funded status and amounts recognized in the balance sheet were as follows:

	Pension Benefits						Other Benefits
(In millions)	2013			2012			2013			2012
Beginning benefit obligations	$	463.6		$	402.7		$	35.1		$	30.2
Service cost—benefits earned during the year	5.2			3.9			1.1			1.0
Interest cost on projected benefit obligations	14.4			15.6			1.3			1.3
Actuarial assumptions (gains) losses	(25.7		)	72.2			(3.8		)	2.6
Settlements and curtailments	(50.4		)	(30.9		)	—			—
Benefits paid	(2.8		)	(2.2		)	(1.3		)	(0.1		)
Exchange rate changes	(0.3		)	2.3			0.2			0.1
Benefit obligations at end of year	$	404.0		$	463.6		$	32.6		$	35.1
Beginning fair value of plan assets	$	312.1		$	280.7		$	—		$	—
Actual return on plan assets	(1.4		)	32.8			—			—
Employer contributions	18.5			28.2			0.9			0.1
Settlements	(50.4		)	(29.3		)	—			—
Benefits paid	(2.8		)	(2.2		)	(1.3		)	(0.1		)
Exchange rate changes	0.1			1.9			0.4			—
Fair value of plan assets at end of year	$	276.1		$	312.1		$	—		$	—
Underfunded status at end of year	$	(127.9	)	$	(151.5	)	$	(32.6	)	$	(35.1	)
Amounts in the consolidated balance sheets include:
Other assets	$	1.3		$	2.2		$	—		$	—
Pension, post retirement and post employment liabilities	(129.2		)	(153.7		)	(32.6		)	(35.1		)
Balance in the consolidated balance sheet at end of year	$	(127.9	)	$	(151.5	)	$	(32.6	)	$	(35.1	)
Amounts in accumulated other comprehensive loss include:
Net actuarial loss	$	197.7		$	242.6		$	11.8		$	17.3
Prior service (benefit)	1.2			—			(0.3		)	(0.5		)
Transition obligation	0.1			0.2			—			—
Balance in accumulated other comprehensive loss at end of year	$	199.0		$	242.8		$	11.5		$	16.8
Accumulated benefit obligation	$	375.7		$	428.0		$	32.6		$	35.1

        The Company’s defined benefit pension and post retirement benefit plans with an accumulated benefit obligation in excess of plan assets were as follows:

	Years Ended December 31,
(In millions)	2013		2012
Projected benefit obligation	$	366.3	$	449.3
Accumulated benefit obligation	356.1		430.2
Fair value of plan assets	210.8		263.1

        The net periodic benefit cost of the Company’s defined benefit pension and post retirement benefit plans includes:

	Pension Benefits									Other Benefits
	Years Ended December 31,									Years Ended December 31,
(In millions)	2013			2012			2011			2013			2012			2011
Service cost — benefits earned during the period	$	5.2		$	3.9		$	3.5		$	1.1		$	1.0		$	0.9
Interest cost on projected benefit obligations	14.4			15.6			17.0			1.3			1.3			1.3
Expected return on plan assets	(16.4		)	(16.2		)	(18.2		)	—			—			—
Amortization of net actuarial loss	6.6			5.3			3.3			1.7			1.9			1.7
Amortization of prior service (benefit)	—			—			—			(0.2		)	(0.2		)	(0.2		)
Amortization of transition cost	0.1			0.1			0.1			—			—			—
Sub-total	$	9.9		$	8.7		$	5.7		$	3.9		$	4.0		$	3.7
Settlements and curtailments	29.3			15.2			9.7			—			—			—
Total net periodic benefit cost	$	39.2		$	23.9		$	15.4		$	3.9		$	4.0		$	3.7

        The estimated net actuarial loss and prior service cost that will be amortized from accumulated other comprehensive loss into net periodic benefit cost in 2014 are:

(In millions)	Pension Benefits		Other Benefits
Amortization of net actuarial loss	$	5.2	$	1.1
Amortization of prior service (benefit)	0.1		(0.1		)
Amortization of transition cost	0.1		—
	$	5.4	$	1.0

Actuarial assumptions

        Weighted-average assumptions used to determine benefit obligations are established as of the balance sheet date and were as follows:

	Pension Benefits				Other Benefits
	December 31,				December 31,
	2013		2012		2013		2012
Discount rate	4.08	%	3.21	%	4.98	%	3.75	%
Rate of compensation increase	3.22	%	3.58	%	3.08	%	3.48	%

        The discount rate was determined based on the yield to maturity of high-quality corporate bonds and considering the duration of the pension plan obligations. The Citigroup Pension Discount Curve is used in developing the discount rate for the U.S. Pension Plan.

        Weighted-average assumptions used to determine net periodic benefit cost are established at the beginning of the plan year and were as follows:

	Pension Benefits						Other Benefits
	Years Ended December 31,						Years Ended December 31,
	2013		2012		2011		2013		2012		2011
Discount rate	3.26	%	4.03	%	5.59	%	3.75	%	4.29	%	5.28	%
Expected long term return on plan assets	5.22	%	5.65	%	6.91	%	—	%	—	%	—	%
Rate of compensation increase	3.59	%	4.00	%	4.02	%	3.48	%	3.94	%	3.94	%

        The yield on high-quality corporate bonds that matches the duration of the benefit obligations was used in determining the discount rate. The Citigroup Pension Discount Curve is used in developing the discount rate for the U.S. plans. The expected long-term return on plan assets was determined based on the target asset allocation, expected rate of return by each asset class, and estimated future inflation.

        For the U.S. Pension Plan, the expected long-term return on plan assets assumption to be used to determine net periodic benefit cost for the year ending December 31, 2014 is 7.00%. The expected long-term return on plan assets was determined based on the Company’s target asset allocation, expected rate of return by each asset class, and estimated future inflation. The Company anticipates moving towards an asset mix that is more heavily focused on equity securities in 2014.

        Gains and losses have resulted from changes in actuarial assumptions, such as changes in the discount rate, and from differences between assumed and actual experience, such as differences between actual and assumed returns on plan assets. These gains and losses are adjusted for the difference between the fair value and the market-related value of the plan assets and are amortized to the extent they exceed 10% of the higher of the market-related value or the projected benefit obligation for each respective plan. The majority of the remaining actuarial losses are amortized over the life expectancy of the plans’ participants for the frozen U.S. plans and expected remaining service periods for the other plans.

        Assumed health care cost trend rates were as follows:

	December 31,
	2013		2012		2011
Health care cost trend rate assumed for next year	6.9	%	7.8	%	7.4	%
Rate to which the cost trend rate is assumed to decline (the ultimate trend rate)	4.9	%	4.9	%	5.0	%
Year that the rate reaches the ultimate trend rate	2023		2023		2017

        Assumed health care cost trend rates affect the amounts reported for the retiree medical plans. A one-percentage-point change in assumed health care cost trend rates would have the following effects:

(In millions)	1-Percentage-Point Increase		1-Percentage-Point Decrease
Effect on total of service and interest cost	$	—	$	—
Increase/(decrease) in post retirement benefit obligation	0.2		0.3

Plan assets

        The Company’s investment strategy for the U.S. Pension Plan assets consists of a mix of equities and fixed income in order to achieve returns over a market cycle which reduces contribution and expense at an acceptable level of risk. The target asset allocation as ofDecember 31, 2013was40%public equity and60%fixed income. Cash flow (i.e., cash contributions, benefit payments) was used to rebalance back to the targets as necessary. Investments are well diversified within each of the two major asset categories. All of the U.S. equity investments are actively managed. Investment strategies for international pension plans are typically similar, although the asset allocations are usually more conservative.

        The fair values of the Company’s pension plan assets by asset category were as follows:

	December 31, 2013						December 31, 2012
(In millions)	Total		Level 1		Level 2		Total		Level 1		Level 2
Cash and cash equivalents	$	13.0	$	13.0	$	—	$	11.4	$	11.4	$	—
Equity securities:
U.S. large-cap	16.3		—		16.3		13.6		—		13.6
U.S. mid-cap growth	3.1		—		3.1		2.8		—		2.8
U.S. small-cap growth	0.1		—		0.1		1.5		—		1.5
Emerging markets	2.8		—		2.8		3.1		—		3.1
Real estate investment trusts	5.6		—		5.6		13.4		—		13.4
International large-cap value	37.0		8.5		28.5		28.3		—		28.3
Hedge fund	17.4		—		17.4		15.7		—		15.7
Fixed income securities:
Government bonds	72.8		—		72.8		83.5		—		83.5
Corporate bonds	101.7		—		101.7		138.8		—		138.8
Emerging markets	6.3		—		6.3		—		—		—
Total	$	276.1	$	21.5	$	254.6	$	312.1	$	11.4	$	300.7

        Level 1 cash and cash equivalents, which excluded money market funds, are recorded at closing prices in active markets. Level 2 money market, equity, and fixed income funds are recorded at the net asset values per share, which were determined based on quoted market prices of the underlying assets contained within the funds. The Level 2 hedge fund is recorded at the net asset value per share, which was derived from the underlying funds’ net asset values per share; this diversified hedge fund may be redeemed quarterly with 60 days notice.

Contributions

        In 2014, the funding policy for the pension plans is to contribute amounts to provide for current service and to fund past service liability. MJN contributed $18.5 million, $28.2 million and $9.5 million to the pension plans in 2013, 2012 and 2011, respectively. The Company is not required to make any contributions to its pension plans in 2014 and does not foresee making a discretionary contribution. There will be no cash funding for other post retirement benefits in 2014, except funding to cover benefit payments.

Estimated Future Benefit Payments

        The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

(In millions)	Pension Benefits		Other Benefits
2014	$	29.3	$	0.8
2015	29.5		1.0
2016	29.5		1.1
2017	30.8		1.1
2018	29.7		1.3
Years 2019 - 2023	147.8		6.5

Defined Contribution Benefits

        Employees who meet certain eligibility requirements may participate in various defined contribution plans. Total cost recognized for all defined contribution benefit plans were $19.9 million, $21.3 million and $19.3 million for the years ended December 31, 2013, 2012, and 2011, respectively.

XML

NONCONTROLLING INTERESTS (Details)	Dec. 31, 2013
Argentina
Noncontrolling interest disclosures
Noncontrolling interests (as a percent)	20.00%
China
Noncontrolling interest disclosures
Noncontrolling interests (as a percent)	11.00%
Indonesia
Noncontrolling interest disclosures
Noncontrolling interests (as a percent)	10.00%

XML

SEGMENT INFORMATION

12 Months Ended

Dec. 31, 2013

Segment Reporting [Abstract]

SEGMENT INFORMATION

SEGMENT INFORMATION

        MJN operates infourgeographic operating segments: Asia, Europe, Latin America and North America. In the fourth quarter of 2013, the Company revised its reportable segments. Previously the Company presented two reportable segments: Asia/Latin America and North America/Europe. In the fourth quarter of 2013, the Company expanded the number of reportable segments tothreeas it separated the Asia/Latin America segment into two reportable segments: Asia and Latin America. The North America/Europe reportable segment remains unchanged. This change in segment reporting presentation does not change any consolidated totals. The Company made this segment reporting change because it believes that the new presentation will provide investors with greater insight into the Company's consolidated results and operating performance. Prior year comparative information has been revised to conform to the current reportable segment presentation.

Corporate and Other consists of unallocated general and administrative expenses; global business support activities, including research and development, marketing and supply chain costs; and income or expenses incurred within the operating segments that are not reflective of ongoing operations and affect the comparability of the operating segments’ results. The Company’s products are sold principally to wholesalers, retailers and distributors. One customer in the North America/Europe and Latin America segments accounted for 10%, 11% and 12% of the Company’s gross sales for each year ended December 31, 2013, 2012, and 2011; a second customer in the Asia segment accounted for 16%, 15%, and 14% of the Company’s gross sales for the years ended December 31, 2013, 2012, and 2011, respectively.

        The Company's segment, product and geographic results consisted of:

(In millions)	Net Sales		Earnings Before Interest and Income Taxes			Year-End Assets		Payments for Capital Expenditures		Depreciation and Amortization
Year ended December 31, 2013
Asia	$	2,179.3	$	795.8		$	1,390.7	$	168.1	$	19.4
Latin America	861.4		207.2			716.9		33.3		10.5
North America/Europe	1,160.0		248.5			798.5		31.6		29.1
Total operating segments	4,200.7		1,251.5			2,906.1		233.0		59.0
Corporate and Other	—		(326.9		)	568.0		7.4		24.1
Total	$	4,200.7	$	924.6		$	3,474.1	$	240.4	$	83.1
Year ended December 31, 2012
Asia	$	1,967.0	$	725.3		$	1,097.3	$	87.4	$	16.9
Latin America	752.5		176.0			712.8		10.7		8.9
North America/Europe	1,181.8		246.1			740.5		22.3		27.4
Total operating segments	3,901.3		1,147.4			2,550.6		120.4		53.2
Corporate and Other	—		(277.4		)	707.6		4.0		23.7
Total	$	3,901.3	$	870.0		$	3,258.2	$	124.4	$	76.9
Year ended December 31, 2011
Asia	$	1,827.8	$	672.5		$	1,008.6	$	34.0	$	17.2
Latin America	619.4		139.1			467.4		12.0		7.6
North America/Europe	1,229.8		308.4			764.0		33.4		30.7
Total operating segments	3,677.0		1,120.0			2,240.0		79.4		55.5
Corporate and Other	—		(345.9		)	526.8		30.1		19.8
Total	$	3,677.0	$	774.1		$	2,766.8	$	109.5	$	75.3

Net Sales (in millions)	Infant Formula		Children’s Nutrition		Other		Total
Year ended December 31, 2013	$	2,459.7	$	1,653.3	$	87.7	$	4,200.7
Year ended December 31, 2012	$	2,295.5	$	1,487.0	$	118.8	$	3,901.3
Year ended December 31, 2011	$	2,188.7	$	1,394.4	$	93.9	$	3,677.0

Geographic (in millions)	United States		China/ Hong Kong		Mexico		Singapore	Other		Total
Year ended December 31, 2013
Net Sales	$	948.2	$	1,315.8	$	328.2	28.0	$	1,580.5	$	4,200.7
Long-Lived Assets	446.6		64.7		134.8		245.9	427.0		1,319.0
Year ended December 31, 2012
Net Sales	$	990.1	$	1,160.1	$	317.2	22.5	$	1,411.4	$	3,901.3
Long-Lived Assets	456.0		65.1		180.1		104.9	437.1		1,243.2
Year ended December 31, 2011
Net Sales	$	1,019.7	$	1,083.5	$	321.0	20.8	$	1,232.0	$	3,677.0
Long-Lived Assets	457.3		60.7		171.6		1.3	169.7		860.6

XML

EMPLOYEE STOCK BENEFIT PLANS

12 Months Ended

Dec. 31, 2013

EMPLOYEE STOCK BENEFIT PLANS [Abstract]

EMPLOYEE STOCK BENEFIT PLANS

EMPLOYEE STOCK BENEFIT PLANS

        MJN 2009 Stock Award and Incentive Plan—The MJN 2009 Amended and Restated Stock Award and Incentive Plan (“Award and Incentive Plan”) provides for the grant of stock options, performance share awards, restricted stock units and other stock-based awards. Executive officers and other key employees of MJN, and non-employee directors and others who provide substantial services to MJN, are eligible to be granted awards under the Award and Incentive Plan. Twenty-five million shares of stock were approved and registered with the Securities and Exchange Commission (the “SEC”) for grants to participants under the Award and Incentive Plan. Shares used for awards assumed in an acquisition or combination will not count against the shares reserved under the Award and Incentive Plan. The shares reserved may be used for any type of award under the Award and Incentive Plan. Stock-based compensation expense is based on awards ultimately expected to vest. Forfeitures are estimated based on the historical experience of participants in the Award and Incentive Plan since its inception in February of 2009.

        MJN may grant options to purchase common stock at no less than 100% of the closing market price on the date the option is granted. Stock options generally become exercisable in installments of either 25% per year on each of the first through the fourth anniversaries of the grant date or 33% per year on each of the first through the third anniversaries of the grant date. Stock options have a maximum term of 10 years. Generally, MJN will issue shares for the stock option exercises from treasury stock, if available, or will issue new shares.

        MJN may also grant performance share awards, which are granted in the form of a target number of performance shares to be earned and have a three-year performance cycle consisting of three one-year performance periods. The performance share awards have annual goals set at the beginning of each performance period, at which time the awards are considered granted. The maximum payout is 200%. If targets are not met for a performance period, no payment is made under the plan for that annual period.

        MJN may also grant restricted stock units under the Award and Incentive Plan. Restrictions generally expire over a 1- to 5-year period from the date of grant. Stock-based compensation expense is recognized over the restricted period. A restricted stock unit is a right to receive stock at the end of the specified vesting period. A restricted stock unit has non-forfeitable rights to dividend equivalent payments and has no voting rights.

        MJN Stock Options—The fair value of stock options granted in 2013, 2012, and 2011 was estimated on the date of grant using the Black-Scholes option pricing model. No stock options with market conditions were granted in 2013, 2012 or 2011. The following assumptions were used in the valuations:

	2013		2012		2011
	Black-Scholes Model		Black-Scholes Model		Black-Scholes Model
Expected volatility	27.0	%	26.9	%	26.7	%
Risk-free interest rate	0.9	%	1.2	%	2.6	%
Dividend yield	1.9	%	1.6	%	1.7	%
Expected life	5.3 years		6.0 years		6.0 years

        The 2013 and 2012 expected volatility assumption required in the Black-Scholes model was calculated based principally on the Company’s historical volatility, and to a lesser extent, on implied volatility from publicly-traded options on the Company’s stock.As MJN has not yet accumulated six years of historical stock trading data, the full history of MJN over the period of February 2009 through December 2013 is used to calculate the expected volatility assumption required in the Black-Scholes model. The 2011 expected volatility assumption required in the Black-Scholes model was calculated based on an equal weighting between the Company’s historical volatility and implied volatility from publicly-traded options on the Company’s stock.

        The risk-free interest rate assumption in the Black-Scholes model is based upon the U.S. Treasury yield curve in effect at the time of grant. The dividend yield assumption is based on MJN’s expectation of dividend payouts. The expected life is based on the vesting period and the contractual term for each grant, or for each vesting tranche for awards with graded vesting. The selection of this approach was based on MJN’s assessment that this simplified method is appropriate given the terms of the stock option granted and given that there is not sufficient historical stock option exercise experience upon which to estimate expected terms.        

        Stock option activities were as follows:

	Shares (in thousands)	Weighted Average Exercise Price of Shares		Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in millions)
Balance—January 1, 2011	1,404	$	34.36	8.6	$	48.2
Granted	558	59.18
Exercised	(140)	31.65			$	5.2
Forfeited or expired	(33)	45.03
Balance—December 31, 2011	1,789	42.12		8.1	$	47.6
Granted	491	78.12
Exercised	(325)	35.60			$	11.6
Forfeited or expired	(53)	57.50
Balance—December 31, 2012	1,902	52.11		7.7	$	99.2
Granted	485	74.76
Exercised	(377)	36.06			$	17.6
Forfeited or expired	(51)	73.57
Balance—December 31, 2013	1,959	60.12		7.4	$	46.3
Vested—December 31, 2013	1,119	50.24		6.5	$	37.5
Vested and expected to vest—December 31, 2013	1,940	59.98		7.4	$	46.1

        The weighted-average grant date fair value of stock options granted is $15.08, $17.55 and $14.73 for 2013, 2012 and 2011 respectively.

        Cash proceeds received from options exercised during the years ended December 31,2013,2012and2011were$13.6 million,$11.6 millionand$4.5 million, respectively. The tax benefit realized from stock options exercised was$5.9 millionin2013,$4.8 million in 2012and$1.8 millionin2011.

        At December 31, 2013, total unrecognized compensation cost related to stock options of $7.4 million is expected to be recognized over a weighted average period of 1.8 years.

        MJN Performance Share Awards—The fair value of performance share awards is based on the closing trading price of MJN’s stock on the date of the grant, discounted using the risk-free interest rate as the awards do not participate in dividends. Information related to performance share awards activity is summarized as follows:

Grant Date	Performance Cycle Measurement Date	Shares Granted and Earned (in thousands)	Weighted- Average Grant- Date Fair Value		Performance Shares Outstanding at December 31, 2013
February 27, 2013	Annually on 12/31	203	$	72.30	143
March 2, 2012	Annually on 12/31	418	$	67.22	197
March 2, 2011	Annually on 12/31	275	$	57.03	79

        Shares granted and earned in the table above assumes 100% plan performance adjusted for the actual plan achievement level for completed performance periods. At December 31, 2013, total unrecognized compensation cost related to the performance share awards granted of $6.5 million is expected to be recognized over a weighted average period of 1.5 years.

        MJN Restricted Stock Units—The fair value of restricted stock units is determined based on the closing trading price of MJN’s common stock on the grant date. A summary of restricted stock unit activity is as follows:

	Shares (in thousands)		Weighted- Average Grant Date Fair Value
Nonvested restricted stock units—January 1, 2011	588		$	35.15
Granted	134		59.40
Vested	(170	)	44.44
Forfeited	(19	)	40.39
Nonvested restricted stock units—December 31, 2011	533		38.09
Granted	146		76.98
Vested	(146	)	32.28
Forfeited	(19	)	47.57
Nonvested restricted stock units—December 31, 2012	514		50.24
Granted	133		74.85
Vested	(189	)	39.14
Forfeited	(35	)	62.68
Nonvested restricted stock units—December 31, 2013	423		61.59

        At December 31, 2013, total unrecognized compensation cost related to nonvested restricted stock units was $12.8 million and is expected to be recognized over a weighted average period of 2.5 years.

        Stock-Based Compensation Expense—The following table summarizes stock-based compensation expense related to MJN stock options, MJN performance share awards and MJN restricted stock units for the years ended December 31, 2013, 2012, and 2011:

	Years Ended December 31,
(In millions)	2013			2012			2011
Stock options	$	6.5		$	7.5		$	5.9
Performance share awards	16.1			16.1			22.8
Restricted stock units	10.0			8.6			11.2
Total pre-tax stock-based compensation expense	$	32.6		$	32.2		$	39.9
Net tax benefit related to stock-based compensation expense	$	(11.4	)	$	(9.8	)	$	(14.1	)

        Stock-based compensation expense was recognized in the consolidated statements of earnings as follows:

	Years Ended December 31,
(Dollars in millions)	2013		2012		2011
Cost of products sold	$	3.0	$	3.0	$	4.0
Selling, general and administrative	26.6		26.2		31.9
Research and development	3.0		3.0		4.0
Total stock-based compensation expense	$	32.6	$	32.2	$	39.9

        There were no costs related to stock-based compensation that were capitalized.

XML

REDEEMABLE NONCONTROLLING INTEREST (Notes)

12 Months Ended

Dec. 31, 2013

Business Acquisition [Line Items]

Business Combination Disclosure [Text Block]

REDEEMABLE NONCONTROLLING INTEREST

On March 15, 2012, the Company acquired 80% of the outstanding capital stock of Nutricion para el Conosur S.A. which manufactures, distributes and sells infant formula and children’s nutrition products in Argentina under the SanCor Bebé and Bebé Plus brands (the “Argentine Acquisition”). Under the terms of an agreement related to the Argentine Acquisition, the noncontrolling interest owner has the right to require MJN to purchase (the “Put Right”) its remaining 20% interest or to sell (the “Call Right”) up to an additional 20% of the outstanding capital stock of Nutricion para el Conosur S.A. The Put Right is exercisable from September 15, 2015 to September 15, 2018 and the decision to exercise is not within the control of MJN. The price paid upon exercise will be determined based on established multiples of sales and earnings of the acquired business and is currently estimated to equate to fair value at the earliest exercise date. As a result of the Put Right, the noncontrolling interest is presented as redeemable noncontrolling interest outside of equity on the balance sheet. Accretion to the redemption value of the Put Right is being recognized through equity using an interest method over the period from March 15, 2012 to September 15, 2015.

XML

LONG LIVED ASSETS (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, plant and equipment disclosures
Accumulated depreciation	$ (607.1)	$ (568.2)
Property, plant, and equipment-net	867.5	689.9
Depreciation expense	63.7	55.8	57.2
Interest capitalized	5.7	0.6	0.2
Asset Retirement Obligations, Noncurrent	3.6	3.3
Expected amortization expense related to intangible assets
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	16.0
Finite-Lived Intangible Assets, Amortization Expense, Year Two	15.0
Finite-Lived Intangible Assets, Amortization Expense, Year Three	12.3
Finite-Lived Intangible Assets, Amortization Expense, Year Four	9.4
Finite-Lived Intangible Assets, Amortization Expense, Year Five	1.8
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	1.7
Land
Property, plant and equipment disclosures
Property, Plant and Equipment, Gross	12.6	6.0
Buildings
Property, plant and equipment disclosures
Property, Plant and Equipment, Gross	550.8	506.0
Machinery, equipment and fixtures
Property, plant and equipment disclosures
Property, Plant and Equipment, Gross	650.3	595.7
Construction in progress
Property, plant and equipment disclosures
Property, Plant and Equipment, Gross	$ 260.9	$ 150.4

XML

LONG LIVED ASSETS Non-cash activity (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Noncash activity [Abstract]
Capital Expenditures Incurred but Not yet Paid	$ 89.5	$ 78.7	$ 32.8

XML

INVENTORIES (Details) (USD $) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]
Finished goods	$ 312.7	$ 264.6
Work in process	82.5	56.9
Raw and packaging materials	139.6	114.4
Inventories	$ 534.8	$ 435.9

XML

EMPLOYEE STOCK BENEFIT PLANS (Tables)

12 Months Ended

Dec. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of assumptions used in the valuations of stock options

	2013		2012		2011
	Black-Scholes Model		Black-Scholes Model		Black-Scholes Model
Expected volatility	27.0	%	26.9	%	26.7	%
Risk-free interest rate	0.9	%	1.2	%	2.6	%
Dividend yield	1.9	%	1.6	%	1.7	%
Expected life	5.3 years		6.0 years		6.0 years

Schedule of stock option activity

	Shares (in thousands)	Weighted Average Exercise Price of Shares		Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in millions)
Balance—January 1, 2011	1,404	$	34.36	8.6	$	48.2
Granted	558	59.18
Exercised	(140)	31.65			$	5.2
Forfeited or expired	(33)	45.03
Balance—December 31, 2011	1,789	42.12		8.1	$	47.6
Granted	491	78.12
Exercised	(325)	35.60			$	11.6
Forfeited or expired	(53)	57.50
Balance—December 31, 2012	1,902	52.11		7.7	$	99.2
Granted	485	74.76
Exercised	(377)	36.06			$	17.6
Forfeited or expired	(51)	73.57
Balance—December 31, 2013	1,959	60.12		7.4	$	46.3
Vested—December 31, 2013	1,119	50.24		6.5	$	37.5
Vested and expected to vest—December 31, 2013	1,940	59.98		7.4	$	46.1

Summary of performance share awards activity

Grant Date	Performance Cycle Measurement Date	Shares Granted and Earned (in thousands)	Weighted- Average Grant- Date Fair Value		Performance Shares Outstanding at December 31, 2013
February 27, 2013	Annually on 12/31	203	$	72.30	143
March 2, 2012	Annually on 12/31	418	$	67.22	197
March 2, 2011	Annually on 12/31	275	$	57.03	79

Summary of restricted stock unit activity

	Shares (in thousands)		Weighted- Average Grant Date Fair Value
Nonvested restricted stock units—January 1, 2011	588		$	35.15
Granted	134		59.40
Vested	(170	)	44.44
Forfeited	(19	)	40.39
Nonvested restricted stock units—December 31, 2011	533		38.09
Granted	146		76.98
Vested	(146	)	32.28
Forfeited	(19	)	47.57
Nonvested restricted stock units—December 31, 2012	514		50.24
Granted	133		74.85
Vested	(189	)	39.14
Forfeited	(35	)	62.68
Nonvested restricted stock units—December 31, 2013	423		61.59

Summary of stock-based compensation expense by award type

	Years Ended December 31,
(In millions)	2013			2012			2011
Stock options	$	6.5		$	7.5		$	5.9
Performance share awards	16.1			16.1			22.8
Restricted stock units	10.0			8.6			11.2
Total pre-tax stock-based compensation expense	$	32.6		$	32.2		$	39.9
Net tax benefit related to stock-based compensation expense	$	(11.4	)	$	(9.8	)	$	(14.1	)

Schedule of stock-based compensation expense recognized in the consolidated statements of earnings

	Years Ended December 31,
(Dollars in millions)	2013		2012		2011
Cost of products sold	$	3.0	$	3.0	$	4.0
Selling, general and administrative	26.6		26.2		31.9
Research and development	3.0		3.0		4.0
Total stock-based compensation expense	$	32.6	$	32.2	$	39.9

XML

INCOME TAXES (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred tax assets:
Accrued expenses	$ 33,500,000	$ 28,000,000
Accrued rebates and returns	42,200,000	44,500,000
Pension, post retirement and post employment liabilities	58,100,000	65,300,000
Stock-based compensation	20,200,000	18,300,000
Obsolescence reserves and other inventory items	7,900,000	6,300,000
Net operating loss carryforwards	13,500,000	17,200,000
Other-net	6,700,000	23,200,000
Valuation allowance	(7,300,000)	(6,100,000)
Deferred Tax Assets, Net of Valuation Allowance	174,800,000	196,700,000
Deferred tax liabilities:
Depreciation and amortization	(68,500,000)	(76,500,000)
Unremitted earnings and cumulative foreign currency translation adjustments	(9,700,000)	(26,100,000)
Deferred Tax Liabilities, Net	78,200,000	102,600,000
Deferred Tax Assets, Net	96,600,000	94,100,000
Recognized as:
Deferred income taxes-current-net	74,900,000	85,500,000
Deferred income taxes-noncurrent-net	21,700,000	8,600,000
Deferred Tax Assets, Net	96,600,000	94,100,000
Gross net operating loss (NOL) carryforwards	49,000,000
Operating Loss Carryforwards - indefinite lived	22,300,000
Increase (decrease) in valuation allowance recorded for NOL carryforwards	5,000,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	6,900,000
State tax credit carryforwards valuation allowance	2,300,000
Income taxes paid	159,300,000	226,800,000	174,300,000
Undistributed Earnings of Foreign Subsidiaries	1,400,000,000
Deferred tax liability not recognized on undistributed foreign earnings	$ 494,000,000

XML

LONG LIVED ASSETS

12 Months Ended

Dec. 31, 2013

Property, Plant and Equipment [Abstract]

Long-lived Assets

LONG-LIVED ASSETS

Property, Plant, and Equipment

The major categories of property, plant, and equipment were as follows: 

(In millions)	December 31, 2013			December 31, 2012
Land	$	12.6		$	6.0
Buildings	550.8			506.0
Machinery, equipment, and fixtures	650.3			595.7
Construction in progress	260.9			150.4
Accumulated depreciation	(607.1		)	(568.2		)
Property, plant, and equipment—net	$	867.5		$	689.9

        Depreciation expense was $63.7 million, $55.8 million and $57.2 million for the years ended December 31, 2013, 2012 and 2011, respectively, and is primarily included in costs of products sold. Interest capitalized during the year was $5.7 million, $0.6 million and $0.2 million for the years ended December 31, 2013, 2012 and 2011, respectively.

        The Company’s liability for asset retirement obligations was $3.6 million and $3.3 million at December 31, 2013 and 2012.

Other Intangible Assets

The gross carrying value and accumulated amortization by class of intangible assets were as follows: 

	As of December 31, 2013							As of December 31, 2012
(In millions)	Gross Carrying Amount		Accumulated Amortization			Net Book Value		Gross Carrying Amount		Accumulated Amortization			Net Book Value
Indefinite-lived intangible assets
Trademark(1) .	$	34.5	$	—		$	34.5	$	45.3	$	—		$	45.3
Non-compete agreement(1) .	6.8		—			6.8		8.9		—			8.9
Total	41.3		—			41.3		54.2		—			54.2
Amortizable intangible assets
Computer software	132.8		(79.3		)	53.5		132.2		(60.2		)	72.0
Distributor-customer relationship(2) 10 year life	3.3		(0.6		)	2.7		4.4		(0.7		)	3.7
Total	136.1		(79.9		)	56.2		136.6		(60.9		)	75.7
Total other intangible assets	$	177.4	$	(79.9	)	$	97.5	$	190.8	$	(60.9	)	$	129.9

⁽¹⁾Changes in balances result from currency translation.

⁽²⁾Changes in balances result from currency translation and amortization.

        Amortization expense for other intangible assets was $19.4 million, $21.1 million and $18.1 million for the years ended December 31, 2013, 2012 and 2011, respectively.

        Expected amortization expense related to intangible assets is as follows:

(In millions) Years Ending December 31,
2014	$	16.0
2015	15.0
2016	12.3
2017	9.4
2018	1.8
Later years	1.7

Non-Cash Activity

Additions to long-lived assets not yet paid were $89.5 million, $78.7 million and $32.8 million for the years ended December 31, 2013, 2012 and 2011, respectively.

XML

LEASES

12 Months Ended

Dec. 31, 2013

Leases [Abstract]

Leases of Lessee Disclosure [Text Block]

LEASES

        Minimum rental commitments under all non-cancelable operating leases, primarily real estate leases for offices, manufacturing-related leases and vehicle leases, in effect at December 31, 2013, are:

(In millions) Years Ending December 31,
2014	$	36.4
2015	29.5
2016	20.8
2017	15.5
2018	14.3
Later Years	22.3
Total Minimum Payments	$	138.8

        Operating lease rental expenses were $39.7 million, $37.4 million and $35.5 million in the years ended December 31, 2013, 2012, and 2011, respectively. At December 31, 2013 and 2012, MJN had capital lease obligations outstanding in the amount of $2.9 million and $2.7 million, respectively.

XML

EARNINGS PER SHARE (Details) (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Basic earnings per share:
Weighted-average shares outstanding									202.4	203.6	204.3
Net earnings attributable to shareholders	$ 153.2	$ 161.6	$ 162.2	$ 172.5	$ 134.2	$ 140.3	$ 165.8	$ 164.2	$ 649.5	$ 604.5	$ 508.5
Dividends and undistributed earnings attributable to unvested shares									(1.2)	(1.4)	(1.4)
Net earnings attributable to shareholders used for basic earnings per share calculation									648.3	603.1	507.1
Net Earnings Attributable to Shareholders (in dollars per share)	$ 0.76	$ 0.80	$ 0.80	$ 0.85	$ 0.66	$ 0.69	$ 0.81	$ 0.80	$ 3.20	$ 2.96	$ 2.48	$ 2.48
Diluted earnings per share:
Weighted-average shares outstanding									202.4	203.6	204.3
Incremental shares outstanding assuming the exercise/vesting of dilutive stock options/performance shares									0.7	0.7	0.7
Weighted-average shares - diluted									203.1	204.3	205.0
Net earnings attributable to shareholders	153.2	161.6	162.2	172.5	134.2	140.3	165.8	164.2	649.5	604.5	508.5
Dividends and undistributed earnings attributable to unvested shares									(1.2)	(1.4)	(1.4)
Net earnings attributable to shareholders used for diluted earnings per share calculation									$ 648.3	$ 603.1	$ 507.1
Net Earnings Attributable to Shareholders (in dollars per share - diluted)	$ 0.75	$ 0.79	$ 0.80	$ 0.85	$ 0.66	$ 0.69	$ 0.81	$ 0.80	$ 3.19	$ 2.95	$ 2.47
Potential shares outstanding	2.8				2.7				2.8	2.7	2.9
Potential shares outstanding, not included in the diluted earnings per share calculation									2.1	2.0	2.2

XML

DEBT (Tables)

12 Months Ended

Dec. 31, 2013

Debt Disclosure [Abstract]

Components of long-term debt

The components of long-term debt were as follows: 

(Dollars in millions)	December 31, 2013			December 31, 2012
Principal Value:
3.50% Notes due 2014	$	500.0		$	500.0
4.90% Notes due 2019	700.0			700.0
5.90% Notes due 2039	300.0			300.0
Subtotal	1,500.0			1,500.0
Adjustments to Principal Value:
Unamortized basis adjustment for terminated interest rate swaps	16.7			26.0
Unamortized bond discount	(2.0		)	(2.8		)
Less amount due within one year	505.6			—
Long-term debt	$	1,009.1		$	1,523.2

Components of interest expense-net

The components of interest expense-net were as follows: 

	Years Ended December 31,
(In millions)	2013			2012			2011
Interest expense	$59.2			$70.9			$	60.2
Interest income	(8.6		)	(5.9		)	(8.0		)
Interest expense-net	$50.6			$65.0			$	52.2
Interest payments, net of amounts related to interest rate swaps	$	72.0		$	74.9		$	61.4

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]
Receivables, allowances (in dollars)	$ 6.5	$ 7.6
Common Stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common Stock, authorized	3,000	3,000
Common Stock, issued	206.8	206.0

XML

ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

ACCOUNTING POLICIES

ACCOUNTING POLICIES

        Basis of Presentation—The financial statements present the results of operations, financial position, and cash flows of MJN and its majority-owned and controlled subsidiaries. Intercompany balances and transactions have been eliminated. The Company prepared the accompanying consolidated financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”). These financial statements consider subsequent events through the date of filing with the Securities and Exchange Commission.

In the Consolidated Statements of Cash Flows for the years ended December 31, 2012 and 2011, operating cash flow amounts reflected as pension and other postretirement benefit expense have been reclassified to conform to the presentation for the year ended December 31, 2013. These amounts were previously classified as a component of the change in other assets and liabilities.

        Use of Estimates—The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used in revenue recognition, including sales rebate and return accruals, impairment testing of goodwill and other indefinite-lived intangible assets, income tax assets and liabilities, income tax expense, and legal liabilities, as well as the accounting for stock-based compensation and retirement and post retirement benefits, including the actuarial assumptions. Actual results may or may not differ from estimated results.

        Fair Value Measurements—The fair value of financial assets and liabilities are classified in the fair value hierarchy as follows: Level 1—unadjusted quoted prices in active markets for identical assets or liabilities, Level 2—observable prices that are based on inputs not quoted on active markets, and Level 3—unobservable inputs that reflect estimates about the assumptions market participants would use in pricing the asset or liability.

        Revenue Recognition—MJN recognizes revenue when substantially all the risks and rewards of ownership have transferred to the customer. Revenue is recognized on the date MJN’s products are received by the purchaser. Revenues are reduced at the time of recognition to reflect expected returns that are estimated based on historical experience and business trends. Additionally, provisions are made at the time of revenue recognition for discounts, Women, Infants and Children (“WIC”) rebates and estimated sales allowances based on historical experience, updated for changes in facts and circumstances, as appropriate. Such provisions are recorded as a reduction of revenue. The Company offers sales incentives to customers and consumers through various programs consisting primarily of customer pricing allowances, merchandising funds and consumer coupons. Provisions are made at the time of revenue recognition for these items based on historical experience, updated for changes in facts and circumstances, as appropriate. Such provisions are recorded as a reduction of revenue.

        WIC rebate accruals were $199.7 million and $206.5 million at December 31, 2013 and 2012, respectively, and are included in accrued rebates and returns on the Company’s balance sheet. MJN participates on a competitive bidding basis in nutrition programs sponsored by states, tribal governments, the Commonwealth of Puerto Rico, and U.S. territories for WIC. Under these programs, MJN reimburses these entities for the difference between wholesaler list price and the contract price on eligible products. The Company accounts for WIC rebates by establishing an accrual in an amount equal to the Company’s estimate of WIC rebate claims attributable to a sale. MJN determines its estimate of the WIC rebate accrual primarily based on historical experience regarding WIC rebates and current contract prices under the WIC programs. The Company considers levels of inventory in the distribution channel, new WIC contracts, terminated WIC contracts, changes in existing WIC contracts and WIC participation, and adjusts the accrual periodically throughout the year to reflect actual expense. Rebates under the WIC program reduced revenues by $702.3 million, $730.0 million, and $700.7 million in the years ended December 31, 2013, 2012, and 2011, respectively.

        Sales return accruals were $44.8 million and $46.4 million at December 31, 2013 and 2012, respectively, and are included in accrued rebates and returns on the Company’s balance sheet. The Company accounts for sales returns by establishing an accrual in an amount equal to its estimate of sales recorded for which the related products are expected to be returned. The Company determines its estimate of the sales return accrual primarily based on historical experience regarding sales returns, but also considers other factors that could impact sales returns such as discontinuations and new product introductions. Returns reduced sales by $81.0 million, $82.5 million, and $81.8 million for the years ended December 31, 2013, 2012 and 2011, respectively.

        Income Taxes—The provision for income taxes has been determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable earnings in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when changes are enacted.The ultimate liability incurred by the Company may differ from the provision estimates based on a number of factors, including interpretations of tax laws and the resolution of examinations by the taxing authorities.

        Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.The assessment of whether or not a valuation allowance is required often requires significant judgment including the long-range forecast of future taxable earnings and the evaluation of tax planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made.

        Uncertain tax positions that relate to deferred tax assets are recorded against deferred tax assets; otherwise, uncertain tax positions are recorded as either a current or noncurrent liability.

Cash and Cash Equivalents—Cash and cash equivalents consist of bank deposits, time deposits and money market funds. The Company maintains cash and cash equivalent balances in U.S. dollars and foreign currencies, which are subject to currency rate risk. Cash equivalents are primarily highly liquid investments with original maturities of 3 months or less at the time of purchase and are recorded at cost, which approximates fair value. Money market funds, which totaled $447.8 million and $520.7 million at December 31, 2013 and 2012, respectively, are classified as Level 2 in the fair value hierarchy.

        Inventory Valuation—Inventories are valued at the lower of cost or market. The Company determines cost on the basis of the average cost or first-in, first-out methods.

        Property, Plant and Equipment—Expenditures for additions and improvements, including capitalized interest, are recorded at cost. Depreciation is computed on a straight-line method based on the estimated useful lives of the related assets. The estimated useful lives of the major classes of depreciable assets are up to 50 years for buildings and 3 to 40 years for machinery, equipment, and fixtures. Maintenance and repair costs are expensed as incurred.

        Capitalized Software—Certain costs to obtain internal-use software for significant systems projects are capitalized and amortized on a straight-line basis over the estimated useful life of the software, which ranges from 3 to 7 years. Costs to obtain software for projects that are not significant are expensed as incurred.

        Impairment of Long-Lived Assets—The Company periodically evaluates whether current facts or circumstances indicate that the carrying value of its depreciable assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived asset, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. An estimate of the asset’s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company reports an asset to be disposed of at the lower of its cost less accumulated depreciation or its estimated net realizable value.

        Goodwill and Other Intangible Assets—During the third quarter of 2013 the Company changed its annual impairment testing date from January 1 to July 1, which did not result in any delay, acceleration or avoidance of an impairment charge. The Company believes that moving the goodwill impairment testing date to the third quarter is preferable because it better aligns with MJN’s annual and long-term planning timeline, which is a significant element in the testing process. The Company completed impairment testing in both the first and third quarters of 2013 and concluded that no impairment of goodwill exists (see Note 14).

The Company’s policy is to test Goodwill for impairment on an annual basis or when current facts or circumstances indicate that a potential impairment may exist. The Company compares the carrying value of a reporting unit, including goodwill, to the fair value of the unit. If the carrying amount of a reporting unit exceeds its fair value, the Company revalues all assets and liabilities of the reporting unit, excluding goodwill, to determine if the fair value of the net assets is greater than the net assets including goodwill. If the fair value of the net assets is less than the carrying amount of net assets including goodwill, impairment has occurred. The Company’s estimates of fair value are primarily determined based on a discounted cash flow model. Growth rates for sales and profits are determined using inputs from the Company’s annual long-range planning process. The Company also makes estimates of discount rates, perpetuity growth assumptions, market comparables, and other factors. The Company completed its most recent goodwill impairment assessment during the third quarter and monitored for any potential impairment during the remainder of 2013. No impairment of goodwill was required in2013,2012or2011.

The Company evaluates the useful lives of its other intangible assets to determine if they are finite or indefinite-lived. Reaching a determination on useful life requires significant judgments and assumptions regarding the future effects of obsolescence, demand, competition, other economic factors (such as the stability of the industry, known technological advances, legislative action that results in an uncertain or changing regulatory environment, and expected changes in distribution channels), the level of required maintenance expenditures, and the expected lives of other related groups of assets. Intangible assets that are deemed to have definite lives are amortized on a straight-line basis, over their useful lives.

The Company’s indefinite-lived intangible assets are also tested for impairment annually and whenever events or changes in circumstances indicate that their carrying value may not be recoverable. Estimates of the fair value of indefinite-lived intangible assets is based on a discounted cash flow model using inputs which included projected revenues from the Company’s annual long-range plan, assumed royalty rates that could be payable if MJN did not own the brands, and a discount rate. The Company completed its most recent indefinite-lived intangible asset impairment assessment during the third quarter and monitored for any potential impairment during the remainder of 2013, determining that no impairment was required.

        Contingencies—In the ordinary course of business, the Company is subject to loss contingencies, such as lawsuits, investigations, government inquiries and claims, including, but not limited to, product liability claims, advertising disputes and inquiries, consumer fraud suits, other commercial disputes, premises claims and employment and environmental, health, and safety matters. The Company records accruals for such loss contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. The Company does not recognize gain contingencies until realized. Legal costs are expensed as incurred.

        Derivatives—Derivatives are used by the Company principally in the management of its foreign currency, interest rate and commodity pricing exposures. The Company records all derivatives on the balance sheet at fair value. The Company does not hold or issue derivatives for speculative purposes.

        The Company designates and assigns derivatives as hedges of forecasted transactions, specific assets or specific liabilities. When the hedged assets or liabilities are sold, extinguished or the forecasted transactions being hedged are no longer expected to occur, the Company immediately recognizes the gain or loss on the designated hedging financial instruments in the consolidated statements of earnings.

        If derivatives are designated as a cash flow hedge, the effective portion of changes in the fair value is temporarily reported in accumulated other comprehensive loss and is recognized in earnings when the hedged item affects earnings or is deemed ineffective; cash flows are classified consistent with the underlying hedged item. The Company assesses hedge effectiveness at inception and on a quarterly basis. These assessments determine whether derivatives designated as qualifying hedges continue to be highly effective in offsetting changes in the cash flows of hedged items. Any ineffective portion of the change in fair value is included in current period earnings. The Company will discontinue cash flow hedge accounting when the forecasted transaction is no longer probable of occurring on the originally forecasted date, or 60 days thereafter, or when the hedge is no longer effective.

        If derivatives are designated as a fair value hedge, both the changes in the fair value of the derivatives and of the hedged item attributable to the hedged risk are recognized in the consolidated statements of earnings; cash flows are classified consistent with the underlying hedged item.

        Pension and Other Post Retirement Benefits—The funded status of the Company’s defined pension and post retirement benefit plans is measured as the difference between the fair value of the plan assets and the benefit obligation. For the defined benefit plans, the benefit obligation is the projected benefit obligation; for any other defined benefit post retirement plans, the benefit obligation is the accumulated post retirement benefit obligation. The net over- or under-funded status is recognized as an asset or a liability on the balance sheet. Any unrecognized actuarial gain or loss, or service cost or benefit is reported as a component of accumulated other comprehensive loss.

        Shipping and Handling Costs—The Company typically does not charge customers for shipping and handling costs. Shipping and handling costs, including warehousing expenses, were $119.1 million, $115.6 million, and $104.3 million in the years ended December 31, 2013, 2012, and 2011, respectively, and are included in selling, general and administrative expenses.

        Advertising Costs—Advertising costs are expensed as incurred and were $226.7 million, $180.3 million, and $180.6 million in the years ended December 31, 2013, 2012, and 2011, respectively.

        Research and Development—Research and development costs are expensed as incurred.

        Foreign Currency Translation—The statements of earnings of the Company’s foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using average exchange rates for the period. The net assets of the Company’s foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using exchange rates as of the balance sheet date. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in accumulated other comprehensive income (loss).

Recently Adopted Accounting Standards—In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, requiring entities to provide information about the amounts reclassified out of accumulated other comprehensive income by component. For significant reclassifications related to net income, the ASU required disclosure in the consolidated statement of earnings or within the footnotes. For other amounts, the ASU required a cross-reference to other disclosures that provide additional detail about those amounts. This ASU did not change the current requirements for reporting the consolidated statement of earnings or other comprehensive income in the financial statements. The Company adopted the required financial reporting presentation effective January 1, 2013.

Recently Issued Accounting Standards—In March 2013, the FASB issued ASU No. 2013-05, Foreign Currency Matters (Topic 830), clarifying the applicable guidance for the release of the cumulative translation adjustment. ASU 2013-05 is effective for the Company in the period beginning January 1, 2014. The Company does not expect the adoption of this update to have a material impact on the consolidated financial statements.   

In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or Tax Credit Carryforward Exists. ASU 2013-11 requires that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, with certain exceptions. ASU 2013-11 is effective for the Company in the period beginning January 1, 2014 and the Company does not anticipate that the adoption of this standard to have a material impact on its consolidated financial statements.

XML

PENSION AND OTHER POST RETIREMENT BENEFIT PLANS (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Changes in net periodic benefit cost
Percentage in total pension assets and obligations	75.00%
Change in fair value of plan assets:
Beginning fair value of plan assets	$ 312.1
Fair value of plan assets at end of year	276.1	312.1
Amounts in the consolidated balance sheets include:
Pension, Post Retirement and Post Employment Liabilities	(161.8)	(188.8)
Accumulated benefit obligation in excess of plan assets
Projected benefit obligation	366.3	449.3
Accumulated benefit obligation	356.1	430.2
Fair value of plan assets	210.8	263.1
Weighted-average assumptions used to determine net periodic benefit cost
Expected long term return on plan assets in next fiscal year (as a percent)	7.00%
Defined Benefit Plan, Alternative Method Used to Amortize Net Gains and Losses	.1
Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]
Defined Benefit Plan, Health Care Cost Trend Rate Assumed for Next Fiscal Year	6.90%	7.80%	7.40%
Defined Benefit Plan, Ultimate Health Care Cost Trend Rate	4.90%	4.90%	5.00%
Defined Benefit Plan, Year that Rate Reaches Ultimate Trend Rate	2023	2023	2017
Defined Benefit Plan, Effect of One-Percentage Point Change in Assumed Health Care Cost Trend Rates [Abstract]
Defined Benefit Plan, Effect of One Percentage Point Increase on Service and Interest Cost Components	0
Defined Benefit Plan, Effect of One Percentage Point Decrease on Service and Interest Cost Components	0
Defined Benefit Plan, Effect of One Percentage Point Increase on Accumulated Postretirement Benefit Obligation	0.2
Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation	0.3
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	276.1	312.1
Period of notice for quarterly redemption of diversified hedge	60 days
DefinedContributionBenefits [Abstract]
Defined Benefit Plan, Estimated Future Employer Contributions in Current Fiscal Year	0
Defined Benefit Plan, Expected Future Benefit Payments, Fiscal Year Maturity [Abstract]
Defined Contribution Plan, Cost Recognized	19.9	21.3	19.3
Cash and Cash Equivalents [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	13.0	11.4
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	13.0	11.4
US large cap equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	16.3	13.6
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	16.3	13.6
US mid cap growth equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	3.1	2.8
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	3.1	2.8
US small cap growth equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	0.1	1.5
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0.1	1.5
Emerging market equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	2.8	3.1
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	2.8	3.1
Real estate investment trusts [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	5.6	13.4
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	5.6	13.4
International large cap value equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	37.0	28.3
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	37.0	28.3
Hedge Funds [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	17.4	15.7
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	17.4	15.7
Municipal Bonds [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	72.8	83.5
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	72.8	83.5
Corporate Bond Securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	101.7	138.8
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	101.7	138.8
Emerging markets Fixed Income [Domain]
Change in fair value of plan assets:
Fair value of plan assets at end of year	6.3	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	6.3	0
Pension Benefits
Changes in benefit obligations
Beginning benefit obligations	463.6	402.7
Service cost - benefits earned during the period	5.2	3.9	3.5
Interest cost on projected benefit obligations	14.4	15.6	17.0
Actuarial assumptions (gains) losses	(25.7)	72.2
Settlements and curtailments	(50.4)	(30.9)
Benefits paid	(2.8)	(2.2)
Exchange rate changes	(0.3)	2.3
Benefit obligations at end of year	404.0	463.6	402.7
Change in fair value of plan assets:
Beginning fair value of plan assets	312.1	280.7
Actual return on plan assets	(1.4)	32.8
Employer contributions	18.5	28.2	9.5
Settlements	(50.4)	(29.3)
Benefits paid	(2.8)	(2.2)
Exchange rate changes	0.1	1.9
Fair value of plan assets at end of year	276.1	312.1	280.7
Underfunded status at end of year	(127.9)	(151.5)
Amounts in the consolidated balance sheets include:
Other assets	1.3	2.2
Pension, Post Retirement and Post Employment Liabilities	(129.2)	(153.7)
Defined Benefit Plan, Amounts Recognized in Balance Sheet	(127.9)	(151.5)
Amounts in accumulated other comprehensive loss include:
Net actuarial loss	197.7	242.6
Prior service (benefit)	1.2	0
Transition obligation	0.1	0.2
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax	199.0	242.8
Accumulated benefit obligation	375.7	428.0
Accumulated benefit obligation in excess of plan assets
Service cost - benefits earned during the period	5.2	3.9	3.5
Interest cost on projected benefit obligations	14.4	15.6	17.0
Expected return on plan assets	(16.4)	(16.2)	(18.2)
Amortization of net actuarial loss	6.6	5.3	3.3
Amortization of prior service (benefit)	0	0	0
Amortization of transition cost	0.1	0.1	0.1
Net periodic benefit cost	9.9	8.7	5.7
Settlements and curtailments	29.3	15.2	9.7
Total net periodic benefit cost	39.2	23.9	15.4
Estimated net actuarial loss and prior service cost that will be amortized from accumulated other comprehensive income into net periodic benefit cost in the next fiscal year
Amortization of net actuarial loss	5.2
Amortization of prior service (benefit)	0.1
Other Comprehensive Income (Loss), Reclassification, Pension and Other Postretirement Benefit Plans, Net Transition Asset (Obligation), Recognized in Net Periodic Benefit Cost, before Tax	0.1
Pension and Other Postretirement Benefit Plans, Amounts that Will be Amortized from Accumulated Other Comprehensive Income (Loss) in Next Fiscal Year	5.4
Weighted-average assumptions used to determine benefit obligations
Discount rate (as a percent)	4.08%	3.21%
Rate of compensation increase (as a percent)	3.22%	3.58%
Weighted-average assumptions used to determine net periodic benefit cost
Discount rate (as a percent)	3.26%	4.03%	5.59%
Expected long term return on plan assets (as a percent)	5.22%	5.65%	6.91%
Rate of compensation increase (as a percent)	3.59%	4.00%	4.02%
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	276.1	312.1	280.7
DefinedContributionBenefits [Abstract]
Employer contributions	18.5	28.2	9.5
Defined Benefit Plan, Expected Future Benefit Payments, Fiscal Year Maturity [Abstract]
Defined Benefit Plan, Expected Future Benefit Payments, Next Twelve Months	29.3
Defined Benefit Plan, Expected Future Benefit Payments, Year Two	29.5
Defined Benefit Plan, Expected Future Benefit Payments, Year Three	29.5
Defined Benefit Plan, Expected Future Benefit Payments, Year Four	30.8
Defined Benefit Plan, Expected Future Benefit Payments, Year Five	29.7
Defined Benefit Plan, Expected Future Benefit Payments, Five Fiscal Years Thereafter	147.8
Other Benefits
Changes in benefit obligations
Beginning benefit obligations	35.1	30.2
Service cost - benefits earned during the period	1.1	1.0	0.9
Interest cost on projected benefit obligations	1.3	1.3	1.3
Actuarial assumptions (gains) losses	(3.8)	2.6
Settlements and curtailments	0	0
Benefits paid	(1.3)	(0.1)
Exchange rate changes	0.2	0.1
Benefit obligations at end of year	32.6	35.1	30.2
Change in fair value of plan assets:
Beginning fair value of plan assets	0	0
Actual return on plan assets	0	0
Employer contributions	0.9	0.1
Settlements	0	0
Benefits paid	(1.3)	(0.1)
Exchange rate changes	0.4	0
Fair value of plan assets at end of year	0	0	0
Underfunded status at end of year	(32.6)	(35.1)
Amounts in the consolidated balance sheets include:
Other assets	0	0
Pension, Post Retirement and Post Employment Liabilities	(32.6)	(35.1)
Defined Benefit Plan, Amounts Recognized in Balance Sheet	(32.6)	(35.1)
Amounts in accumulated other comprehensive loss include:
Net actuarial loss	11.8	17.3
Prior service (benefit)	(0.3)	(0.5)
Transition obligation	0	0
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax	11.5	16.8
Accumulated benefit obligation	32.6	35.1
Accumulated benefit obligation in excess of plan assets
Service cost - benefits earned during the period	1.1	1.0	0.9
Interest cost on projected benefit obligations	1.3	1.3	1.3
Expected return on plan assets	0	0	0
Amortization of net actuarial loss	1.7	1.9	1.7
Amortization of prior service (benefit)	(0.2)	(0.2)	(0.2)
Amortization of transition cost	0	0	0
Net periodic benefit cost	3.9	4.0	3.7
Settlements and curtailments	0	0	0
Total net periodic benefit cost	3.9	4.0	3.7
Estimated net actuarial loss and prior service cost that will be amortized from accumulated other comprehensive income into net periodic benefit cost in the next fiscal year
Amortization of net actuarial loss	1.1
Amortization of prior service (benefit)	(0.1)
Other Comprehensive Income (Loss), Reclassification, Pension and Other Postretirement Benefit Plans, Net Transition Asset (Obligation), Recognized in Net Periodic Benefit Cost, before Tax	0
Pension and Other Postretirement Benefit Plans, Amounts that Will be Amortized from Accumulated Other Comprehensive Income (Loss) in Next Fiscal Year	1.0
Weighted-average assumptions used to determine benefit obligations
Discount rate (as a percent)	4.98%	3.75%
Rate of compensation increase (as a percent)	3.08%	3.48%
Weighted-average assumptions used to determine net periodic benefit cost
Discount rate (as a percent)	3.75%	4.29%	5.28%
Expected long term return on plan assets (as a percent)	0.00%	0.00%	0.00%
Rate of compensation increase (as a percent)	3.48%	3.94%	3.94%
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0	0	0
DefinedContributionBenefits [Abstract]
Employer contributions	0.9	0.1
Defined Benefit Plan, Expected Future Benefit Payments, Fiscal Year Maturity [Abstract]
Defined Benefit Plan, Expected Future Benefit Payments, Next Twelve Months	0.8
Defined Benefit Plan, Expected Future Benefit Payments, Year Two	1.0
Defined Benefit Plan, Expected Future Benefit Payments, Year Three	1.1
Defined Benefit Plan, Expected Future Benefit Payments, Year Four	1.1
Defined Benefit Plan, Expected Future Benefit Payments, Year Five	1.3
Defined Benefit Plan, Expected Future Benefit Payments, Five Fiscal Years Thereafter	6.5
U.S. Pension Plan | Equity Securities [Member]
Defined Benefit Plan, Assets, Target Allocations [Abstract]
Defined Benefit Plan, Target Allocation Percentage	.4
U.S. Pension Plan | Fixed Income [Member]
Defined Benefit Plan, Assets, Target Allocations [Abstract]
Defined Benefit Plan, Target Allocation Percentage	.6
Fair Value, Inputs, Level 1 [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	21.5	11.4
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	21.5	11.4
Fair Value, Inputs, Level 1 [Member] | Cash and Cash Equivalents [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	13.0	11.4
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	13.0	11.4
Fair Value, Inputs, Level 1 [Member] | US large cap equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	0	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0	0
Fair Value, Inputs, Level 1 [Member] | US mid cap growth equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	0	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0	0
Fair Value, Inputs, Level 1 [Member] | US small cap growth equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	0	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0	0
Fair Value, Inputs, Level 1 [Member] | Emerging market equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	0	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0	0
Fair Value, Inputs, Level 1 [Member] | Real estate investment trusts [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	0	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0	0
Fair Value, Inputs, Level 1 [Member] | International large cap value equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	8.5	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	8.5	0
Fair Value, Inputs, Level 1 [Member] | Hedge Funds [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	0	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0	0
Fair Value, Inputs, Level 1 [Member] | Municipal Bonds [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	0	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0	0
Fair Value, Inputs, Level 1 [Member] | Corporate Bond Securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	0	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0	0
Fair Value, Inputs, Level 1 [Member] | Emerging markets Fixed Income [Domain]
Change in fair value of plan assets:
Fair value of plan assets at end of year	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0
Fair Value, Inputs, Level 2 [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	254.6	300.7
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	254.6	300.7
Fair Value, Inputs, Level 2 [Member] | Cash and Cash Equivalents [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	0	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0	0
Fair Value, Inputs, Level 2 [Member] | US large cap equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	16.3	13.6
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	16.3	13.6
Fair Value, Inputs, Level 2 [Member] | US mid cap growth equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	3.1	2.8
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	3.1	2.8
Fair Value, Inputs, Level 2 [Member] | US small cap growth equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	0.1	1.5
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	0.1	1.5
Fair Value, Inputs, Level 2 [Member] | Emerging market equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	2.8	3.1
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	2.8	3.1
Fair Value, Inputs, Level 2 [Member] | Real estate investment trusts [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	5.6	13.4
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	5.6	13.4
Fair Value, Inputs, Level 2 [Member] | International large cap value equity securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	28.5	28.3
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	28.5	28.3
Fair Value, Inputs, Level 2 [Member] | Hedge Funds [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	17.4	15.7
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	17.4	15.7
Fair Value, Inputs, Level 2 [Member] | Municipal Bonds [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	72.8	83.5
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	72.8	83.5
Fair Value, Inputs, Level 2 [Member] | Corporate Bond Securities [Member]
Change in fair value of plan assets:
Fair value of plan assets at end of year	101.7	138.8
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	101.7	138.8
Fair Value, Inputs, Level 2 [Member] | Emerging markets Fixed Income [Domain]
Change in fair value of plan assets:
Fair value of plan assets at end of year	6.3	0
DefinedBenefitPlanFairValueofPlanAssets [Abstract]
Defined Benefit Plan, Fair Value of Plan Assets	$ 6.3	$ 0

XML

DEBT (Details 2) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Long-Term Debt
Principal value of long-term debt obligations	$ 1,500.0	$ 1,500.0
Unamortized basis adjustment for terminated interest rate swaps	16.7	26.0
Unamortized bond discount	(2.0)	(2.8)
Long-term Debt Current Portion	505.6	0
Long-term debt	1,009.1	1,523.2
Long-term debt - fair value	1,611.1
Interest expense	59.2	70.9	60.2
Interest income	(8.6)	(5.9)	(8.0)
Interest expense-net	50.6	65.0	52.2
Interest payments, net of amounts related to interest rate swaps	72.0	74.9	61.4
3.50% Notes due 2014
Long-Term Debt
Principal value of long-term debt obligations	500.0	500.0
Stated rate (as a percent)	3.50%
4.90% Notes due 2019
Long-Term Debt
Principal value of long-term debt obligations	700.0	700.0
Stated rate (as a percent)	4.90%
5.90% Notes due 2039
Long-Term Debt
Principal value of long-term debt obligations	$ 300.0	$ 300.0
Stated rate (as a percent)	5.90%

XML

CONTINGENCIES

12 Months Ended

Dec. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

CONTINGENCIES

CONTINGENCIES

In the ordinary course of business, the Company is subject to lawsuits, investigations, government inquiries and claims, including, but not limited to, product liability claims, advertising disputes and inquiries, consumer fraud suits, other commercial disputes, premises claims and employment and environmental, health, and safety matters.

The Company was served with a lawsuit filed on October 16, 2012 in St. Clair County (Illinois) Circuit Court under the caption Shelby Schrack, et al. v. Mead Johnson Nutrition Company and Mead Johnson & Company, which lawsuit alleges that certain bacteria in powdered formula were responsible for the death of one infant and serious illness in two others and seeks unspecified monetary damages. These events were widely publicized in December 2011 and January 2012. The infants allegedly consumed formula from batches that were extensively tested by the Company, the Centers for Disease Control (“CDC”) and the U.S. FDA. These tests detected no bacteria in our infant formula. The CDC further noted that while these bacteria have sometimes been found in formula, they also exist in the environment and may potentially cause illness through person to person contact or through contamination of infant feedings at the point of use. The Company believes that the claims in this matter are without merit. Nevertheless, in November 2013, the Company and the plaintiffs agreed to settle the disputed claims asserted in this litigation, and on December 12, 2013, the Company obtained court approval of the proposed settlement and release of all such claims. The settlement did not materially affect the Company’s consolidated financial position, results of operations or cash flows.

The Company records accruals for contingencies when it is probable that a liability will be incurred and the loss can be reasonably estimated. Although the Company cannot predict with certainty the final resolution of lawsuits, investigations and claims asserted against the Company, MJN does not believe any currently pending legal proceeding to which the Company is a party will have a material effect on the Company’s business or financial condition, although an unfavorable outcome in excess of amounts recognized as of December 31, 2013, with respect to one or more of these proceedings could have a material effect on the Company’s results of operations and cash flows for the periods in which a loss is recognized.

The Company incurred costs for an administrative penalty assessed by China's National Development and Reform Commission ("NDRC") in connection with the NDRC’s antitrust review of the infant formula industry’s resale pricing practices (the “China Antitrust Review”) and was resolved during the third quarter of 2013. In connection with the China Antitrust Review, the NDRC assessed an administrative penalty of $33.4 million against the Company, which penalty was paid during the third quarter and is non-deductible for tax purposes.

Following an SEC request for documents relating to certain business activities of the Company’s local subsidiary in China, the Company is continuing an internal investigation of such business activities. The Company’s investigation is focused on certain expenditures that were made in connection with the promotion of the Company’s products or may have otherwise been made. Certain of such expenditures were made in violation of Company policies and may have been made in violation of applicable U.S. and/or local laws, including the U.S. Foreign Corrupt Practices Act (the “FCPA”).  The investigation is being conducted by outside legal counsel and overseen by a committee of independent members of the Company’s board of directors. The status and results of the investigation are being discussed with the SEC and other governmental authorities.  At this time, the Company is unable to predict the scope, timing or outcome of this ongoing matter or any regulatory or legal actions that may be commenced related to this matter.  If a violation of the FCPA or other laws is determined to have occurred, the Company could become subject to monetary penalties as well as civil and criminal sanctions.

XML

LEASES (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Leases [Abstract]
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 36.4
Operating Leases, Future Minimum Payments, Due in Two Years	29.5
Operating Leases, Future Minimum Payments, Due in Three Years	20.8
Operating Leases, Future Minimum Payments, Due in Four Years	15.5
Operating Leases, Future Minimum Payments, Due in Five Years	14.3
Operating Leases, Future Minimum Payments, Due Thereafter	22.3
Operating Leases, Future Minimum Payments Due	138.8
Operating Leases, Rent Expense, Net	39.7	37.4	35.5
Capital Lease Obligations	$ 2.9	$ 2.7

XML

INVENTORIES (Tables)

12 Months Ended

Dec. 31, 2013

Inventory Disclosure [Abstract]

Major categories of inventories

(In millions)	December 31, 2013		December 31, 2012
Finished goods	$	312.7	$	264.6
Work in process	82.5		56.9
Raw and packaging materials	139.6		114.4
Inventories	$	534.8	$	435.9

XML

INVENTORIES

12 Months Ended

Dec. 31, 2013

Inventory Disclosure [Abstract]

INVENTORIES

INVENTORIES

        The major categories of inventories were as follows:

(In millions)	December 31, 2013		December 31, 2012
Finished goods	$	312.7	$	264.6
Work in process	82.5		56.9
Raw and packaging materials	139.6		114.4
Inventories	$	534.8	$	435.9